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Mission of the Summer Experience Program
The mission of the MD Anderson Summer Experience Program is to eliminate cancer, through training of high
School, undergraduates and first year medical students to make a lasting impact on training the next generation
of scientist and physicians through research and education.
The MD Anderson Summer Experience is an umbrella program that comprises 18 summer academic programs at
MD Anderson.
The summer research program is an 8 to 10 week program that offers hands-on experience in biomedical,
translational or clinical research. In this program, students are matched with a mentor from MD Anderson’s
research or clinical faculty. Participants work alongside the mentor in a lab or clinic, on projects designed by
faculty to reflect current research. Workshops and lectures provide opportunities to connect with faculty,
residents, postdoctoral and clinical fellows, and other participants. Through the program, students assess goals
related to careers in oncology research and patient care. The program culminates with a symposium in which
participants present talks and posters on their research projects to peers and faculty.
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CPRIT-CURE Summer Undergraduate Program
Abstract number: 1
Ultraconserved Enhancer Roles in Cancer
Romina Adel; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Linda Fabris; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
George A Calin; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Ultraconserved elements (UCEs) are DNA segments with 100% conservation between the
orthologous genomes of human, mouse and rat, and high conservation in other species. It has been
demonstrated that UCEs are involved in cancer studies in multiple ways. Mutation in UCEs sequence can be
used as prognostic factor in cancer, since as hypermutation in UCE is associated with resistance to treatments
and decreased overall survival. Another way UCEs can influence cancer susceptibility is working as enhancers.
In this way, mutated UCEs can alter the expression of many of their neighboring genes and overall gene
expression. The focus of this study was to characterize the potential enhancing ability of three UCE regions,
UCE_2272, UCE_11409 and UCE_1943, found to be important in human cancers by a large mutational screen
and CRISPR-Apf screen of cell proliferation by the mentor group and collaborators.
Methods: The UCE_2272, UCE_11409 and UCE_1943 were selected as enhancers in mouse tissues according
to VISTA data (enhancer.lbl.gov). To characterize the potential enhancer function in 293T/17 cells, I performed
Luciferase reporter assays. UCE_2272, UCE_11409 and UCE_1943 genomic regions were amplified from normal
human male DNA and both sense and antisense direction constructs were cloned in pGL3-control-TK plasmid
(Promega) downstream luciferase sequence. Plasmids were extracted using HiSpeed Plasmid Purification
(QIAGEN) then transfected in 293T/17 cell line using lipofectamine. The luciferase activity was measured using
Dual Luciferase Reporter Assay System (Promega) 48 hours after transfection. Obtained Luciferase data were
normalized using Renilla luciferase activity.
Results: The normalized luciferase activity data obtained for UCE_2272 and UCE_1943 were compared to the
respective empty vector (pGL3-control-TK). These UCEs showed only a partial increase in Luciferase activity,
which is not sufficient at this time to prove that these genomic regions are enhancers. The Luciferase Reporter
assay for UCE_11409 is currently ongoing. Based on previous experiment (by mentor collaborators), this UCE is
expected to behave as an enhancer, at least in vitro, thus it is anticipated to show increased luciferase expression
when cloned in both sense and antisense direction.
Conclusion: UCEs can function as enhancer to regulate gene expression in cancer. Based on data collected so
far, we did not identify UCE_2272 and UCE_1943 as enhancers in 293T/17 cell line at this time. Additional
studies on these regions, along with UCE_11409, are currently performed. Further experiments are required to
verify our data and to determine which are the pathways altered by these genomic regions in cancer.
Keywords: Ultraconserved elements, gene regulations, enhancer regions, Luciferase reporter assay
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 2
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Awurama Akyianu; Systems Imaging; University of Texas MD Anderson Cancer Center
Brian Grindel; Systems Imaging; University of Texas MD Anderson Cancer Center
Steven Millward; Systems Imaging; University of Texas MD Anderson Cancer Center
Florian Muller; Systems Imaging; University of Texas MD Anderson Cancer Center
Sunada Khadka; Systems Imaging; University of Texas MD Anderson Cancer Center
Background: Inhibiting glycolysis and other metabolic pathways in cancer is challenging due to the heightened
toxicity of normal cells. Collateral lethality therapies capitalize on the 'cancer-specific metabolic vulnerabilities'
arising from the deletion of genes neighboring tumor suppressors. A prime example is the homozygous deletion
of the 1p36 tumor suppressor locus resulting in the concomitant deletion of the glycolytic enzyme gene, ENO1
(encoding enolase 1), in cancers like glioblastoma. The two enolase paralogs, ENO1 and ENO2, are essential in
the glycolytic pathway given their roles in the catalytic conversion of 2-phosphoglycerate (2 PG) to
phosphoenolpyruvate. Cells lacking ENO1 are especially sensitive to inhibition of ENO2 and using this premise
treatments were developed. One such treatment involves a phosphonate-containing ENO2 inhibitor. Dubbed
HEX, this drug shows higher specificity for ENO2 over ENO1. Since HEX bears a resemblance structurally to the
2 PG, it inhibits ENO2 competitively. But, with HEX being anionic in nature, a cell-permeable version, POMHEX,
was also developed. In this work, the inhibitory concentration (IC50) of HEX was determined on glioblastoma cells
with different ENO1 deletions and combined with a standard-of-care glioblastoma drug, temozolomide (TMZ), to
assess any synergistic effects.
Methods: Cell culture experiments to test HEX sensitivity were performed in multiple cell lines with two different
cell viability assays. Glioma cell lines with different ENO1 status (D423: ENO-/-; D423 ENO1 rescue; U343:
ENO1+/-; LN319: ENO1+/+; D502: ENO1+/- ) were treated for 5 days and subjected to a sulfrhodamine B (SRB)
assay and MTT assay. Cell viability via the SRB and MTT assay uses total protein content and cell metabolic
activity, respectively. The cell binding substrate Matrigel was also tested for its ability to better adhere cells that
detach during the assays. TMZ was also tested in combination with HEX for the ENO1 deleted and heterozygous
glioma cell lines.
Results: With both assay types, HEX showed an (IC50) of ~1100 nM-1300 nM against ENO-/- D423 cells while
the ENO1 rescue cells showed essentially no sensitivity to HEX. These values are in line with previous
observations using crystal violet assays. Matrigel coating increased initial adherence of cells but failed to mitigate
assay detachment. Further experiments will combine TMZ and HEX to observe additive or synergistic effects.
Conclusion: HEX is effective against ENO1-deleted cells leaving wild type cells unaffected. Viability assays
employing different mechanisms gave similar results. HEX needs to be further assessed as a combo treatment
with TMZ for glioma treatment.
Keywords: Enolase inhibitor, HEX
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 3
Aid for a more accurate dose accumulation tracking in radiation therapy
Lusmeralis Almodovar Abreu; Chemistry; University of Puerto Rico-Humacao Campus
Yulun He; Imaging Physics; University of Texas MD Anderson Cancer Center
Kristy K. Brock; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Fractionation regimens are frequently used in radiotherapy (RT) to maximize the destruction of
tumors and minimize the damage to surrounding tissues. The dose uptake by surrounding tissues during RT is
defined as dose accumulation and, one objective in RT is to improve the delivered dose estimation. Algorithms
like deformable image registration, establishes a voxel-voxel correspondence between two images, allowing dose
mapping from different time points, which can be summed to estimate the delivered dose. However, factors such
as tumor regression diminish the precision of these algorithms. The acknowledge that dose is delivered in
fractions and the importance of tumor regression identification is important for a better-accumulated dose
estimate. Hence, we aimed to determine the fractionation scheme and identify tumor regressions of non-small cell
lung cancer (NSCLC) patients treated with RT using weekly four-dimensional computed tomography (4DCT).
Methods: A clinical database of NSCLC patients treated with proton and photon RT was imported into RayStation,
a treatment planning system. By assigning the fractions to the nearest 4DCT week, the weeks of the fractionation
scheme were established. For each patient, tumor change was identified using pre-treatment planning 4DCT and
the last weekly 4DCT during treatment. Previously performed contours showed the gross tumor volume (GTV) in
the planning week and using automatically segmented tumor contour in the last week, the GTV change was
quantified. Changes greater than 25% were categorized as progress and lower than -25% as regression. To
identify the type of regression, four landmarks were placed on the vessels closest to the tumor.
Results: A total of 65 fractionation schemes was performed. 49 were not considered for the tumor regression
identification due to its location or other complications. For photon non-adaptive RT, two inelastic cases of 36.19% and -64.55% and in the, an elastic regression of -32.25% were identified. For proton non-adaptive RT,
inelastic regressions of -38.01%, -49.88%, -52.70%, -54.58%, -62.55%, -66.96% and an elastic case of -71.43%
were identified. Lastly, for the proton adaptive RT, inelastic regressions of -29.53%, -30.75%, -31.05%, -42.49%, 51.69% and -54.55% were identified.
Conclusion: The fractionation scheme and the identification of tumor regression of 65 NSCLC patients treated
with RT was performed. This work will facilitate the determination of the accumulated dose at each week where
4DCTs were taken and the tumor regression identification will allow the implementation of hybrid finite-element
registration method.
Keywords: Deformable image registration, Fractionation scheme, Non-small cell lung cancer, Tumor shrinkage
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 4
Determining and characterizing essential genes from CRISPR knockout screens
Yamini Ananth; Applied Math/Computer Science; Columbia University
Background: Genome-wide loss-of-function screens offer a data source for identifying core essential genes, which
are required for the survival of an organism. Identifying and characterizing human essential genes is a critical step
for functional genomics and cancer target-finding.
Methods: CRISPR knockout screens for 808 mammalian cell lines across 18,111 genes were filtered for quality
using Bayes factors and Cohen’s D Statistic. An essentiality percentage was assigned to each gene based on
how many cell lines in which a gene was essential. Energetic cost was calculated using amino acid biosynthetic
costs and each gene’s UniprotKB canonical sequence. Genes were analyzed for association with a phenotype in
the GWAS Catalog, association with a disease using the OMIM Morbid Map dataset.
Results: 717 core, 5,991 contextual, and 11,413 never essential genes were identified based on their essentiality
percentage. For further analysis, genes were binned by essentiality percentage with all never-essential genes in a
single bin and 800 genes in all other bins. No relationship was observed between gene essentiality and
energetic cost; both total gene energetic cost and mean cost per amino acid were found to have no correlation
with gene essentiality, as the distributions of cost across all bins was virtually identical. Similarly, no correlation
was found between gene essentiality and phenotype expression in the GWAS dataset, with approximately 70% of
genes being related to a phenotype across all bins. A relationship between a gene’s essentiality percentage and
its association with organism level disease association was observed. Peripherally essential genes, with
essentiality percentages of 85-97%, were significantly enriched for disease compared to core essential genes,
which had essentiality percentages of 98-100%. 28-33% of peripherally essential genes were associated with
disease, but only 20.6% of core essentials were associated with disease, compared to 21-26.5% across all other
genes.
Conclusion: Distinguishing between core and contextually essential genes and better understanding these genes
is of broad interest to understand necessary cell functions and disease origin/mechanisms. Here, no relationship
was found between essentiality and energetic cost, suggesting that organisms are energetically efficient enough
not to have energetic cost constraints on essentiality. A relationship between phenotype expression and
essentiality was also not determined. Previous literature supports the discovered relationship between
peripherally essential genes and association with disease, as peripherally essentials are more likely to show
deleterious mutations compared to core essentials. CRISPR screens offer a more complete view of gene
essentiality, adding robustness to these earlier findings.
Keywords: gene essentiality, functional genomics, computational biology
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 5
Evaluating microRNA Binding Using Luciferase Constructs
Matthew Anderson; Translational Molecular Pathology; Biology Department; University of Texas MD Anderson
Cancer Center; Hillsdale College
Melanie Winkle, Ph.D.; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
George Calin, M.D., Ph.D.; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Sepsis is a severe and life-threatening condition that results from an abnormal immune response to
widespread infection and is characterized by an initial period of a hyper inflammatory response followed by a
period of gross immunosuppression. As sepsis is the result of systemic immune dysregulation, there are many
contributing factors at play both at the molecular and clinical level. This results in varied presentations and
contributes to difficulty in identifying the causative mechanisms at work and potential therapeutics. Previous work
by the Calin laboratory has identified several microRNAs that are dysregulated in sepsis, with miR-93-5p being
proposed as a potential targeted therapeutic for sepsis. To further explore the therapeutic potential of miR-93-5p,
we have created constructs that function as either a prototype miRNA sponge for use in screening potential small
molecule inhibitors of miR-93-5p or further validate the binding of miRNA to the mRNA of genes with predicted
miRNA binding sites using the luciferase assay.
Methods: We created oligonucleotides that contained several miR-93-5p binding sites that are expected to
function as miRNA sponges as well as portions of the CD28 gene that contained predicted miR-93-5p binding
sites for use in luciferase assays. The miRNA sponge construct was cloned into the psiCHECK-2 vector, while the
constructs containing CD28 binding sites were subcloned into the TOPO TA vector prior to ligation into the pGL3Control target vector. The presence of the inserts was validated using colony PCR. Validated samples were then
introduced via lipofection into several Jurkat cell lines that either express miR-93-5p or are miR-93-5p knockouts
in order to introduce the DNA of interest into the cells. A luciferase assay was then performed on the Jurkat cells
to evaluate the constructs’ binding affinities for miR-93-5p.
Results: We anticipate that for all constructs, the luciferase signal should decrease in the presence of miR-93-5p
which would indicate that the miRNA does bind to the created constructs. Conversely, if the difference between
highly expressing cells and low expressing cells is not significant, this would suggest that the constructs do not
have as high of an affinity to the miRNA as anticipated or in the case of the CD28 constructs, could suggest that
miR-93-5p does not directly bind to the predicted CD28 binding regions.
Conclusion: miR-93-5p binding can be evaluated using oligonucleotide constructs containing regions of predicted
miR-93-5p binding sites via the luciferase assay.
Keywords: Sepsis, microRNA, Luciferase
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 6
NMR-based Metabolic Profiling of Pancreatic Cancer and Response to Glutamine Transport Inhibition
Hawk Azordegan; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Xiaoxia Wen; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Seong-Woo Bae; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Jose S. Enriquez; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Pratip K. Bhattacharya; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Henry C. Manning; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Background: Glutamine is the most abundant free amino acid in plasma; it is utilized by cancer cells for survival
and rapid reproduction. Cancer cells can metabolize glutamine through a transporter ASCT2 (SLC1A5) and the
process is catalyzed via an enzyme. V9302, an inhibitor of the amino acid transporter, ASCT2, was developed
with the objective of targeting glutaminolysis. This proposes a promising therapeutic approach focused on a
primary metabolic pathway employed by cancer cells, thus preventing the tumor from proliferating. With an aim of
gaining an understanding regarding cancer metabolism, it was hypothesized that by using the developed inhibitor
of the ASCT2 amino acid transporter, V9302, malignant tumors will be unable to metabolize glutamine, leading to
difficulties in proliferation and an imbalance of metabolites in the microenvironment.
Methods: We sought to characterize the effect of V9302 treatment on macroscale metabolite concentrations in the
pancreatic cancer microenvironment. The investigation was conducted using a genetically engineered mouse
model (GEMM) of pancreatic cancer. The mice bred to express the Cre/+, Kras/+, and Smad4 -/- genes
specifically in the pancreas, which lead to cancer. For treatment, they were divided into three groups to be treated
with V-9302: chronic exposure (group 1), control (group 2), and a single acute exposure (group 3). Group 1
received 12.5mg/kg twice a day for four weeks. Group 2 received vehicle treatment for 4 weeks before
euthanizing. Group 3 received 75mg/kg as acute administration for 4 hours before euthanizing. Post-treatment,
the metabolites of the microenvironment were measured by nuclear magnetic resonance (NMR) spectroscopy,
and tumors were extracted and stained with hematoxylin and eosin for histological investigation.
Results: We found that V9302 treatment altered the metabolic profile of the tumor microenvironment. NMR
showed lower levels of glutamine, glutamate, and total choline in treated mice compared to the control group.
Lactate, a hallmark of tumorigenesis, was lower at elevated doses of V9302. Finally, acetate displayed lower
levels in group 3 while group 1 saw no change. Histologically, chronic exposure of V9302 led to tumors that were
less advanced than tumors from the acute dose control groups.
Conclusion: These studies illustrate that V9302 treatment alters the macroscale metabolic profile of the tumor
microenvironment, with implications towards nutrient partitioning and nutrient availability to potentially important
anti-cancer immunity.
Keywords: Cancer, Glutamine, Metabolites, Microenvironment
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 7
The Immune Landscape of Thyroid Cancer
Olga Batarse; Immunology; Houston Baptist University
Rim Ouni; Immunology; University of Texas MD Anderson Cancer Center
Roza Nurieva; Immunology; University of Texas MD Anderson Cancer Center
Background: The incidence of thyroid cancers has increased worldwide over the past few decades. Anaplastic
thyroid carcinoma (ATC) is a rare and aggressive form of cancer of the thyroid gland that is often metastasized.
Most cases of ATC are untreatable and almost universally fatal with median survival of less than six months after
diagnosis. The thyroid cancer microenvironment is rich in immune cells, making it a reasonable candidate for
immunotherapy; however, in order to develop new and efficient targeted immunotherapy approaches, further
studies determining the immune cells and the mediators that favor tumor progression or play a role in tumor
elimination are required.
Methods: In order to detect the contribution of immune cells in thyroid cancer, first, we have characterized the
ATC cell line, MCH-2-2-luc. Our analysis revealed that MCH-2-2 expressed T-cell activation and suppression
factors (MHCI, MHCII, CD86 and PD-L1) and cytokines (GM-CSF, IL-6, IL-10, IL-17, IL-12, IL-4, IFNg and TNFa).
We have next assessed the immune environment of orthotopically transplanted ATC cell line, MCH-2-2-luc into
syngeneic mice (B6/129 and C67BL/6).
Results: In both mouse strains, the tumors were highly enriched with immune cells including T cells (TILs), B
cells, and myeloid cells (dendritic cells (DCs) and macrophages. Among tumor-infiltrated CD4+ T cells (TILs), T
follicular helper (Tfh) cells and regulatory T (Treg) cells were both enriched. Both CD4+ and CD8+ TILs displayed
proliferation and anti-apoptotic markers (Ki67 and Bcl-2) as well as showed an exhausted phenotype
(PD1+Lag3+Tim3+). Tumors were enriched with immunosuppressive M2 macrophages (type 2 macrophages),
neutrophils and myeloid-derived suppressor cells (MDSCs).
Conclusion: Thus, the mouse transplanted ATC mouse model is highly immunogenic with predominance of
exhausted T cells and immunosuppressive cells including Tregs, M2 Macrophages, and MDSCs; therefore,
adequate to test therapies, including immunotherapies.
Keywords: Anaplastic thyroid carcinoma (ATC), Immunotherapy, Immune Environment
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 8
Planning a Phase 1 Clinical Trial: Target Product Profile for a Novel Target CAR T-cell Therapy
Emma Becker; Biologics Development; University of Texas MD Anderson Cancer Center
Sattva Neelapu; Lymphoma and Myeloma; University of Texas MD Anderson Cancer Center
Agathe Bourgogne; Biologics Development; University of Texas MD Anderson Cancer Center
Jason Bock; Biologics Development; University of Texas MD Anderson Cancer Center
Chimeric antigen receptor (CAR) T-cell therapy is a recently developed treatment for large B-cell lymphoma that
uses a patient’s genetically modified immune cells to attack tumor cells. CD4+/CD8+ T-cells are collected from a
patient through apheresis and transduced with a lentiviral vector to express a CAR specific to an antigen found on
the surface of B-cells. The T-cells are infused back into the patient and attack target lymphoma cells with high
specificity.
The B-cell surface antigen targeted most often for treatment of lymphoma through CAR T-cell therapy is CD19,
but half of all patients relapse within six months of treatment due to downregulation of the target antigen and
tumor resistance. The discovery of new targets is necessary to treat relapsed lymphomas after anti-CD19
therapy. In this upcoming phase 1 clinical study headed by Dr. Sattva Neelapu, the maximum tolerated dose
(MTD) will be determined for an autologous novel target CAR T-cell therapy through both dose escalation and
dose expansion cohorts. This Target Product Profile (TPP) will be an evolving live document that follows the
development of the drug from clinical to commercial development, providing a description of the drug’s indications
and characteristics.
To construct this document, I met with each team member involved to compile their information about the project
and observed the laboratory steps in the development process. I also conducted a literature review of CAR T-cell
therapy research to provide a description of the drug’s pharmacology and the likely adverse reactions,
contraindications, and drug interactions that will affect treatment. I collected information about the upcoming dose
escalation and expansion clinical trial, release testing and qualification requirements, and the clinical procedures
for administering the treatment. Because CAR T-cell therapy is a biologic drug, the process of manufacturing the
cells affects the final treatment and must be included in the drug product—therefore, I also included a detailed
process description. The document will be continually updated as the manufacturing process is finalized and
clinical data is collected on the drug’s safety and efficacy.
Keywords: Target Product Profile, clinical trial, lymphoma, CAR T-cell therapy
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 9
Predicting Ki67 and cellular density via MR images as a prognostic indicator
Emily Blitz; Imaging Physics; University of Texas MD Anderson Cancer Center
Adrian Celaya; Imaging Physics; University of Texas MD Anderson Cancer Center
Dawid Schellingerhout; Neuroradiology; University of Texas MD Anderson Cancer Center
David Fuentes; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Ki67 is present at all proliferative phases of the cell cycle, thus making it a useful indicator of cellular
division. The ability to measure Ki67 expression to determine the rate of cellular division allows it to be used as a
prognostic tool in some tumors and previous studies have linked higher Ki67 expression to higher tumor grade.
Traditionally, the Ki67 index is measured through staining and manual counting of positively stained tumor cells, a
method that requires biopsy/resection of tumor tissue. This study looks at the potential for using medical imaging
to predict Ki67 index and cellular density as well as correlating the results with other common prognostic tools
such as IDH mutation status, 1p19q codeletion status, and WHO grade.
Methods: The Erasmus Glioma Database, a retrospectively assembled database of patients with gliomas, each
with 4 structural MRIs and a manual or auto tumor segmentation mask, was analyzed. 46 of the available patients
were included in this analysis. The database included IDH mutation status, 1p/19q codeletion status, and WHO
grade for the patients when data was available. Each MRI was skull stripped, registered, and normalized before
the Ki67 and cell density values were predicted using a random forest classifier. Descriptive statistics were
analyzed for different subsets of patients - such as IDH mutated vs IDH wild type, 1p/19q codeletion vs normal,
and WHO grade II vs II vs IV – in order to determine relationships between data.
Results: The analysis showed that both the predicted Ki67 index and predicted cell density of the tumors had a
positive correlation with IDH wild type status, 1p/19q normal chromosome expression, and higher WHO grading.
Conclusion: Ki67 intensity, or the mitotic index, is used as an indicator for increased cell division and tumor
progression within glioma patients. This analysis showed that Ki67 has a positive correlation with IDH wild type
status, 1p/19q normal chromosome status, and higher WHO grading, all of which are indicators of poorer overall
survival for glioma patients. Thus, Ki67 intensity and cellular density as calculated through imaging techniques
has the potential to be developed into a prognostic tool that limits the need for biopsy/resection.
Keywords: Ki67, EGD, MRI, neuroimaging
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 10
Developing a Radiogenomics Model for NSCLC
John Boom; Imaging Physics; University of Texas MD Anderson Cancer Center
Dr. Jia Wu; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Profiling the gene expression of solid tumors can assist in predicting patients’ responses to
immunotherapy. However, extracting gene expression traditionally requires invasive biopsies or surgeries, which
is impracticable for late-stage patients with multiple lesions. Additionally, biopsies are time-consuming, expensive,
and invasive nature, they are usually taken only once before treatment. However, gene expression is expected to
change in response to treatment, and this longitudinal information could improve physicians’ decision making.
Novel techniques for monitoring gene expression in solid tumors have the potential to improve personalized
cancer treatment. Radiogenomics is an emerging field that principally aims to correlate features from imaging to
gene expression. In this way, it is non-invasive and easily integrates into the current clinical workflow. This
approach is particularly important for patients with late-stage, metastatic cancer, who cannot get a biopsy at every
lesion. This study aims to bridge this gap by predicting gene expression for late-stage patients with non-small cell
lung cancer (NSCLC).
Methods: Gene expression and pre-treatment CT scans were identified from multiple institutions for 274 patients
with early-stage NSCLC. The gene expression data was normalized across each cohort, and then, using gene set
enrichment analysis, converted into common pathways associated with immune response. The patients were then
clustered into multiple groups according to their immune profiles. Deep learning features were extracted using an
autoencoder. Univariate testing correlated each radiomic feature with the gene expression clusters. Additionally,
machine learning (ML) was used to predict the gene expression cluster from the whole set of radiomic features.
To validate the utility of this method, the ML model was applied to a cohort of 182 patients with late-stage NSCLC
from the LONESTAR clinical trial that do not have gene expression data. The gene expression clusters were
correlated to the patients’ RECIST score.
Results: Genomic data has been normalized and clustered. The radiomics features have been fully extracted, and
progress will soon begin on the autoencoder. Meanwhile, the imaging from the LONESTAR trial has been fully
curated, organized, and normalized. The patients on average had lesions in three tissues, which differs from the
early-stage patients that the models are being trained on.
Conclusion: Based on a multi-institution study of 274 patients, it appears that the genomic expression of NSCLC
patients can be clustered into at least three distinct groups. As the data curation and normalization was completed
only recently, no conclusions can be made on the model’s efficacy.
Keywords: radiogenomics, radiomics, machine learning, deep learning, genomics
Program Affiliation: CPRIT-CURE Summer Undergraduate Program
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Abstract number: 11
Manipulation of MAP3K Signaling to Improve CAR-T Cell Therapy
Raul Caballero Montes; Immunology; University of Texas MD Anderson Cancer Center
Meidi Gu; Immunology; University of Texas MD Anderson Cancer Center
Xiaofei Zhou; Immunology; University of Texas MD Anderson Cancer Center
Shao-Cong Sun; Immunology; University of Texas MD Anderson Cancer Center
Background: Adoptive cell therapy using chimeric antigen receptor (CAR)-T cells represents a promising
approach for human cancer immunotherapy. CAR-T cells targeting specific tumor biomarkers have been
particularly effective against B cell malignancies and leukemia, but less successful with solid tumor therapy, partly
due to functional exhaustion. Genetic manipulation of CAR-T cells by deleting or overexpressing signaling
regulators has been actively explored as an approach to improve CAR-T cell survival and efficacy. A recent study
from Dr. Shao-Cong Sun’s laboratory has identified a MAP kinase kinase kinase (MAP3K) as a crucial mediator of
T cell metabolism and antitumor immunity. However, this MAP3K is highly labile and subject to proteasomal
degradation, which is prevented by the deletion of its N-terminal portion. Hence, in this study, we aim to examine
the role of this MAP3K in mediating CAR-T cell function and to achieve CAR-T cell optimal metabolic fitness by
generating CAR-T cells expressing a stable form of MAP3K lacking its N-terminal region (MAP3KΔN). We
hypothesize that MAP3KΔN expression will promote CAR-T cell activation and metabolic fitness in the tumor
microenvironment.
Methods: Using molecular cloning, a retroviral vector encoding a human CD19 (hCD19)-specific CAR and mouse
MAP3KΔN was constructed and confirmed by DNA sequencing. CD8+ T cells were isolated from C57BL/6 mice,
activated in vitro, and then transduced with the hCD19-CAR-MAP3K∆N vector. For functional analysis, B16hCD19 tumor-bearing mice were injected with CAR-T cells expressing either wildtype MAP3K (MAP3KWT) or
MAP3K∆N, and tumor growth was monitored.
Results: Expression of MAP3KWT improved the tumor-suppression function of hCD19-CAR-T cells. Surprisingly,
CAR-T cells expressing the stable form of MAP3K (MAP3K∆N) displayed a lower antitumor efficacy than those
expressing MAP3KWT. Furthermore, these results were correlated in vitro, where MAP3KΔN showed a response
similar to control CAR and reduced tumor inhibition in comparison with MAP3KWT.
Conclusion: Expression of MAP3KWT, but not MAP3K∆N, profoundly improves the antitumor function of CAR-T
cells. It is possible that MAP3KΔN expression results in T cell overactivation, thereby promoting T cell exhaustion
and activation-induced cell death. These results suggest that optimal, rather than excessive, T cell activation is
critical for potential therapeutic applications using MAP3K expression. However, it is also possible that deletion of
the N-terminal portion of MAP3K impairs its facilitation of T cell metabolic functions. Future studies will explore
these possibilities and also develop an inducible MAP3K expression system to manipulate the metabolic activity
and function of CAR-T cells based on temporary MAP3K expression.
Keywords: MAP3K, MAP3KΔN, chimeric antigen receptor (CAR) T cells, adoptive cell therapy, antitumor
immunity
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Abstract number: 12
Characterizing Disease Related Mutations in Proteins Involved in Liquid-Liquid Phase Separation
Sueda Cetinkaya; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Raymond Zou; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Sairahul Pentaparthi; Oncology; Livestrong Cancer Institutes, Dell Medical School, University of Texas at Austin
David Shih; Systems Biology; University of Texas MD Anderson Cancer Center
Wendy Olivares; Epigenetics and Molecular Carcinogenesis;
Stephen Yi; Oncology; Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Nidhi Sahni; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Background: The various roles of liquid-liquid phase separation (LLPS) in human disease development are still
waiting to be uncovered. LLPS is a physicochemical process where a liquid forms two phases: a condensed
phase and a dilute phase. This process produces membraneless organelles in the cell, which play major roles in
cellular functions. Physicochemical properties of cellular particles like protein can impact the probability of forming
a phase-separated condensate and consequently so will mutations that alter these properties. These mutations
can result in either a loss-of-function or gain-of-function phase separation that leads to disease development. The
relationships between genotype and phenotype of LLPS diseases are unknown so to understand this better, we
have begun to characterize disease-related mutations within LLPS genes.
Methods: We systematically analyzed the structural property changes of proteins involved in LLPS caused by
single nucleotide disease mutations to understand their impact on LLPS. After curating a list of experimentally
validated LLPS genes, we analyzed the wild-type structural features, gene expression profiles, and gene-disease
associations. Then, we filtered the disease-related mutations from Human Gene Mutation Database (HGMD) and
cancer-related mutations from Genomic Data Common for LLPS genes. The following structural changes on all
mutation databases were analyzed so far: hydrophobicity, damage level, prion-like-domains, disorder regions,
mutation location, and protein interaction domains. Finally, two phase separation predictors were used to observe
any changes in prediction scores by the mutations.
Results: The LLPS genes in our list were associated with various cancer and brain diseases and similar diseases
were found to be significantly enriched with LLPS gene mutations. We also observed significant changes in some
structural properties of LLPS proteins compared to non-LLPS proteins, which give promising results for
understanding the structural impact of mutations and how they lead to LOF or GOF LLPS in different diseases.
Conclusion: Overall, we were able to begin characterizing the disease and cancer mutations in LLPS genes in an
effort to better understand how genotypes relate to LLPS related disease phenotypes.
Keywords: Liquid-liquid phase separation, Cancer, Mutations, GOF/LOF, Systematic Analyses
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Abstract number: 13
Generation of in vivo mouse model to recapitulate arthritis after ICI therapy
Guo Chen; Immunology; Northwestern University
Sang Taek Kim, MD, PhD; Immunology; University of Texas MD Anderson Cancer Center
Roza Nurieva, PhD; Immunology; University of Texas MD Anderson Cancer Center
Background: Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer therapy, while causing the lifethreatening inflammatory phenomenon, termed immune-related adverse events (irAEs). However, the
mechanisms of irAEs are unknown. Inflammatory arthritis is the most common rheumatic irAEs. Like other irAEs,
there is no pre-clinical model recapitulating arthritis-irAE. This project aims to generate the arthritis-irAE murine
model for clinical investigation.
Methods: We immunized chicken collagen (CII) emulsified with complete Freud media (CFA) to 8-10 weeks male
C57/B6 mice on Day 0. Mice were re-challenged on Day 21 with CII emulsified with incomplete Freud media (IFA)
on Day 21. 100-200 ug of PBS, anti-CTLA-4, and/or anti-PD-1 antibodies were intraperitoneally implemented on
Day 19, 22, 25, and 28. Mice with CII-CFA on Day 0 and Day 21 were used as a positive control. The severity of
arthritis was measured until they were sacrificed on Day 43. At sacrifice, we harvested the spleen, which was
homogenized and washed with PBS. Subsequently, splenocytes were stained with flow cytometry antibodies to
identify key surface molecules, effector cytokines, and/or transcription factors. For intracellular staining,
splenocytes were cultured in the presence of CII collagen (300 ug/mL) overnight followed by stimulation of
PMA/Ionomycin for 4 hours. Stained samples were acquired using LSR II FORTESSA X-20 (BD Bioscience) and
analyzed with FlowJo. The means between groups were compared and analyzed with unpaired t-test. P<0.05 was
considered statistically significant.
Results: Mice receiving ICIs developed arthritis after CII-CFA (D0) and CII-IFA (D21) immunizations. Further,
arthritis of mice receiving either PD-1 inhibitor or combined ICIs was more severe than mice receiving CTAL-4
inhibitor alone. Our clinical observations support that our model well recapitulates arthritis-irAE. Next, since
immune profiles were different between patients with PD-1 inhibitor arthritis and combined ICI arthritis-irAE, we
focused more on these two groups in our in vivo system. Compared with PD-1 inhibitor arthritis group, Th17,
Th1.17, CXCR5+ CD8T cells, Tc1, Tc1.17 were expanded in the combined ICI arthritis group. In contrast, TNFa+
CD4T cells, GM-CSF+ CD8T cells, both pro-inflammatory and anti-inflammatory Tregs were expanded in PD-1
inhibitor arthritis group. Together, like humans, our data suggested that immune profiles underpinning arthritis
differ by ICI regimen in our in vivo system.
Conclusion: We successfully generated in vivo mouse models recapitulating the human arthritis-irAE model. Our
model will serve as a powerful tool for us to understand mechanisms underlying arthritis-irAE as well as formulate
appropriate therapeutic strategies to treat arthritis-irAE.
Keywords: Immune checkpoint inhibitor (ICI) therapy, immune-related adverse events (irAEs), mice models,
arthritis
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Abstract number: 14
Predicting High-Grade Glioma Response to Chemoradiation via MRI-Calibrated Mechanistic Models
Brandon Curl; Radiation Oncology; University of Texas MD Anderson Cancer Center
David A. Hormuth II; Oden Institute for Computational Engineering and Sciences; University of Texas at Austin
Maguy Farhat; Radiation Oncology; University of Texas MD Anderson Cancer Center
Thomas E. Yankeelov; Oden Institute for Computational Engineering and Sciences; University of Texas at Austin
Caroline Chung; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: High-grade gliomas (HGG) are aggressive brain cancers that can evolve and progress during
chemoradiation, resulting in underdosing of the tumor when using the original radiotherapy (RT) plan. While
adaptive RT can react to tumor changes, spatially-resolved predictions of progression could enable anticipatory
modifications of RT and improve tumor control. To this end, we aim to create personalized spatiotemporal
forecasts of HGG response to chemoradiation via a family of 60 mechanism-based mathematical models
calibrated with serial multi-parametric magnetic resonance imaging (mpMRI).
Methods: Serial mpMRI was acquired at baseline and weekly during chemoradiotherapy (CRT) for two patients
with histologically confirmed HGG following surgical resection. Enhancing disease was segmented on postcontrast T1-weighted (T1+C) images at baseline and week three, while non-enhancing disease was segmented
on T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) images weekly. Physiological heterogeneity
(cellularity, white/grey matter, and perfusion via enhancement ratio) was quantified weekly using diffusionweighted imaging (DWI), diffusion tensor imaging (DTI), T2-FLAIR images, and pre- and post-contrast T1weighted (T1 / T1+C) images. Using the imaging data from baseline to week three of CRT, patient-specific model
parameters were calibrated for each of the 60 mathematical models with the Levenberg-Marquardt algorithm. All
models are based on the 3D reaction-diffusion model but vary in the number of model species, parameterization
of tumor cell proliferation, and coupling of treatment efficacy. Selected using the Akaike information criteria (AIC),
the two most parsimonious models were employed to forecast spatially-resolved maps of tumor response at the
end of CRT (week 6) using the finite difference method in MATLAB. These individualized forecasts were then
compared to the ground truth imaging data and evaluated on a global scale with the percent error in tumor volume
and on a local, voxel-wise scale with the concordance correlation coefficient (CCC).
Results: The two most parsimonious models described the enhancing and non-enhancing disease with (3-species
model) or without (2-species model) vasculature dynamics, each with a spatially varying proliferation rate and the
efficacy of radiotherapy coupled to perfusion. Across both patients, we achieved low mean percent errors in tumor
volume (2-species 4.85%; 3-species 2.45%) and high mean CCC values (2-species 0.76; 3-species 0.62).
Conclusion: With good agreement on both the global and local levels, this preliminary data demonstrates the
plausibility of spatially predicting HGG response to chemoradiotherapy. Future modifications, such as the
integration of advanced perfusion imaging, may further inform each patient’s unique spatiotemporal dynamics and
improve clinical outcomes by enabling anticipatory, adaptive radiotherapy.
Keywords: glioma, personalized radiotherapy, computational oncology, multi-parametric magnetic resonance
imaging
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

17

Abstract number: 15
Assessment and comparison of physician-reported staging using the AJCC staging system in Head and
Neck Cancer
Andrea De Leon; Experimental Radiation Oncology; Houston Baptist University
Laura Pareja; Radiation Oncology; Texas Woman's University
Setareh Sharafi; Radiation Oncology; University of Texas MD Anderson Cancer Center
Vivian Salama; Radiation Oncology; University of Texas MD Anderson Cancer Center
Travis Salzillo; Radiation Oncology; University of Texas MD Anderson Cancer Center
Clifton Fuller; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Head and neck cancers account for nearly 4% of all cancers in the United States. The staging of
these cancers is important for physicians to analyze and treat the patients. Furthermore, the American Joint
Committee on Cancer provides a comprehensive framework to guide physicians on staging these cancers. This
study explores both the staging of Oral Cavity and Oropharyngeal cancers, and the AJCC editions utilized
between three Oncology specialties--Head and Neck Surgery, Medical Oncology, and Radiology Oncology.
Methods: A cohort of 100 Head and Neck cancer patients with either Oral Cavity or Oropharyngeal cancers were
extracted from the EPIC electronic medical records system. The tumor stages and the edition of AJCC (7th
edition or 8th edition) utilized by the Head and Neck Surgeon, Medical Oncologist, and Radiology Oncologist were
collected and analyzed. The analysis is still ongoing. The mechanism utilized to obtain this data was through the
REDcap database. Furthermore, the effect of the AJCC staging criteria on survival was determined.
Results: AJCC edition usage for staging among the different oncology specialties was recorded. Descriptive
statistics were calculated for AJCC edition usage. Kaplan-Meier survival curves were produced demonstrating
differences in survival between the two AJCC criteria for each oncology specialty. Statistical analysis was
performed using ANOVA and follow-up t-tests. So far, the results show an inconsistency in the utilization of the
editions of AJCC by the physicians.
Conclusion: This work demonstrates the frequency of the staging data inputted by the physicians. Ongoing efforts
to assess the survival of the patients diagnosed with the 7th versus 8th edition AJCC are underway. The longterm goal of this work is to create an automated method for oncologists across specialties to consistently stage
head and neck cancers.
Keywords: Staging, Radiation Oncology, AJCC, Oral Cavity Cancer, Oropharyngeal Cancer
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Abstract number: 16
Investigating the genetic architecture of a HSP90-dependent trait in the budding yeast Saccharomyces
cerevisiae
Selena Y. Ding; Genetics; University of Texas MD Anderson Cancer Center
Hatim Amiji; Genetics; University of Texas MD Anderson Cancer Center
Dipak Patel; Genetics; University of Texas MD Anderson Cancer Center
Georgios I. Karras; Genetics; University of Texas MD Anderson Cancer Center; Genetics and Epigenetics
Graduate Program, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Background: The heat-shock protein 90 (Hsp90) evolved to help cells maintain protein homeostasis under
proteotoxic stress conditions. Yet, Hsp90 has important biological roles under basal conditions. In cancer cells,
Hsp90 helps stabilize diverse oncogenic proteins, while in normal cells Hsp90 can buffer the effects of disease
mutations. However, how traits become addicted to Hsp90 function remains unknown. To address this question in
a simple system, we focused on the role of Hsp90 in palatinose -- a naturally occurring disaccharide in plants and
rich carbon source for diverse yeasts -- utilization in the budding yeast Saccharomyces cerevisiae. Palatinose
utilization provides a simple model for studying Hsp90 dependent traits.
Methods: Growth curves: To study the effects of Hsp90 inhibition on the ability of yeast to utilize palatinose, we
grew yeast strains of diverse backgrounds in 384 well plates and measured optical density (600 nm) every 15
minutes for 37 hours. To determine the effects of Hsp90 inhibition on growth we used the naturally-occurring
Hsp90 inhibitor radicicol (10 µM) and the structurally distinct second generation Hsp90 inhibitor NVP-HSP990 (25
µM). Tetrad dissection: To test whether HSP90 dependence of palatinose utilization follows a Mendelian pattern
of inheritance, we crossed yeast strains harboring various degrees of robustness to Hsp90 inhibition to strains
that were less robust or were unable to utilize palatinose. We performed bulk sporulations and tetrad dissections
to isolate spores for six independent crosses, and determined the ability of each strain to utilize palatinose in the
presence vs. absence of Hsp90 inhibitors. Genetic screens: We utilized a gene deletion library and performed
growth curve assays for each deletion strain under basal conditions vs. Hsp90 inhibition. As a control we used
isolates of the original parental yeast strain.
Results: We found that the robustness of palatinose utilization to Hsp90 inhibition by radicicol or NVP-HSP990
varies drastically across strains. Our genetic crosses reveal a strong genetic basis for these differences and imply
a role for epistasis. Preliminary results from our genome-wide genetic screen point to several gene candidates
that warrant further mechanistic investigation.
Conclusion: Our results demonstrate a unique role for Hsp90 in palatinose utilization in yeast. Additionally,
genetic variation influences this trait and epistatic interaction between genes point to its Hsp90 dependence. In
conclusion, our results establish a model for the genetic basis of an Hsp90-dependent trait, identify specific genes
involved, and lay a foundation to characterize the evolutionary significance of underlying mechanisms.
Keywords: Hsp90, S. cerevisiae, genetic architecture, palatinose
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Abstract number: 17
THE MORPHOLOGICAL PROGRESS OF MÜLLERIAN DUCT FUSION IN MICE
Phuong Anh Dinh; Genetics; Albion College
Diana A. Machado; Genetics; University of Texas MD Anderson Cancer Center
Richard R. Behringer; Genetics; University of Texas MD Anderson Cancer Center
Background: Early mammalian embryonic development in both sexes involves the formation of two pairs of
urogenital ducts termed the Wolffian ducts (WD) and the Müllerian ducts (MD). While the former gives rise to
several male reproductive organs, the latter differentiates into the oviduct, uterus, cervix, and the upper 2/3 of the
vagina. It is known that the two MD will fuse to form the uterine corpus, and it is thought that the degree of fusion
leads to the variation of uterus morphology such as a simplex uterus in humans vs. bicornuate uterus in mice.
Several observed uterine anomalies are the result of MD fusion failure. However, there is a gap in our knowledge
with regards to the MD fusion with little research investigating this process. Here, we choose mice as our
research organism and focus on (1) characterizing the timing, position, and morphological landmarks during the
fusion process and (2) determining the regions of interest of the fusing MD for single cell transcriptome analysis.
Methods: Previous work in the lab showed that MD fusion occurs in the E13.5 – E15.5 embryonic time window. In
order to achieve our first goal, Lim1-LacZ mouse embryos at three different embryonic stages (E13.5, E14.5, and
E15.5) were dissected, stained with X-gal, and imaged under a dissecting microscope. Measurements between
potential landmarks were made using Leica imaging software. To shed light on the underlying molecular
mechanism, the fusion regions in E13.5 and E14.5 mouse embryos were dissected, dissociated using enzyme
and physical methods, and cell counts were determined. In addition, trypan blue staining was used to determine
cell viability.
Results: Analysis of the MD at different embryonic stages demonstrates that MD fusion occurs in the E13.5-E14.5
time window. Measurements between potential landmarks and analysis suggest potential regions with different
growth rates along the length of the MD, suggesting a MD growth and fusion model. Female embryo regions of
interest at E13.5 and E14.5 will be isolated to generate transcriptomes by single-cell RNA sequencing.
Conclusion: We have confirmed that the MD fusion window is between E13.5-E14.5. We have determined the
lengths of the developing MD and the physical relationships between the two ducts before, during and after
fusion. We have defined the regions of interest of the fusing MD for single cell transcriptome analysis. These
studies should lead to a cell and molecular understanding of MD fusion for uterine morphogenesis.
Keywords: Müllerian duct fusion; Uterus
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Abstract number: 18
Mechanism of APR-246 and sensitization of cells to targeted agents
Allyson Drawdy; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Shady Tantawy; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Varsha Gandhi; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Background: Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy with heterogeneous prognosis. Deletion
of chromosome 17p and mutation of p53 are considered poor prognosis. 5% to 8% of CLL patients have a
del17p while mutations in p53 are found in 10-15% of previously untreated CLL which is increased to 40-50% in
relapsed/refractory disease. Despite effectiveness of targeted therapeutics such as venetoclax and ibrutinib in
p53-mutated CLL, these patients still experience shorter progression-free survival. APR-246 is a novel agent with
a proposed mechanism of reactivation of mutant p53 and consequential down-stream biological effect. However,
the mechanism of APR-246 remains unclear. Further, biological effect of APR-246 as a single agent or in
combination with targeted agents remains unknown. The primary objectives of this study are to evaluate APR-246
alone and in combination with venetoclax and ibrutinib in isogenic cell line with different p53 background and to
determine role of p53 in the mechanism of APR-246 induced cytotoxicity.
Methods: We used HG3, a CLL cell line. Four isogenic cell lines were produced with different p53 gene status
using homologous recombination. These were wild-type (WT), knock-out (KO), and with two hot-spot mutations:
R175H and R248Q. p53 protein expression, pro-apoptotic markers, and glutathione-related proteins were
visualized via immunoblotting. Cytotoxicity, cellular ROS, and mitochondrial membrane potentials were assessed
using annexin/propidium iodide, DCFDA, and TMRE dye, respectively and were measured by flow cytometry.
Results: APR-246 induced time and dose-dependent cytotoxicity in all four lines independent of the p53 status.
APR-246 exhibited a bimodal mechanism of cell death. At low doses it induced caspase-mediated apoptosis,
while at high doses cell death was induced via an unknown mechanism. APR-246 treatment increased cellular
ROS and decreased mitochondrial transmembrane potential and cellular glutathione. Glutathione replenishment
rescued APR-246-mediated cytotoxicity, suggesting a role of glutathione in cell death induced by APR-246.
Combination of APR-246 sensitized all four cell lines to venetoclax or ibrutinib.
Conclusion: In HG3 CLL cell line, loss of glutathione appears to be a primary mechanism of APR-246-mediated
cytotoxicity. Because this mechanism is independent of p53 status, the drug was effective in cells proficient,
deficient, or with mutated p53. Couplet of APR-246 with venetoclax or with ibrutinib were highly efficacious.
Collectively, these data suggest testing APR-246 in treating CLL disease with diverse p53 background. A clinical
trial has been designed for patients with CLL to test APR-246 with ibrutinib or venetoclax.
Keywords: CLL, p53, APR-246, ibrutinib
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Abstract number: 19
Fibroblast Growth Factor Receptor as a potential target for Eliminating Dormant Autophagic Ovarian
Cancer Cells
Shafqat Ehsan; Biological Sciences; St. Mary's University
Janice Santiago-O'Farrill; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Zhen Lu; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Robert Bast Jr.; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Background: High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological malignancy. The
persistence of dormant, drug-resistant cancer cells is a major factor contributing to poor outcomes for HGSOC
patients. Persistent cancer cells are found in poorly vascularized scars on the peritoneal cavity. In more than 80%
of cases residual cancer cells express DIRAS3 and are undergoing autophagy. DIRAS3 is an imprinted tumor
suppressor gene that is downregulated in 60% of primary ovarian cancers (OvC) whose expression is associated
with prolonged progression free survival, but not overall survival. Drugs that target autophagic cancer cells might
eliminate residual disease, particularly for those cancer cells that are dependent upon autophagy for their survival.
Previously the Bast Lab identified several potential targets for eliminating autophagic OvC cells, including
Fibroblast Growth Factor Receptor (FGFR). In this study, we used an FDA approved FGFR inhibitor, Infigratinib,
to evaluate its selective toxicity for autophagic OvC cells as a potential new therapy.
Methods: We used small-interfering RNA (siRNA) to knockdown FGFR. FGFR inhibitor, Infigratinib, was
evaluated for its selectivity against autophagic ovarian cancer cells. Autophagy was induced by expression of
DIRAS3 and was evaluated by Western blot analysis and fluorescence imaging. Also, western blot was used to
evaluate the expression of different isoforms of FGFR. The effect of Infigratinib on cell viability and cell
proliferation was measured with SRB and clonogenic assays, respectively.
Results: Knockdown of FGFR reduced cell viability of autophagic OvC cells to a greater extent than nonautophagic OvC cells. Re-expression of DIRAS3 induced autophagy and decreased the cell viability in DIRAS3inducible cells. We also observed that re-expression of DIRAS3 or treatment with Infigratinib significantly
decreased clonogenic growth of SK-OV-3-ARHI cells and the combination was even more effective.
Conclusion: An FGFR inhibitor significantly decreased cell viability in ovarian cancer cell undergoing autophagy
and it should be seriously considered for further evaluation of their effect on the elimination of dormant,
autophagic, drug resistant ovarian cancer cells that remain after primary surgery and conventional chemotherapy.
Keywords: Autophagy, FGFR, Ovarian Cancer, Infigratinib, DIRAS-3
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Abstract number: 20
Assessing the Hypoxic Response in Intestinal Organoids
Romina Falahaty; Experimental Radiation Oncology; MD Anderson Cancer Center
Neeraj Kumari; Experimental Radiation Oncology; MD Anderson Cancer Center
Cullen M. Taniguchi; Experimental Radiation Oncology; MD Anderson Cancer Center
Background: Surgery is the only curative therapy in pancreatic cancer, but almost 90% of patients cannot have an
operation. When surgery is not possible, radiation therapy is the only option left for treatment one chemotherapy
is done. Unfortunately, the close proximity of the gastrointestinal tract to the pancreas makes it difficult to give a
curative radiation dose without damaging normal tissues. We previously found that enhancing the expression of
hypoxia inducible factor-2 (HIF2) can protect the intestines from radiation injury in a mouse model. Here, we build
on these previous data by building a model system to understand how HIF2 might also protect human intestinal
tissues from radiation damage.
Methods: Methods: Patient-derived enteroids (PDEs) were obtained with from the Baylor Digestive Disease Core
as part of a collaboration. These PDEs were collected from discarded tissues after gastric bypass surgery. The
enteroids were grown in Matrigel plugs within 24 well plates and supported by conditioned media from L-WRN
cells, which produce Wnt3a, R-Spondin and Noggin. HIF expression in these human enteroids were evaluated
under normoxic (20% O2) and hypoxic (5% O2) conditions. To further enhance the hypoxic responses, the
hypoxia mimic, FG-4592 (50uM), or DMSO control was added the culture media and enteroids were harvested
after 24, 48, or 72 hours of treatment. Protein expression of HIF2 was evaluated by western blot.
Results: We observed no morphological changes in enteroids grown in either normal (20%) or low oxygen (5%)
levels, however there was greater HIF2 stabilization at baseline at 5% compared to normoxia. The addition of FG4592 led to enhanced HIF2 expression detectable starting at 48 hours of incubation, with maximal expression at
72 hours. The protein expression of HIF2 was normalized by the protein expression of Actin (loading control).
Conclusion: We demonstrate that the radioprotective drug FG-4592 raising HIF2 in human enteroids, which
suggested that this medication might also be radioprotective in human tissues. Further testing will need to be
done to verify the radioprotective effects of FG-4592 in these PDEs. If successful, this might open the done for
clinical trials combining radioprotective drugs with ablative radiation in unresectable pancreatic cancer.
Keywords: Hypoxia, Pancreatic Cancer, Organoids
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Abstract number: 21
Assessing the contribution of activated STAT1 and STAT3 on survival, resistance to platinum-based
chemotherapy and radiation in Head and Neck Squamous Cell Carcinoma cells
Alina Feng; Infectious Disease, Infection Control, and Employee Health, Internal Medicine; University of Texas
MD Anderson Cancer Center
Uddalak Bharadwaj; Infectious Disease, Infection Control, and Employee Health, Internal Medicine; University of
Texas MD Anderson Cancer Center
David Tweardy; Infectious Disease, Infection Control, and Employee Health, Internal Medicine; University of
Texas MD Anderson Cancer Center
Background: Signal Transducers and Activators of Transcription 3 (STAT3) has been validated as a target in
head and neck squamous cell carcinoma (HNSCC). Increased pY-STAT3 or nuclear STAT3 levels are reported in
37-75% of HNSCC tumor samples and correlated with more advanced disease stage, tumor size, and lower
survival rates, while activated STAT1 has also been correlated with radioresistance. TTI-101, the dual STAT3 and
STAT1 inhibitor, inhibited growth of xenografts of pY-STAT3-high, pY-STAT1-high chemoradioresistant cell line
UM-SCC-17B by successfully reducing both pY-STAT3 and pY-STAT1 levels and downregulating oncogenic
genes. The individual functions of STAT3 and STAT1 is not fully delineated.
Methods: To delineate the individual functions of STAT3 and STAT, we undertook the following studies.We
evaluated the IC50 of inhibition of pY-STAT3, pY-STAT1 and cell growth of 12 HNSCC cell lines by TTI-101. We
also tested the ability of TTI-101 to sensitize the chemoresistant HNSCC cell line HN31, to platinum-based
chemotherapy and radiation. We developed CRISPR-knockout (KO) of STAT3 and STAT1 in UM-SCC-17B and
mice HNSCC cell lines ROC1 and ROC2. Luminex measured levels in STAT KO’s; double STAT3/1 KO’s were
developed validated clones.
Results: Our data using 12 HNSCC cell lines with various pY-STAT3 and pY-STAT1 levels revealed that
activation of IFN/STAT1/IRDS pathway correlated with radioresistance (Pearson R: 0.9150, p = 0.0294). TTI-101,
our dual STAT3/1 inhibitor to inhibit cell-growth correlated with its ability to inhibit pY-STAT3 in these cells
(Pearson R: 0.8354, p = 0.0014). Co-treatment with 3 M of TTI-101 sensitized the chemoresistant line HN31 to
platinum-based chemotherapy drugs cisplatin (IC50 shift from 14 M to 0.01 M), carboplatin (IC50 shift from
163.4 M to 0.04 M) and oxaliplatin (IC50 shift from 15.7 M to 2.9 M) through successful reduction of pYSTAT3 (IC50:~7M) but not pY-STAT1, indicating a role of activated STAT3 in HNSCC cell chemoresistance.
Beta-tubulin normalized tSTAT3 protein levels (Luminex) showed successful KO clones (p<0.05) in mice HNSCC
cells ROC1 and ROC2 as well as human line UM-SCC-17B. We are currently in the process of testing the (1) rate
of growth, (2) relative sensitivities of KO and control cell lines to cisplatin, carboplatin, oxaliplatin, and (3) ionizing
radiation. In line with results from STAT3 inhibitors, we expect to see reduced proliferation and increased
chemosensitivity in STAT3 KO clones and decreased radioresistance in STAT1 KO clones.
Conclusion: Our preliminary data indicates a role of activated STAT3 in growth and chemoresistance of HNSCC
cells while STAT1 seems to lead to radioresistance.
Keywords: STAT3, STAT1, TTI-101, HNSCC
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Abstract number: 22
Characterizing human enteriods for response by FG-4592 and preparation for RNA sequence
Maya Ferrell; Radiation Oncology; University of Texas MD Anderson Cancer Center
Neeraj Kumari; Radiation Oncology; University of Texas MD Anderson Cancer Center
Cullen M. Taniguchi; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer cannot be cured without surgically removing the tumor from the pancreas.
Unfortunately, only 10-15% of patients can have an operation because pancreatic cancer is often diagnosed at a
stage where surgery is not safe or feasible. In those patients with unresectable disease, chemotherapy along
with radiotherapy is often the best approach to treating pancreatic cancer. However, the proximity of many
sensitive organs such as the small intestine make radiation treatments risky, and therefore only a limited dose of
radiation can be given. Our lab has previously found that stabilizing the expression of hypoxia-inducible factor 2
(HIF2) can improve survival in mouse models of radiation injury, however the mechanisms of the effect are still
unknown. Moreover, although murine and human intestines have similar cellular composition, it is unknown
whether human tissues will also be protected by the induction of HIF2.
Methods: To determine the role of HIF2 in the radiation response of human intestinal tissue, we generated
duodenal enteroids from tissue obtained from patient during gastric bypass surgery on an institutional protocol
through Baylor School of Medicine and MD Anderson. The intestinal stem cells were isolated and grown in
Matrigel plugs using the Clevers’ protocol. We tested whether duodenal enteroids would express HIF2 by treating
them with the hypoxia mimicking drug, FG-4592 (50uM), which inhibits the prolyl hydroxylation of HIF2. Enteroids
were incubated with FG-4592 for 24-, 48-, and 72- hours and cell lysates for protein expression analysis were
prepared for HIF2 immunoblotting (1:500, Cat#NB100-122). We also tested whether the effects of HIF2 were
dose dependent using a HIF2 antagonist, PT-2399. We optimized the combination treatment of PT-2399 (0.1, 1.0
and 10nM) along with FG-4592 (50uM) for gene analysis by quantitative PCR.
Results: Treatment with the hypoxia mimic, FG-4592, or the HIF2 inhibitor, PT-2399, induced no morphological
differences or toxicity in the enteroids. Immunoblot analysis shows that HIF2 expression is maximally stabilized
after 48 hours but is detectable after 24 hours. Quantitative reverse transcription polymerase chain reaction
(qRT–PCR) analysis was performed for hypoxia target genes.
Conclusion: Together, these data demonstrate that human intestinal tissue expresses HIF2 in conditions similar to
hypoxia. Mechanistic studies on HIF2 should be conducted after 48 hours of FG-4592 incubation since that
appears to be the ideal length of time for HIF2 induction.
Keywords: enteroids, hypoxia, radioprotection, pancreatic cancer, HIF, intestine
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

25

Abstract number: 23
Modified bispecific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 show higher ADCC
potential and in vivo anti-tumor response
Ashley Gelin; Immunology; University of Texas MD Anderson Cancer Center
Coline Couillault; Immunology; University of Texas MD Anderson Cancer Center
Anu Srinivasamani; Immunology; University of Texas MD Anderson Cancer Center
Qinying Liu; Immunology; University of Texas MD Anderson Cancer Center
Michael Curran; Immunology; University of Texas MD Anderson Cancer Center
Background: Antibody immune checkpoint (ICP) blockade has presented superior efficacy to improve the
outcome of a fraction of patients in some cancers. ICP blockade increases the proportion of tumor-infiltrating
lymphocytes and their functionality, including cytotoxicity, proliferation, and cytokine production. Programmed
Cell Death-1 (PD-1) blockade, for instance, inhibits the interaction between PD-1 and its receptors PD-L1 and PDL2. PD-L1 itself can be targeted to address both engagements to PD-1 and B7-1, although PD-L1 blockade alone
fails to address the engagement between PD-L2 and PD-1. Unlike monospecific antibodies, bispecific antibodies
(BsAbs) provide dual ligand specificity, allowing blockade of multi-inhibitory pathways. I thus compared the
efficacy and specificity of BsAbs with clinical anti-PD-L1 antibodies, as well as their in vivo efficacy.
Methods: I compared the efficacy of the anti-PD-L1/2 BsAbs with a modified Fc receptor (GASDIE) to induce
antibody-dependent cell-mediated cytotoxicity (ADCC) relative to its clinical anti-PD-L1 counterpart using an in
vitro assay. The different antibodies were incubated with PD-L1-expressing target cells and FcγRIIIa+ Jurkat Tcells inducing luciferase activity after receptor engagement. I then determined whether BsAbs bind to the same
region on PD-L1 and PD-L2 as commercially available antibodies, performing a flow cytometry competition assay
with AF594-labeled BsAbs against clinical anti-PD-L1 antibodies (Atezolizumab, Avelumab, Durvalumab) or a
commercial anti-PD-L2 incubated with PD-L1/2-expressing CHOs. Finally, I analyzed tumor growth and survival of
mice implanted with a colon cancer cell line and treated with BsAbs or an anti-PD-1.
Results: BsAbs (27869-, 27907-, 38002-, and 38004-GASDIE) induced overall higher luminescence intensity
compared to Durvalumab with slight variations. Additionally, 27869 and 27907 stainings were not inhibited by preincubating cells with Atezolizumab and Avelumab, but 37464, 38002, and 38004 stainings were. Anti-PD-L2 preincubation inhibited staining by 27869 and 38002, but not 27907, 37464, and 38004. In vivo, BsAbs showed
reduced tumor growth and increased survival after 40 days.
Conclusion: My findings show that BsAbs targeting PD-L1 and PD-L2 and bearing the Fc modification promote
superior ADCC activity against target cells that express either ligand by effector cells expressing Fc receptors. It
also suggests that our BsAbs mostly share the same epitope as clinical antibodies. Finally, BsAbs possess
higher in vivo efficacy than a reference anti-PD-1 therapeutic antibody.
Keywords: Immune checkpoint blockade, Bispecific antibodies, ADCC, programmed death-ligand 1
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Abstract number: 24
Molecular Adaptations of Mouse Lung Endothelial Cells Exposed to Different Durations of Laminar Shear
Stress and Disturbed Flow
Viraj Govani; Pediatrics Research; University of Texas MD Anderson Cancer Center
Riccardo Ballarò; Pediatrics Research; University of Texas MD Anderson Cancer Center
Keri Schadler; Pediatrics Research; University of Texas MD Anderson Cancer Center
Background: Endothelial cells (ECs) are constantly exposed to shear stress, the tangential frictional force acting
on the vessels due to blood flow. Shear stress may be divided into two main types, depending on the intensity
and flow patterns: laminar shear stress (LSS), characterized by unidirectional, regular flow patterns found in
straight regions of vessels, and disturbed flow (DF), which has a low and oscillatory flow pattern found in curved
and bifurcated sites of vessels as well as in tumor vasculature. Whereas LSS promotes healthy vasculature by
stabilizing the EC layer, DF impairs EC function by doing the opposite. This project aims to characterize the
molecular signature of mouse lung endothelial cells (mLECs) in response to LSS or DF at different durations,
mimicking in vitro the conditions that may be found in vessels under exercise training (high LSS) or in tumor
vasculature (DF). We evaluated the gene expression of S1PR1 and S1PR2 (two G-protein coupled receptors
involved in EC stabilization and function), LSS-induced proteins (KLF2 and KLF4), inflammation-related proteins
(ICAM-1 and VCAM-1), and mitochondrial indicators such as cytochrome c, SDHA, and PGC-1α.
Methods: Lungs from C57BL/6J mice were extracted and enzymatically digested to get a single-cell suspension
containing ECs. ECs were isolated using CD31 magnetic micro-beads and exposed to LSS (20 dyn/cm2) or DF (3
dyn/cm2) for 1, 4, 12, or 24 hours using the cone-and-plate viscometer system. In addition, to mimic the shearing
condition found in vessels during exercise, mLECs were exposed to steady low LSS (9 dyn/cm2) for 2 days with
intermitting 1 hour of high LSS (20 dyn/cm2 ) twice a day. The gene expression pattern of mLECs under LSS or
DF was analyzed by real-time PCR.
Results: We expect to see an increase in laminar shear-stress-induced proteins (KLF2 and KLF4), S1PR1, and
mitochondrial indicators and a decrease in inflammation-related proteins (ICAM-1 and VCAM-1) and S1PR2
under LSS conditions. The opposite is anticipated for DF.
Conclusion: These results will clarify the amount of shear stress needed to induce changes in the
aforementioned indicators in mLECs in vitro. In addition, the novelty of this work is to understand how LLS, or DF
may modulate S1PR1 and S1PR2 expression, as well as mitochondrial homeostasis for future translational
studies involving EC-related pathologies and exercise as a therapeutic approach to improving tumor vasculature.
Keywords: Laminar shear stress, disturbed flow, endothelial cells, exercise training, tumor vasculature
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Abstract number: 25
Low-Cost Microfluidic and Microscopic Instrumentation
Avi Gupta; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Background: Single-cell analysis using droplet-based techniques has lacked instruments that are cost-effective
and user-friendly. This has caused droplet microfluidics techniques to not be widely applied despite their benefits
in high throughput cell profiling and new tests that could not be performed before without single-cell isolation. In
order to fix these issues, a droplet microfluidic control instrument was designed to replace the need of large, bulky
machines costing tens of thousands of dollars.
Methods: The designs of this device first had to be studied in order to learn the build and user process along with
find all of the materials needed to construct the device. The program used by the device was also studied and
downloaded in order to test it for our own applications. After studying the designs and program, all the parts were
ordered. The parts are being put together to construct the device. One of these parts is a Raspberry Pi which is
the main computer that runs the program for this device. The designs for this device were modified in order to
remove all of the components needed for the microfluidics leaving just a microscope. This microscope design was
then constructed.
Results: The microfluidics device is being completed successfully with delays only occurring due to shipment of
materials purchased online. Additionally, the microscope design’s construction is being carried out successfully as
well. (Images taken from the microscope can be included on the actual poster)
Conclusion: Finally, once these devices are constructed, they can have a wide range of applications such as
RNA-sequencing single-cells that have been through transcription gene knockout with CRISPR. This is the main
project that our device will be used for alongside the microscope device which can be used for anything within the
lab. These two devices provide young students and high-level researchers with the option to construct their own
low-cost device that can reproduce the same results as large, expensive machinery in the fields of microscopy
and microfluidics studies.
Keywords: Microfluidics, Device Design, RNA-sequencing, Single-cell, Transcription Gene Knockout
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Abstract number: 26
Validation of valosin-containing protein (VCP) as a therapeutic target for triple negative breast cancer
Margaret Han; Rice University
Yanxia Ma; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
William Tahane; Clinical Cancer Prevention Department; University of Texas MD Anderson Cancer Center
Jing Qian; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Abhijit Mazumdar; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Powel Brown; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Background: Breast cancer has become the most prevalent cancer type globally as of 2021. Triple-negative
breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes and lacks effective treatment
strategies for advanced disease. It was previously demonstrated that the transcription factor SOX9 directly
regulates genes controlling apoptosis and knockout of SOX9 reduces TNBC tumor growth and lung metastasis.
However, as a transcription factor, SOX9 is difficult to target directly for therapeutics development. Therefore, it is
of great interest to evaluate more druggable SOX9 binding proteins as potential targets for inhibiting SOX9
function.
Valosin-containing protein (VCP) is a member of the AAA-ATPase superfamily. Elevated expression of VCP has
been correlated with increased metastatic potential and poor prognosis in some cancers but has not been studied
specifically in TNBC. VCP has been identified as a SOX9 binding protein through IP/Mass spectrometry. Thus, we
hypothesize that targeting VCP will disrupt the function of SOX9 and lead to reduced cancer cell growth and
survival in TNBC.
Methods: The Oncomine platform was used to analyze VCP expression in TNBC and Non-TNBC breast cancer
patients and its impact on survival. Data from six different datasets were analyzed and compared. Protein and
mRNA levels were examined by western blotting and qRT-PCR assays. MDA MB-231 cells were treated with
siRNAs to knockdown VCP. Cell growth was measured using an automated cell counting assay. RNA-Seq
analysis was used to identify SOX9 downstream targets in MDA MB-231 cells with support from MD Anderson’s
Genomic Biostatistics core.
Results: The Oncomine analysis showed that VCP expression is significantly higher in tumors from TNBC
patients than those from non-TNBC breast cancer patients. Additionally, a higher VCP expression correlates with
a lower overall 5-year survival rate. Western blotting analysis showed that VCP protein expression is relatively
higher in TNBC cell lines compared to non-TNBC cell lines. The interaction between VCP and SOX9 in TNBC
cells was confirmed using IP and Western blotting assay. In addition, VCP knockdown significantly decreased the
expression of SOX9 downstream effector genes (RGCC and PRTN3) and inhibited TNBC cell growth.
Conclusion: VCP, a SOX9 binding protein, was found to be highly expressed in TNBC cell lines and patient
tumors. High VCP expression correlated with poor patient survival in TNBC. Knockdown of VCP disrupted SOX9
function and resulted in reduced cell proliferation. These results indicate that VCP is a potentially viable target for
developing effective therapeutics for the treatment of patients with TNBC. Keywords: Valosin-containing protein
(VCP), SOX9, triple-negative breast cancer, cell growth
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Abstract number: 27
Differences in In Vivo and In Vitro cDC1 Maturation After Stimulation with Different TLR Agonists
Bailey Harmon; Immunology; University of Texas MD Anderson Cancer Center
Katherine Nowak; Immunology; University of Texas MD Anderson Cancer Center
Allison Dyevoich; Immunology; University of Texas MD Anderson Cancer Center
Stephanie Watowich; Immunology; University of Texas MD Anderson Cancer Center
Background: Dendritic cells (DCs) are efficient antigen‐presenting cells and mediate adaptive immune responses.
In vivo type 1 conventional dendritic cells (cDC1s) are found throughout the body, eliciting many immune
functions important for immunity against cancer and other foreign antigens. The Watowich lab pioneered an in
vitro cDC1culturing method that generates high cell yields to mimic in vivo cDC1s, providing insight into their
function. However, it is unknown whether these DC populations mature and behave similarly when stimulated with
different agonists in vitro.
Methods: We generated in vivo cDC1s in mice through Flt3 Ligand hydrodynamic gene transfer via tail vein
injection 8 days before harvesting splenocytes. In vitro cDC1s were generated using the Watowich lab’s
established culture system: culturing bone marrow with Flt3L and GM‐CSF cytokines for 15‐21 days. Cells were
fluorescence‐activated cell sorted (FACS) to obtain purified samples. Both cell types were stimulated with toll‐like
receptor (TLR) agonists: polyinosinic:polycytidylic acid (poly I:C), imiquimod, or both. At 16, 20, and 24 hours
post‐stimulation, we measured and quantified expression of five distinct, known DC maturation markers of each
cell type using flow cytometry.
Results: Both cell types showed the greatest upregulation of maturation markers 24 hours poststimulation with
TLR agonists. Major histocompatibility complex class I (MHC I) expression is most upregulated by poly I:C and
combination treatment in in vivo cDC1s but not upregulated in in vitro cDC1s. MHC class II expression showed
similar upregulation to MHC I for both cell types. CD80 expression for both cell types was upregulated effectively
by poly I:C and combination treatment, however, upregulation of CD80 is significantly greater for in vivo cDC1s.
Interestingly, basal CD86 expression was found to be greater for in vitro cDC1s compared to in vivo cDC1s. Both
cell types upregulate CD86 expression upon stimulation with all the tested agonists. CD40 expression was not
upregulated for in vitro cDC1s stimulated by TLR agonists, while both TLR agonists upregulated CD40 expression
for in vivo cDC1s.
Conclusion: These data indicate differences in the maturation of in vitro and in vivo cDC1s over a 24‐ hour period
in stimulated and unstimulated conditions. In vivo cDC1s were more susceptible to maturation when stimulated
with poly I:C and imiquimod, but typically have a lower basal level of maturation compared to in vitro cDC1s.
These data provide valuable insights in how long‐term immune responses may alter between DC subtypes, with
future work involving measuring subsequent T cell responses.
Keywords: Dendritic cell, In vitro cDC1, In vivo cDC1, Dendritic cell maturation, TLR agonists
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Abstract number: 28
Assessing the response of mixtures of EGFR amplified and non-amplified glioma stem cell lines in
response to MEK inhibitor treatment
Erin Harrison; Neurosurgery; University of Texas MD Anderson Cancer Center
Sabbir Khan; Neurosurgery; University of Texas MD Anderson Cancer Center
Veerakumar Balasubramaniyan; Neurosurgery; University of Texas MD Anderson Cancer Center
John de Groot; Neurosurgery; University of Texas MD Anderson Cancer Center
Background: Glioblastoma (GBM) treatment resistance arises in part from the heterogeneity of glioma stem-like
cells (GSCs) and the surrounding tumor microenvironment. EGFR amplification (EGFRAmp) is the most common
genetic alteration present in GBM, found in more than 40% of all IDHwt GBM tumors. EGFRAmp can promote
tumor cell proliferation and survival through aberrant ERK pathway activation. The impact of MEK inhibitor
treatment on signaling between EGFRAmp and non-amplified cells and its impact on GSC phenotype and drug
sensitivity remains unexplored.
Methods: Using an in-vitro model, we assessed the MEK inhibitor (MEKi) sensitivity in EGFR amplified (MEKi
sensitive) or non-amplified (MEKi resistant) patient-derived GSCs. To differentiate cell lines, cells were
engineered to express either GFP or RFP. We treated various proportions of mixtures of sensitive and resistant
GSC lines with one of several MEK inhibitors, inactivating ERK signaling. We then assessed the cell viability,
phenotype, and expression of ERK pathway components of both cell lines in the mixtures via Cell Titer-Glo, flow
cytometry, and qPCR analysis. We also assessed if overexpression of ETV-5, a product of the ERK pathway,
could alter GSC proliferation and MEKi sensitivity.
Results: From the initial Cell Titer-Glo and flow cytometry screenings, we have identified ten MEKi-sensitive and
ten resistant GSC lines. In the mixing experiments, there is a sharp increase in the IC50 value of the mixtures with
proportions composed of more than 50% resistant cells. However, GSC lines with ETV-5 overexpression were not
significantly more resistant to MEKis than ETV-5 wild-type GSCs.
Conclusion: Out of the GSC lines surveyed, most GSC lines with high sensitivity to MEKis also display EGFR
amplification. However, ETV-5 overexpression in a previously sensitive cell line does not increase MEKi
resistance, indicating MEKi sensitivity may be associated with increased expression of other signaling
components of the ERK pathway. Future work will investigate how treating sensitive and resistant GSC lines with
MEKis together impacts gene expression in both cell lines and could possibly elucidate mechanisms through
which MEKi resistance is conferred between heterogeneous GSCs.
Keywords: Glioblastoma, MEK inhibitors, EGFR, GSC
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Abstract number: 29
SPOP Mutations Promote Prostate Cancer Progression and Metastasis
Jingwen Hu; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Chenling Meng; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Di Zhao; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Prostate cancer is the most common cancer in American men and is second worldwide. Cancer
whole-genome and exome sequencing studies have shown that Speckle-type POZ (pox virus and zinc finger
protein) protein (SPOP) is the most frequently mutated gene in primary prostate cancer (PCa). It is also believed
that SPOP is characterized to play a role in tumorigenesis. SPOP mutations in prostate cancer occur at a high
frequency in a few specific residues (or so‐called “hotspots”) in the MATH domain, such as F133V, W131G, and
F102C. Moreover, SPOP mutations have been identified as an early event in the development of genomic
instability and tumorigenesis in PCa.
Methods: Immunohistochemistry (IHC) – We performed IHC on FLAG F10 (CST 14793S, 1:200), P-AKT (CST
4060S, 1:100), H3K36 (CST 4909S, 1:1600), H3K4 (CST 9751S, 1:5000) to examine protein expression levels
and localization on mouse prostate tumors. Mice – We crossed Pten KO mice (P) with SPOP mutant F133V mice
to generate Pten SPOP mutant mice (PSP) and then crossed with Pb-Cre mice to generate PSP prostate cancerspecific KO SPOP mutations prostate cancer GEMM with GFP reporter. Transwell – We performed transwell
assay using 8um pore size on DU145 WT, F133V, W131G, and F102C mutant cells to determine cell migration
ability.
Results: 1. We performed DX1 (mouse prostate cell lines) subQ mouse model with SPOP WT and SPOP F133V
mutation and found that SPOP mutation increase tumor volume and weight. 2. We performed transwell assay on
DU145 WT, F133V, W131G, and F102C mutant cells and found SPOP mutations promote DU145 prostate
cancer cell migration in vitro. 3. We successfully generated PSP mouse model and the IHC data showed that
H3K36me3 and H3K4me3 were robustly upregulated in PSP mice compared to Pten KO mice.
Conclusion: SPOP mutation frequently occurs in prostate cancer, here we use DX1 subQ mouse model showing
that mutant SPOP drives prostate tumorigenesis in vivo, and the in vitro data shows SPOP mutations promote
tumor metastasis. Thereafter, we generate SPOP mutation genetic engineering mouse model (PSP) and found
that the transcription factors related activate H3K36me3 and H3K4me3 were drastically upregulated in PSP mice,
so our next goal is to perform RNA-seq to identify the downstream transcriptional factor of SPOP which regulates
histone modification.
Keywords: SPOP, Tumor, Prostate Cancer, mutation, metastasis
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Abstract number: 30
Gene expression and biological pathways associated with differential responsiveness to anti-PD1
immunotherapy in preclinical HPV+ tumors
Kai Hung; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Venkatesh Hegde; Thoracic-Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Jagannadha Sastry; Thoracic-Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Human papillomavirus induced (HPV+) oropharyngeal cancer is quickly rising in the United States,
accounting for as much as 70% of oropharyngeal cancers. Understanding the genetic determinants in the tumor
microenvironment (TME) is important for rational designing of therapeutic strategies. The mouse tonsil derived
epithelial tumor cell line expressing HPV-16 E6 and E7 genes is well-established as a surrogate preclinical oral
HPV cancer model. In a recent study using this model, it was observed that mEER tumors implanted in the
orthotopic site (tongue) were responsive to anti-PD1 immunotherapy, while those implanted in the flank (nonorthotopic) were resistant to treatment.
Methods: We used tongue or flank implanted mEER tumor samples to investigate the gene expression signatures
and specific signaling pathways associated with responsiveness or resistance to immunotherapy. Total RNA
extracted from tumor samples which also include immune cell infiltrates was subjected to RNA-Seq analysis. I
used the normalized RNA-seq data and identified differentially expressed genes (DEG) through the R software.
The DEG were further analyzed using Ingenuity Pathway Analysis (IPA) to obtain insights on potential pathways
associated with treatment responsiveness.
Results: We identified 485 differentially expressed genes altered by >2 fold in tongue-implanted mEER tumors
relative to flank tumors. Statistically significant association of several immunological pathways such as interferon
signaling as well as crosstalk between dendritic cells and natural killer cells, were identified in IPA alongside
significant upregulation in the expression of immune function related genes encoding IFNγ, Cxcl9, Chil1, and
Gzmb in mEER oral tumors. The downstream function analysis predicted an increase in natural killer cell
movement or trafficking, cytotoxic T-cell activity, and activation of antigen-presenting cells consistent with these
upregulated genes. Upon further examination of natural killer activator and inhibitory molecules, we identified
overexpression in CD96 and PDCD1 (PD-1) in mEER tongue tumors, as potential targets for immunotherapy
using anti-CD96 and anti-PD-1 checkpoint antibodies. Importantly, these gene expression analyses data are
validated in experiments where tongue-implanted tumors showed better response to anti-CD96 (unpublished) and
anti-PD-1 immunotherapies.
Conclusion: Our genomics analyses reveal that flank-implanted mEER tumors appear to be immunologically
‘cold’, whereas tongue-implanted mEER exhibit molecular signatures indicative of an immunologically ‘hot’ tumors
with the expression of checkpoint molecules identified for targeting and successful treatment by immunotherapy.
Keywords: HPV, Immunotherapy, Oropharyngeal Cancer, RNA-Seq Analysis
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

33

Abstract number: 31
A Combined Habitat Analysis and Autoencoder Neural Network Approach for Feature Extraction to
Predict COVID-19 Infection in CT Images
Thinh T. Huynh; Imaging Physics, Division of Diagnostic Imaging; University of Texas MD Anderson Cancer
Center
Sheeba J. Sujit; Imaging Physics, Division of Diagnostic Imaging; University of Texas MD Anderson Cancer
Center
Maliazurina Saad; Imaging Physics, Division of Diagnostic Imaging; University of Texas MD Anderson Cancer
Center
Kristy K. Brock; Imaging Physics, Division of Diagnostic Imaging; University of Texas MD Anderson Cancer
Center
Carol C. Wu; Thoracic Imaging, Division of Diagnostic Imaging; University of Texas MD Anderson Cancer Center
Jia Wu; Imaging Physics, Division of Diagnostic Imaging; University of Texas MD Anderson Cancer Center
Background: For only over two years since its emergence, COVID-19 pandemic has caused an immerse burden
on the global healthcare system and claimed over 4 million lives. Early detection and diagnosis are the keys to
improve treatment outcome, control disease spreading, and alleviate logistical burden for healthcare facilities.
Previous studies on incorporation of artificial intelligence-based methodologies have shown promising results for
COVID-19 screening on medical images. However, one drawback of these studies is to not incorporate radiomics
even though it has shown to possess powerful diagnostic and prognostic power in disease screening. In this
study, we propose a combined approach integrating deep learning and radiomics for COVID-19 detection in CT
scans obtained from different patient cohorts.
Methods: We analyzed 240 CT scans of cancer patients diagnosed with COVID-19 at MD Anderson and 227 CT
scans retrieving from the RSNA International COVID-19 Open Radiology Database (RICORD). Within the
RICORD scans, 110 are of COVID-19 positive patients, and 117 are of non-infected patients. We performed
habitat analysis, which is a consensus clustering approach, to spatially partition the infection sites into subregions,
or habitats, and extracted quantitative features from those habitats. Concurrently, an autoencoder neural network,
originally built for 3D image reconstruction, was used for feature extraction. A series of machine learning
classifiers including logistic regression, support vector machine, and random forest were employed for infection
prediction based on extracted features.
Results: My project is still on-going without any significant result yet.
Conclusion: No conclusion has been made yet.
Keywords: COVID-19 Prediction, Deep Learning, Radiomics, Habitat Analysis
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Abstract number: 32
Radiolabeling of Radiopharmaceuticals for PET Imaging of Tumors
Elaijah Islam; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Riccardo Muzzioli; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Federica Pisaneschi; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Background: Positron Emission Tomography (PET) is a non-invasive diagnostic nuclear imaging modality.
[18F]FDG, the most commonly used PET tracer, is heavily used in the clinic for tumor diagnosis and staging.
Other PET agents are under investigation for monitoring tumor response to treatment. PET relies on agents
labeled with a positron-emitting radionuclide. Therefore, radiolabeling new small molecules and antibodies is an
active research field, aimed to find new PET agents for a variety of innovative applications. Small molecules
differ from antibodies in how they are radiolabeled. Because of their in vivo properties, small molecules are
usually labeled via formation of covalent bonds, with short-lived isotopes such as 18F and 11C. This reaction
requires a pre-synthesized precursor molecule. On the other end, a monoclonal antibody (mAb) is usually labeled
with long-lived radiometals, such as 64Cu or 89Zr; therefore labeling a mAb requires conjugation with a chelator
that enables complex formation between the ligand and radiometal. Antibodies are advantageous in tumor
imaging due to their high specificity of targeting receptors on cancer cells. In this study, we focused on the
synthesis of the chemical precursor of the PET tracer 4-fluoronaphtol (4FN), the bio-conjugation of NOTA chelator
to an mAb, and a comparative radiolabeling study of 68Ga ligand: NOTA and a new 68Ga ligand (ENBPI).
Methods: The 4FN precursor was synthesized for the commercially available 4-(4,4,5,5-tetramethyl-1,3,2,dioxaboran-2-yl)naphthalen-1-ol by reaction with a t-butyl protecting agent (BOC) to protect the hydroxyl group
and purified on silica gel, using an automated Biotage Isolera chromatography system. Mouse IgG2a antibody
was conjugated with NOTA-NCS chelator to bind 68Ga. IgG2a mAb was placed into a dialysis cassette for three
buffer exchanges with NaHCO₃ (pH 8) to reach the optimal pH for the conjugation reaction. The mAb was then
recovered from the dialysis cassette and incubated with NOTA-NCS (in a 5:1 NOTA-NCS:mAb ratio) for 1 hour at
37°C. The conjugated antibody was recovered and placed into a second dialysis cassette for three buffer
exchanges with NH4OAc (pH 7); buffer in which the NOTA-mAb can be stored at 4 °C. IgG2a-NOTA, free NOTA
and ENBPI were radiolabeled with 68Ga. After buffering the 68Ga solution with AcONa (pH 6.5), each compound
was added and the mixture allowed to react at 37°C or 80°C. The reaction was monitored via radioTLC after 20
minutes.
Results: 4FN precursor was synthesized with a yield of 59% (n=3) and was fully characterized using 1H, 13C, 2D
NMR and mass spectrometry. IgG2a-NOTA was successfully radiolabeled with 68Ga and characterized using
radioTLC. RadioTLC and radioHPLC was used to analyze 68Ga-ENBPI complex, which was synthesized with a
radiochemical yield of 27.4% and activity yield of 9.6%.
Conclusion: Overall, the 4FN precursor was successfully synthesized and purified. Additionally, the IgG2a was
conjugated with NOTA and radiolabeled with 68Ga. Although we are aware that the half-life of 68Ga (67.71
minutes) is not ideal for the radiolabeling of mAbs, unforeseen circumstances caused us to use this radioisotope.
Similar reaction conditions can be applied when more suitable radiometals are used. ENBPI ligand was also
successfully radiolabeled with 68Ga. Comparison of labeling conditions of ENBPI and NOTA are underway.
Keywords: Radiochemistry, Gallium-68, NOTA
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Abstract number: 33
Single-cell transcriptomics of intrahepatic cholangiocarcinoma (iCC) reveals novel tumor epithelialstromal interactions
Richa John; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Maria E. Monberg; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Jaewon J. Lee; Biostatistics; University of Texas MD Anderson Cancer Center
Mohamed M. Zaid; Radiation Oncology; University of Texas MD Anderson Cancer Center
Naruhiko Ikoma; Surgical Oncology; University of Texas MD Anderson Cancer Center
John Lowengrub; Mathematics; The University of California, Irvine
Anirban Maitra; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Eugene J. Koay; Radiation Oncology; University of Texas MD Anderson Cancer Center
Paola A. Guerrero; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Cholangiocarcinoma (CCA) is the second leading form of liver cancer, and the incidence of this
cancer is rising globally. CCAs can originate from any point along the biliary tree and are classified as one of the
following, based on location of primary: intrahepatic (iCCA), perihilar (pCCA) or distal CCA (dCCA). Due to its
aggressive nature and difficulty in early diagnosis, CCA has a high mortality rate. Thus, there is an urgent need to
analyze and characterize the molecular underpinnings of these lesions. Single-cell RNA sequencing (scRNAseq)
technology has provided unprecedented insights into tumor heterogeneity and in elucidating aberrant pathways
that can form the basis for biomarker discovery or therapeutic actionability.
Methods: In this study, scRNAseq was utilized to analyze the transcriptomic landscape of six iCCA cases at three
pathologically defined locations: central area of the tumor (Tcent), tumor periphery (Tperi) and tumor-adjacent
normal (TAN). The data collected from all six patients were then analyzed using CellChat to investigate ligandreceptor interactions in TAN, Tperi, and Tcent compartments of the resected liver samples. CellChat is a
bioinformatic package that is able to quantify, map, and visualize ligand-receptor interactions, including multimeric
receptors, while considering the presence of cofactors, across samples contained in multimodal datasets. Our
analysis was able to detect 17,996 cells from the six patients which were further clustered into epithelial,
fibroblast, endothelial, T-cell, B-cell, and myeloid cells based on well-defined transcripts (such as EpCAM for
epithelial cells and CD3D for T-cells).
Results: We discovered increased representation of B-cells in the Tcent and Tperi compartments compared to
TAN, suggesting the presence of robust humoral responses within the juxta-tumoral milieu. We then applied
CellChat to identify tumor-stromal cell interactions that might enhance tumor growth, elucidating several cognate
ligand-receptor pairs, such as AREG-EGFR, which was differentially expressed in the Tperi compartment, and
APP-CD74, which were found in both Tperi and Tcent compartments. We are currently validating these
interactions by multiplex immunohistochemistry (Opal Polaris) in FFPE sections from the same patients.
Conclusion: The disruption of the tumor-stromal interactions discovered via CellChat might serve as novel and
potent therapeutic opportunities in this lethal disease.
Keywords: Cholangiocarcinoma, single-cell RNA sequencing, transcriptomics
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

36

Abstract number: 34
Imaging Mass Cytometry Analysis via Unsupervised Clustering
Aparajith Kannapiran; Imaging Physics; University of Texas at Austin
Pingjun Chen; Imaging Physics; University of Texas MD Anderson Cancer Center
Jianjun Zhang; Thoracic-Head & Neck Med Oncology; University of Texas MD Anderson Cancer Center
Jia Wu; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: The understanding of the tumor environment at a cellular level facilitates better comprehension of
cancer mechanisms and the development of new therapeutic strategies. The advent of imaging-mass cytometry
(IMC) empowers researchers to simultaneously analyze dozens of single cell parameters in situ, potentially
yielding profound insights into cancer biology. Manual analysis is limited in clinical application and significance
due to IMC data’s high dimensional and heterogenous characteristics. Computational tools like machine learning
and deep learning demonstrate great potential to extract knowledge from complex data. This exploratory work
adopts clustering techniques to explore cell phenotypes in IMC data, aiming to better understand tumor
microenvironments.
Methods: We first collect IMC data, including 35 lung nodule tissues with 297 regions of interest stained using 35
unique markers. Then, the whole-cell and nuclei are segmented using a convolutional neural network (CNN)
model developed at Stanford. Next, we explore the clusters of these segmented cells via their marker staining
signals. We then investigate through clustering algorithms, including Phenograph, and t-SNA repeatedly with
varying cell numbers. The results provide us with a robust image of the cell clusters, and what features each
group exemplifies the most. Finally, we focus on the spatial analysis of cells belonging to different clusters, to
inspect cell neighborhood interactions and tumor immune borders.
Results: Currently, the clustering stage has been completed with various key features already present. First, when
clustering with 10,000 cells, there appears to be 16 groups, but as this number increases to 20,000 or above, we
see the clusters plateau at 19. These 19 individual clusters share some unique features that can classify their cell
type and behavior more accurately. The categorization of the features in the clusters allowed us to create a heat
map, and mark mean trait intensities in each cluster. With the heat map, we can determine shared and unique
features. Furthermore, the results produced by the t-SNE algorithm provide a graphic heat map showing the
spread of features across clusters. Not only does this provide a secondary heat map visual, but we can then
analyze social networks of distinctive clusters.
Conclusion: To conclude, by utilizing unsupervised clustering on IMC data, we have been able to cluster cells into
unique categories, providing a considerable amount of insight into what may be present in the tissue
microenvironment. This project is ongoing as we plan to continue deeper levels of analysis to elucidate patterns of
cellular interactions.
Keywords: Spatial Analysis, Clustering, Imagining Mass Cytometry, High Dimensional Analysis
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Abstract number: 35
Analyzing Cryo-fluorescence Tomography Images to Determine Optimum Time for F-19 MRI Acquisition
in NK-cells Immunotherapy of Osteosarcoma
Prabhat Kattel; Biology Department; The University of Texas at Tyler
Gary V. Martinez; Imaging Physics; University of Texas at MD Anderson Cancer Center
James A. Bankson; Imaging Physics; University of Texas at MD Anderson Cancer Center
Background: As a part of innate immune system, NK-cells are first-line responders and they do not require
antigen, making them promising candidates for immunotherapy. Cancer cells downregulate MHC-I to evade Tcells, which NK-cells can detect and destroy such cancer cells by direct cytotoxicity. However, NK-cell
immunotherapy has not shown desirable outcome in solid tumors and detecting whether the NK-cells have been
delivered to specific tumor sites is challenging. High-resolution non-invasive techniques like F-19 MRI can be
potentially used to detect the localization of NK-cells in the targeted tumor. Similarly, hyperpolarized C-13 MRI
may be able to detect metabolic response to immunotherapy in a localized manner. In this study, we aimed to
detect the localization of NK-cells in lung tumor of mice and speculate the optimum time to perform 19-F MRI after
NK-cell immunotherapy.
Methods: F-19 probed NK-cells were administered contralaterally and seven mice were sacrificed using standard
protocol at 1, 4,8, 24, 48, 72, and 96 hours after the injection. CFT was done using Xerra and 3D images were
constructed using vivo-quant. The fluorescence level was visualized in liver and lung tumor of the mice and the
intensity of NK-cells was calculated within a desired ROI.
Results: Localization of F-19 NK cell was indicated by DiR in the liver and lung tumor of all mice. Besides liver
and lungs, localization of some NK-cells was observed in spinal cord and tail region in some mice. The ratio of the
intensity of NK-cells in lung tumor vs liver was high for 4 hours and 8 hours after NK-cell immunotherapy.
Conclusion: The significant number of NK-cells found in the lung tumor suggests that NK-cell immunotherapy is
promising in the treatment of osteosarcoma. The ratio of NK-cells in lung tumor/liver was higher during initial 8
hours, so 4-hour can be a good timing for doing 19-F MRI. The high intensity of fluorescence, further, suggests
that 19-F MRI can be used to detect the localization of NK-cells in targeted organ(s) if 19-F imaging is sensitive
enough. In order to verify the localization of NK-cells in-vivo, more data are needed because tumor burden and
pathogenesis usually varies among different mice and the sensitivity of the 19-F MRI experiment needs to be
optimized through hardware and better 19-F tags.
Keywords: NK-cell immunotherapy, F-19 MRI
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

38

Abstract number: 36
Immune checkpoint molecule CD276 regulates prostate cancer through the p53-SP1 axis
Justin Kim; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Wei Shi; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Di Zhao; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: TP53 is the most commonly mutated gene in cancers. More than 50% of cancers involve TP53
deletion or mutations. CD276, also known as B7-H3, is an immune checkpoint molecule. Recent findings have
shown that CD276 inhibits T cells to promote tumor proliferation and invasion. Previous studies using CD276 as a
target for immunotherapy have found promising anti-tumor effects with anti-CD276 antibodies. Therefore, we
aimed to characterize the underlying mechanisms regulating CD276 in prostate cancer.
Methods: CD276 expression was analyzed in 6 prostate cancer cell lines by Western blot, quantitative RT-PCR,
and flow cytometry. CRISPR/Cas9 and shRNA were used to target p53, SP1, and CD276. Chromatin
immunoprecipitation assays were used to explore the mechanisms of protein binding. Subsequently, dualluciferase assays will be used to identify the functionality of a potent transcriptional factor to regulate CD276
expression.
Results: Through the TCGA database, we found that CD276 was the most overexpressed immune checkpoint
molecule in prostate cancer patients with p53 alterations. Flow cytometry data validated CD276 expression in
multiple human and murine prostate cancer tumor cell lines. Furthermore, we established p53 knockout within the
LNCaP cell line and found p53 loss enhanced CD276 expression in prostate cancer cells. To study CD276’s
function, we depleted CD276 in p53-deficient prostate cancer cells and validated the knockdown efficiency using
western blot analysis and flow cytometry. Specificity Protein 1 (SP1), a negative regulator of p53, was found to
upregulate CD276 both at the mRNA and protein levels. Furthermore, we observed SP1 binding on the promoter
region of CD276.
Conclusion: The immune checkpoint molecule CD276 was identified as a promising therapeutic candidate in
prostate cancer. Our study demonstrated that the p53-SP1 axis is involved in the transcriptional regulation of
CD276 in prostate cancer, suggesting the potential of immunotherapy targeting CD276 in p53-deficient cancers.
Keywords: Prostate Cancer, CD276, SP1, p53
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Abstract number: 37
NUDT5 is a critical growth regulator of triple-negative breast cancer
Negar Koupaei; University of Texas at Austin
Qian, Jin; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Brown, Powel; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Tahaney, William; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Mazumdar, Abhijit; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Moyer, Cassandra; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Background: Triple-negative breast cancers (TNBC), about 15% of all breast cancer, have poor clinical outcome.
Previous Brown lab’s publications have identified several phosphatases that are overexpressed in TNBC
compared to the ER-positive breast cancers. NUDT5, one of these phosphatases, is part of NUDIX family. This
family eliminates toxic nucleotide metabolites along with regulating the concentrations of nucleotide substrates,
cofactors, and signaling molecules. NUDT5 has a key role in ADP-ribose and 8-oxo-guanine metabolism.
Therefore, it could be hypothesized that NUDT5 is an important phosphatase in regulating the growth of cancer
cells.
Methods: We did a comparison across NUDIX family’s mRNA expression level using the publicly available
datasets Curtis, Esseman and Kao. Further, using the same datasets, a survival analysis of this family has been
performed which we used log-rank p values to determine the difference of NUDIX family as prognosis factor for
the overall survival of breast cancer patients. Western blot is performed to compare the NUDT5 protein level
across ER-positive vs. TNBC. Furthermore, Inducible NUDT5-Knockout TNBC cell lines, iCas9-sgNUDT5
MDA231, have been generated to test the growth suppression effect of NUDT5 on TNBC. These cells have been
induced with Dox to knockout NUDT5. Then their growth has been measured by counting cell numbers over
seven days. Lastly, the knockout efficiency is demonstrated by western blot and qRT-PCR.
Results: Based on the mRNA expression level analysis, NUDT5 has the highest mRNA expression level among
other NUDIX family members in breast cancer in Curtis dataset. In all three datasets, Curtis, Esseman and Kao,
high NUDT5 expression level is correlated with poor overall survival in breast cancer. Among breast cancer cell
lines, T47D, MDA-231, HCC1143 and HCC1937 has the highest NUDT5 protein level. Next, the quantification of
NUDT5 protein in breast cancer cells shows that the there is a trend of higher expression level of NUDT5 in
TNBC compared to the ER-positive breast cancer. The iCas9-sgNUDT5 MDA231 proliferation analysis has
shown that the NUDT5 knockout reduces cell growth.
Conclusion: The obtained results demonstrate that NUDT5 has a critical role in regulating TNBC growth. Future
experiments will further study the function of NUDT5 in regulating the growth in breast cancers. These
phosphatases could provide necessary information for development of a potential treatment for TNBC.
Keywords: TNBC, NUDT5, Cancer, targeted therapy, regulator
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Abstract number: 38
Probabilistic Segmentation of Differently-sized Brain Metastases Using an Ensemble of Neural Networks
Maggie Lee; Radiation Oncology; University of Texas MD Anderson Cancer Center
Andrew Elliott; Radiation Oncology; University of Texas MD Anderson Cancer Center
Carlo Torres; Radiation Oncology; University of Texas MD Anderson Cancer Center
Sarah Thrower; Radiation Oncology; University of Texas MD Anderson Cancer Center
Maguy Farhat; Radiation Oncology; University of Texas MD Anderson Cancer Center
Holly Langshaw; Radiation Oncology; University of Texas MD Anderson Cancer Center
Lily Erickson; Radiation Oncology; University of Texas MD Anderson Cancer Center
Brandon Curl; Radiation Oncology; University of Texas MD Anderson Cancer Center
Divya Yadav; Radiation Oncology; University of Texas MD Anderson Cancer Center
Caroline Chung; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: In order to volumetrically track brain tumors or treat them with radiation therapy, physicians currently
manually contour tumors (i.e. define the tumor margin). This process is tedious and prone to inter- and intraobserver variability that could impact treatment efficacy and the ability to reliably measure changes in tumor
volume. Researchers have been looking into machine-learning (ML) auto-segmentation, but differing ML methods
may best serve certain tumor sizes or tumor types. We aim to develop an ensemble that includes three different
neural networks, each suited to tumors in a particular size range, to optimize segmentation for all sizes of brain
metastases.
Methods: 3D post-contrast T1-weighted MRI that were manually annotated with tumors and size-specific tumor
data were used to train these 3 neural networks to create tumor probability maps. (1) For small tumors (<0.5 cm
diameter), an LSM (liquid state machine) ensemble and random forest classification is used. The signal
separating properties of LSMs are used to overcome the problem that small tumors can appear identical to
enhancing blood vessels in 2D. (2) For medium tumors (0.5-1.5 cm), a 3D CNN (convolutional neural network)
has been shown to effectively detect tumors in this size range. (3) For large (1.5-3 cm) and very large (>3 cm)
tumors, a U-net deep learning network is used because the tumors occupy a large portion of the MRI image. The
maps from each neural network are then combined to form the final probability map for each patient scan.
Results: The LSM ensemble detected small tumors in the testing dataset with 90-100% probability and no false
positives (i.e. non-tumor regions with a nonzero probability). The ensemble outperformed both a single LSM and
CNN, which both contained false positives with probabilities of 80-100%. Over 900 data points have been verified
for use to train the 3D CNN to detect medium tumors. This CNN is Bayesian and will output both the probability
and uncertainty of the model. The U-net network is being developed to detect large and very large tumors.
Conclusion: The LSM has proven useful in detecting tumors of < 0.5cm without detecting veins as false positives.
CNN and U-nets are being developed to accurately detect medium and (very) large tumors, respectively. A
combination of the 3 neural networks could be used to automatically segment tumors in a clinical setting to enable
consistent segmentation for quantitative outcomes assessment.
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Abstract number: 39
Convolutional neural network-based autoencoder on lung cancer patient CTs informs potential prognosis
capability
Richard Lee; Imaging Physics; University of Texas MD Anderson Cancer Center
Morteza Salehjahromi; Imaging Physics; University of Texas MD Anderson Cancer Center
Jia Wu; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Currently, lung cancer is the second most prevalent type worldwide. While diagnostic imaging tools
for the disease like computed tomography (CT) scans deliver invaluable data to clinicians, the majority of
information about the patient’s condition lies within the individual pixels, invisible to the eye. Deep learning is able
to analyze these images, making interpretations and classifications based upon their embedded features.
Autoencoders, a type of deep learning, learn to compress an image input into a lower dimension (encoder). This
compression of data generates a latent space that encapsulates the most important features of a certain input for
its reconstruction (decoder). An autoencoder can be applied to CTs in order to identify specific features of tumors.
Methods: Here, we train a convolutional neural network-based autoencoder to reconstruct slices of lung cancer
patient CTs from a Stanford University radiogenomic dataset. Each CT was converted into individual slices
represented by an array. Various representations of the slices were inputted into the 2-dimensional autoencoder,
including the CT itself, the CT mapped with the lung segmentation, and wavelet representation of the CT mapped
with the lung segmentation. Using batch training sizes of 16, we varied the learning rate and bottleneck
dimensions to reduce reconstruction error while also minimizing latent dimensionality. All training was done with a
learning rate scheduler to optimize stochastic gradient descent.
Results: We were able to optimize our autoencoder hyperparameters to best accommodate each type of input.
When inputting the entire CT into our autoencoder, we discovered that a bottleneck layer of 4096 dimensions
produced loss rate of under 0.01 in our validation set. Although this was a 64-fold compression in features, the
output images still displayed similarities with the input after 120 epochs of training. A bottle neck of 4096
dimensions for the CT mapped with lung segmentation demonstrated similarly positive results; the loss in our
validation set was under 0.01 while the image reconstructions resembled closely to the input. Further testing must
still be done with our wavelet representations to better optimize our autoencoder.
Conclusion: Overall, deep learning has the potential to detect subtle nuances within the etiology of a patient’s
disease. Once our autoencoder is fully trained, we can continue with feature extraction, eventually aggregating
those features in order to potentially inform us of the true nature of a patient’s disease. Moving forward, we will try
to predict survivability and histology of the tumors.
Keywords: Autoencoder, convolutional, imaging, CT
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Abstract number: 40
Characterization of Invasive Streptococci Isolated in a Limited Nosocomial Outbreak with Illumina and
Nanopore Whole Genome Sequencing
Mark Li; Diagnostics Genetics and Genomics Program, School of Health Professions; University of Texas MD
Anderson Cancer Center
Awdhesh Kalia; Diagnostics Genetics and Genomics Program, School of Health Professions; University of Texas
MD Anderson Cancer Center
Xiaojun Liu; Diagnostics Genetics and Genomics Program, School of Health Professions; University of Texas MD
Anderson Cancer Center
Background: Immunosuppressed patients are highly susceptible to nosocomial bacterial infections. Pathogens
causing nosocomial outbreaks tend to be multidrug-resistant and complicate management of
immunocompromised patients. By analyzing different phenotypic and molecular characteristics such as strain
type or virulence/resistance features through whole genome sequencing (WGS), hospitals can accurately
determine genetic information on bacterial genomes and improve outbreak management. While short-read
sequencing with Illumina remains the standard for WGS, it often produces fragmented genome assemblies.
Recent advances in long-read sequencing such as MinION Nanopore sequencing have shown potential for highquality complete bacterial genomes. Here, we employ Illumina and MinION sequencing to characterize a small,
localized outbreak of invasive bacteria in immunocompromised patients.
Methods: Four beta-hemolytic isolates - UT1775, UT1778, UTD421, and UTMGAS338 - causing invasive
infection in immunocompromised patients from the same unit were cultured using standard microbiological
practices and then genotyped using multilocus sequence typing (MLST) and 16S ribosomal rRNA sequencing
based species identification. We then performed paired-end sequencing on the Illumina MiniSeqTM platform and
long-read nanopore sequencing with the ONT MinION platform. The resulting sequencing data was assessed for
quality and trimmed to remove adapters prior to performing genome assembly. Paired-end reads from Illumina
were assembled using SPAdes with k-mer values of 45, 55, 65, and 75. Presently, we are performing genome
assembly with raw MinION reads using Flye assembly, which will then be polished off by incorporating Illumina
MiniSeq reads. Genome annotations were performed using RASTtk with specific focus on antimicrobial resistance
and virulence-associated genes.
Results: BLAST analysis of 16S sequences classified all four bacterial isolates as Streptococcus dysgalactiae
subspecies equisimilis (SDSE), which is considered normal human flora. MLST analysis of seven housekeeping
genes showed that each isolate belonged to a unique sequence type (ST68, ST29, ST8, and ST3), represented
as singletons in a global SDSE database of 1585 strains. Draft genomes assembled from paired-end sequencing
had an average depth of greater than 300x, ranged in size from 2.08 MB to 2.14 MB, and harbored approximately
2000 genes. Strikingly, each isolate harbored ermB MDR gene, MATE family, and pmrA MDR efflux pumps which
confer resistance to erythromycin and fluoroquinolones respectively. Nanopore data is currently being processed
and will be integrated upon availability.
Conclusion: While the beta-hemolytic outbreak was caused by different genotypes of SDSE, each isolate had
resistance markers for multiple antibiotics. Integration of nanopore sequencing should help assembly of complete
genomes and deeper analysis of genomic markers for pathogenicity.
Keywords: genomics, sequencing, NGS, bacteria, outbreak
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Abstract number: 41
Kinetic Analysis of Model PET Redox Reporters Using Dynamic Bioluminescence Imaging with
Biologically-Relevant Reactive Oxygen Species
Michael Li; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Seth Gammon; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
David Piwnica-Worms; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Background: Innate immunity plays a central role in physiological responses to pathogens, but can also
exacerbate diseases, such as breast cancer and hepatocellular carcinoma through pro-inflammatory signaling.
Innate immune cells rapidly generate high redox potential reactive oxygen species (ROS) and activate
myeloperoxidase as a host defense response in a process known as respiratory burst (RB). These ROS species
are key effector molecules in diseased inflammatory states, but excessive amounts lead to oxidative stress and
damage in cells, contributing to disease progression. A novel imaging assay that effectively localizes
inflammation-induced radical species would allow for precise imaging of activation sites in vivo of innate immune
responses and monitoring of ROS activity that can be applied to many inflammatory diseases. Naphthol and L012 are known to be oxidized by ROS derived from innate immune systems. Recently, 4-[18F]fluoro-1-naphthol
([18F]4FN) has been tested in pre-clinical studies as a Positron Emission Tomography (PET) reporter for innate
immunity activation, and L-012 BLI activity was strongly correlated with 4FN retention. Marcus Theory of single
electron redox reactions in chemistry posits that the kinetics of single electron reactions correlates non-linearly
with the thermodynamics of the reaction. This may be relevant for understanding the selectivity of a variety of
bioluminescent and PET reporters toward reactive oxygen and nitrogen species. Herein, we examined the
dependence of the reaction of bioluminescent reporters on the known standard reduction potential of a series of
ROS.
Methods: Photonic reactivities in vitro of L-012 or luminol (100 uM) with reactive oxygen and nitrogen species,
such as singlet oxygen, hydrogen peroxide, hypochlorite, nitric oxide, and hydroxyl radical (100 uM), were
detected through Bioluminescence Imaging (BLI). Reactions were monitored dynamically pre- and post-addition
of hydrogen peroxide for 40 additional minutes by BLI.
Results: Reactions with L-012 rapidly reached a steady state with minimal change in photonic production rate
over one hour. Herein, the reduction potential of ROS species showed a positive correlation versus the
bioluminescent radiance of L-012 (r = 0.9429, P (two-tailed) = 0.0167) and luminol
Conclusion: The radiance of model bioluminescent substrates positively correlated with the standard reduction
potential of RONS, and the non-linear response provides strong selectivity for those species above a threshold
standard reduction potential intrinsic to each reporter. Understanding this property will assist further quantitation
of current probes and potentially develop new reporters for different regimes of reactive oxygen species.
Keywords: Bioluminescence, Fluorescence, L-012, Luminol, 4-[18F]fluoro-1-naphthol
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Abstract number: 42
Assessment of enhanced anti-tumor immunity in estrogen receptor negative mammary tumors via
vitamin E administration
Kathryn Lingen; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Yuan Zhang; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Yi Xiao; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Dihua Yu; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Background: There is an unmet need for preventative strategies targeting estrogen receptor (ER) negative breast
cancer. One promising avenue is immunoprevention, specifically vaccines that enhance immune surveillance.
However, many cancer vaccines do not induce effective responses in all patients, especially in poorly
immunogenic cancers such as breast cancer. Increased antigen uptake & presentation by dendritic cells may aid
in enhancing the efficacy of these vaccines and is known to be crucial for a properly functioning immune system.
Dendritic cells play a critical role in boosting adaptive immunity by acting as professional antigen presenting cells
that uptake, process, and present antigens to the surface of T cells. Finding ways to increase the function of
these cells may be a critical step in increasing the effectiveness of cancer vaccines. The Yu lab previously found
that Vitamin E boosts dendritic cell activity and in a retrospective study, found that cancer patients who took
Vitamin E exhibited the best survival rates compared to patient groups who took other dietary supplements or
none. Therefore, Vitamin E has been proposed as a potential immunologic adjuvant to increase the efficacy of
cancer vaccines. Objective: Although previous research has demonstrated that Vitamin E plays a role in the
immune system, it is not known whether Vitamin E can enhance an antigen specific, anti-tumor immune response
and increase the efficacy of cancer vaccines .
Methods: Both in vitro and in vivo models were utilized to assess the ability of Vitamin E to enhance antigen
specific uptake by dendritic cells. The capability of Vitamin E to increase the efficacy of cancer vaccines through
an antigen specific, anti-tumor immune response was assessed via flow cytometry and enzyme-linked
immunosorbent spot (ELISpot).
Results: The addition of Vitamin E alongside cancer vaccines was found to increase antigen uptake in both
models. Analysis of T-cell response by Carboxyfluorescein succinimidyl ester (CFSE) via flow cytometry revealed
that T-cell proliferation increased when the vaccines were supplemented with Vitamin E. Likewise, analysis via
interferon gamma (IFNγ ) ELISpot confirmed increased antigen specific T-cell responses when Vitamin E was
present in combination with cancer vaccines.
Conclusion: We identified increased antigen-specific T-cell responses in ER negative breast cancer models when
cancer vaccines were administered with vitamin E. In view of the limited response rate of many patients to cancer
vaccines, Vitamin E may present itself as an effective and safe addition to current treatment plans to increase the
immunoprevention effects of these vaccines.
Keywords: Immunoprevention, ER- breast cancer, Vitamin E, vaccine, dendritic cell
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Abstract number: 43
Oxidative Phosphorylation (OXPHOS) Modulates Immune Response in Melanoma Brain Metastasis (MBM)
Alice Liu; Melanoma Medical Oncology, Translational Molecular Pathology; University of Texas MD Anderson
Cancer Center
Renato A. Guerrieri; Melanoma Medical Oncology, Translational Molecular Pathology; University of Texas MD
Anderson Cancer Center
Michael A. Davies; Melanoma Medical Oncology, Translational Molecular Pathology, Systems Biology; University
of Texas MD Anderson Cancer Center
Background: Melanoma is the rarest but most aggressive form of skin cancer, making up <5% of skin cancer
cases, but >75% of deaths. Melanoma brain metastases (MBMs) are a leading cause of morbidity and mortality
for patients with advanced melanoma. Previous studies have implicated oxidative phosphorylation (OXPHOS) in
the pathogenesis of MBM and in suppression of the anti-tumor immune response. The role of OXPHOS in
modulating the tumor immunity in the setting of MBM remains unclear To better understand the role of OXPHOS
in MBM pathogenesis and immunosuppression, we investigated the metabolic and immunologic effect of
pharmacologically inhibiting OXPHOS using IPN-60090 and IACS-010759 on D4M melanoma cells.
Methods: D4M murine melanoma cells were cultured and stably transfected with lentiviral particles co-expressing
firefly luciferase and RFP, and blasticidin antibiotic resistance. D4M sensitivity to blasticidin treatment (0.1 ug/mL
– 1000 ug/mL) was evaluated by Cell Titer Blue (CTB) assay. Transfected D4M cells underwent dual-selection
with blasticidin antibiotic treatment (100 ug/mL) and FACS. We evaluated the effect of OXPHOS inhibition in D4M
melanoma using pharmacologic inhibitors of mitochondrial complex I (IACS-010759) and glutaminase (IPN60090) (0.1 uM – 5 uM) via the Seahorse MitoStress Test. We then performed cytokine array using the
Mesoscale U-PLEX platform to assess the effect of OXPHOS inhibition on D4M melanoma secretion of cytokines
and chemokines involved in immune system regulation.
Results: Blasticidin selection (via CTB) saw IC50, IC90, and IC99 levels for D4M cells at 5, 15, and 100 μg/mL,
respectively. Fluorescent microscopy showed cells expressing RFP 48 hours post-transfection, and dual selection
with 100 μg/mL blasticidin and FACS enriched for RFP+ D4M population. Treatment with 0.5 μM IACS-010759
significantly reduced basal OCR by 39.6% (p = 0.0212), and 0.5 μM of IPN-60090 reduced basal OCR by 56.8%
(p = 0.0206). The max OCR was reduced by 66% with 0.5 μM IPN-60090 (p = 0.02059), while IACS did not have
a significant effect. Cytokine analysis results are still pending, but we expect that OXPHOS inhibition would
increase the amount of immune activators and decrease levels of immune regulators.
Conclusion: Our results are consistent with growing data suggesting OXPHOS is a mediator of
immunosuppression in MBMs. The D4M line’s high sensitivity to glutaminase inhibition suggests that its OXHPOS
is particularly dependent on glutamine metabolism. In the future, better understanding of cancer metabolism and
its effect on immune response will allow for new, efficient treatments combining metabolic inhibitors with immunecheckpoint therapy.
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Abstract number: 44
Mimicking vimentin phosphorylation results in multinucleation and loss of stemness in aggressive breast
cancer cells
Jojo Yuzhou Liu; Biology; Emory University
Nick A. Kuburich; Translational Molecular Pathology; University of Texas MD Anderson
Petra den Hollander; Translational Molecular Pathology; University of Texas MD Anderson
Sendurai A. Mani; Translational Molecular Pathology; University of Texas MD Anderson
Background: Epithelial-mesenchymal transition (EMT) is a critical step in cancer metastasis. During EMT,
epithelial cancer cells lose their cell polarity and adhesion to acquire migratory and invasive properties. This
process also generates cancer stem-like cells (CSCs) that are involved in chemoresistance and cancer
recurrence. Vimentin is a mesenchymal marker, which is upregulated during EMT, that functionally increases
motility and migratory properties. Vimentin’s regulation is tightly controlled through phosphorylation by multiple
different kinases. The small molecule compound, FiVe1 leads to an increase of phosphorylation of vimentin, most
strikingly at serine 56, a site important in cell division. When the vimentin phosphorylation process is dysregulated
by FiVe1, cells that have undergone EMT become multinucleated resulting in a loss of stemness and decreased
metastasis in vivo. We hypothesize that mimicking vimentin phosphorylation with a glutamic substation at serine56 will replicate the inhibitory effects of FiVe1 regarding multinucleation and stemness inhibition.
Methods: Doxycycline inducible vectors with vimentin wild type (VIM-WT) or serine-56-Glutamic acid (VIM-S56E)
mutation were constructed and transduced into 4T1 murine breast cancer cells. 4T1 cells that were properly
transduced were selected with geneticin. The resulting cells were exposed to increasing doses of doxycycline to
observe HA-Vimentin expression by western blot with anti-HA and anti-vimentin with anti-actin for loading control.
Multinucleated cells were counted by fluorescence microscopy following treatment with increasing doses of
doxycycline and staining with Hoechst and CellBrite Membrane Dyes. Stemness properties were assessed by
mammosphere formation assay in serum-free, non-attachment conditions. The number of mammospheres was
counted following treatment with an increasing concentration of doxycycline.
Results: Properly transduced cells that were resistant to geneticin saw a dose-dependent increase of HA-tagged
vimentin by western blot. Furthermore, the VIM-S56E cells had an increase of multinucleation by fluorescent
microscopy relative to cells expressing VIM-WT. Additionally, a reduction of mammosphere formation was
observed supporting a loss of stemness properties in cells expressing VIM-S56E relative to cells expressing VIMWT.
Conclusion: Our data shows that Vimentin phospho-mimetic mutation for Serine 56 (S56E) results in
multinucleation and inhibition of stemness in 4T1 cells. In future works, we plan to conduct mouse studies for
gauging the impact of this mutation on metastasis. Ultimately, our data suggest that the hyperphosphorylation of
serine 56 in vimentin is the mechanism behind the ability of FiVe1 to disrupt EMT-enriched carcinoma cells. This
work supports that the increased phosphorylation of vimentin by FiVe1 at serine 56 leads to a loss of stemness
properties.
Keywords: Epithelial mesenchymal transition, vimentin, cancer stem-like cells
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Abstract number: 45
PREDICTION OF TREATMENT RESPONSE AND RESISTANCE IN METASTATIC HORMONE RECEPTOR
POSITIVE BREAST CANCERS THROUGH CLINICAL DATA AND BIOSPECIMEN COLLECTION
Catherine K Luo; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Nicole M Kettner; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Akshara Raghavendra; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Khandan Keyomarsi; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Kelly K Hunt; Breast Surgical Oncology; University of Texas MD Anderson Cancer Center
Background: Endocrine therapies and cdk4/6 inhibitors have improved clinical outcomes and progression-free
survival in metastatic hormone receptor positive (HR+) breast cancers. However, a majority of HR+ breast
cancers acquire resistance to cdk4/6 inhibitors (cdk4/6i) or develop insensitivity to endocrine therapies, resulting
in disease progression. Although multiple pathways involved in the development of resistance have been
identified, improved clinical outcomes are largely limited. Focusing on clinical biomarkers contributing to
resistance would better identify disease progression.
Methods: In this study, we aim to determine distinct tumor features at baseline that predict response or resistance
to therapies. In addition, by investigating changes that occur during disease progression, additional therapies can
be determined. These changes will be assessed through biospecimen collection, data integration into a shared
database for all contributors, and comparisons at pre- and post-cdk4/6i stages, helping predict treatment
response. Tumor biopsies and blood samples were prospectively collected from metastatic HR+ breast cancer
patients at monthly intervals during cdk4/6i treatment and at baseline and progression. Interleukin-6 (IL-6), shown
to promote tumor survival and progression, was investigated as a potential biomarker due to relative ease in
obtaining patient blood samples compared to obtaining tissue biopsies. IL-6 levels were measured from patient
blood samples through ELISA and analyzed with GraphPad Prism. Patient clinical data relevant to study
objectives were collected through Epic, an electronic medical record system, and recorded into RedCap, an
online database, for centralization, organization, and availability of clinical data to researchers involved in this
study.
Results: Of the patients in the study, IL-6 levels at progression were higher than those at baseline, even when IL6 on treatment trends were variable across patients. IL-6 levels did not exhibit significant change in on-treatment
stages where the tumor was stable and had not yet developed therapeutic resistance. Patient clinical data were
transferred to the Redcap project database to track information including ER/PR/HER2-scores, IL-6 levels
throughout the study, primary and metastatic tumor details, and specimen collection, which will be used to later
correlate patient outcomes.
Conclusion: IL-6 is a potential biomarker for the development of resistance to cdk4/6i and endocrine therapies in
metastatic HR+ breast cancers. Further investigation into additional biomarkers in plasma and tumor biopsies
needs to be conducted for more conclusive analyses. Integration of data into RedCap boosts collaboration in
tracking patient information and biospecimen collection, allowing an organized approach in assessing potential
biomarkers, treatment effects, and tumor details in determining patient outcomes and contributors to resistance.
Keywords: breast cancer, biological markers, database, resistance, biospecimen
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Abstract number: 46
Enhancement of type 1 interferon induction with drug and radiation treatments to increase antitumor
immunity
Nothando Mangena; Biology Department; Carleton College
Nan Li; Radiation Oncology; University of Texas MD Anderson Cancer Center
Steven Lin; Radiation oncology; University of Texas MD Anderson Cancer Center
Background: Accumulating evidence indicates that the efficacy of a variety of cancer treatments, including
radiation, relies on type 1 interferon signaling. Research shows that some anti-tumor effects are lost with IFNAR1
(interferon receptor) neutralizing monoclonal antibodies. Radiotherapy (RT), in a type 1 IFN-dependent manner,
promotes innate immune responses that support an adaptive immune response and antitumor immunity.
However, direct administration of interferon to patients has major adverse outcomes due to inflammation. While
the intracellular DNA sensing pathway mediated by cGAS-STING has been shown to induce IFN production,
other pathways are being discovered and targeted to improve RT efficacy. 406 chemicals were screened for IFN
induction and SR1001 (RORα agonist) and SK4112 (Rev-erbα agonist) were found to enhance radiation-induced
type 1 IFN production. RORα is part of a family of nuclear receptors that act as transcription factors and is a key
regulator of cellular differentiation, immunity and circadian rhythm. REV-ERBα functions in DNA-binding
transcription repressor activity and sequence-specific DNA binding and is involved in immunity and the circadian
rhythm. We hypothesize that RORα and Rev-erbα work together with radiation to augment type 1 IFN production.
Methods: To test for efficacy of the drug to trigger type 1 IFN response with radiation in cells, we developed a cell
system that induces luciferase expression upon type 1 IFN promoter activation. 293A cells were transformed
using IFN-b-Luciferase and Renilla-Luciferase plasmids from an E. coli transformation. These cells were then
treated with drug and radiation and compared to cells that were not treated, treated with drug alone and treated
with radiation alone. 293A cells treated with the SR1001 and SK4112 drugs, in combination with RT, were
quantitatively assessed for type 1 IFN induction using qPRC.
Results: The results showed a significantly larger increase in type 1 interferon production in cells treated with the
drugs (SR1001 and SK4112) and radiation combination than in cells treated with just radiation, just drug or no
treatment, as confirmed by the luciferase assays and the qPCR.
Conclusion: The results show that RORα and Rev-erbα work together with radiation to augment type 1 IFN
production. Importantly, both RORα and Rev-erbα are circadian controlled, this implies a link between the
circadian rhythm and the immune response to radiation. Thus, future directions will focus on determining if the
time of drug and radiation delivery relative to the 24-hour circadian cycle play an important role in increasing RT
induced antitumor immunity.
Keywords: RORa, Rev-erba,
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Abstract number: 47
Utilizing Tissue Microarrays (TMA) as a Medium-Throughput Method for Antibody Validation
Sujay Marisetty; Genomic Medicine; University of Texas MD Anderson Cancer Center
Joe Daniele; TRACTION; University of Texas MD Anderson Cancer Center
Annette Machado; TRACTION; University of Texas MD Anderson Cancer Center
Jing Han; TRACTION; University of Texas MD Anderson Cancer Center
Daniel Zamler; Genomic Medicine; University of Texas MD Anderson Cancer Center
Joe Marszalek; TRACTION; University of Texas MD Anderson Cancer Center
Jian Hu; Cancer Biology; University of Texas MD Anderson Cancer Center
Giulio Draetta; Genomic Medicine; University of Texas MD Anderson Cancer Center
Background: Antibody validation is an essential step for research involving antibodies. Lot-to-lot variation,
antibody degradation, and epitope availability all make validation of antibodies critical for avoiding false data.
Despite this, there are no community-wide respected guidelines for validating antibodies against the epitopes of
interest. We propose here to perform immunohistochemistry (IHC) validation utilizing tissue microarrays (TMAs).
On-slide controls, technical replicates, and identical staining conditions for tissues of interest are easily facilitated
with TMAs. Obviating the need for single-tissue staining and image analysis in antibody validation, TMAs allow
efficient analysis of tissue sections.
Methods: Ten organs (liver, lung, pancreas, thymus, lymph node, retina, brain, kidney, heart, and spleen) were
collected from three C57Bl6/j female mice and three NSG female mice. 5um slices - sectioned from paraffinembedded single-organ blocks (donor) - were stained with hematoxylin and eosin (H&E), scanned, and annotated
with QuPath to mark the location of tissue extraction. Utilizing a semiautomatic tissue microarrayer, we extracted
1mm tissue cores from the donor blocks to generate the TMA block. 5um slices sectioned from the TMA block
underwent staining and were scanned on a Vectra Polaris using a brightfield preset specific to TMAs. RNA and
protein expression databases (Genecards, Human Protein Atlas (HPA)) and existing literature were referenced
during the analysis of stained tissues. In all, 5 antibodies against immune markers were tested.
Results: We classified antibodies into one of three categories: specific, moderately specific, or non-specific.
Specific refers to antibodies that only bind tissues expressing the target protein. Non-specific refers to antibodies
that bind to tissues that do not express the target protein. Any antibody that leads to a small amount of staining in
tissues lacking the target protein is moderately specific. Among the 5 antibodies tested with our validation
method, none were specific to their target of interest, three [anti-CD20, anti-CSF1R, and anti-FOXP3] were
moderately specific, and two [anti-LAG3, anti-NCR1] were non-specific. A previously validated antibody, antiMBP, was used as an internal control and determined to have a correct staining profile.
Conclusion: TMAs mediate rapid analysis of multiple tissues and specimens, which can be used to validate
antibodies against proteins of interest. Here, we demonstrated that TMAs are an efficient platform to validate
antibodies against immune markers. Our next step is to optimize multiplex imaging utilizing TMAs to further
increase the efficiency of antibody validation. We will also generate metrics to quantify antibody staining of
tissues.
Keywords: Tissue Microarray (TMA), Antibody validation, Immune markers, Immunohistochemistry (IHC)
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Abstract number: 48
Elucidating the Niches Microenvironment of Dormant and Metastatic Breast Cancers
Nafiza Meher; Cancer Biology; University of Texas MD Anderson Cancer Center
Sreeharsha Gurrapu; Cancer Biology; University of Texas MD Anderson Cancer Center
Filippo Giancotti; Cancer Biology; University of Texas MD Anderson Cancer Center
Background: In situations where a tumor stays dormant, metastatic relapse can occur. This has been observed in
many different cancers, including Breast cancer. Recent studies show that such metastasis can occur due to rare
subclones, also known as cells from the primary tumors that diverge due to differences in mutations. These new
micro-metastases are more prone to attacks from the immune system until they develop the ability to evade the
immune system and re-establish an immunosuppressed microenvironment for cancer growth. In addition, there
are likely complex signals at hand that control the reactivation of dormant cells triggering subclones and thus
micro-metastases in these specialized microenvironments called niches. There is a possible analogous system
between that and the development of stem cells through regulation by immune cell niches. We hypothesize that
metastasis-initiating cells reside within specific niches that support their survival and self-renewal capacity.
Moreover, the dormant and metastatic cells might have a distinct niche and stromal cell subsets that regulate
metastasis.
Methods: Dormant breast cancer cell line 4TO7 and metastatic 4T1 cells were modified to express eGFP and
soluble mCherry labeling dye so that the metastatic niches can be labeled. They are also modified to express
reporter gene luciferase, in order to study metastatic reactivation in vivo. Breast tumor cells are injected into the
tail vein of syngeneic mice. The cells seed into the lungs of the female BALB/c mice. Tail vein injected 4TO7 cells
enter a dormant stage and 4T1 cells undergo metastatic reactivation. This allows us to examine the dormant
niches (from day 3), early (≥ 1 week) and late reactivated niches (≥ 2 weeks), and macro-metastases (≥ 3 weeks).
The target organs of the mice are collected and tumors and niche cells are isolated by fluorescence-activated cell
sorting. eGFP positive and mCherry positive cells are tumor cells, and only mCherry positive cells are the niche
cells. The cells undergo scRNA-sequencing, bioinformatics and single-cell cluster analyses.
Results: Our preliminary data show that dormant and reactivated niches are mostly immune subpopulations.
Dormant niches show a large presence of macrophages, B cells, and T cells. In contrast, the reactivated
metastatic niches show an increased number of monocytes but a decrease in macrophages, B cells, and T cells.
Conclusion: Looking at the microenvironment, niches, of the cancer cells helps us identify the differences in
dormant cells and metastatic cells surrounding growth conditions. Our data suggest the possibility of metastatic
cells evading the immune system by building a niche that activates specific signaling pathways that allow for
immune evasion and immunosuppression. By identifying the niches' specifics and conducting further research into
the pathways, we can figure out how to target the reactivation of metastasis. This can lead to understanding
prevention methods through immunotherapy.
Keywords: breast cancer, niches, dormant cells, metastatic relapse, immune system
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Abstract number: 49
Process Optimization of Mixed Lymphocyte Reaction in Immunotherapy
Avha Mohanty; Therapeutics Discovery and Development / ORBIT; University of Texas MD Anderson Cancer
Center
Timothy Lofton; Therapeutics Discovery and Development / ORBIT; University of Texas MD Anderson Cancer
Center
Amin Al Shami; Therapeutics Discovery and Development / ORBIT; University of Texas MD Anderson Cancer
Center
Background: Immunotherapy has proven to be an effective method of cancer treatment that utilizes the patient’s
own immune system to fight cancer. Before such treatments are tested in humans, these procedures must be
tested in vitro. However, capturing the complexity of the human immune system on plastic poses a major
challenge. The mixed lymphocyte reaction, or MLR, is a technique used to measure the immune response of T
cells when mixed with antigen presenting cells from a different human donor. This assay is useful in determining
whether therapeutic antibody candidates can enhance immune response, but the required readout assays are
time consuming and provide minimal time dependent data in current practice. The present study aims to optimize
the speed and range of data of the MLR, using high throughput flow cytometry.
Methods: Peripheral blood mononuclear cells (PBMC’s) are isolated from two different human blood donors.
PBMC’s from Donor 1 are stimulated with human GM-CSF and IL-4 to induce dendritic cell (DC) differentiation.
On day seven, CD4+ T cells are isolated from Donor 2’s blood. DC’s from Donor 1 are then combined with T cells
from Donor 2 along with antibodies capable of triggering the anti-cancer immune response. Markers of T cell
activation such as cytokine production, viability, and proliferation are measured over eight days using the iQue3
flow cytometer.
Results: The MLR assay readout conducted on the iQue flow cytometer provides multiple time points of data over
the eight-day period, including detection of cell surface antigens, cytokine secretion, activation, and survival. This
provides significantly more information about the assay than the traditional protocol which only measures cytokine
secretion on day five of the culture. Collection of multiple time points reveals that the expression of CD25 and
CD69 is not robust during the first three days but increases significantly at day six. Furthermore, INFg and TNFa
cytokine secretions, which are critical indicators of T cell activation status, also increase significantly on day six.
Conclusion: High throughput flow cytometry suggests a more effective method of conducting MLR. In addition to
being more time efficient and providing a wider range of data, the modification allowed simultaneous
measurements of different parameters of T cell activation on a small sample. These improvements are extremely
useful in the field of immunotherapeutic discovery as drug efficacy can be tested more efficiently and new
treatments can reach patients in clinical trials faster.
Keywords: Flow cytometry, mixed lymphocyte reaction, multiplex, iQue3, immuno-oncology
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Abstract number: 50
Impact of a whole foods based high fiber diet on gut microbiome in melanoma survivors
Daniel C Mousavi; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Yan Jiang; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Tessa Kus; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Erma Levy; Behavior Science; University of Texas MD Anderson Cancer Center
Marco Montalvo; Behavior Science; University of Texas MD Anderson Cancer Center
Jian Wang; Biostatistics; University of Texas MD Anderson Cancer Center
Jennifer Wargo; Surgical Oncology; University of Texas MD Anderson Cancer Center
Nadim Ajami; Genomic Medicine; University of Texas MD Anderson Cancer Center
Carrie MacDougall; Epidemiology; University of Texas MD Anderson Cancer Center
Background: The development and approval of checkpoint inhibitor immunotherapy (ICI) has revolutionized the
treatment of many cancers. However, patient responses are mixed. Recent evidence has demonstrated that the
gut microbiome influences response to ICI, and observational data in melanoma supports that a habitual highfiber diet is associated with a pro-response microbiome and improved response to ICI. To test our hypothesis that
a whole foods, plant-based, fiber-rich diet can favorably modulate the microbiome, we conducted a pilot study of a
high-fiber dietary intervention (HFDI) in melanoma survivors.
Methods: Ten patients with a history of melanoma with no current evidence of disease were enrolled to the HFDI
study. As a controlled feeding study, for the duration of the six weeks of HFDI, participants were provided with all
meals from our Bionutrition Research Core with whole-food-based meals enriched in fiber from fruits, vegetables,
and legumes with a target of 50 grams of fiber daily. The primary outcome was compliance. Blood and stool were
collected longitudinally for exploratory microbiome and immune profiling. Significant pathways were differentiated
via a linear mixed-effects model as well as graphically in RStudio.
Results: Participants were 60% female and average age was 49 years with average baseline fiber intake of 15.05
grams. Of the nine participants that have completed the study, compliance was 88% with consuming provided
meals and an average of 45 grams of fiber daily was reached. One participant experienced grade 2 diarrhea and
all other toxicities were grade 1. WGS data from the stool samples of the first five individuals demonstrated that
the baseline microbiome taxonomic and pathway abundance was heterogenous among the five individuals. Upon
a high fiber diet, there was no significant change in overall fiber-processing pathways of the gut microbiota.
However, the data reveals a significant increase in the abundance of fiber-processing pathways in three specific
genera of bacteria: Roseburia, Alistipes, and Faecalibacterium.
Conclusion: A HFDI is well-tolerated and feasible in a melanoma population. Significant variation is seen in
baseline and on-treatment microbiome profiles reflecting the heterogeneity and redundancy of the gut
microbiome. However, our preliminary WGS pathway analysis suggested shifts in fiber-responsive pathways in
three specific genera. Further studies are needed to link these genera/pathways to short chain fatty acid
production and immunity. Results from this study will be used to test the effects of fiber-enriched diet on the antitumor immune response and tumor biology in patients with metastatic melanoma beginning systemic
immunotherapy.
Keywords: microbiome, immunotherapy, fiber, melanoma
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Abstract number: 51
Functional Characterization of MITF Enhancers in Melanoma Drug Response
Navya Murugesan; Genomic Medicine; Tulane University, New Orleans, LA
Mayinuer Maitituoheti; Genomic Medicine; University of Texas MD Anderson Cancer Center
Kunal Rai; Genomic Medicine; University of Texas MD Anderson Cancer Center
BACKGROUND: Enhancer aberrations is a fundamental epigenetic feature of cancers. However, the functionality
has been established only for a few of these enhancers. Current cancer therapies are hindered by innate drug
resistance mediated by upregulation of specific receptors and most mechanisms mediating such genomic
responses to targeted therapy are unknown. MITF (melanocyte-inducing transcription factor) is the master
regulator of melanocyte development and functions as an oncogene by maintaining tumor survival, enhancing
proliferation, and promoting differentiation in human melanoma. H3K27ac, an epigenetic modification to histone
H3 protein, has the capacity to distinguish between active and poised enhancer regions; typically, H3K27ac is
associated with a higher activation of transcription and is an active enhancer mark. Genome-wide binding
patterns of H3K27ac allows for a systematic understanding of the enhancer landscape and its contribution to
disease progression.
METHODS: ChIP-seq, a technique to profile histone modifications, for H3K27ac was performed on twenty CCLE
(Cancer Cell Line Encyclopedia) human melanoma lines. Then, ChIP-seq data was integrated with RNA-seq to
gain insight on how enhancer changes may impact gene expression. Response to drug treatment was assessed
by standardizing the treatment group to the untreated control. AVANA dataset, a large-scale genome-wide
CRISPR screen datasets for cancer cell lines from Broad Institute and Novartis, was used to confirm the
functional capability of MITF melanoma cells. Lastly, in vitro inhibitor treatment was performed to validate the drug
response. Unsupervised clustering was used to unbiasedly identify groups of cells based on their enhancer
patterns.
RESULTS: Unsupervised clustering of enhancer data depicted two distinct enhancer subgroups of melanoma cell
lines. Specifically, DiffBind was used to identify statistically significant protein binding sites which are differentially
enriched between two sample groups, and this worked primarily with the ChIP-seq peak data. Among other
enhancers, those for MITF were found to be differentially present between the two subgroups. We found that
MITF super enhancer gain correlates with gene expression; additionally, MITF enhancer gain is also associated
with responses to BRAFi. BRAF is known to regulate MITF expression and BRAFi can slow the growth of
metastatic melanoma in patients whose tumors have a BRAF mutation.
CONCLUSION: Our data suggest that MITF enhancers correlate with BRAF inhibitor response in melanoma.
Future research entails silencing the MITF enhancer with CRISPR dCas9-KRAB (transcriptional repression of
genes) to validate its functionality. Understanding molecular mechanisms of MITF and its emerging activities in
malignancy will pave ways to improve therapeutic approaches for melanoma.
Keywords: MITF; ChIP-seq; H3K27ac; melanoma; enhancers
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Abstract number: 52
Utilizing Visium FFPE to Characterize Spatial Transcriptome Variability Contributing to Extranodal
Extensions Formation in Head and Neck Cancers
Shivani Nellore; Head and Neck; University of Texas MD Anderson Cancer Center
Shamima Akhter; Head and Neck; University of Texas MD Anderson Cancer Center
Priyadharshini Nagarajan; Pathology; University of Texas MD Anderson Cancer Center
Moran Amit; Head and Neck; University of Texas MD Anderson Cancer Center
Background: Cancer is a disease unique to every patient. Accurate assessment of each patient’s tumors is
essential for physicians and researchers to determine prognosis and provide the best care. Inaccurate
characterization of tumor aggressiveness can lead to undertreatment, increasing reoccurrence probability, and
worsening prognosis for the patient. An essential diagnostic tool to determine the tumor aggressiveness in Head
and Neck cancers is the presence of Extranodal extensions (ENE). ENE is the metastasis of neoplastic cells
through the lymph node capsule into the perinodal adipose tissue. A patient with ENE has a worse prognosis and
elevated occurrence rates than a patient with the same staging but lacks ENE. Further understanding of the gene
expression causes of ENE is necessary to identify aggressively infiltrated lymph nodes and ultimately lead to
more precise treatment plans.
Methods: The novel Visium FFPE combines spatial imaging with transcriptome data such that gene expression
results and dimensionality reduction clustering trace back to exact spots on the tissue. This technology highlights
and promotes a better understanding of the genes promoting metastasis heterogeneity and ENE growth. Before
utilizing Visium FFPE, a tissue quality check of H&E stained slides and RNA quality check of the tissue were
necessary for sample selection. After conducting Visium FFPE, the bright-field images of H&E stains and the
sequencing results of the cDNA library will be compiled using the Linux SpaceRanger application and visualized
with the Loupe browser. These programs will later identify the transcriptome and transcriptome motifs correlated
with ENE tissue.
Results: Currently, we completed two Visium FFPE slides, where each slide contains four samples from the same
patient. For each sample, we took Bright-field images of the H&E staining and made cDNA libraries. In the future,
these libraries will need to be sequenced and compiled with the bright-field images using SpaceRanger and
visualized using Loupe Browser.
Conclusion: The innovative Visium FFPE technique has been a necessary development to fully understand the
magnitude of gene expression variance contributing to the development of ENE. Previous technologies only allow
for sequencing of transcriptomes at the single-cell level without considering the cells’ locations in the tissue. In the
future, using Visium FFPE will help isolate a transcriptome or a gene expression motif correlated and possibly
contributing to the development of ENE. Clinically, this discovery will help with accurate characterization of tumor
aggressiveness, significantly impacting treatment decisions.
Keywords: Extranodal extensions, Spatial Transcriptomics, Visium FFPE
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Abstract number: 53
Optimization of molecular ultrasound imaging using nanodroplet contrast agents for in vivo translation
Linh Nguyen; Imaging Physics; University of Texas MD Anderson Cancer Center
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Background: While microbubble contrast agents (MCAs) can be utilized as molecular imaging targets to probe
tissue properties using contrast-enhanced ultrasound (US) imaging, their applications are limited to vascular
targets because the physical size of MCAs does not allow for cellular uptake in extravascular space. To overcome
this limitation, high-clinical-frequency US imaging and activation of phase-changing perfluorocarbon nanodroplet
contrast agents (PNCAs) have been explored. PNCAs are a novel class of contrast agent which are small enough
to reach tumor cell surface receptors and can then undergo a size and phase change to provide US contrast.
While PNCAs have been optimized for US imaging in a PNCA-embedded phantom model, the objective of this
study was to translate this work to in vivo imaging. To this end, we investigated the injection and activation of
PNCAs in in vivo models using US and photoacoustic (PA) imaging.
Methods: A Verasonics Vantage 128 system was used with a Kolo L228-8v CMUT transducer with co-registered
B-Mode and pulse-inversion harmonic imaging (9 MHz) before and after US activation pulses (12 MHz, 6 cycles)
to assess PNCA contrast. PNCAs with and without Cy7 dye in the coating were first activated and imaged when
embedded in a polyacrylamide (PAA) phantom. The particles were then injected into PAA and tissue-containing
phantoms under US guidance to investigate the effect of injection on the PNCAs. Then, Cy7-labeled PNCAs were
injected intratumorally in an athymic nude mouse to track particle drainage through the lymphatic system using an
iThera MSOT inVision PA imaging system and an Emit Xerra post-mortem fluorescence imager. Finally, an
intramuscular injection of PNCAs was performed in the hind limb of an athymic nude mouse to visualize USspecific PNCAs activation in vivo.
Results: PNCAs in the PAA phantom did not experience spontaneous activation at 37⁰C and provided contrast of
10.2 dB upon US activation. However, upon injection into tissue-containing phantom, spontaneous activation was
observed, resulting in lower contrast upon activation. PA imaging showed the drainage of Cy7-labeled PNCAs to
the lymph node 2 hours post-injection, and in vivo US imaging demonstrated significant contrast enhancement of
injected PNCAs upon US activation.
Conclusion: The in vivo activation of optimized PNCAs demonstrated in this work suggested that PNCAs are
promising molecular imaging targets for US-mediated multimodality imaging. Successful injection and activation
of PNCAs in vivo with US-mediated imaging modalities could provide additional molecular information to clinicians
during intraoperative procedures, such as detection of micro-metastases during lymph node biopsy.
Keywords: molecular imaging, diagnostic ultrasound, photoacoustic imaging, phase-changing nanodroplet
contrast agent, perfluorocarbon
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Abstract number: 54
Evaluation of the Combination of HDACi and IL-21 in TIL Initial Phase of Expansion
Joshua Ni; Biomedical Engineering; Johns Hopkins University
Tamara Griffiths; Biologics Development; University of Texas MD Anderson Cancer Center
Marie-Andree Forget; Biologics Development; University of Texas MD Anderson Cancer Center
Donastas Sakellariou-Thompson; Biologics Development; University of Texas MD Anderson Cancer Center
Chantale Bernatchez; Biologics Development; University of Texas MD Anderson Cancer Center
Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a promising new cancer
treatment utilizing the patient’s own antitumor T cells to enhance the immune response. However, while TIL-ACT
has demonstrated therapeutic efficacy in generating durable, complete tumor regression, many patients still fail to
respond1. Our research has focused on improving the phenotype of the TIL product. Recently, our group has
optimized the TIL pre-REP generation process (TIL3.0) which combines anti-CD3 stimulation with high doses of
IL-2 and agonistic 4-1BB stimulation and produces a stronger cytotoxic CD8+TIL profile than growth with IL-2
alone to better target the tumor. Cytotoxic CD8 are presumed to be effector cells with less capacity for selfrenewal and persistence in contrast to central memory CD8+T cells (TCM). Recent work has demonstrated that
use of a histone deacetylation inhibitor (HDACi) and IL21 in the rapid expansion protocol (REP) leads an
increased frequency of TIL expressing costimulatory marker CD28 and lymph node homing marker CD62L, which
are attributes of TCM. The goal for this project is to explore whether the combination of TIL3.0 pre-REP process
and HDACi+IL21 can expand a great number of CD8+TIL displaying TCM attributes.
Methods: Colorectal tumor samples were minced in small fragment from which TIL were propagated using the
lab’s developed TIL3.0 Growth Protocol (High IL-2, Anti-CD3, and Anti-4-1BB). Additionally, conditions with TIL3.0
supplemented with HDACi (Panobinostat) and IL21 or modified low-dose IL2 were used to test the impact on
growth and phenotype. Cultures were carried until confluence or 3 weeks after which TIL were counted and
phenotype was evaluated via flow cytometry for the following marker: CD62L, CD28, CD27, CD127 (IL7r), PD1,
LAG3.
Results: Based on the TIL3.0 threshold of ≥40e6 TIL within 3 weeks, the addition of HDACi + IL21 to the TIL 3.0
process successfully expanded TIL in 1 out of 2 cultures, while the combination of low dose of IL2 with HDACi
and IL21 failed in both cases. The successful culture maintained with HDACi and IL21 also showed an increase in
the percentage of CD62L+CD28+CD8+ TIL (indicative of a central memory-like phenotype) compared to TIL 3.0
control culture. Counterintuitively, LAG3 and PD1 were elevated compare to TIL3.0 alone, while the expression of
CD127 and CD27 was decreased, suggesting an effector state.
Conclusion: This study suggests the potential of the addition of HDACi and IL21 to the TIL 3.0 expanded TIL,
altering their phenotype to TCM attributes. Further evaluation is required to validate this observation.
Keywords: TIL Therapy, Adoptive Cell Therapy, T cells
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Ube2S Regulates Transcription at Double Stranded DNA Break Sites
Zainab Niaz; Genetics; University of Texas MD Anderson Cancer Center; Rice University
Shichang Liu; Genetics; University of Texas MD Anderson Cancer Center
Bin Wang; Genetics; University of Texas MD Anderson Cancer Center
Background: Genomic instability, an enabling hallmark of cancer, arises from a variety of endogenous and
exogenous DNA damage factors, the most lethal of which are double stranded DNA breaks (DSB). DSBs can be
repaired through the DNA repair pathway, an ATM-mediated network that utilizes phosphorylated H2AX to initiate
a signaling cascade for repair proteins. Previously, this pathway was characterized by the conjugation of Lys63linked ubiquitin chains on damaged chromatin via enzymes RNF8 and Ubc13. However, recent research has
demonstrated that RFN8 works with another conjugating enzyme, Ube2S, to add K11-linked ubiquitin chains at
sites of DNA damage, allowing for transcriptional inhibition. Further investigation is needed to characterize the
specific mechanisms by which this method of ubiquitination contributes to the DNA damage response at DSB
sites.
Methods: To investigate the role of Ube2S in regulating transcription following DNA damage, double stranded
DNA breaks were induced at specific sites in control and Ube2S knockdown DiVA cells by treatment with 4hydrotamoxifen (4-OHT). RNA was extracted from cells following 4 hours of treatment and reverse transcribed
into cDNA. Transcription of specific genes near damage sites in treated and untreated cells was evaluated using
qPCR with SYBR Green reagent and quantified through the following equation: Fold change = 2-ΔΔCt. Success
of Ube2S knockdown was confirmed through Western blot.
Results: Treatment with 4-OHT resulted in lower levels of transcription of genes at DSB sites in control DiVa cells.
Conversely, Ube2S knockdown cells demonstrated higher levels of transcription, suggesting lower levels of
transcriptional inhibition taking place at DSB sites in these cells.
Conclusion: Ube2S aids in transcriptional inhibition at DSB sites following DNA damage.
Keywords: DNA damage response, Ube2S, Lys11-linkage ubiquitination, transcription inhibition
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Abstract number: 56
Effects of different TLR agonists on in vivo cDC1 and in vivo cDC2 activation
Katherine Nowak; Immunology; University of Texas MD Anderson Cancer Center
Bailey Harmon; Immunology; University of Texas MD Anderson Cancer Center
Allison Dyevoich; Immunology; University of Texas MD Anderson Cancer Center
Stephanie Watowich; Immunology; University of Texas MD Anderson Cancer Center
Background: Mature dendritic cells (DCs) are critical to the proinflammatory regulatory immune system response.
Toll-like receptors (TLRs) including TLR3 and TLR7/8 promote the activation of type 1 and type 2 conventional
dendritic cells (cDC1s and cDC2s, respectively). Activated cDC1s and cDC2s contribute to anti-tumor immunity
by presenting tumor antigens to lymphocytes. Tumor specific immune responses are mediated by costimulatory
molecules which regulate antigen-specific T cell responses. Conventionally, cDC1s respond to TLR3 stimulation
and cDC2s respond to TLR7/8 stimulation. However, it is unknown whether these DC subtypes can be activated
by unconventional TLR stimulation.
Methods: We generated cDC1s and cDC2s in vivo by utilizing Flt3L hydrodynamic gene transfer via large volume
tail vein injection and harvested splenic cells eight days later. DCs were sorted using fluorescence-activated cell
sorting (FACS) to obtain pure populations. cDC1s and cDC2s were stimulated with poly I:C, a TLR3 agonist,
imiquimod, a TLR7/8 agonist, or a combination of both agonists. After stimulation, we examined DC costimulatory
expression levels of CD40, CD80, CD86, MHC I, and MHC II at 16, 20, and 24 hours post-stimulation using flow
cytometry.
Results: Our studies demonstrated that costimulatory expression increased over time, and in vivo cDC1s and
cDC2s were most activated at 24 hours post-stimulation. cDC1s expressed higher overall levels of costimulatory
molecules compared to cDC2s. cDC1s were most activated after stimulation with poly I:C, indicated by
significantly higher expression of CD40, CD80, and CD86 after 24 hours, while imiquimod failed to significantly
increase cDC1 activation. Poly I:C had a minor effect on cDC2 activation; However, the poly I:C and imiquimod
solution had the highest number of significant increases in cDC2 activation, with significant increases of CD86
and MHC I at 24 hours post-stimulation.
Conclusion: This data demonstrates that cDC1s and cDC2s are largely activated 24 hours after TLR agonist
stimulation. Poly I:C is most effective for promoting cDC1 activation, while the combination of poly I:C and
imiquimod is most effective for activating cDC2s. Thus, it is ineffective to use imiquimod to promote cDC1
activation, although there is a potential for poly I:C, which was previously not believed to promote robust cDC2
activation, to increase cDC2 maturation in conjunction with imiquimod. Further research would investigate the
communication between T cells, cDC1s, and cDC2s after dendritic cell stimulation with poly I:C and imiquimod to
elucidate the effects of different agonists on the quality of the immune response.
Keywords: cDC1, cDC2, dendritic cell activation, costimulatory molecules, TLR agonists
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Abstract number: 57
Investigating the Mechanisms of Breast Cancer Metastasis Reactivation by Generating a New DNA
Construct That Targets a Mediator Complex Subunit
Janice Oh; Cancer Biology; University of Texas MD Anderson Cancer Center
Seong-Yeon Bae; Cancer Biology; University of Texas MD Anderson Cancer Center
Filippo Giancotti; Cancer Biology; University of Texas MD Anderson Cancer Center
Background: Metastasis is a serious threat to cancer patients, as it is one of the major causes of all cancer
deaths. Metastases can evade immune surveillance, resist current treatments, and contribute to organ failure.
Genetic screening in mice has identified Med4, a subunit of the Mediator complex, as a potential dormancy
enforcer, or repressor of metastatic reactivation. The Mediator complex is a multiprotein coactivator that regulates
RNA polymerase II-related transcription. Interestingly, cancer patient dataset analyses indicate that lower levels of
Med4 correlate with poorer outcomes. Med4 also has significantly reduced expression in breast cancer cells.
Testing of this candidate has confirmed that Med4 functions to maintain the dormant state of solitary tumor cells
at the pre-metastatic niche and prevent rapid metastatic outgrowth. However, the specific role that Med4 plays in
enforcing dormancy and the mechanisms of metastasis upon Med4 deregulation remain to be elucidated.
Methods: The mechanisms of metastatic reactivation and how Med4 enforces dormancy can be investigated by
silencing Med4 in breast cancer cells. For my project, I cloned microRNA-E-based (miR-E) short hairpin Med4
(shMed4) into a lentiviral vector via DNA cloning. By utilizing this approach, I was able to knock down Med4 in
dormant breast cancer cells. This process comprised of ligating shMed4-encoded templates with lentiviral vectors,
transforming the vectors into bacterial cells, and transfecting the isolated vectors into 293FT cells to produce
lentiviruses. These lentiviruses were then transduced into dormant breast cancer cells, in which the shMed4
sequence integrated into the cancer cell genome to knock down Med4.
Results: Western Blot Analysis and qPCR of the transduced cells confirmed that Med4 was successfully knocked
down, as Med4 protein expression and mRNA transcription were lower in the transduced cells compared to the
control. Fluorescence imaging and the fluorescence-activated cell sorting results also confirmed the expression of
Crimson-tagged shMed4 in the transduced cells.
Conclusion: With the successful knockdown of Med4 in dormant breast cancer cells, this knockdown method can
be used to further investigate Med4 and metastatic reactivation through RNA-sequencing, immunofluorescence
staining, and drug treatment. shRNA targeting other mediators for metastasis can also be cloned for coknockdown of genes. These additional studies would permit the exploration of the interactions and signaling
pathways related to Med4 and metastatic reactivation. Understanding the mechanisms through which depletion of
Med4 promotes metastatic relapse may lead to the identification of novel biomarkers and therapies that may
benefit a substantial fraction of breast cancer patients.
Keywords: Mediator complex, Metastasis, miR-E shRNA, Cloning
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Abstract number: 58
Digital Drop PCR & Benzonase Treatment for Vector Copy Number Assays
Alisha Patel; Biochemistry; University of Florida
Yue Li; Therapeutics Discovery and Development; University of Texas MD Anderson Cancer Center
Background: Digital Drop PCR or ddPCR is a relatively new technology(2011) and method for digital PCR. Like
quantitative PCR (qPCR), ddPCR can determine the Vector Copy Number (VCN) of gene-modified cell therapy
products. The FDA recommends that the VCN be less than five copies per genome in gene-modified cell therapy
products as there is an increased risk of oncogenesis when the VCN is high. Benzonase treatment removes
residual DNA from transduced cells before DNA extraction and ddPCR. Benzonase treatment may not be
required before ddPCR and is not a requirement for VCN assays; therefore, the necessity of Benzonase
treatment was ascertained. More ever, at least two washes with dPBS after Benzonase treatment is needed, so
the effectiveness of four washes compared to two washed was measured as well. The effectiveness of two
ddPCR reference genes, RPP30 and RNase P was determined too.
Methods: Half of the transduced cells were treated with Benzonase and ddPCR with reference genes RPP30 or
RNase P was carried out in both treated and non-treated cells to compare the VCN of both Benzonase and NonBenzonase treated cells. To determine the optimal wash number, transduced cells were treated with Benzonase,
treated cells were either washed two or four times with dPBS, and ddPCR with RNase P as a reference gene was
completed.
Results: Benzonase treatment reduced RNase P concentration in the final ddPPC products but did not affect the
concentration of the Gene of Interest-1 and RPP30. Benzonase treatment did not affect the DNA of Interest-2
VCN with RPP30 as a reference but did affect Gene of Interest-1 VCN with RPP30. Four washes after Benzonase
treatment reduced the VCN compared to two washes after Benzonase treatment.
Conclusion: Residual Benzonase or impurity of the product may have affected the RNase P PCR Product.
Residual Benzonase may also account for the effectiveness of four washes after Benzonase treatment compared
to two washes. Based on the results and supporting published literature where Benzonase treatment is not
necessary for VCN assays, it is suggested that VCN assay sample preparation does not need to include
Benzonase treatment.
Keywords: Digital Drop PCR (ddPCR), Vector Copy Number (VCN), gene-modified cell therapy, Benzonase
treatment, reference gene
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Abstract number: 59
Effect of Combined PD-1 and IL-6 Blockade on K-ras Mutant Lung Cancer
Stephen Peng; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Bo Yuan; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Marco Ramos; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Background: Lung cancer is by far the leading cause of cancer death worldwide. K-ras mutations are the most
common mutations in non-small cell lung cancer (NSCLC), encompassing up to 30% of them, and are associated
with poor prognosis. Unfortunately, targeting K-ras directly has substantially failed thus far, and there are no
therapies that adequately address this mutation. Immunotherapy has revolutionized the way we approach treating
cancer, and recently, immune checkpoint blockade, such as PD-1 blockade, has shown promise in patients with
NSCLC. However, these treatments only provide therapeutic benefits to a minority of patients. Our lab has
previously shown the vital role IL-6 has in the pathogenesis of K-ras mutant lung cancer by inducing a pro-tumor
myeloid and lymphoid contexture in the tumor microenvironment (TME) and promoting tumor cell proliferation.
Additionally, we have shown that IL-6 blockade reprograms the TME to have an antitumor polarization of
macrophages (M2->M1) and a more robust cytotoxic immune response, including Th1 and CD8 responses.
Accordingly, we hypothesized that there might be an additive/synergistic effect of modulating the
immunosuppressive TME and augmenting anti-tumor immunity through combined PD-1 and IL-6 blockade.
Methods: Four cohorts of 14-week old K-ras mutant mice were treated with control IgG, anti-PD-1 Ab, anti-IL-6
Ab, or a combination of both. Mice were harvested after four weeks of treatment, and tumor burden was
assessed.
Results: We found that both single treatments significantly reduced tumor burden. Interestingly, the anti-PD-1
treatment group and combination group contained clustered responses, with some mice responding exceptionally
well and others receiving no benefit.
Conclusion: Further experiments and analysis will determine changes in tumor and immune cells and TME
contexture. Dissecting why certain mice are responders or nonresponders will elucidate resistance mechanisms
and help clinicians create individualized treatment strategies.
Keywords: K-ras, NSCLC, IL-6, PD-1, Immunotherapy
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Abstract number: 60
Re-expression of DIRAS3 in KRAS mutant pancreatic and ovarian cancers increases sensitivity to
autophagy inhibitors
Alexandre R. S. Ribeiro; Biology; Houston Baptist University
Gamze B. Elcik; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Zhen Lu; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Robert C. Bast, Jr.; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Background: Mutant KRAS drives human cancers from several sites, including pancreatic ductal adenocarcinoma
(PDAC) and low-grade serous ovarian cancer (LGSOC). More than 90% of PDACs and up to 40% of low-grade
serous ovarian cancers are driven by mutant KRAS. Despite the prevalence of RAS mutations in many different
cancers, effective RAS-targeted treatment remains a challenge. KRAS is a molecular switch and when mutated
becomes permanently stuck in the ON position, inducing oncogenic transformation. Genetic suppression of KRAS
or pharmacological inhibition of its effectors, ERK/MAPK, enhances the reliance of PDAC on autophagy which
can become a target for treatment. Our group has discovered that mutant KRAS protein can be targeted directly
by DIRAS3 (ARHI), a novel endogenous physiological KRAS inhibitor. DIRAS3, an imprinted tumour suppressor
gene, shares 50-60% homology with classical RAS family members but has a distinctive 34 amino acid N-terminal
extension that reverses RAS function, suppressing oncogenesis. In this study, we tested whether inhibiting RAS
signalling by re-expressing DIRAS3 would sensitise RAS-driven PDAC and LGSOC cell lines to autophagy
inhibition. We hypothesised that the effects of DIRAS3 re-expression would differ depending on the KRAS
mutational status of the cell lines.
Methods: Autophagy inhibitors, chloroquine (CQ) and di-chloroquine (DC661), were used to examine their effect
on DIRAS3-inducible cells including AsPC1-DIRAS3 (KRASG12D), BxPC3-DIRAS3 (WT/BRAF mutation),
Capan2-DIRAS3 (KRASG12V), HOC7 (WT), HCC5075 (KRASG12V) and PM-LGSOC01-DIRAS3 (KRASG12V).
Western blot assays were performed to examine the levels of phospho-ERK1/2, LC3B-I, LC3B-II and DIRAS3.
Sulforhodamine B colorimetric (SRB) assays were used to examine cell viability in presence and absence
autophagy inhibitors with or without DIRAS3 expression.
Results: Re-expression of DIRAS3 had many effects in relation to autophagy. It decreased phosphorylation of
ERK/2 (pThr202/Tyr204) in KRAS mutant cells, but not in KRAS wild type cells. DIRAS3 expression-induced
autophagic flux in mutant cell lines, judged by the increased conversion of LC3B-I to LC3B-II. In addition, we
confirmed that DIRAS3-induced autophagy enhanced the sensitivity of cancer cells to autophagy inhibition as
evidenced by the decrease of IC50 of both CQ and DC661 in human KRAS-driven cancer cell lines (AsPC1DIRAS3, Capan2-DIRAS3 and PM-LGSOC01-DIRAS3).
Conclusion: Expression of DIRAS3 inhibits RAS-RAF-MEK-ERK signalling, induces autophagy and enhances
sensitivity of autophagy inhibitor in KRAS mutant cancer cells. In addition, our data suggest that the greater
potency of DC661, blocking autophagy with an IC50 in the low nanomolar range, should prove more effective for
combinatorial therapies in patients with KRAS mutant PDAC and LGSOC.
Keywords: KRAS, DIRAS3, autophagy, chloroquine.
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

63

Abstract number: 61
Exploring Automatic Differentiation and Finite Differences Using the Rosenbrock Function
Nicholas Rubino; Imaging Physics; University of Texas MD Anderson Cancer Center
Adrian Celaya; Imaging Physics; University of Texas MD Anderson Cancer Center
David T. Fuentes; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Computer models are growing increasingly complex as more accurate models are created.
Optimizing parameters in these models relies on efficiently taking derivatives. Our model is used to find the
optimum flip angles for hyperpolarized magnetic resonance imaging (HPMRI). Automatic Differentiation (Autodiff)
is a differentiation technique that is based on the chain rule. The Sum of Finite Differences is a technique used to
approximate derivatives based on the limit definition of a function. These two techniques were compared to
determine which was best suited for application in the significantly more complex HPMRI model.
Methods: Using MATLAB’s optimization framework and the Extended Rosenbrock Function of 2, 4, 10, 50, 100,
500, and 1000 parameters as an objective function benchmark, both Automatic Differentiation and Sum of Finite
Differences were tested for computational expense and speed.
Results: For 2, 4, and 10 parameters, Finite Differences was faster than Autodiff. However, for all parameters,
Autodiff completed the objective function optimization with fewer function evaluations.
Conclusion: Autodiff consistently optimized the benchmark objective function with fewer function evaluations
making it significantly less computationally expensive. This makes it a better choice for application in the HPMRI
flip angle optimization where the objective function is much more complex.
Keywords: Automatic Differentiation, Sum of Finite Differences, Rosenbrock Function
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Abstract number: 62
The Effect of Aerobic Exercise on Tumor Hypoxia and Metabolism in a Murine Melanoma Model
Mumina Sadullozoda; Pediatric Oncology; City University of New York Brooklyn College
Hannah Savage; Pediatric Oncology; University of Texas MD Anderson Cancer Center
Keri L. Schadler; Pediatric Oncology; University of Texas MD Anderson Cancer Center
Background: Solid tumor vasculature is dysfunctional containing structural abnormalities, heterogeneous
perfusion patterns, and hyper-permeability. These abnormalities make it a challenge to deliver systemic therapies
effectively. In addition, poor vasculature function promotes a hypoxic tumor environment conducive to therapeutic
resistance. One method to normalize tumor vasculature is aerobic exercise. Unexpectedly, our lab has observed
significant reductions in hypoxia after exercise but no change in vessel perfusion in a murine model of melanoma.
This may be due to an alteration in tumor metabolic flux or oxygen consumption after exercise. Thus, this project
aims to study the effect of exercise on tumor metabolism. We hypothesized that exercise reduces expression of
genes associated with metabolism in tumors, contributing to decreased hypoxia within the tumor
microenvironment.
Methods: YUMMER melanoma cell line was injected into C571Bl/6 male mice subcutaneously. When tumors
became palpable, mice were exercised 45 min/day, 5 days/week, for 2 weeks at 12 meters/minute using a forced
treadmill model to achieve moderate aerobic exercise training. Prior to mouse euthanasia, pimonidazole was
injected intravenously in tumor bearing mice and tissue was frozen for analysis. Hypoxia and metabolism related
proteins and genes were measured in frozen tumor pieces by western blot and qPCR, respectively. Differentially
expressed metabolites were mined in a public dataset using the limma package on R.
Results: We observed a reduction in pimonidazole staining, indicating a reduction in hypoxia, after exercise.
However, changes in HIF1a mRNA and protein levels were not detected. We measured expression of genes
associated with electron transport chain function (ATP5b, ATPaf2, and Cox4i1) and observed no change after
exercise. Genes associated with Krebs cycle function showed increasing trend in tumors from exercised mice
(Idh2, p=0.09; and Fh1, p=0.16). To support this data, we mined a publicly available metabolomics dataset to
identify differentially expressed metabolites in sedentary and exercised mouse plasma. Consistent with our
findings, Krebs cycle related metabolites including fumarate, malate, alpha-ketoglutarate increased in samples
after exercise.
Conclusion: Our original hypothesis was not supported as we saw an increase in metabolic related genes,
specifically in Krebs cycle genes. These results support that aerobic exercise does modulate metabolism,
however, why exercise may increase metabolism in tumor tissue and its implications on tumor hypoxia remains
unclear. Additional studies like seahorse assay to more directly determine metabolic flux and oxygen consumption
are necessary to further elucidate the role of exercise on tumor metabolism.
Keywords: Melanoma, hypoxia, metabolism, exercise
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Abstract number: 63
Assessing the expression of MHC-I, MHC-II, and PD-L1 in the Yumm1.7-3.D8.B7 melanoma cell line upon
IFN-g stimulation
Jean Schneider; Immunology; University of Texas MD Anderson Cancer Center
Matthew Gubin; Immunology; University of Texas MD Anderson Cancer Center
Charmelle Williams; Immunology; University of Texas MD Anderson Cancer Center
Background: T cell recognition of tumor-derived antigens on major histocompatibility complex (MHC) is critical for
effective anti-tumor immune responses. MHC class I (MHC-I) and MHC-II present antigens to CD8+ T cells and
CD4+ T cells, respectively. When a T cell recognizes peptide-MHC, along with co-stimulation, it becomes
activated. The cytokine interferon-gamma (IFN-g) can induce upregulation of MHC-I and MHC-II and facilitate
antigen presentation and activation of T cells. IFN-g may also upregulate PD-L1, a ligand for PD-1 and this can
suppress the T cell. In most solid tumors, IFN-g upregulates MHC-I and PD-L1. MHC-II is generally not
upregulated on solid tumors with the exception of some subsets, including certain melanomas. It is unclear how
MHC-II expression in melanoma affects anti-tumor responses. I therefore assessed expression of MHC-I, MHC-II,
PD-L1, and the co-stimulatory molecule CD80 on the Yumm1.7-3.D8.B7 melanoma cell line and hypothesized
that MHC-I, MHC-II, and PD-L1 would be upregulated by IFN-g in a time-dependent manner.
Methods: We stimulated Yumm1.7-3.D8.B7 cells in culture with different concentrations of recombinant IFN-g (0,
100, 300 U/mL) for 24 or 72 hours. Afterwards, we removed growth media, washed cells, and trypsinized cells to
remove cells from flask. Cells were then stained with fluorescently-conjugated antibodies for MHC-I, MHC-II, PDL1, and CD80 and analyzed by flow cytometry.
Results: Tumor cells expressed little to no MHC-I, MHC-II or PD-L1 in the absence of IFN-g. IFN-g upregulated
MHC-I and PD-L1 on tumor cells in a dose and time-dependent manner. IFN-g also induced upregulation of MHCII, but only on a subset of tumor cells. CD80 was expressed in the absence of IFN-g, with only slight change in
expression upon stimulation with IFN-g.
Conclusion: Our results reveal the IFN-g-signaling pathway is intact in YUMM1.7-3.D8.B7 and that MHC-I tumor
antigens are likely presented in vivo and PD-L1 on the tumor cells is likely interacting with PD-1 on T cells when
IFN-g is present. The CD80 expression in the absence of stimulation indicates constitutive expression of this costimulatory molecule. These would presumably increase the immunogenicity of the tumor cells in vivo, so the role
of CD80 on the YUMM1.7-3.D8.B7 will be interesting to further explore in the future. MHC-II upregulation on only
a fraction of the cells indicates heterogeneity within the tumor cells. Perhaps stimulating with IFN-g for longer will
promote MHC-II expression, possibly making them susceptible to CD4+ T-cells. It will also be interesting to
assess whether inflammatory signals besides IFN-g upregulate MHC-II.
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Abstract number: 64
Assessing the Speed and Accuracy of Real-time Motion Tracking Algorithms for Abdominal Organ Motion
Management in a 1.5T MR-Linac System
Mohammed Mehdi Shahid; Physics & Astronomy; Carleton College, Northfield, Minnesota
Travis Salzillo, PhD; Radiation Oncology; MD Anderson Cancer Center, Houston, Texas
Jihong Wang, PhD; Radiation Physics; MD Anderson Cancer Center, Houston, Texas
Background: Real-time magnetic resonance imaging (MRI) using the novel MR-Linac provides the opportunity for
organ motion tracking during MRI-guided radiotherapy. Managing organ motion is important in radiotherapy to
mitigate normal tissue toxicities. This work investigates the efficacy of three algorithms for real-time organ motion
tracking.
Methods: Algorithms based on template matching were chosen to determine the 2-D displacement of an
abdominal target region. We measured the efficacy of Normalized Cross Correlation (NCC), Mutual Information
(MI) and OpenCV's Kernelized Correlation Filter (KCF) motion tracking methods by measuring the computation
speed of the algorithm and the spatial accuracy of the predicted template location throughout the exam.
Results: OpenCV's KCF algorithm provides the fastest speed of 35 ± 1 ms per frame and the most accurate
motion tracking for real-time abdominal targets.
Conclusion: This work shows the feasibility of three motion tracking algorithms to track organ motion during MRguided radiotherapy on the MR-Linac. Further development to incorporate the algorithm with MR-Linac
technology is needed in implementing such trackers for continuous clinical use.
Keywords: MR-Linac, motion tracking, organ motion
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Abstract number: 66
Is Immune system signaling responsible for PARP inhibitor killing of BRCA2 depleted cells?
Mona Shirvani; Cancer Biology; University of Texas MD Anderson Cancer Center
Eszter Dombi; Cancer Biology; University of Texas MD Anderson Cancer Center
Katharina Schlacher; Cancer Biology; University of Texas MD Anderson Cancer Center
Background: PARP inhibitors (PARPi) have been found to be most effective when targeting BRCA1 and 2 breast
and ovarian cancers. The enzyme PARP repairs single strand DNA lesions, which turn into double strand lesions
if not repaired before DNA replication. BRCA2 repairs double strand breaks. Defects in both these complementary
pathways underlie the principle of synthetic lethality that is proposed to be driving PARPi killing of BRCA2
depleted cells. Yet if that was the case, PARPi should kill cells shortly after being administered, not after ~4 days.
While chronic inactivation of BRCA2 leads to pro-inflammatory cytokine production (i.e. TNFα), the addition of
PARPi has been found to reduce the amount of time it takes to activate the immune signaling to ~3 days. We
propose that immune signaling events triggered by PARPi treatment may contribute to its cytotoxicity in cancer
cells.
Methods: BRCA2 depleted and WT control cells were seeded in multiple 96-well plates. The next day cells were
treated with differing concentrations of Olaparib (a PARPi) and Cisplatin (a chemo drug). Two days later,
supernatant (SN) from treated and untreated cells was transferred to naïve BRCA2 depleted and WT cells with
and without the addition of Humira (a TNFαi). Cell survival was assessed after 3 days using the MTS assay.
Results: Cell survival of BRCA2 knockdown vs control did not appear to vary greatly so the experiment is being
repeated with extra steps to make sure BRCA2 knockdown is working properly, reagents aren’t defective, etc.
Earlier experiments determined the optimal drug concentrations to use with which cell lines and numbers.
Conclusion: We wanted to see if the SN of PARPi-treated cells- theoretically containing cytokines (i.e. TNFα)would also kill untreated cells as that would suggest immune signaling is the reason behind PARPi killing of
BRCA2 depleted cells, and not synthetic lethality. If cells treated with SN died while those with SN + TNFαi didn’t,
that means that TNFα is the main immune signaling factor that is involved with PARPi killing.
Keywords: BRCA2, PARP inhibitor (PARPi), TNFα, immune signaling, synthetic lethality
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Abstract number: 67
RAS pathway up-regulation as a mechanism of resistance to vertical MAPK inhibition therapies in KRAS
mutant colorectal cancer.
Jovan Stanisavic; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Soumya Somani; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Mohamad Karim Koleilat; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Lawrence Kwong; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the United States.
Despite 30-50% of all cases harboring the KRAS mutation in the MAPK pathway, chemotherapy remains the
standard of care. Although a MEK plus CDK4/6 inhibitor combination therapy is currently in a Phase II clinical trial
for KRASmut CRC (NCT03981614), most cancers quickly develop resistance to targeted therapies and we
anticipate this to be no different. The aims of this project include (1) modeling resistance of KRAS-mutated CRC
to vertical MAPK inhibitor therapies in vitro and (2) investigating the mechanisms driving the resistance.
Methods: To establish the in-vitro model of MEKi-resistant cells, SW837 (KRASmut, PI3Kwt) cells underwent long
term (~50 days) exposure to high-dose MEKi-based triple combination therapy consisting of ERKi (BVD-523 –
1uM), MEKi (Binimetinib – 1uM) and SHP2i (SHP099 – 10uM). Resistant and parental lines were subjected to
Reverse-Phase-Protein-Array (RPPA) and RNA-seq analysis to identify potential resistance drivers. To determine
which differentially expressed genes are critical for conferring resistance to vertical MAPK inhibition, we
performed gateway cloning to individually induce the expression of these genes in KRASmut cells.
Results: Long-term exposure to high-dose vertical MAPK inhibition induced resistance in KRASmut CRC cells. In
addition to acquired resistance, the resistant cells exhibited morphological changes, including reduced
proliferation. RPPA revealed up-regulation of the JNK pathway, a major signaling cascade of the MAPK pathway.
RNA-seq confirmed the up-regulation of the JNK pathway and identified 11 additional potential key resistance
drivers. These genes are known RAS downstream effectors and sensors, and act as transcription factors. To
determine which of the differentially expressed genes are critical for developing resistance, we successfully
designed and validated doxycycline-inducible plasmids containing each of the 12 genes and used lentivirus
transfection to introduce them to KRASmut cells.
Conclusion: Our team found that prolonged high dose vertical MAPK inhibition induced JNK-pathway upregulated resistance in KRASmut CRC cells in vitro and identified 12 potential drivers of resistance, including the
members of the JNK pathway. Furthermore, we successfully designed inducible plasmids for over-expression of
these genes in KRASmut cells.
Keywords: Colorectal cancer, KRAS, Resistance
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Abstract number: 68
Harnessing Nature to Treat High-Grade Gliomas and Metastatic Cancer
William Symmans; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Dong Ho Shin; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Taylor Southward; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Teresa Nguyen; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Sagar Sohoni; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Juan Fueyo; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Candelaria Gomez-Manzano; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Background: High-grade gliomas like glioblastoma, the most frequent primary brain tumor, carry a dismal
prognosis, a 5-year survival rate of just 5%, even with the currently optimal clinical treatment. However, despite
this disease having proven refractory for decades, several preclinical and clinical studies indicate that oncolytic
viruses have the potential to effectively eradicate cancers. The oncolytic adenovirus Delta-24-RGD includes a
deletion in the E1A region that confers tumor-selective infectivity and an RGD peptide motif insertion that
improves infective power. Data from a recently completed first-in-human Phase I clinical trial using Delta-24-RGD
to treat recurrent glioblastoma (NCT00805376) demonstrated that the oncolytic virus successfully excites an
antitumor immune response. We hypothesize that this effect might be amplified by the expression of positive
immune checkpoints. To test this, we incorporated a costimulatory ligand (OX40L) after the fiber region to
maximize T-cell activity, which generated our new oncolytic virus Delta-24-RGDOX-DH.
Methods: The genomes of Delta-24-RGD and Delta-24-RGDOX-DH were amplified by PCR and sequenced to
ensure each viral construct incorporated the appropriate genetic modifications. Next, the expression of murine
OX40L in the membrane of infected cells was assessed using western blot and flow cytometry. Afterwards, the
oncolytic effect of the viruses was tested over time by infecting A549 human lung carcinoma cells, GL-261 glioma
cells, and M12 gastric cancer cells with different viruses. Expression of viral proteins by infected cells was
analyzed using western blotting. Then, studies of mice were conducted to measure the therapeutic effect of
viruses on 4T1-derived breast tumors compared to a mock infection.
Results: Sequencing indicated that the Delta-24-RGDOX-DH genome had all the desired genomic alterations that
give it the ability to selectively infiltrate and lyse gliomas. It produced the necessary viral proteins to maximize
infection and reinvigorate immune lymphocytes. Viability assays showed that Delta-24-RGDOX-DH was 85%
more effective than the control at destroying cancer cells (p<0.0001). Our in vivo studies showed that the virallytreated mice had the greatest decrease of tumor size and metastatic disease.
Conclusion: Experiments performed using Delta-24-RGDOX-DH, incorporating OX40L to stimulate an antitumor
immune response, demonstrated that this novel agent produces a reliable infection in vitro and in vivo with
effective cancer cell lysis and prolonged survival in tumor-bearing mice. Delta-24-RGDOX-DH shows promising
signs of efficacy as an anti-cancer therapy, so our data should propel the development of clinical trials with Delta24-RGDOX-DH for patients with high-grade glioma, or other aggressive types of cancer.
Keywords: Oncolytic Virus, Glioma, Adenovirus
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Abstract number: 69
The Effects of Fluorescence Intensity on Quantifying Radiation-induced Rad51 Foci
Hongshen Wang; Biology; Carleton College
Li Wang; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Xiaochun Wang; Radiation Physics; University of Texas MD Anderson Cancer Center
Eric Lin; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Yupeng Li; Radiation Physics; University of Texas MD Anderson Cancer Center
Yinhan Zhang; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Jennifer Heldring; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Charles E Holmes Jr; Radiation Physics; University of Texas MD Anderson Cancer Center
Matthew D Kerr; Radiation Physics; University of Texas MD Anderson Cancer Center
Narayan Sahoo; Radiation Physics; University of Texas MD Anderson Cancer Center
Xiaorong Ronald Zhu; Radiation Physics; University of Texas MD Anderson Cancer Center
Steven J. Frank; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Radiation can induce DNA double-strand breaks. These breaks are commonly assessed by manual
quantification of foci formed by different DNA damage repair-related proteins in the nucleus. Rad51 is a wellestablished biomarker of DNA homologous recombination repair (HRR) to assess the extent of DNA damage. The
molecular weight of Rad51 is small (37 KDa). Early on after radiation, Rad51 foci are small in size but the number
of Rad51 foci is abundant. This leads to a high workload for manual quantification of Rad51 foci, and the
quantification results may be influenced by inter-observer variations. Herein, we investigate the potential of
measuring nucleus fluorescence intensity to determine Rad51 foci changes after radiation.
Methods: Head and neck cancer cells (SqCC/Y1) were exposed to a single dose of 4-Gy X-ray or proton
radiation. At 2 hours, 5 hours, and 24 hours post irradiation, immunocytochemical analysis was used to assess
Rad51 foci formation. A secondary antibody was conjugated to Cy3 to visualize immunoreactivity. DNA was
stained with 4',6-diamidino-2-phenylindole (DAPI). Immunoreactions were visualized with a Leica Microsystem.
ImageJ software (rsbweb.nih.gov/ij/) was used to manually count Rad51 foci and quantify the fluorescence
intensity of nucleus.
Results: At 2 hours post radiation, compared with the control group, manual counting indicated a 10% increase of
Rad51 foci in cells treated with X-ray versus a 20% increase of foci in cells treated with proton; whereas, the
increase of Rad51 foci was 19% after X-ray versus 39% after proton in average fluorescence intensity of nucleus.
Increased Rad51 foci were observed at both 5 hours (57% in the X-ray group; 122% in the proton group) and at
24 hours (60% in the X-ray group; 123% in the proton group) in manual counting. Nevertheless, no increase in
average fluorescence intensity of the nucleus was observed after radiation at both 5 hours and 24 hours.
Conclusion: Our results indicate that the average fluorescence intensity of the nucleus may be able to reflect the
radiation-induced increase of Rad51 foci at early time point (2 hours) after radiation in the SqCC/Y1 cell line. More
experiments in more cell lines are warranted to determine the value of using fluorescence intensity of the nucleus
to reflect the extent of radiation-induced DNA damage.
Keywords: Radiation, DNA damage, Foci, Rad51, fluorescence intensity of nucleus
Program Affiliation: CPRIT-CURE Summer Undergraduate Program

72

Abstract number: 70
Targeting Low Molecular Weight Cyclin E in ER-positive Breast Cancer
Lucas Warma; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Chen Braun; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Khandan Keyomarsi; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Cyclin E is an important cell cycle regulator controlling the G1/S phase. In many cancer types, cyclin
E is overexpressed causing dysregulation of the G1/S checkpoint and cell cycle progression. Low molecular
weight cyclin E (LMW-E) has been associated with breast cancer tumorigenesis, genomic instability, and
resistance to aromatase inhibitors. No approved therapeutic agents exist to target ER-positive breast cancer
patients that overexpress LMW-E. The purpose of this research is to 1) study the underlying mechanism in which
ER-positive breast cancer cells that overexpress LMW-E become resistant to endocrine therapy and 2) test the
efficacy of various cell cycle inhibitors on full length (FL-E) and LMW-E expressing ER-positive breast cancer cell
growth.
Methods: MCF7 cell lines were used in this study as a model for ER-positive breast cancer. Cells were stably
transfected to express full length cyclin E, LMW-E, or empty vector (4.0) and were grown in the presence and
absence of cell cycle inhibitors at varying doses for 14 days. Cell growth was monitored to assess the effect of
drug treatment on cell viability for each cell type. Western blot and flow cytometry analysis were conducted on
each cell condition to determine differential patterns of cell cycle status and protein expression.
Results: A specific cell cycle inhibitor was found to significantly inhibit the growth of LMW-E expressing cells in the
presence of estrogen, compared to estrogen deprived media (IC50 = 0.96 uM and IC50 2.70 uM, respectively).
Additional cell cycle inhibitors that were tested in this study did not show specificity for LMW-E expressing cells.
However, these inhibitors differentially altered protein expression, cell cycle status and cell growth for FL-E and
4.0 cells in the presence and absence of estrogen – providing evidence for the role of their respective targets in
driving differences between FL-E and LMW-E pharmacological resistance.
Conclusion: These data suggest a unique mechanism that is essential for LMW-E expressing cells to resist
estrogen-dependent therapeutics. The cell cycle inhibitor that was found to inhibit LMW-E expressing cell growth
provides promising translational implications for LMW-E expressing patients with intrinsic resistance to breast
cancer therapies.
Keywords: cell cycle regulation, cyclin E, LMW-E, breast cancer
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Abstract number: 71
The Independent Epigenetic Regulation of Mesenchymal and Stem Cell Like Properties
Alvina Zia; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Maria Castaneda; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Petra den Hollander; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Sendurai Mani; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Epithelial-Mesenchymal Transition (EMT) is a biological program that induces epithelial cells to
morph into a mesenchymal stem cell-like phenotype. Recently our lab identified that cell division is critical for the
gain of stem cell properties during EMT but not for mesenchymal properties. During cell division the epigenetic
programming is critical and gene expression changes during EMT are mediated by epigenetic regulation.
Epigenetic regulators include various histone or chromatin remodeling proteins. Here, we analyze whether
inhibition of epigenetic regulators can separate the gain of mesenchymal and stemness properties.
Methods: Methods: To test this hypothesis, we analyzed two cell lines. MCF10A which exhibits an epithelial
phenotype and can undergo EMT with TGF-β stimulation and SUM159 which exhibits a mesenchymal-like
phenotype. MCF10A the cells were treated with TGFβ and plated with small molecule inhibitors targeting DNA
methyltransferase (5-aza), histone deacetylase (SAHA), and EZH2 (TAZ). An IC50 was conducted on the cell
lines to determine necessary drug concentrations. These cells were then treated with the inhibitors using the
concentration in which 25% of the viability was affected (IC25). Western blot was conducted on the cells to
examine the protein expression of specific EMT markers that correlate with mesenchymal properties. The
presence of Fibronectin 1 (FN1), N-Cadherin, and Vimentin indicated that the cell presented mesenchymal
properties. The presence of E-Cadherin indicated the opposite, meaning the cell possessed epithelial properties.
Mammosphere assays were conducted to determine the inhibition of stemness by the inhibitors. We examined
whether these epigenetic inhibitors could inhibit mesenchymal or stemness properties or both. In order to
correlate these results with clinical treatment in the future we will determine the effectiveness of these drug
treatments in vivo mouse models. The mouse trials will look at epigenetic inhibition drug treatment in tandem with
chemotherapy to test the efficacy.
Results: It was found that the EZH2 inhibitor (Tazemetostat) was able to separate the gain of mesenchymal and
stemness properties. The Western Blot showed that the MCF10A drug-treated cell line exhibited proteins (FN1,
N-Cad, and Vimentin) that are known indicators of mesenchymal properties. The mammosphere data showed
that those same cells did not exhibit stem cell like properties. This indicates that Tazemetostat inhibits the
acquisition of stem cell like properties yet has no real effect on the gain of mesenchymal properties.
Conclusion: Preliminary results indicate that epigenetic drugs have the capability of independently regulating
mesenchymal and stem cell like properties.
Keywords: Key Words: EMT, EPIGENETIC INHIBITION, STEM CELLS, MESENCHYMAL
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Abstract number: 72
A Systematic Review of Smoking Cessation Strategies and Meta-analysis of Cessation Rates in Patients
with Rheumatoid Arthritis
Maria A. Lopez-Olivo; Health Services Research; University of Texas MD Anderson Cancer Center
Gaurav Sharma; Internal Medicine; University of South Alabama
Gagandeep Singh; Government Medical College
Justin James; Health Services Research; University of Texas MD Anderson Cancer Center
Kate J. Krause; Research Medical Library; University of Texas MD Anderson Cancer Center
Paul Cinciripini; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Maria Suarez-Almazor; Health Services Research & General Internal Medicine; University of Texas MD Anderson
Cancer Center
Background: Smoking rates among patients with rheumatoid arthritis (RA) exceed those reported in the general
population. In addition, people with RA who smoke are more likely to develop lung cancer than smokers who do
not have RA. We sought out to identify smoking cessation strategies and synthesize the reported cessation rates
and the effects of the interventions in patients with RA.
Methods: We conducted a review of the literature in electronic databases (i.e., MEDLINE, EMBASE, Cochrane,
CINAHL, and Web of Science) from inception until August 2020. We included studies that reported on the results
of interventions for smoking cessation in patients with RA. Screening, quality appraisal and data collection were
done independently by two reviewers. We collected smoking cessation outcomes, referrals to smoking cessation
services, knowledge about the benefits of smoking cessation, and disease measures.
Results: We included 17 studies evaluating smoking cessation strategies. These included interventions for
patients and providers. For patients, there were 5 educational interventions with advice on the harms of smoking;
5 interventions with advice to quit smoking delivered by educators, nurses, or providers; 2 interventions with
counseling sessions; and 1 assessing a social marketing campaign. For providers 3 studies evaluated the
effectiveness of implementing a Quit connect protocol, and one the use of questionnaire in the waiting are before
seeing their provider. Less than half of the studies (41%) provided follow-up support sessions. One month to 2
years after the implementation of the cessation strategy, the pooled smoking cessation rate was 33%, 95% CI
16% to 52% and referrals to quit services increased from 4 to 23% (7% to 44%). One study reported increased
awareness of the lessened effects of RA treatment when smoking. After 1 month, increased disease activity
(defined by a DAS28 CRP >5.1) was observed in 20% of non-smokers and 30% of smokers in one study (RR 1.5,
95% CI 0.68 to 3.4).
Conclusion: Studies largely varied in patient characteristics, the interventions used, and their implementation
structure. Only two studies were randomized clinical trials. The smoking cessation rate observed after the
implementation of the reported strategies was lower than the published national rate of 62%. Additional controlled
studies are needed to determine best practices for smoking cessation education, counsel, and pharmacological
treatment offered to patients with RA.
Keywords: rheumatoid arthritis, smoking cessation, systematic review, meta analysis
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Abstract number: 73
Financial stress on the patient-caregiver dyad
Esomsidima Azuike; Behavioral Science; University of Texas MD Anderson Cancer Center
Juliet Kroll; Behavioral Science; University of Texas MD Anderson Cancer Center
Background: Cancer impacts patient’s families and disturbs the stability previously seen in the home. Given the
likelihood of an inevitable physical burden, another burden that is being considered as a harmful consequence:
financial toxicity. Financial Toxicity is something that can impact QoL and influence how cancer permeates certain
aspects of life. Financial toxicity is the burden brought on by cancer treatment expenses, job loss, and a
significant change in “normal” life/schedule for the patient and their family. This burden is estimated in prior
studies to affect anywhere from 30% to 50% of patients. The purpose of this study is to address the lack of
information on Financial Toxicity and collect data by way of observational study, meanwhile an analysis of
language used by the patient and their loved one will be analyzed for interpretation of current mental status.
Methods: 100 patients with Stage 3 or Stage 4 breast cancer and their spousal caregiver will participate in an
assessment. Patients with metastatic breast cancer (MBC) and their spousal caregiver (i.e., romantic partner) will
participate. Participants will individually complete questionnaires through Redcap. Patients and their caregiver
will be audio recorded during a spousal interaction task during Zoom or in person at MD Anderson Cancer Center
based on the couple’s choice with personal and institutional distancing practiced. These Audio recordings will be
coded using a newly created guideline for positive language analysis.
Results: In this study, we are exploring financial stress as correlated and/or associated to lower Quality of Life.
We are also to determine financial stress as correlated to lower relationship satisfaction through exploration of
Caregiver and Patient dynamics and satisfaction as measured by DAS-7. There is a lack of knowledge regarding
the impact financial stress does in fact have on a patient and caregiver relationship.
Conclusions: Determining the relationship between Financial Stress and Patient and Caregiver dynamics is
important to see if Quality of Life is lowered or Relationship Satisfaction in lowered.
Keywords: psychological ,processes, financial, stress, cancer
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Abstract number: 74
Metabolic Profiling of Pancreatic Cancer for Early Detection and Determining Therapeutic Efficacy
Trinity Brigham; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
José Enriquez; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Pratip Bhattacharya; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer is a deadly cancer due to its asymptomatic nature, causing the disease to be
detected later when it has already metastasized. At Stage I, the five-year survival rate is 34% but drops to 3% at
Stage IV. Imaging techniques such as endoscopic ultrasounds and MRIs can detect pancreatic cancer, but not in
earlier stages. As cancer cells have a different metabolism than normal cells, analysis of metabolites can be used
to detect pancreatic cancer or the efficacy of a specific treatment. Targeting glutaminolysis, the breakdown of
glutamine, via glutaminase inhibition, is emerging as a promising strategy to disrupt cancer metabolism and tumor
progression.
Methods: The main goal of this project is to study the metabolites of pancreatic tumors from mouse models
treated with a glutaminase inhibitor (V9301) to understand the metabolic changes of pancreatic cancer and the
effect of treatment. Four groups of pancreatic cancer mice were employed. One was treated with a low dosage of
V9301 twice per day for four weeks; another was treated with a high single bolus dosage for 4 hours; a third and
fourth group are control mice that received a sham vehicle treatment in low and high dosage, respectively. The
identity of the groups is unknown as this is a blinded study. Frozen tumor samples were collected and lysed to
extract metabolites, and nuclear magnetic resonance (NMR spectroscopy) was then used to analyze the
metabolic profiles.
Results: Lactate, alanine, and glutamine were the primary metabolites analyzed. Lactate is high in cancer; if the
treatment is working, the amount of lactate decreases. Alanine levels are low in cancer, so a successful treatment
would increase levels. Glutamine causes tumor growth, so a glutaminase inhibitor reduces glutamine levels and
tumor progression. Our results show changes in the level of these three metabolites. The amount of lactate was
high in Groups 1 and 2 compared to Groups 3 and 4. The level of alanine was low in Group 1 and high in Group
4. The level of glutamine was high in Group 2 compared to the other three groups. The results strongly indicate
Group 1 and 2 are possibly controls, while Group 3 and 4 received the glutaminase inhibitor treatments.
Conclusion: Comparing metabolites can effectively detect the progression of pancreatic cancer and determine the
efficacy of novel treatments. This method could serve as an alternative to expensive imaging-based
methodologies that utilize MRI to determine real-time metabolic changes.
Keywords: Pancreatic Cancer, Metabolites, Glutaminase Inhibitor, NMR Spectroscopy
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Abstract number: 75
HPV Vaccination Interventions Among Young Adults: A Systematic Review
Jade Buford; Epidemiology; Emory University
Lenna Dawkins-Moultin; Health Disparities Research; University of Texas MD Anderson Cancer Center
Sarah Siddiqui; Psychology; University of Houston
Qian Lu; Health Disparities Research; University of Texas MD Anderson Cancer Center
Background: The Human Papillomavirus (HPV) is the most common sexually transmitted infection in the United
States with nearly 14 million infections annually. HPV vaccination can prevent up to 74% of HPV-associated
invasive cancer. The CDC recommends routine vaccines through the age of 26; however, completion rates
remain low, while HPV infection rates remain high among 18 to 26 year-olds. Ethnic and racial minorities have a
higher HPV prevalence and suboptimal rates of vaccination uptake and completion among adult women. Studies
show that educational interventions can improve immunization uptake by influencing knowledge and attitudes.
However, it is not clear the extent to which instruments used in these interventions are validated. The purpose of
this review is to identify the outcomes measured in HPV vaccination interventions conducted among young adults
and assess the extent to which the instruments used are validated.
Methods: We searched PubMed, Web of Science, Embase, and Cochrane from 2006 to May 2021 for English
language reports of HPV vaccination interventions conducted among young adults aged 18-26. Screening was
based on relevance and outlined inclusion criteria which included studies that (1) focused on HPV vaccination
interventions, (2) examined young adults aged 18-26, (3) occurred after FDA approval of the HPV vaccine in
2006, (4) conducted within the United States, (5) peer-reviewed, and (6) used quantitative or mixed-method
approaches.
Results: We identified 33 studies of HPV vaccination interventions. Preliminary result indicates common
outcomes are HPV knowledge, intention, susceptibility, self-efficacy, and social norms. The majority of these
studies were conducted at universities and health clinics in minority, low-income, and MSM populations which are
often identified as having lower uptake and are at a greater risk for infection. Most studies used a RCT study
design and the intervention was adapted from previous research and validated models, such as the Health Belief
Model. Lastly, validity was not reported for most, while some only reported acceptability and internal consistency
scores.
Conclusion: Preliminary results suggest that many studies either do not use validated questionnaires or fail to
report validation evidence. This limits comparison and raises questions about the validity of findings. The absence
of standardized HPV scales challenges the validity and credibility of research findings. This review will improve
the quality of HPV vaccination promotion research by clarifying the status of HPV vaccination research and
informing the future development of validated instruments to measure HPV intervention outcomes.
Keywords: HPV, Papillomavirus vaccines, Intervention studies, systematic review, validation
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Abstract number: 76
Colorectal Cancer Screening Guidelines: Analysis of 2019 NHIS
Isabela Bumanlag; McGovern Medical School; The University of Texas Health Science Center at Houston
Abi Jaoude, Joseph; GI Radiation Oncology; University of Texas MD Anderson Cancer Center
Nieves-Jiménez, Humberto R.; GI Radiation Oncology; University of Texas MD Anderson Cancer Center
Ludmir, Ethan B.; GI Radiation Oncology; University of Texas MD Anderson Cancer Center
Taniguchi, Cullen M.; GI Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Colorectal cancer (CRC) has well-established screening guidelines with strong evidence for
decreasing incidence and mortality. In light of recent changes to screening guidelines, we sought to examine
screening patterns in the US population.
Methods: The purpose of this study is to investigate whether or not participants met the specific screening
guidelines set by the U.S. Preventive Services Task Force (USPSTF) before 2021. Using the 2019 National
Health Interview Survey (NHIS), we performed descriptive statistics on participant demographics and CRC
screening with sigmoidoscopy (SIG) and colonoscopy (COL) within the last 10 years. Bivariate and multivariable
logistic regression were utilized to highlight variables that were associated with whether or not participants met
the proper USPSTF SIG/COL screening guidelines.
Results: Overall, we gathered answers from 21,863 respondents aged 40 years or older, from a total of 31,997
participants in the 2019 NHIS survey. Over half of respondents (13,383; 60.8%) reported that they had undergone
COL/SIG in the past. Similarly, over half of respondents were shown to have followed the USPSTF guidelines for
CRC screening (12,188; 55.7%). Our stratified analysis found that, compared to Whites, Blacks/African
Americans were more likely to have met COL/SIG screening guidelines (aOR = 1.27, P <0.05) while Asians were
less likely (aOR = 0.69, P <0.05). The higher the educational status of a participant, the more likely a participant
would meet the guidelines (high school graduates, OR = 1.55, P <0.05; college degrees, OR = 1.66, P <0.05)
compared to those who did not go to high school or complete high school. Those without any form of health
insurance coverage (aOR = 0.46, P <0.05) and without a usual place of care (aOR = 0.32, P <0.05) were less
likely to have met screening criteria. When assessing socioeconomic status, we found that those with higher
levels of SES were more likely to have met CRC guidelines (aOR = 1.72, P <0.05). Additionally, respondents that
were foreign born were less likely to have met the correct guidelines (aOR = 0.83, P <0.05).
Conclusion: There are patient, physician, and health-system related factors that can independently affect CRC
screening uptake. Differences in CRC screening may still exist among various populations, so it is crucial to
further examine populations who have high CRC burdens.
Keywords: NHIS, colorectal cancer, screening, health disparities
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Abstract number: 77
Determinants of Patient-Reported Dysphagia Among Oropharyngeal Cancer Survivors
Camille Charles; Epidemiology; University of Texas MD Anderson Cancer Center
Puja Aggarwal; Epidemiology; University of Texas MD Anderson Cancer Center
Sanjay Shete; Epidemiology; University of Texas MD Anderson Cancer Center
Dysphagia, or difficulty swallowing, is a commonly reported side effect of head and neck cancer (HNC) patients
after surgery, radiation therapy (RT) or chemoradiotherapy. Impaired swallowing, if prolonged, can cause a
patient to experience detrimental effects on their quality of life. Among oropharyngeal cancer patients (OPC) with
prolonged dysphagia, clinicians worry about dehydration, malnutrition, and depression among others. As it is a
worrisome experience for the patient, it is imperative that clinicians consider these possible adverse effects when
selecting individual treatment approaches. The aim of this study is to investigate clinico-demographic risk factors
and their association with patient-reported dysphagia.
This study population included OPC survivors treated at MD Anderson between January 2000 to December 2013.
Dysphagia was rated using the MD Anderson Symptom Inventory for HNC (MDASI-HN) and moderate to severe
dysphagia was defined as score ≥5. Clinico-demographic risk factors including age, total RT dose, and smoking
among others, were abstracted. Statistical methods included descriptive statistics and multivariable logistic
regression (MLR) to identify factors associated with moderate to severe dysphagia.
A total of 880 responded to the MDASI-HN difficulty swallowing symptom question, of which 672 (76.4%) reported
none to mild dysphagia and 208 (23.6%) reported moderate to severe dysphagia. Upon MLR analysis, patients
with advanced tumor staging of T3+T4 (OR, 1.62; 95% CI, 1.06-2.48; p=0.025), those with late lower cranial
neuropathy (LCNP) (OR, 3.46; 95% CI, 1.59-7.51; p=0.002) and patients that were current smokers during the
survey (OR, 2.19; 95% CI, 1.01-4.75; p=0.048) were associated with an increased risk of moderate to severe
dysphagia. Additionally, MLR found patients with greater than high school education (OR, 0.65; 95% CI, 0.420.98; p=0.041), those who underwent intensity-modulated radiation therapy (IMRT) bilateral (OR, 0.27; 95% CI,
0.12-0.60; p=0.001), and IMRT ipsilateral (OR, 0.12; 95% CI, 0.04-0.36; p=<0.001) were associated with a
decreased risk moderate to severe dysphagia post-treatment.
Risk factors assessed prior to cancer treatments may predict the development of dysphagia in HNC patients. The
results of this study are intended to inform clinicians while selecting optimal treatment and supportive patient
interventions, such as swallowing exercises and continued assessment by speech pathologists. In addition, this
research also can be used to apprise future research to decrease the burden of dysphagia, guide patient
prophylaxis, highlight the importance of smoking cessation and the management of late cancer treatment effects
like LCNP, and preserve necessary neuromuscular structures and function used in the act of swallowing.
Keywords: Dysphagia, swallowing, survivorship, oropharyngeal, cancer
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Abstract number: 78
Follow Through: Improving Exercise Adherence Through Follow-Up Contact in Pancreatic Cancer
Survivors
Alicia Cotto; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Nathan H. Parker; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer treatment and its sequelae may negatively impact patients’ functional ability and
quality of life (QOL). Physical activity (PA) can offset these anticipated declines, with increases in aerobic activity
volume alone showing positive effects (Ngo-Huang & Parker et al. 2019). As few as 24% of pancreatic cancer
survivors meet ACSM PA recommendations (Parker et al. 2020). Self-efficacy – an individual’s belief in their
capacity to execute the behaviors necessary in given situations – may be a critical factor in improving survivor
exercise adherence. In healthy geriatric populations, self-efficacy is positively correlated with improved exercise
behaviors (Neupert et al. 2013). Conversely, low levels of self-efficacy were associated with low levels of PA in a
sample of lung and gastrointestinal cancer survivors (Wasley et al. 2016). This study investigates the efficacy of
follow-up contact on self-reported PA in pancreatic cancer survivors. Follow-up contact consisting of reminders
and recommendations for exercise may significantly improve exercise adherence by improving exercise selfefficacy (ESE) and barrier self-efficacy (BSE).
Methods: Participants were randomized to receive a general recommendation to exercise (Arm A) vs. a formal,
home based exercise program (Arm B). Data was collected via baseline and pre-operative survey. Self-reported
PA was measured using a modified Godin scale, ESE/BSE were measured using validated surveys. Paired t-tests
identified significant changes in baseline to pre-op scores. ANOVAs were used to quantify group differences in
aerobic activity, strength training, ESE, and BSE. Associations between BSE, ESE, and PA were calculated using
bivariate association.
Results: Of 82 total subjects, 39% (n=32) identified as female and 61% (n=50) identified as male. Paired
samples t-test revealed significant mean difference in strength training frequency from baseline (M=.79,
SD=1.546) to pre-op (M=1.89, SD=1.905); t(81) = -4.557, p <.001. There were no significant mean differences in
Godin score, ESE, or BSE. One-way ANOVA found significant effects of study arm on strength training
frequency [F(1,80)=11.919, p=.001, η2=.130]. Follow-up contact increased strength training frequency when
compared to usual care. No significant interaction was observed between study arm and Godin, ESE, or BSE
scores.
Conclusion: While existing literature ties SE to exercise adherence, this study aims to determine whether homebased aerobic and resistance exercise programs could increase PA among individuals undergoing pancreatic
cancer treatment. Moreover, we sought to determine the role of SE as an intermediary for these changes.
Identifying key intermediates for behavioral change in these unique populations will help future exercise
interventions utilize targeted behavioral modification strategies to address the specific needs of this group.
Keywords: self-efficacy, exercise, pancreatic cancer, adherence, physical activity
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Abstract number: 79
5-Year Survival by Race, Gender, Stage, and Site
Taylor Curry; Epidemiology; University of Texas MD Anderson Cancer Center
Kristin Primm; Epidemiology; University of Texas MD Anderson Cancer Center
Shine Chang; Epidemiology; University of Texas MD Anderson Cancer Center
Background: Recent literature has shown an increasing trend in Colorectal Cancer (CRC) survival across all
minority groups due to initiatives like improving patient awareness of screening resources and improving
accessibility through subsidized screening programs in medically underserved communities. However, this
increasing trend has not eliminated the disparities in survival experienced by ethnic minority groups (i.e.,
American Indian/Alaskan Native, Non-Hispanic (NH) Black, Hispanic/Latinx, and API). While existing research
confirms that ethnic minorities continue to experience lower CRC survival when compared to NH white
populations, few studies compare survival by Race/ethnicity, gender, stage, and subsite. Analyzing this data
addresses a fundamental gap in CRC survival research, improving our ability to create tailored interventions
specific to these communities.
Methods: This study will examine survival data among specific minority populations from 2000-2013 using the
SEER* database. After compiling the data into group-specific CRC survival trends over time, between-group
comparisons will illustrate existing disparities amongst ethnic minority groups. Data will also be compared to NH
white CRC mortality, but with greater specificity than minority group comparison data which currently exists.
Comparing these populations will facilitate the creation of ethnically and culturally specific interventions, as well as
an improved understanding of where existing interventions may have failed to reach a subset of minority
communities. The study population included patients (age ≥ 20 years) with a primary diagnosis of CRC from 2000
to 2013. We excluded in situ cases, patients with unknown/missing race/ethnicity, missing/unknown staging
information, cases reported through death certificate or autopsy report only, records with no survival time, those
with missing or unknown cause of death, and cases with missing diagnoses dates. Five-year cause specific
survival rates for CRC were calculated using SEER*stat version 8.3.9. We examined temporal trends in 5-yr
survival rates by race/ethnicity (White, Black, American Indian, Asian/PI, and Hispanic), sex, stage at diagnosis
(localized, regional, distant), and CRC subsite. Trends in 5-yr survival rates were characterized in terms of
percent change in rates from the year 2000 to 2013.
Results: When looking at survival rates by stage for both males and females, NHB have the lowest 5-year survival
for all stages from 2000 to 2013, however due to the increase in survival for all race/ethnicities this has caused a
greater or equal PC in all stages compared to their NHW counterparts. API’s had the highest survival rate for all
stages in 2000, but in 2013 AI/AN were recorded to have the highest survival generating the largest PC for
localized and distant stage. While a higher survival rate in 2000 was recorded for HIS, in 2013 the survival rate
between HIS and NHW were found to be the same, producing the lowest PC for all stages. These disparities can
be seen in greater detail when CRC is also divided into site.
Conclusion: Understanding the disparities between different populations is the first step to creating equitable
health care. Research has shown existing interventions effectively improve overall survival but fail to moderate
CRC survival disparities between racial minorities and their NH white counterparts. To effectively combat
disparities, we must first identify where and how they exist in each community. By improving the specificity of data
regarding CRC survival amongst minorities future interventions can address both overall survival and population
specific disparities.
Keywords: Colorectal Cancer, Survival, Race, Stage, Site
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Abstract number: 80
Preliminary investigation of Latino cultural constructs to guide adaptation of mindfulness program
Hannah Fuchs; Health Disparities Research; University of Texas MD Anderson Cancer Center
Elizabeth Dominguez; Health Disparities Research; University of Texas MD Anderson Cancer Center
Larkin Strong, PhD; Health Disparities Research; University of Texas MD Anderson Cancer Center
Background: Cancer patients have been shown to benefit from psychosocial programming, with evidence of
improved quality of life (QOL). Unfortunately, few interventions have focused their impact on Latino communities,
who display higher levels of unmet needs and distress than non-Hispanic white individuals. The aim of this
research is to identify cultural constructs that will be instrumental to the initial phases of adapting a mindfulness
intervention so that it may be applied to Latino patients with advanced stage disease and their family members.
Methods: An existing mindfulness program, called Mindful Purpose Training (MPT), will be culturally adapted for
Latino cancer patients with stage III-V solid tumors at Lyndon B. Johnson Hospital and their family caregivers. In
preparation for phase 1 feasibility interviews with participants (n=40, 20 dyads), bilingual screening questionnaires
were created in the REDCap survey and database system. Internal (strengths/weaknesses) and external factors
(opportunities/threats) that will affect the process of achieving better cultural competency within the program—
including the interviews— were assessed using a SWOT analysis.
Results: In the Latino community, familismo, simpatía, personalismo, and fatalismo were identified as important
cultural ideologies relevant to the adaptation of this program. Within the TOWS matrix, familismo—the importance
of family closeness—and personalismo—the emphasis on personal relationships—were highlighted as
opportunities because the program centers around family connections. Conversely, simpatía—the pressure to
keep problems to oneself— and fatalismo—the idea that health outcomes are predetermined— were threats to
improving QOL and continued participant engagement.
Conclusion: Core values, attitudes, beliefs, and ideas impact how cultural groups engage with health behaviors. It
is vital to understand the cultural constructs of the Latino community before creating programs for these
individuals. Highlighting which constructs align with the program and which may present problems in the future is
important preliminary work in order to create a functional and helpful program for this community. Pairing these
findings with input from forthcoming formative interviews will provide more evidence on the feasibility,
acceptability, and efficacy of mindfulness interventions in Latino populations with cancer. Eventually, information
from this analysis and phase 1 interviews will be used to create a culturally sensitive mindfulness program to be
tested in a randomized controlled trial.
Keywords: Hispanic people, mental health, mindfulness, cultural competency, cancer
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Abstract number: 81
Multi-factorial Etiology of Gallbladder Cancer: A USA Case-Control Population Study
Grace Hamadeh; Epidemiology; University of Texas MD Anderson Cancer Center
Rikita Hatia; Epidemiology; University of Texas MD Anderon Cancer Center
Adam Khalifa; Epidemiology; University of Texas MD Anderson Cancer Center
Donghui Li; Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center
Milind Javle; Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center
Manal Hassan; Epidemiology; University of Texas MD Anderson Cancer Center
Background: Gallbladder cancer (GBC) is a common belligerent malignancy in the biliary tract characterized by
unknown etiologies, lethality, and poor prognosis due to late diagnoses. This study aims to highlight the risk
factors of GBC among the multi-ethnic US population.
Methods: A total of 79 cases and 660 healthy controls were recruited from MD Anderson Cancer Center between
2017 and 2021. Under IRB approval of MD Anderson, cases and controls were personally interviewed for different
risk factors. SPSS and STATA were used to perform multivariable logistic regression to estimate odds ratios.
Results: We observed a significant association between alcohol drinking and gallbladder stones with GBC. The
multivariable-adjusted OR 95% (CI) were 7.97 and 1.97 for gallstones and alcohol intake, respectively. On the
other hand, restricted analysis among 44 women cases and 257 women controls yielded a 94% reduction in GBC
risk among estrogen users. The reduction was associated with the duration of estrogen intake. Despite that 19%
of the GBC patients had pathological evidence of steatosis, we found no impact of obesity or diabetes on GBC
development.
Conclusion: Validation of our findings in a multi-site study is necessary to identify the etiology of GBC in the USA
which may assist in disease prevention and screening for high-risk populations.
Keywords: Gallbladder Cancer, Hormone Replacement, Gallstones, Cholecystitis
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Abstract number: 82
The role of Macrophage Migration Inhibitory Factor (MIF) in Apoptotic Extracellular Vesicle Mediated
Signaling in Breast Cancer
Kristy Hernandez; Genetics; University of Texas MD Anderson Cancer Center
Safia Essien; Genetics and Epigenetics Graduate Program, The University of Texas Graduate School of
Biomedical Sciences at Houston, University of Texas MD Anderson Cancer Center
George T. Eisenhoffer; Genetics and Epigenetics Graduate Program, The University of Texas Graduate School of
Biomedical Sciences at Houston, University of Texas MD Anderson Cancer Center
Background: The ability to prevent tumor repopulation after anticancer treatments has been a significant barrier
to reducing morbidity and mortality of malignant tumors. Chemotherapeutic agents induce the death of rapidly
dividing cells, and dying cells can produce mitogenic cues that stimulate proliferation and promote repair. Whether
these regenerative mechanisms are co-opted by tumor cells after cancer treatment is not well understood. Our
data show that small membrane-bound vesicles generated during cell death (called apoptotic extracellular
vesicles, or AEVs) serve as vehicles for the transfer of genetic information and the activation of signaling
pathways that promote cell proliferation. We have identified the known mitogen and cytokine macrophage
migration inhibitor factor (MIF) as enriched on apoptotic extracellular vesicles derived from epithelial stem cells in
zebrafish. The goal of this project is to test if apoptotic extracellular vesicles from human breast cancer cells
(bcAEVs) use MIF to evade the immune system and stimulate proliferation.
Methods: Apoptotic extracellular vesicles from MDA-MB231 breast cancer cells after exposure to
chemotherapeutic agents were isolated by differential centrifugation for downstream studies. Immunogold labeling
with transmission electron microscopy was used to determine the localization of the mitogenic and immunogenic
protein Macrophage Migration Inhibitory Factor (MIF). Isolated bcAEVs were fluorescently labeled and injected
into larval zebrafish where confocal microscopy was used to track interaction with macrophages expressing
EGFP. Cell proliferation was also assessed using a BrdU incorporation assay. Chemical inhibitors against MIF
were used to perturb the activity of specific breast cancer derived apoptotic bodies to assay for effects on
proliferation.
Results: Foci of MIF were detected on the surface of the apoptotic extracellular vesicles (AEVs) purified from
human breast cancer cells. Fluorescently labeled AEVs were tracked after injection into the zebrafish and were
observed interacting with macrophages, providing a novel assay for probing interactions with the immune system
in vivo. We observed an in increase in proliferation in larvae injected with bcAEVs, however before examination of
MIF inhibition could be performed, further adjustments of drug controls timing and concentration are needed.
Conclusion: Here we show that the mitogenic and immunogenic protein MIF is present on the surface of bcAEVs,
and characterize the immunogenic and proliferative responses after introduction into zebrafish larvae. Future
studies will inhibit MIF after delivery of the bcAEVs to the zebrafish larvae, with the goal of providing new insights
into molecular pathways that can be leveraged against cancer by preventing the unwanted addition of new cells.
Keywords: Tumor repopulation, apoptosis, extracellular vesicles, MIF
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Abstract number: 83
Defining acquired mutations in healthy breast tissue and their association with breast cancer risk factors
and breast cancer risk
Raven Hollis; Epidemiology; University of Texas MD Anderson Cancer Center
Background: The World Cancer Research Fund indicated that Breast Cancer in women is the most common in
women worldwide, and contributes to 25.4 % of the total number of new cases diagnosed in the year of
2018(WCRF, 2021). Every breast cancer case is different, but once cancer spreads it is identified as
metastatic(WebMD, n.d). As time progresses, there has been continued research in cancer and its prevention
methods. However, there is limited knowledge regarding acquired mutations in the breast tissue of women without
breast cancer, and their association with known breast cancer risk factors and incident breast cancer risk(Nead,
2020).
Methods: The project will utilize the Komen Tissue Bank to analyze healthy breast tissue taken from women
donors without any indications of breast cancer. These women do in fact have Breast cancer risk factors which
include; pregnancy history, menstrual history, and hormone replacement therapy use. We will use sequencing
data to detect rare acquired mutations, and then relate these findings to epidemiological factors and clinical
outcomes.
What I will learn: During my time at MD Andeson this summer, I will learn how to analyze sequencing data to be
able to detect mutations within breast tissue. In addition, I will be able to report the quantitative and qualitative
findings throughout my time working with my principal investigator. I will learn the purpose of a biomarker, and
how this can impact the future health of patients in the realm of breast cancer.
Conclusion: The study will present a new platform for breast cancer prevention by utilizing acquired mutations in
healthy breast tissue as a biomarker for breast cancer risk. This effective development of a novel prevention
paradigm has the opportunity and potential to positively impact the health of women who are at risk for breast
cancer.
Keywords: Breast Cancer, Biomarkers
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Abstract number: 84
HPV-induced Epigenetic Modifications in the Initiation of Oropharyngeal Cancer
Joy Ihedilionye; Epidemiology; University of Texas MD Anderson Cancer Center
Jian Gu; Epidemiology; University of Texas MD Anderson Cancer Center
Yifan Xu; Epidemiology; University of Texas MD Anderson Cancer Center
Haidee Chancoco; Epidemiology; University of Texas MD Anderson Cancer Center
Background: Among the cancers that routinely afflict the aerodigestive tract, oropharyngeal squamous cell
carcinoma (OPSCC) is of particular importance due to its increasing incidence rate despite successful tobacco
control. It is evidenced that this annual 2.5% increase is due in part to the infection with Human papillomavirus
(HPV) which induces oncogenic and molecular modifications. DNA methylation at CpG sites is a major epigenetic
modification that regulates gene expression and plays important roles in carcinogenesis. Recent studies
compared the DNA methylation patterns in peripheral blood leukocytes in 20 pairs of HPV(+) and HPV(-) OPSCC
patients and found that leukocyte DNA in HPV(+) patients have a global hypomethylation pattern in comparison to
HPV(-) patients. In contrast, a non-coding RNA, nc886, was significantly hypermethylated in HPV(+) patients and
in HPV(+) OPSCC tumor tissues as compared to HPV(-) tumor tissues. No study has been performed in OPSCC
and no study has linked nc886 to HPV infection. The aim of this study is to decode the functional roles and
molecular mechanisms of nc886 in HPV-induced oropharyngeal carcinogenesis.
Methods: Using an OPSCC cell line, FaDu, as an in vitro model, we will generate nc886 gene knockout cells via
the CRISPR-Cas9 system, nc886 knockdown cells via siRNA, and nc886 over-overexpression cells using
transfection of nc886-expression plasmids. We will determine the expression of nc886 using quantitative real-time
PCR. We will determine the effect of down- and up-regulation of nc886 on apoptosis by flow cytometry. We will
use Western blot to observe the effects of nc886 inhibition or overexpression on PKR phosphorylation.
Results: Through in vitro cell culturing, DNA transfection, gene knockdown/knockout, cellular phenotypic assays,
and molecular characterization, we are striving to observe and understand the discrete processes that may spur
the initiation of OPSCC infected with HPV. The process of gene knockdown and overexpression of nc886 in
selected OPSCC cells may provide insight into the mechanical role of nc886 in the etiology of HPV-induced
oropharyngeal cancer by defining its effect on PKR phosphorylation and apoptosis
Conclusion: The implications of this study should yield the first evidenced event that two prominent epigenetic
events (DNA methylation and non-coding RNA regulation) can synchronize to initiate HPV-induced modulations in
the onset and progression of oropharyngeal cancers. This result may further distinguish the pivotal functionality of
nc866 in OPSCC and assume precedent for the continued exploration and treatment advancements of DNA
methylation and non-coding RNA regulation in HPV-related cancers.
Keywords: DNA methylation, HPV-induced oropharyngeal cancer
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Abstract number: 85
Investigation of T Cell Responses to Neoantigens and Share, Non-Mutant Antigens in Mouse Melanoma
During Anti-CTLA-4 Immune Checkpoint Therapy
Amangelin Diore Jalbuena; Immunology; University of Texas MD Anderson Cancer Center
Sunita Keshari; Immunology; University of Texas MD Anderson Cancer Center
Matthew Gubin; Immunology; University of Texas MD Anderson Cancer Center
Background: The immune system influences cancer development and progression in multiple ways. T-cell
recognition of tumor antigens presented on major histocompatibility complex (MHC) is central to immunemediated cancer prevention and response to immunotherapy [e.g., anti-CTLA-4 immune checkpoint therapy
(ICT)]. Two types of tumor antigens exist: (1) non-mutant antigens derived from overexpressed or germline
proteins; (2) neoantigens derived from cancer mutations. Using mouse melanoma lines that express defined
neoantigens (mLama4 and/or mAlg8) and non-mutant antigens (Pmel, p15E, Trp2) presented on MHC-I to CD8+
T-cells, we can track these responses using peptide-MHC tetramers.
Methods: We used YUMM1.7 parental and three YUMM 1.7 melanoma lines expressing the same MHC-II
neoantigen but different MHC-I neoantigens (YUMM 1.7 mLama4, YUMM 1.7 mAlg8, YUMM 1.7 mAlg8-mLama4)
to determine how expression of the neoantigens mLama4 and/or mAlg8 affect T-cell responses to distinct
neoantigens and non-mutant antigens. On day 0, 350,000 tumor cells in 150µl PBS were intradermally injected
into the flank of syngeneic mice and subsequently injected intraperitoneally (days 3, 6, 9, 12, 15, 21, 27) with antiCTLA-4 blocking antibody or control. On day 15, tumors were harvested, minced, and digested. Immune cells
were enriched from digested tumor using a CD45+ enrichment kit. Enriched cells were stained with fluorescentlylabeled peptide-MHC tetramers and antibodies to identify and quantitate mLama4- or mAlg8-specific T-cells using
flow cytometry.
Results: Parental YUMM1.7 grew progressively in both control and anti-CTLA-4 groups. However, enforced
expression of mLama4 and/or mAlg8 facilitated tumor rejection in anti-CTLA4-treated mice. Flow analysis
revealed enhanced T-cell infiltration in mice bearing mLama4- and/or mAlg8-expressing tumors upon anti-CTLA-4
treatment. In YUMM1.7.mAlg8.mLama4 tumors, 8.64% of the CD8+ T-cells were specific for mAlg8, whereas
2.09% were specific for mLama4.
Conclusion: As compared to the control group, the anti-CTLA-4 group displayed increased intratumoral T-cell
infiltration likely due to the anti-CTLA-4 antibody blocking the inhibitory CTLA-4 engagement on T-cells, allowing
increased T-cell priming and proliferation. Preliminary data revealed a higher percentage of intratumoral mAlg8specific CD8+ T-cells as compared to mLama4. These response differences indicate that the choice of the
antigen may be a critical factor for efficacious cancer vaccines. Investigating whether expression of one
neoantigen influences the response to other tumor antigens through epitope spread or immunodominance will
help determine the most effective peptide combination. Coupled with ICT, vaccines may effectively prevent tumor
growth and metastasis. This work may facilitate development of novel immunotherapies that can prevent cancer
development/metastasis and improve ICT and genomic cancer screening.
Keywords: mLama4, mAlg8, CD8 T-cells, vaccine, Immune Checkpoint Therapy (ICT)
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Abstract number: 86
Association of Visceral and Subcutaneous Fat with Adiponectin Levels in Obese Postmenopausal Women
with Prediabetes
Hannah Johnston; Behavioral Science; University of Texas MD Anderson Cancer Center
Karen Basen-Engquist; Behavioral Science; University of Texas MD Anderson Cancer Center
Background: Higher levels of body fat and obesity as well as diabetes and prediabetes have been linked to
increased risk of many cancers in postmenopausal women due to the creation of an inflammatory environment,
which allows tumor cell invasion and proliferation. Adiponectin (APN), an adipokine protein, shows antiinflammatory, antiproliferative, and proapoptotic properties. APN is decreased in women with obesity and is
believed to be a link between obesity and cancer risk. Although the circulating level of APN has been shown to be
inversely correlated with obesity, whether APN can be correlated with specific types of fat has not been
investigated. I therefore conducted this data review to determine whether visceral fat (around the internal organs
and along the muscle wall) or subcutaneous fat (just beneath the skin) are correlated with APN levels.
Methods: I retroactively analyzed the baseline data from a prospective randomized biomarker study of metformin
and lifestyle intervention for prevention in obese women at increased risk for endometrial cancer. The study
included 26 obese, post-menopausal women with prediabetes that were randomized into four groups for a 16week intervention. I searched for a correlation between APN levels (obtained from a fasting blood draw) and both
visceral fat area and subcutaneous fat mass. The visceral fat area measurement was directly obtained from a
dual-energy x-ray absorptiometry (DXA) scan and has been shown to have the best agreement with
measurements from a CT scan. The subcutaneous fat mass was approximated by subtracting the visceral fat
mass from the total fat mass. To investigate any association between APN and the fat measurements, I found the
correlation between visceral fat area and APN and subcutaneous fat mass and APN. I also did a multiple
regression controlling for participant weight and other confounding variables.
Results: A bivariate correlation test showed a Pearson’s coefficient of -.178 between visceral fat area and APN
levels and a Pearson’s coefficient of .098 between subcutaneous fat mass and APN levels. A multiple regression
was run to predict APN levels from visceral fat and subcutaneous fat. These variables predicted APN levels
F(3,21) = .998, p<.413, R2=.577.
Conclusion: Visceral fat area and subcutaneous fat mass cannot be used to predict APN levels. Visceral fat was
weakly negatively correlated with a decrease in APN, whereas subcutaneous fat was weakly positively correlated
with APN. More investigation is needed to determine if there is a connection between visceral fat or subcutaneous
fat and APN.
Keywords: fat, adiponectin, obesity, visceral, subcutaneous
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Abstract number: 87
Quality of Life Outcomes & Behavioral Response to Melanoma in Children and Young Adults
Gabrielle Kupferman; Cancer Prevention and Population Sciences; University of Texas MD Anderson Cancer
Center
Background: Melanoma is the most common skin cancer diagnosed in children, adolescents, and young adults,
and in most cases, the patients have good long-term survival. its survival outcomes are generally very favorable.
Given that most of these patients survive for decades following their cancer diagnosis, it is important to
understand the impact of melanoma at an early age on overall quality of life and whether or not this diagnosis
impacts future preventative behavior in this patient population. The purpose of our study was to conduct a
systematic review of the literature to determine if health related quality of life and preventative behavior are
impacted by a diagnosis of melanoma in childhood or early adulthood.
Methods: The relevant literature on Medline and EMBASE databases from January 2000 to May 2021 was
searched for studies in English surrounding melanoma survivorship in children, adolescents and young adults,
general melanoma survivorship, and survivorship of childhood, adolescent, and young adult cancer. The studies
were then filtered based on relevance, and then summarized and analyzed for the purposes of the study. The
study was done according to PRISMA guidelines.
Results: Our original search was confined to pediatric melanoma, and after removing duplicate entries, 133
citations remained. Of these 133, only 17 were relevant to our topic. We expanded the search to include pediatric,
adolescent, and young adult melanoma, which yielded 673 citations, of which 161 were duplicates. After removing
duplicates, we had 512 citations of which, 166 were germane to our topic. The total number of citations included
in the full review were 183. It is expected that our findings will demonstrate that a diagnosis of melanoma as a
child, adolescent or young adult will adversely affect quality of life metrics later in life. Additionally, we expect that
the adult survivors of melanoma will be more likely to practice sun-exposure prevention behavior than the general
public due to the prior experience undergoing the hardships of cancer treatment.
Conclusion: This research project has the potential to help clinicians, patients, and families understand the
broader implications of a melanoma diagnosis in early years on the patient’s future adult life. Furthermore, it will
provide health professionals with a better understanding of how to structure public health interventions regarding
sun safety for patients diagnosed with melanoma at a young age. Melanoma survivors have a greater risk of
being diagnosed with various types of skin cancer in the future than the general population. Thus, understanding
the common preventive practices of survivors can help uncover the most effective types of educational and
practical interventions to prevent such relapse.
Keywords: quality of life, melanoma, survivor, pediatric
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Abstract number: 88
Cancer-related stigma and screening adherence: a scoping review
Eduardo Levi; Health Disparities Research; University of Texas MD Anderson Cancer Center
Lisa Wigfall; Health Disparities Research; University of Texas MD Anderson Cancer Center
David Farris; Research Services; University of Texas MD Anderson Cancer Center
Background: Early detection of cancer through screening methods is vital to cancer prevention and control. The
US Preventive Services Task Force (USPSTF) sets screening recommendations to maximize early detection and
optimize quality of life. However, psychological stressors related to cancer, such as stigma, may inhibit individuals
from adhering to the screening recommendations. A thorough review of the literature will scope the existing data
and bridge knowledge gaps to determine best practices for addressing and resolving cancer-related stigma and
screening adherence.
Methods: A scoping review will be conducted to answer five research questions which span from investigating the
operationalization of cancer-related stigma to the types of research frameworks used to study the association
between cancer-related stigma and screening adherence. The review will draw from online databases such as
MEDLINE, PubMed, Web of Science, Scopus, and the Cochrane Library. The screening of titles and abstracts
and the subsequent selection of journal articles will be completed by two independent reviewers using the
software, Rayyan. If there are differences in the assessments, then a third reviewer will be solicited. Data
extraction will also be conducted independently to create tables and figures that present the results. The review
will also be guided by the Population, Concept, Context (PCC) framework.
Results: It is hypothesized that the literature will describe certain types of cancers more than others. Some
cancers such as cervical cancer and lung cancer are often associated with a stigma that may inhibit patients from
adhering to screening recommendations. Moreover, through this research project, the summer trainee will be able
to identify the advantages and disadvantages of conducting a scoping review and will develop research skills for
future projects.
Conclusion: The scoping review will quantitatively describe the extent of the literature that investigates the
association between cancer-related stigma and screening adherence. The findings will contribute to the
improvement of clinical practices and educational resources offered to researchers, health professionals, and
patients. The published materials will also help inform public policy that seeks to address cancer screening
recommendations.
Keywords: screening, cancer-related stigma, scoping review, cancer stigma, early detection
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Abstract number: 89
Examining Disparities in Incidence of Colorectal Cancer by Race, Ethnicity, Sex, Site, and Stage
Andrea Malabay; Epidemiology; University of Texas MD Anderson Cancer Center
Kristin Primm; Epidemiology; University of Texas MD Anderson Cancer Center
Taylor Curry; Epidemiology; University of Texas MD Anderson Cancer Center
Shine Chang; Epidemiology; University of Texas MD Anderson Cancer Center
Background: Over the past 21 years, while the incidence of colorectal cancer in the US has decreased, disparities
in race and ethnicity have increased but no recent evaluation exists of differences in race and ethnicity by location
of primary tumors within the colon and rectum among all age groups. Recent literature has shown that there are
differences in the rates of colorectal cancer between multiple minority groups; however, many of these studies
only compare CRC among White and Black groups.
Methods: We examined the trends of colorectal cancer incidence by racial/ethnic group and location of the
primary tumors within the colon and rectum to describe disparities. This study used SEER*Stat v 8.3.9 Incidence
– SEER Research Data, 18 Registries, Nov 2020 Sub (2000-2018) to analyze age-adjusted rates in incidence by
race, ethnicity, sex, and site. We examined the sites within the proximal, transverse, and distal colon, as well as
the rectum, and further examined localized, regional, and distant diagnosis stages.
Results: As others have reported, we observed declining incidence in colorectal cancer, but found that some
racial and ethnic groups experienced higher incidence rates compared to other groups by diagnosis site and the
stage of diagnosis. For example, when singling out the proximal colon, Black males had a rate of 12.7/100,000
people at the local stage in 2000. Comparing this localized proximal rate to male Whites (11.7), American
Indian/Alaskan Natives (7.2), Asians/Pacific Islanders (6.9), and Hispanics (7.9), we can see that Blacks have
already experienced a higher diagnosis rate than other races and ethnicities. Examining annual percent changes,
incidence rates for Blacks decreased just as those for other racial and ethnic groups did. However, they do not
experience the largest annual percent decrease. From this portion of the data, we see that some racial and ethnic
groups had decreases in incidence trends. However, when examining each rate individually by subsite and
diagnosis stage, some groups are seeing a trend where the rate is not as favorable.
Conclusion: Despite declining incidence rates of colorectal cancer in the United States overall, comparisons by
race and ethnicity reveal important disparities, particularly by site of primary tumors within the colon and rectum,
which may have critical implications for treatment and long-term survival.
Keywords: Colorectal, Disparities, Trends, Stage, Race
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Abstract number: 90
PGx of Chemotherapy-Induced Peripheral Neuropathy (CIPN): CYP2D6 Genotyping and Validation
Maira Mulla; School of Health Professions; Houston Baptist University
Vibhuti Srivastava, PhD MB(ASCP)CM; Molecular Genetic Technology program, School of Health Professions;
University of Texas MD Anderson Cancer Center
Irene Newsham, PhD, MB(ASCP)CM, FACSc; Molecular Genetic Technology program, School of Health
Professions; University of Texas MD Anderson Cancer Center
Background: Chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients is defined by sensory-motor
neuropathy due to chemotherapeutic drug exposure. Prediction of CIPN could be achieved by characterizing
patient pharmacogenetic (PGx)-related single-nucleotide polymorphism (SNP) profiles. One common PGx genethe cytochrome P450 (CYP) 2D6 (CYP2D6) is involved in the metabolism of ~21% of currently approved
medications including chemotherapeutic drugs commonly prescribed for cancer treatment. We used SingleNucleotide Extension (SNE) and a Sanger sequencing-based approach to genotype common clinical variations in
CIPN patients to profile PGx loci of CYP2D6 gene.
Methods: In a previous study, SNPs in the CYP2D6 gene were analyzed in 23 patients with and without CIPN
using Single-Nucleotide Extension (SNE) technology. SNE is a multi-locus, multiplexed genotyping method where
a single fluorescently-labeled nucleotide incorporated at a primer’s 3’ end identifies the presence/absence of a
specific polymorphism. This approach is known to show design and optimization related variations. In the current
study, we used a Sanger sequencing-based approach to validate the SNE results. Polymorphic patient samples
for *6, *10 and *17 SNPs were selected for locus-specific amplification.
Results: *6 and *17 Sanger sequencing data showed acceptable quality values (QV) and peak threshold. *10
sequencing data failed the QV threshold and showed high signal to noise ratio. Preliminary validation results
indicated a low concordance between Sanger sequencing results and the SNE assay findings in the original CIPN
study. All loci from the original CIPN study/SNE method were monomorphic by Sanger sequencing. However, we
identified additional SNPs in *6 and *17 amplicons. The *6 region showed synonymous rs1058164 polymorphisms
while the *17 region had two intronic SNPs, namely rs28371702 and rs28371701. To examine whether the
synonymous rs1058164 *6 region SNP segregated with CIPN, *6 amplicons from all 23 patients are currently
being sequenced
Conclusion: The original SNE assay resulted in a high degree of false positive base calls, most likely due to
calibration issues on the GeXP Capillary electrophoresis system and design related limitations. Although, Sanger
sequencing of amplicons containing the interrogated CYP2D6 polymorphisms was a better system for evaluating
SNPs for risk assessment studies, this approach is also limited due to low sensitivity, scalability, limit of detection,
and thus discovery power. Future efforts to assess CIPN risk using SNP profiles will utilize a PGx panel run on an
Ion Torrent platform to more broadly detect low and moderate frequency variants at higher coverage and perform
association analyses of these variants with CIPN
Keywords: CIPN, SNP, CYP2D6, Sanger Sequencing
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Abstract number: 91
Impact of Treating Insomnia Symptoms on Abstinence from Smoking
Vijay Nitturi; Behavioral Science; University of Texas MD Anderson Cancer Center
George Kypriotakis; Behavioral Science; University of Texas MD Anderson Cancer Center
Maher Karam-Hage; Behavioral Science; University of Texas MD Anderson Cancer Center
Background: Quitting smoking is one of the best ways to prevent cancer. Even quitting at the time of diagnosis
can increase survivorship among cancer patients by 30-40%. Insomnia symptoms have the potential to hinder
quit attempts. However, no studies have confirmed whether treating insomnia symptoms would increase
abstinence rates. We set out to assess the impact of treating insomnia on the ability to abstain from smoking.
Methods: Data was extracted from the electronic health records of patients who participated in a large cancer
center’s tobacco treatment program and were treated for insomnia. Initial, middle, and late insomnia diagnoses,
abstinence success, severity of nicotine dependence, severity of insomnia symptoms, and insomnia medication
administered were collected. We report 7-day point prevalence, as a measure of continuous 7 days in prior week
in which cigarettes were not smoked at 3, 6, and 9 months after treatment. The relationship between insomnia
treatment and abstinence will be evaluated after controlling for several possible confounders e.g. severity of
nicotine dependence, anxiety, depression and the severity of measured insomnia symptoms.
Results: Patients treated for insomnia had a greater chance of quitting compared to patients not treated for
insomnia. However, at the 3-month abstinence point, patients treated for insomnia with sleep scores greater than
16 had lower abstinence rates than patients not treated for insomnia. At 6- and 9-month abstinence points,
treatment for insomnia either did not improve abstinence rates or worsened them. This could be a signal of having
insomnia associated other severe psychiatric disorders.
Conclusion: Treating insomnia symptoms among cancer survivors and patients trying to quit smoking can be
beneficial in preventing recurrence of cancer or development of a second primary cancer. Current data indicate
that treating individuals with milder cases of insomnia may benefit their tobacco abstinence outcomes more than
individuals with more severe cases of insomnia. Future analyses will aim to control for the impact of other
psychiatric disorders.
Keywords: Smoking, Cancer Prevention, Insomnia, Abstinence, Tobacco Use
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Abstract number: 92
Determinants of Patient-reported Taste Disorders in Oropharyngeal Cancer Survivors
Christopher Wallace Ogboe; Epidemiology; University of Texas MD Anderson Cancer Center
Dr Puja Aggarwal; Epidemiology; University of Texas MD Anderson Cancer Center
Dr Sanjay Shete; Epidemiology; University of Texas MD Anderson Cancer Center
Background: The role of Human Papilloma virus (HPV) in head and neck cancer (HNC) and improvements in
cancer therapy, have contributed to a growing population of HNC survivors and patients experiencing treatmentrelated adverse effects. Patients with oropharyngeal cancer (OPC) experience both acute and chronic taste
disorders with varying degree of hypergeusia, dysgeusia, ageusia, and taste phantoms. These taste changes can
negatively impact quality of life (QOL) and contribute to a decline in nutritional status and medication adherence.
However, a lack of knowledge for risk factors of taste disorders in OPC still exist. The goal of this study is to
investigate the role of age, tumor stage, treatment modality, smoking, and other risk factors associated with taste
disorders in OPC survivors.
Methods: The study population included OPC survivors treated curatively at MD Anderson Cancer Center
between January 2000 and December 2013 who responded to a cross-sectional survivorship survey. Taste
disorder was measured using the MD Anderson Symptom Inventory Head and Neck Cancer module (MDASIHN). The MDASI-HN rates patient symptoms on a 0 (no symptoms) to 10 (worst symptoms) scale. Our primary
outcome variable was patient-rated taste disorders using the MDASI-HN with moderate to severe taste problems
defined as a score ≥5. Descriptive statistics and multivariable logistic regression (MLR) analysis were conducted
to identify risk factors associated with moderate to severe taste disorders.
Results: Among the 873 OPC survivor’s, median survival was 6.0 years (range 1-16 years). 142 (16.3%) reported
moderate to severe taste disorders and 731 (83.7%) reported none to mild taste disorder. On MLR, age at
diagnosis (odd ratio [OR] 1.05; 95% CI, 1.02-1.07) was associated with increased risk, while a greater than high
school education (OR 0.56; 95% CI, 0.35-0.92) and neck dissection (OR 0.37; 95% CI, 0.20-0.65) were
associated with lower risk of moderate to severe taste disorder.
Conclusion: In this large survivorship study, 1 out of 6 OPC survivors developed moderate to severe taste
disorders. Age at diagnosis was a risk factor for taste disorders with a 1.05 times higher risk of developing
moderate to severe symptoms with every 1-year increase in age of diagnosis. Higher education and neck
dissection correlated with lower severity of taste disorders. Our results will inform future research, aid clinicians in
understanding possible disparity in taste disorders, and inform supportive care interventions to improve taste
function and subsequent QOL in OPC survivors.
Keywords: Taste disorder, survivorship, oropharyngeal cancer
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Abstract number: 93
Increasing Referral of LBJ Patients to the ALAC Program
Havisha Pedamallu; Center for Energy Balance in Cancer Prevention and Survivorship; University of Texas MD
Anderson Cancer Center
Patrick Cho; Center for Energy Balance in Cancer Prevention and Survivorship; University of Texas MD Anderson
Cancer Center
Ruth St Fleur; Center for Energy Balance in Cancer Prevention and Survivorship; University of Texas MD
Anderson Cancer Center
Miranda Baum; Center for Energy Balance in Cancer Prevention and Survivorship; University of Texas MD
Anderson Cancer Center
Margret Raber; Center for Energy Balance in Cancer Prevention and Survivorship; Baylor College of Medicine
Karen Basen-Engquist; Center for Energy Balance in Cancer Prevention and Survivorship; University of Texas
MD Anderson Cancer Center
Background: There is evidence to show that physical activity can help cancer patients and survivors improve their
overall quality of life by bettering fatigue, physical functioning, anxiety, and depression. This project focuses on
the oncology patient population in the Acres Homes neighborhood and at LBJ Hospital, which is more likely to be
impoverished and live in a food and parks desert. Low-income cancer patients are more likely to be food insecure
and have lower levels of physical activity, making this population especially vulnerable to cancer-related
complications. Active Living after Cancer (ALAC) is an MD Anderson program for survivors. The center’s goal is
to improve survivors’ quality of life by promoting physical activity and offers services free of charge. This project
aims to increase referrals from a mean of .5 referrals per month in 2019 to a mean of 5 referrals per month by
October 2021.
Methods: We are conducting provider and patient interviews to gather perspectives about the predictors for food
insecurity, the relationship between food insecurity and lower quality of life, and community needs regarding
nutrition/physical activity and food insecurity programming and services. We will next code this data and use
major themes to design an effective referral system and framework.
Results: There is not a large focus on patients’ diet and exercise during their cancer care treatment, and many
patients and physicians report that their first priority is the patients’ treatment. Patients are incredibly exhausted
by their cancer care and often report not having an appetite, so they are unable to engage in conversations about
diet and exercise during treatment. However, no conversations are had during patients’ survivorship care. In
addition, many physicians mention that some of their patients are food insecure or simply do not know about their
patients’ food security status.
Conclusion: Diet and exercise are not viewed as a cancer care priority, and rather, are seen as a function of
primary care. However, they are large issues in the LBJ cancer population. Also, there are no formal procedures
or policies in place to assess or address diet and exercise. Our qualitative interviews have shown us that there is
definitely a need for free diet and exercise programs for cancer survivors. In addition, we must also design new
referral systems that are user-friendly for providers and implement directly connecting patients with programs and
following up on usage.
Keywords: survivorship, exercise, diet, quality improvement
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Abstract number: 94
Factors associated with patient adherence to remote monitoring during radiation treatment for head and
neck cancer
Sarah Phillips; Behavioral Science; University of Texas MD Anderson Cancer Center
Susan K. Peterson, Ph.D, M.P.H.; Behavioral Science; University of Texas MD Anderson Cancer Center
Background: Remote patient monitoring (RPM) can improve the early detection and mitigation of cancer
treatment-related complications, and thus improve health-related outcomes and quality of life. Using mobile and
sensor technology, daily blood pressure/pulse, weight, and patient-reported outcomes were monitored remotely
in head and neck cancer (HNC) patients undergoing radiation treatment (RT) to evaluate symptoms and
dehydration risk, and to enable medical intervention when necessary. RPM’s success depends on patients’
adherence to remote monitoring protocols, yet little is known regarding factors that influence adherence to RPM.
We evaluated the relationship between demographic factors, symptom severity, patient activation and RPM
adherence.
Methods: Patients completed the MD Anderson Symptoms Inventory (MDASI), the Patient Activation Measure
(PAM), and the FACT-HN at baseline and at end of RT; the MDASI also was completed every 2 weeks during
RT. A Device Usability Survey measuring perceived usefulness of RPM was completed at the end of RT.
Adherence to daily monitoring was recorded objectively. Demographic and clinical data were obtained from
patients or the medical record. Statistical methods involved longitudinal analysis to compare the relationship
between demographic, clinical, and patient reported outcome data and monitoring adherence.
Results: Mean symptom severity scores will be reported for each time point using patient MDASI data. Mean
PAM scores worsened between baseline and 8 weeks post-RT across four “activation” categories: believed
patient activation was not important (1% baseline, 8.2% post-RT), lacked confidence and knowledge to take
action (7.9% baseline, 8.2% post-RT), began to take action (30.4% baseline, 26.5% post-RT), and took action
(60.7% baseline, 57.1% post-RT). Patients reported modest levels of perceived usefulness of RPM: 49.4% of
patients reported RPM “mostly or extremely” helped their healthcare providers monitor their illness; 41.4% of
patients reported RPM was “mostly or extremely” helpful for early detection of problems related to their health;
and, 39.9% of patients reported RPM was “mostly or extremely” helpful in managing symptoms related to cancer
treatment. Further data analyses will determine the association of symptom severity, perceived usefulness of
intervention, and PAM scores with patient adherence to remote monitoring during radiation therapy.
Conclusion: Remote patient monitoring could support clinician prevention or detection of medical emergencies in
cancer patients. Low monitoring adherence attributable to patient characteristics is a point of policy intervention
meant to increase patient engagement in care. Improved patient engagement, measured by monitoring
adherence, could decrease hospitalizations/ER visits and overall improve quality of life.
Keywords: remote patient monitoring, patient activation measure, adherence, radiation treatment
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Abstract number: 95
The Changing Landscape of Early-Onset Colorectal Cancer in Texas; A Look at Texas Cancer Registry
Data from 1995-2017
Varun Rao; Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center
Scott Kopetz; Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center
Jennifer Davis; Epidemiology; University of Texas MD Anderson Cancer Center
Background: Early-onset colorectal cancer (EOCRC), defined by presentation in individuals aged < 50, is a
growing problem in the US. Although improvements in screening and symptom awareness have helped drive
notable decreases in overall colorectal cancer incidence1, early-onset cases have grown at an annualized rate of
1.6% since the mid-1990s.2 Alarmingly, cases present at advanced stages relative to later onset cases3-7, and
many cases present without traditional risk factors at time of diagnosis1. Although there is a lack of data from
large, prospective studies, prominent oncology researchers have hypothesized that trends in childhood diet,
obesity, and antibiotic use explain increases in EOCRC incidence rates.8 Regardless, there is an urgent need to
understand determinants of EOCRC risk to target cancer prevention interventions to high-risk groups. This study
utilizes cancer registry data from the Texas Cancer Registry (TCR) to identify and describe risk factors driving
increases in EOCRC incidence rates within Texas.
Methods: The significance of individual SES factors and the distribution of relevant risk factors across the state
was assessed using linear regression and univariate statistics. Regression of predictors was conducted using
SAS, Version 9.4 and GraphPad Prism.
Results: While rates of all age-onset CRC fell significantly over the period from 1995-2017, rates of early-onset
cases increased by 1.5% annually. The largest increases in CRC rate were observed in western and southern
Texas, regions with high concentrations of Hispanics. Notably, early-onset cases rose at an annualized rate of
4.6% among Hispanics, compared with 1.1% among non-Hispanics. Additionally, early-onset case count was
significantly associated with proportion of individuals at or below the poverty line at the case zip-code level. CRC
exhibited birth cohort effect; rising risk ratios since the 1970s implicate temporal trends in exposure accumulation
that could plausibly have stemmed from contemporaneous changes in diet and antibiotic use.
Conclusion: This study provides direction for future research into causal factors driving increases in early-onset
colorectal cancer and highlights demographics at high risk for developing early-onset colorectal cancer within
Texas.
Keywords: colorectal cancer, early-onset, Texas, Hispanic
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Abstract number: 96
Project CONNECT; Providing Resources to Inform Quitline Callers about Lung Cancer Screening
Maria Ribando; Health Services Research, Division of Cancer Prevention and Population Sciences; Tulane
University School of Public Health and Tropical Medicine
Background: Increasing lung cancer screening (LCS) rates nationally is a priority for various groups such as the
American Cancer Society. It is known that patients have a lack of understand around LCS, and are sometimes
screened inappropriately. There is also a know lack of discussion amongst patients and care providers regarding
LCS, and few patients are being referred to screening. Project CONNECT will bridge this gap. Project CONNECT
is an implementation project based on the findings from a previous study, INFORM, which utilized quitline staff to
disseminate evidence-based patient decision aids (PDA) regarding lung cancer screening to eligible smokers
calling in to the quitline. Results from project INFORM showed that individuals that viewed the PDA were
significantly more knowledgeable about (LCS) than were the participants who only received traditional educational
materials. Project CONNECT aims to increase the number of smokers who call in to the quitlines and receive high
quality PDA, and who are then able to make an informed decision regarding if lung cancer screening is right for
them. Although we know that LCS reduces lung cancer mortality 16-20%, we also know that there are important
harms to be considered. Providing information regarding potential benefits and harms of LCS to all eligible
individuals who smoke who call the quitline will allow them to make an informed decision about their care.
Methods: Project CONNECT is partnered with The North American Quitline Consortium (NAQC); eight quitlines
will participate. Smokers who call in to the quitline that meet the eligibility criteria will be referred to a patient
decision aid. Quitline call staff will be trained to assess eligibility and refer callers to educational materials on lung
cancer screening. To evaluate this training, quitline staff will complete questionnaires to evaluate their knowledge
before the training and up to one month after.
Results: During the course of this project I will become familiar with the landscape of knowledge of quitline staff as
far as LCS and the accessibility of LCS to quitline clients. I will also look at primary data, clean data, and run basic
descriptive statistics using statistical software. I will learn about shared decision making and LCS, and also how to
evaluate shared decision making tools.
Conclusion: This important project will increase the number of eligible individuals who smoke who received PDA,
allowing them to make an informed decision about their healthcare.
Keywords: LCS, quitline, lung cancer screening
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Abstract number: 97
Video-Based Germline Genetic Testing for Individuals with Pancreatic Ductal Adenocarcinoma: Before
and After the COVID-19 Pandemic
Kasliwal Saumya; Pathology; Renaissance School of Medicine at Stony Brook University
Seyda, Baydogan; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Devon Harrison; Sheikh Ahmed Pancreatic Cancer Research Center; University of Texas MD Anderson Cancer
Center
Maureen Mork; Clinical Cancer Genetics; University of Texas MD Anderson Cancer Center
Maria Fernanda Montiel; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Antonette Celestino; Sheikh Ahmed Pancreatic Cancer Research Center; University of Texas MD Anderson
Cancer Center
Mark Hurd; Sheikh Ahmed Pancreatic Cancer Research Center; University of Texas MD Anderson Cancer Center
Pinar Kanlikilicer; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Anirban Maitra; Pathology; University of Texas MD Anderson Cancer Center
Florencia McAllister; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Background: National guidelines recommend universal germline genetic testing (GT) for patients with Pancreatic
Ductal Adenocarcinoma (PDAC), but rates of testing remain low. Given the aggressiveness of PDAC, the window
of opportunity for GT is short and often overshadowed by treatment initiation and other clinical milestones. Thus,
there is an unmet need for a model that streamlines GT and makes it available to a wider audience in a rapid
fashion. Moreover, in pandemic times, video-based alternatives for medical care are increasingly relevant.
Methods: We implemented a novel care delivery model in which a 5-minute educational video describing the
benefits, risks, and implications of germline GT was shown to PDAC patients. The video was shown in lieu of an
initial consult with a genetic counselor. After watching the video, patients could elect to pursue GT and get tested
on site or remotely (at home). Genetic counselors disclosed results and provided post-test counseling by phone.
Clinical and germline data were collected through medical records on a cohort of PDAC patients seen at the
Gastrointestinal Center- MD Anderson during a 2-year enrollment period, which included the COVID-19
pandemic period.
Results: A total of 285 PDAC patients saw the educational video, after which 12 patients declined GT. These 12
patients were enrolled pre-pandemic, and no patients declined GT post-pandemic. Out of 242 successfully
collected samples, 179 patients tested negative, while 37 had a Variant of Uncertain Significance (VUS) and 21
patients had a Pathogenic variant (PV). There was no association between PV and age at diagnosis, gender,
race, or personal history of cancer. Family history of PDAC in a first degree relative was associated with having a
PV (p=.01). Survival analysis demonstrated that patients with PV tended to live longer (p=.048).
Conclusion: GT can have tremendously beneficial effects, such as qualifying for targeted treatment options and
facilitating cancer prevention in probands’ at-risk family members. Comparing uptake of GT pre and postpandemic suggests that patients were more willing to trust information from a video platform, likely due to the
global effect of living in a “virtual“ society as a result of the pandemic. We suggest an approach in which every
PDAC patient is shown a genetics educational video and given the choice to undergo GT and post-result
counseling, greatly reducing the burden on genetic counselors. Further investigation is needed to explore the
feasibility of a fully remote GT model (in which the video and saliva collection kit are sent directly to the patient’s
residence) and to assess additional barriers to universal GT.
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Abstract number: 98
Positive Activity Interventions in Asian and Asian American Cancer Patients and Survivors: A Scoping
Review
Amy Senger; Health Disparities; University of Texas MD Anderson Cancer Center
Lilian Shin; Health Disparities; University of Texas MD Anderson Cancer Center
Qian Lu; Health Disparities; University of Texas MD Anderson Cancer Center
Background: Positive activity interventions (PAIs) may present many potential benefits to Asian cancer patients
and survivors, such as reducing healthcare disparities, improving mental health, and increasing overall QOL. The
current scoping review addresses types of PAIs investigated, what Asian populations they have been tested in,
outcomes reported, and PAIs’ efficacy for these populations.
Methods: The review was conducted and written according to PRISMA guidelines. An article was included if it met
the following eligibility criteria: the study was a randomized controlled trial (RCT), the sample had more than 50%
Asian heritage including Asians in non-Asian countries, the sample consisted of cancer patients or survivors, and
the article investigated the use of a PAI. The MEDLINE database was searched using terms from the following
categories, “positive interventions,” “positive constructs,” “cancer,” and “Asian continental ancestry group.” The
database search yielded 173 articles, and the full text of 68 articles were assessed, resulting in 7 articles included
in the study. 671 references from the included articles’ reference sections were searched, and 75 abstracts were
screened, to yield an additional 9 articles, bringing the total number of articles in the current review to 16.
Results: The PAIs investigated can be condensed into three categories: mindfulness/relaxation activities,
expressive writing, and movement-based activities. The populations the PAIs were tested in were Chinese,
Korean, American, Malaysian, and Japanese cancer patients. The primary outcome reported was QOL. The PAIs
examined demonstrated high efficacy in increasing QOL.
Conclusion: Current evidence suggests PAIs are effective for Asian cancer patients and survivors in increasing
QOL and may aid in decreasing health disparities/increasing healthcare accessibility. However, further research is
needed to increase diversity in PAIs (e.g., acts of kindness, gratitude lists, or prompts to engender humility),
populations tested (e.g., Southeast, Southern, and Central Asians), and outcomes (e.g., hope and optimism).
Keywords: Positive activities, literature review, Asian, cancer, cancer survivors
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Abstract number: 99
Predictors of Retention Rates in the Active Living After Cancer Program at MD Anderson Cancer Center:
A Comparison of Classes During and Before COVID-19
Kendahl Servino; Medicine; University of Nevada, Reno School of Medicine
Stacy Mitchell; Behavioral Science; University of Texas MD Anderson Cancer Center
Che Young Lee; Behavioral Science; University of Texas MD Anderson Cancer Center
Yue Liao; Behavioral Science; University of Texas MD Anderson Cancer Center
Karen Basen-Engquist; Behavioral Science; The University of Texas MD Anderson Cancer Center
Background: As an overlooked aspect of cancer, survivorship often begs the question of “what’s next?” once
treatment is complete. Physical activity following treatment has been shown to improve quality of life and
decrease rates of recurrence. The MD Anderson Active Living After Cancer Program (ALAC) has recruited over
900 cancer survivors and caregivers since its establishment in 2013. This study seeks to examine how retention
rates have changed since the transition to virtual classes due to the COVID-19 pandemic, and whether variables
associated with retention differ between in person and virtual classes.
Methods: A retrospective study of baseline surveys completed by participants (N=860) through Redcap was
conducted, excluding those currently enrolled in ongoing ALAC classes. A chi-square test was performed to
determine whether completion rates were significantly different between in person and virtual classes. A bivariate
regression model was used to determine whether participant demographics varied between virtual and in person
classes, based on insurance status and education level. A logistic regression was performed to investigate
whether these factors were predictors of retention in either class.
Results: Retention rates significantly differed between virtual (87.91%) and in person classes (77.20%) (P=0.001).
Medicare was the most common insurance type among participants of in person classes, while private insurance
was the most common among virtual classes (P=0.014). In both classes, participants who never received a high
school diploma or GED constituted the most common education level; the second most common for virtual
classes were Bachelor’s degree holders, while in person classes were high school diploma holders (P=0.001).
While insurance and education composition were significantly different between the two classes, neither were
significant predictors of retention in either class.
Conclusion: Given the success of ALAC since its creation, we are interested in expanding enrollment beyond MD
Anderson Cancer Center. This study provides understanding of the benefits and limitations of virtual classes since
the rise of COVID-19. Because most Medicare beneficiaries are older, inaccessibility to technology may explain
their decline in virtual classes, though further research is merited on possible limitations of ALAC. Overall, greater
retention rates demonstrate the utility of virtual classes. Maintaining a virtual aspect of future ALAC classes, such
as a hybrid program, may help improve survivor outreach by identifying potentially overlooked groups.
Keywords: cancer survivorship, active living, exercise, physical activity
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Abstract number: 100
Socioeconomic Barriers to Breast Cancer Clinical Trial Retention
Julia Shi; Kinesiology; Rice University
Ying-Shiuan Chen; Health Services Research; University of Texas MD Anderson Cancer Center
Benjamin Smith; Radiation Oncology; University of Texas MD Anderson Cancer Center
Grace Smith; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: To optimize generalizability and minimize bias in clinical trial results, diverse participants need to be
enrolled and retained. While it is known that patients with more severe socioeconomic barriers enroll less
frequently in trials, it is not known whether they are less likely retained, that is, receive planned therapy and
outcome assessments. We examined the correlation between socioeconomic barriers and retention among breast
cancer patients in a post-hoc analysis of a therapeutic adjuvant radiation clinical trial. We hypothesized that
participants facing more severe socioeconomic deprivation would be less likely retained.
Methods: The parent trial included 287 women age≥40 years with early stage (Tis-T2 N0-N1a) breast cancer
treated with breast conserving surgery, randomized to conventionally fractionated vs. hypofractionated whole
breast irradiation from 2011-2014. We excluded participants treated outside Texas (n=14) or who did not have a
linkable home address for analysis (n=16), for a sample of N=257. Patients were categorized as retained if they
attended trial follow-up visit and received the trial’s primary outcome assessment, breast cosmesis score at 3
years. Patients’ severity of neighborhood-based socioeconomic deprivation was measured using the Area
Deprivation Index (ADI) linked to their home address abstracted from the medical record. Higher ADI indicated
greater deprivation. Trial dropout reason and social work support needs through trial follow-up were also
abstracted.
Results: Median age was 61 and 74% of patients were White Non-Hispanic. A total of 22% of patients were not
retained. Reasons for not being retained were: lost contact (25.76%), transfer to different facility/provider for care
(16.67%), transportation barrier (16.67%), active decision not to continue in the trial (13.64%), finance barrier
(10.60%), health burden (6.06%), other logistical burden (1.51%), and unknown (9.09%). Median ADI score for
patients retained vs. not retained was 36.5 (IQR, 22-57) and 46 (IQR, 29-60) (P=0.03). Among those who
requested social work support (n=148), resource needs for patients retained vs. not retained was significantly
different (P=0.03), with patients not retained more frequently needing practical resource support (transportation,
housing, financial assistance) and patients retained more frequently needing psychological distress support.
Conclusion: In this study of breast cancer patients, structural socioeconomic barriers were associated with
decreased clinical trial retention. Trial participants with baseline risks of socioeconomic disadvantage or
deprivation may benefit from proactive, early interventions to promote their retention.
Keywords: cancer, clinical trial, retention, socioeconomic status, area deprivation index
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Abstract number: 101
WISE (Writing in Stressful Experiences) A Virtual Study to Explore Stressors for AYA Cancer Patients and
Survivors
Ashley Shin; Health Disparities Research; University of Texas MD Anderson Cancer Center
Lilian Shin; Health Disparities Research; University of Texas MD Anderson Cancer Center
Qian Lu; Health Disparities Research; University of Texas MD Anderson Cancer Center
Background: Adolescent and young adult (AYA) cancer patients and survivors are between the ages of 15 and 39
years old, and they may experience unique stressors due to their age. Expressive writing (EW) has been shown it
can be used as a method to safely cope with thoughts and feelings around the cancer experience. The purpose of
this study was to identify the salient aspects of the cancer experience for adolescent and young adult cancer
patients and survivors through EW.
Methods: The researchers analyzed a total of 45 essays from 21 AYA breast cancer patients and survivors within
three years of diagnosis. This study was conducted completely online during the COVID-19 pandemic. The
participants wrote for 30 minutes once a week for three weeks. Participants first read positive messages intended
to elicit positive emotions while writing their essays. They were then prompted to write about their deepest
thoughts and feelings around a stressful experience. The researchers labeled chunks of the essays with
descriptive codes. The codes were grouped into recurrent themes and subthemes. The researchers organized the
relationship between the recurrent themes into a coding tree divided into positive aspects and negative aspects of
the cancer experience.
Results: The participants’ EWs revealed positive themes of positive feelings, support, post traumatic growth, and
positive coping mechanisms, and negative themes of negative feelings about the cancer experience, lack of
support or isolation, negative physical effects, and negative coping mechanisms.
Conclusion: Because they have concerns about their futures, AYA cancer patients and survivors seek assistance
from their social support systems. By experiencing both the positives and negatives that come from the cancer
experience, AYA cancer survivors experienced post-traumatic growth as they realized the value of maintaining
meaningful relationships with family, friends, and other AYA cancer patients and survivors.
Keywords: AYA cancer patients and survivors, expressive writing, cancer survivors, post-traumatic growth, social
support
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Abstract number: 102
Association Between Quitting Smoking and Survival in Cancer Patients
Taylor Simmons; Behavioral Sciences; University of Mary Hardin-Baylor
George Kypriotakis; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Janice Blalock; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Background: According to the 2014 Surgeon General’s report, there is sufficient evidence that continued smoking
following a cancer diagnosis is associated with a number of adverse health outcomes, including increased poorer
survival. In addition, there is some evidence that smoking cessation improves survival compared to continued
smoking. However, more research is needed to evaluate the relationship between smoking cessation and
survival. The current study explored the association between smoking abstinence and survival in a large sample
of cancer patients who received tobacco cessation treatment in at MD Anderson Cancer Center Tobacco
Treatment Program. We hypothesized that cancer patients who quit smoking would have better survival outcomes
compared to those who do not quit, and this effect varies by cancer diagnosis.
Methods: We used data from TTP electronic health records to compare survival outcomes between those who
entered the TTP program and were identified as abstainers versus those who did not abstain. To examine
associations between smoking abstinence status and survivorship we used bivariate comparisons employing ttest for continued variables and chi-square for categorical variables, and we utilized nonparametric tests as
needed. Survival analysis will examine the effects of abstinence on survival controlling for individual level
characteristics. We also tested for an interaction effect between abstinence status in cancer diagnosis on survival.
Results: To test our first hypothesis of a main effect of abstinence status on survival we performed survival
analysis on N = 4,356 patients using the Cox proportional hazards model controlling for cancer diagnosis, age,
sex, depression, anxiety, positive and negative affect, nicotine dependence and years smoked, and time from
diagnosis to TTP participation. Those who abstained from smoking had a significantly lower hazard of dying
compared to those who did not abstain (HR = 0.65; p < 0.001). The interaction of cancer diagnosis with
abstinence status was also significant. Specifically, the effect of abstinence on survival was significant for lung
cancer (HR= 0.51; p < 0.001), for breast cancer (HR = 0.74; p = 0.040 ) for hematologic (HR = 0.68; p = 0.036 )
and for abdominal cancer (HR = 0.44; p = 0.002 ).
Conclusion: Overall the results confirm the hypothesis that quitting smoking is associated with improved survival
in cancer patient. Moreover, we find that the benefits in survival are not homogeneous across cancer diagnosis
groups. Patients with specific cancer diagnoses, such as lung and abdominal cancer, may be benefit the most
from quitting.
Keywords: smoking, cessation, cancer, survivorship, mortality
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Abstract number: 103
Understanding The Psychophysiological Mechanisms Underlying Context-Dependent Gains And Losses
Among Smokers
Matthew Taing; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Dr. Francesco Versace; Behavioral Sciences; University of Texas MD Anderson Cancer Center
Background: Nicotine, the psychoactive compound that makes smoking addictive, interferes with the brain’s
reward mechanisms. Blunted brain responses to non-nicotine-related rewards may increase vulnerability for
smoking relapse during quit attempts. The goal of this study was to evaluate the feasibility of using event-related
potentials (ERPs, a direct measure of brain activity) to assess brain responses to monetary gains and losses in
smokers. Identifying the psychophysiological mechanisms underlying reward responses may contribute to the
development of treatments to reduce reward deficits and vulnerability to relapse among smokers attempting to
quit.
Methods: 70 smokers interested in quitting were enrolled in our study. Participants performed a reaction time task
while ERPs were recorded using a 129-channel sensor array. During the task, participants pressed one of two
buttons to identify a target among distractors. After each trial, the participants were informed whether their
responses were correct, incorrect, or too slow to be scored. Correct responses could lead to a gain of either 10 or
0 cents, while errors could lead to a loss of either 10 or 0 cents. No monetary gain or loss followed correct, but
slow responses. These ERPs evoked by wins and losses of different magnitudes (i.e., 0 vs. 10 cents) were
analyzed to gain a better understanding of their different, context-dependent, psychological meanings.
Results: From our preliminary analyses, we found a strong positive deflection between 200-600 ms after the onset
of the feedback. This positivity, of increasing magnitude from frontal to parietal sites, likely corresponds to the
P300 component of the ERP. Receiving larger rewards (i.e., 10 cents) prompted greater positivity than receiving
smaller rewards (i.e., 0 cents). However, the unexpected outcome of not receiving a reward following a slow
response increased cortical positivity more than receiving a larger reward.
Conclusion: Taken together, we have isolated an ERP component that is sensitive both to the processing of
rewards’ magnitude and to unexpected outcomes. These findings represent the first step towards a better
understanding of how nicotine and nicotine withdrawal alter our reward responses and they may also serve to
inform targeted interventions for smoking cessation. Future studies will seek to explore how smoking cessation
medications may alter this ERP component.
Keywords: nicotine, reward, event-related potentials, P300
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Abstract number: 104
Factors associated with physical activity among survivors of adolescent and young adult cancer: the
National Health Interview Survey
Kevin Tang; Medicine; Albert Einstein College of Medicine
Clark Andersen; Biostatistics; University of Texas MD Anderson Cancer Center
Michael Roth; Pediatrics; University of Texas MD Anderson Cancer Center
Susan C. Gilchrist; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Background: Physical activity (PA) is associated with lower rates of mortality and lower incidence of
cardiovascular disease in cancer survivors. Unfortunately, PA in survivors of adolescent and young adult (AYA)
cancers remains understudied, and even less is known about the socioeconomic and physical health factors that
affect PA level in this population.
Methods: We identified 5556 AYA cancer survivors who were diagnosed between the ages of 15 and 39 years
from the 1997-2018 National Health Interview Survey and had self-reported physical activity information. Physical
activity was defined as: minutes of moderate or vigorous PA (MVPA) in metabolic equivalents per week
(MET*min*wk). Multiple linear regression was used to determine the demographic, socioeconomic, and additional
health factors that are associated with MVPA.
Results: The median age at survey was 49 (range: 18-84) years and the median time after cancer diagnosis of 20
(range: 0-70) years. The sample was 78% white, 9.3% Hispanic, 7.5% black, 2% Asian, and 3% other, with 76%
identifying as female. The median self-reported weekly MVPA level achieved in AYA survivors was 480 (IQR: 01680) MET*min*wk, corresponding to 90 (IQR: 0-280) weekly minutes of MVPA. Exercise time was 32% lower in
black compared to white AYAs (p=0.01). No other race/ethnic differences were demonstrated. Household income
of >=50K was associated with 79% greater exercise time with comparison to an income of <50K, p<0.0001. High
school graduation through some college degree was associated with 67% greater exercise time (p<0.0001) and a
bachelor’s degree or more was associated with a nearly 4-fold greater exercise time (p<0.0001) compared to less
than a high school education. Diabetes and heart disease were associated with a 27% (p=0.02) and 44%
(p=0.0003) lower exercise time, respectively.
Conclusion: Race, socioeconomic factors, such as household income and educational status, and health factors,
such as diabetes and heart disease, were associated with MVPA in AYA cancer survivors. Future interventions
should be aimed at these subpopulations.
Keywords: Adolescent and young adult, survivors, physical activity, cancer
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Abstract number: 105
Associations Between Religious Fatalism and Modifiable Behavioral Cancer Risk Factors Among Rural
Cancer Survivors
Fanie M Wabwende; Health Disparities Research; University of Texas MD Anderson Cancer Center
Ian M Leavitt; Health Disparities Research; University of Texas MD Anderson Cancer Center
Sara Nofal; Health Disparities Research; University of Texas MD Anderson Cancer Center
Scherezade K Mama; Health Disparities Research; University of Texas MD Anderson Cancer Center
Background: Approximately 2 million people in the US will have a cancer diagnosis in 2021 and over a million will
die from the disease. An overwhelming body of evidence highlights the benefits of health behaviors such as diet,
exercise and normal BMI among cancer survivors. However, many cancer survivors experience barriers to
engage in these health behaviors. Studies have reported an association between religious fatalism and a
decreased drive to participate in physical activity (PA) and maintaining a healthy diet and weight. It has previously
been suggested that socio-demographic factors such as gender, education, and income moderate the relationship
between religious fatalism and health behaviors. The uniqueness of our study is in its focus on this relationship
among rural cancer survivors. We aim to 1) examine the relationship between religious fatalism and health
behaviors among rural cancer survivors and 2) determine whether these associations are moderated by sociodemographic factors.
Methods: This is a secondary analysis of cross-sectional data from the Partnering to Prevent and Control Cancer
(PPCC) study. The parent study examined factors that affect PA and health outcomes among cancer survivors in
Central Pennsylvania. PPCC participants were recruited through an academic-community partnership.
Participants (N = 219) completed an in-depth questionnaire by mail assessing overall religious fatalism and divine
provision, destined plan, and helpless inevitability subscales, health behaviors (PA, fruit and vegetable and fat
intake, alcohol consumption, and sleep quality), and demographic characteristics. Prior to analyses, normality was
checked for all variables. PA and fruit and vegetable (FV) were positively skewed and transformed using a square
root transformation to create a symmetric distribution. Linear regression was used to assess associations
between overall religious fatalism and each subscale and each health behavior individually. Associations between
fatalism and alcohol consumption, were assessed using zero inflated/negative binomial models. All analyses were
adjusted for age, gender, race, income, marital status and education level.
Results: Participants were in the their mid-60s (64.3 ± 12.5 years) and were mostly women (60.7%). Mean
weekly leisure-time PA was 24 (SD = 21.7), FV intake was 2.8 servings/day (SD = 2.0), fat intake was 30.5% of
kcal/day (SD = 1.8), alcohol consumption was 5 drinks/week (SD = 8.7), and sleep quality was 5.6 (SD = 3.3).
Helpless inevitability (β = -0.58, SE = 0.18, p = 0.001) and divine provision (β = -0.32, SE = 0.16, p = 0.044)
subscales were negatively associated with PA, and helpless inevitability was positively associated with sleep
quality (β = 0.53, SE = 0.25, p = 0.034).
Conclusion: Results suggest that helpless inevitability in rural cancer survivors may have a salutary effect on SQ
and a deterrent effect on PA, while divine provision has a negative effect on PA. These findings support previous
studies that associated fatalism with poor health behaviors such as PA. Further research exploring the impact of
religious norms and expectations on the decision to engage in health behaviors may be important in designing
culturally appropriate lifestyle interventions that may promote survivorship in rural cancer survivors.
Keywords: religious fatalism, health behaviors, modifiable behavioral cancer risk factors
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Abstract number: 106
Cost-effectiveness of Chemotherapeutic Colon Cancer Regimens
Emily Wood; Health Services Research; University of Texas MD Anderson Cancer Center
Background: The National Comprehensive Cancer Network recommends for high risk stage II and stage III colon
cancer patients to receive chemotherapy after colectomy. There are currently five combination chemotherapy
regimens available for colon cancer treatment: FOLFOX, CAPOX, FOLFIRI, FOLFOXIRI, and 5-FU/LV. Not many
studies have evaluated the effectiveness and financial costs of these regimens. Our study aims to evaluate these
regimens in terms of both health outcomes and financial burden.
Methods: We propose to use the Surveillance, Epidemiology, and End Results (SEER) linked with Medicare
database for this study. Patients 66-80 years old diagnosed with colon cancer between 2007 and 2015 who
survived at least 6 months since diagnosis and received surgery followed by chemotherapy will be included. Total
cost per patient will be estimated and mean, median, minimum, and maximum will be computed to summarize
costs for different regimens. Linear regression will then be used to compare differences in mean costs while
adjusting for patient characteristics. Lastly, patients’ survival will be estimated and used along with the costs to
compute the life-year and quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) will
then be calculated using these figures. All analysis will be done in SAS 9.4.
Results: As a result of these methods, we will learn the upfront costs of different chemotherapy regimens, the
average survival of diagnosed patients according to which regimen they received, and how these compare to one
another to demonstrate overall cost effectiveness. Future studies will need to be completed based on the same
topic to corroborate our findings and compare them to any new regimens that are potentially developed.
Conclusion: Implications of this study affect patients, physicians, and drug development. This information can be
used by physicians to inform patients of potential results of their treatment course, including financial burden.
Affordable cancer treatment is essential to patient completion and positive health outcome in order to reach ideal
survival.
Keywords: cost, cost-effectiveness, chemotherapy
Program Affiliation: CPRTP Summer Research Experience

110

First Year Medical Student Program
Abstract number: 107
Generation of in vivo mouse model to recapitulate arthritis after ICI therapy
Nigel Blackwood; Immunology; Tulane School of Medicine
Sang Taek Kim, MD; Immunology; University of Texas MD Anderson Cancer Center
Background: Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer therapy; however, ICIs cause
life/organ-threatening inflammatory immune-related adverse events (irAEs). Mechanisms of irAEs are unknown,
mainly due to the lack of pre-clinical mouse models. Arthritis is the most common rheumatic irAE, occurring in 35% of patients receiving ICIs. Like other irAEs, there is no pre-clinical model recapitulating arthritis-irAE. This
project aims to generate an arthritis-irAE murine model, manipulating the collagen-induced arthritis (CIA) model,
which is a well established model to study autoimmune arthritis.
Methods: We immunized chicken collagen (CII) emulsified with complete Freud media (CFA) in 8-10 week old
male C57/B6 mice on Day 0. Mice were re-challenged on Day 21 with incomplete Freud media (IFA). PBS, antiCTLA-4, and/or anti-PD-1 antibodies were injected on Day 19, 22, 25, and 28. CIA mice (CII-CFA on Day 0 and
Day 21) receiving combined ICIs were used as positive controls. The incidence and severity of arthritis were
measured until they were sacrificed on Day 43. At sacrifice, we harvested spleen, bones, and serum. Splenocytes
were stained with flow cytometry antibodies to identify key surface molecules, effector cytokines, and/or
transcription factors. Stained samples were acquired using LSR II FORTESSA X-20 (BD Bioscience) and
analyzed with FlowJo software.
Results: In contrast to mice receiving PBS, mice receiving ICIs developed arthritis after CII-CFA (D0) and IFA
(D21) immunizations. Further, arthritis of mice receiving either PD-1 inhibitor (PD-1 inhibitor arthritis) or combined
ICIs (combined ICI arthritis) was more severe than mice receiving CTLA-4 inhibitor alone. Our clinical
observations support that our model recapitulates arthritis-irAE well. Compared with PD-1 inhibitor arthritis group,
T cells were expanded in combined ICI arthritis group. In contrast, cDC2, Macrophages, Neutrophils, Non T Non
B Cells, CXCR3+ CCR6-, CD4+ T Cells, CXCR3-CCR6+ CD4+ T Cells, CXCR5+ CD8+ T Cells , CXCR3+,
CCR6- CD8+ T Cells , TNFa+ CD4+ T Cells , Tc1 and Tc1.17 CD8+ T Cells were expanded in PD-1 inhibitor
arthritis group.
Conclusion: We successfully generated in vivo mouse models recapitulating human arthritis-irAE model. Our
model will serve as a powerful tool for us to understand mechanisms underlying arthritis-irAE as well as formulate
appropriate therapeutic strategies to treat arthritis-irAE without diminishing anti-tumor immunity.
Keywords: Immune checkpoint inhibitor therapy, immune-related adverse event, mice models, arthritis
Program Affiliation: First Year Medical Student Program
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Abstract number: 108
Hypofractionated radiation therapy for unresectable or metastatic sarcoma lesions provides durable
tumor control and effective palliation
Ethan P. Damron; Radiation Oncology; University of Texas MD Anderson Cancer Center
David Boyce-Fappiano; Radiation Oncology; University of Texas MD Anderson Cancer Center
Ahsan Farooqi; Radiation Oncology; University of Texas MD Anderson Cancer Center
Devarti Mitra; Radiation Oncology; University of Texas MD Anderson Cancer Center
B. Ashleigh Guadagnolo; Radiation Oncology; University of Texas MD Anderson Cancer Center
Andrew Bishop; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Given the relative radioresistance of sarcomas and their often large size, conventional palliative
radiation therapy (RT) provides both limited tumor control and symptom relief. In select patients that warranted
dose-escalated treatment, we have used hypofractionated (HF) RT as a strategy to affect durable control and now
report our findings.
Methods: We retrospectively reviewed 73 consecutive patients with sarcoma who received >10 fractions of HFRT
from 2017-2020. Clinical scenarios included: 1) palliative/symptomatic intent (34%), 2) an unresectable primary
(27%), 3) or oligometastatic (16%) or 4) oligoprogressive (23%) disease.
Results: The HFRT target was a primary tumor in 64% of patients with a median dose of 45 Gy in 15 fractions
(59% ≥45 Gy). The 1-year DSS was 59%, which was more favorable for patients receiving HFRT for
oligometastatic (1-y 100%) or oligoprogressive (1-y 73%) disease (P=0.001). The 1-y targeted lesional control
(TLC) was 73%. A metastatic target (1-y 95% vs 60% primary, P=0.02; HR 0.27, P=0.04) and soft tissue origin (1y 78% vs 61% bone, P=0.01; HR 0.33, P=0.02) were associated with better TLC. The rate of distant failure was
high with a 6-month DMFS of only 43%. For patients not planned for adjuvant systemic therapy (n=53), the
median systemic therapy break was 9 months and notably longer in oligometastatic (13 months), oligoprogressive
(12 months) or unresectable (13 months) disease. HFRT provided palliative relief in 95% of cases with symptoms.
Overall 49% of patients developed acute G1/2 RT toxicities (no grade 3-5). No late grade 2-5 toxicities were
observed.
Conclusion: HFRT is an effective treatment strategy for patients with unresectable or metastatic sarcoma to
provide durable TLC, symptom relief, and systemic therapy breaks with limited toxicity.
Keywords: Hypofractionated radiation therapy, sarcoma, oligometastasis, oligoprogressive disease
Program Affiliation: First Year Medical Student Program
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Abstract number: 109
Cerebral Blood Volume Changes Occur during Radiotherapy and Predict Pseudoprogression versus
Disease Progression for Patients with High Grade Glioma
Jodi Goldman; Radiation Oncology; University of Texas MD Anderson Cancer Center
Maguy Farhat; Radiation Oncology; University of Texas MD Anderson Cancer Center
Brandon Curl; Radiation Oncology; University of Texas MD Anderson Cancer Center
Carlo Torres; Radiation Oncology; University of Texas MD Anderson Cancer Center
Lily G. Erickson; Radiation Oncology; University of Texas MD Anderson Cancer Center
Divya Yadav; Radiation Oncology; University of Texas MD Anderson Cancer Center
Rituraj Upadhyay; Radiation Oncology; University of Texas MD Anderson Cancer Center
Todd A. Swanson; Radiation Oncology; University of Texas MD Anderson Cancer Center
Arnold C. Paulino; Radiation Oncology; University of Texas MD Anderson Cancer Center
Kristina D. Woodhouse; Radiation Oncology; University of Texas MD Anderson Cancer Center
Amol J. Ghia; Radiation Oncology; University of Texas MD Anderson Cancer Center
Chenyang Wang; Radiation Oncology; University of Texas MD Anderson Cancer Center
Jing Li; Radiation Oncology; University of Texas MD Anderson Cancer Center
Thomas H. Beckham; Radiation Oncology; University of Texas MD Anderson Cancer Center
Vinodh A. Kumar; Neuroradiology; University of Texas MD Anderson Cancer Center
James P. Long; Biostatistics; University of Texas MD Anderson Cancer Center
Caroline Chung; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Following concurrent chemotherapy and radiotherapy (RT) for newly diagnosed high-grade glioma
(HGG), anatomical MRI changes are indistinguishable between true disease progression (DP) and a treatmentinduced phenomenon called pseudoprogression (PsP). In the case of DP, increased contrast enhancement of the
tumor region is due to tumor growth, while in the case of PsP, this increased enhancement is due to treatmentrelated changes such as increased capillary permeability. The ability to distinguish between DP and PsP earlier is
fundamental for guiding timely treatment adjustments for patients with DP while avoiding unnecessary toxicity for
patients with PsP. Perfusion imaging with relative cerebral blood volume (rCBV) has shown promise to distinguish
these entities in the post-treatment setting. This study aims to determine if early rCBV changes during the first 3
weeks of RT may help predict for and improve the ability to distinguish DP vs early PsP.
Methods: Patients with newly diagnosed HGG following tumor resection and treated with 6 weeks of
chemoradiation on a prospective adaptive RT trial with at least 6 months follow up were included in this analysis.
Multiparametric MRI, including dynamic susceptibility contrast (DSC) were acquired at baseline and at week 3 of
RT. Residual gross tumor and contralateral normal appearing white matter (NAWM) were contoured on contrastenhanced T1-weighted MRI. We extracted tumor rCBV values with leakage correction based on tumor and
NAWM contours. Patients were separated into groups depending upon radiologist impression and clinical
treatment decision within 6 months, indicating PsP, DP, or stable/responding. Univariate and multivariate
analyses were used to determine if a significant difference in early rCBV change exists between the PsP and DP
groups (primary endpoint). Secondarily, the same analyses were used to determine if demographic and molecular
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variables were predictors for PsP or DP.
Results: Twenty-six patients diagnosed with HGG between April 2019 and January 2021 were included in this
study. Forty-two percent were female, 92% had KPS ≥70, and the median age was 61. Approximately 42% (n=11)
have been categorized as DP, 50% (n=13) as PsP, and 8% (n=2) as stable/responding.
Conclusion: Pending.
Keywords: High grade glioma, pseudoprogression, relative cerebral blood volume, perfusion-weighted imaging
Program Affiliation: First Year Medical Student Program
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Abstract number: 110
Clinical Relevance of MDM2 Testing in Lipomatous Tumors of the Extremities.
Tanner Hafen; Orthopaedic Oncology; University of Texas MD Anderson Cancer Center
Valerae Lewis MD; Orthopaedic Oncology; University of Texas MD Anderson Cancer Center
Background: Lipomas of the extremities are benign soft tumors of adipocytic origin. Extremity Atypical Lipomatous
Tumors or Well-Differentiated Liposarcomas (ALT/LS-WD) are low-grade tumors of adipocytic origin with a
greater potential of local recurrence. Differentiating between lipomas and ALT/LS-WD based on imaging can be
difficult and differentiation often relies on both histological analysis and cytogenetic studies. ALTs are
characterized by amplification of the MDM2 gene (12q13-15) and thus cytogenetic MDM2 testing can be a useful
tool to establish a diagnosis. However, the question arises whether ubiquitous testing of these tumors is
necessary and whether this knowledge changes the treatment algorithm for the patient.
Methods: We evaluated patients diagnosed with ALT/LS-WD and Lipoma between 2011 and 2020. Demographic
data, tumor location, treatment, and pathology were reviewed.
Results: 312 patients were identified: 205 lipomas and 107 ALTs. Overall recurrence was 3.9% (n=8) for lipomas
and 27.1% (n=29) for ALTs. Among the 205 lipomas, 44.39% (n=91) were tested for MDM2 and of the 107 ALTs,
59.8% (n=64) were tested for MDM2, in total 49.68% of the 312-patient cohort (n=155) were tested for MDM2. Of
the lipomas tested for MDM2, 15.38% (n=14) tested positive but only 4 recurred. Treatment for the 4 recurrent
lipomas that tested positive for MDM2 was surgical excision. Of the 4 recurrent lipomas that were either negative
or not tested for MDM2, 2 were treated with surgical excision, 1 was lost to follow-up, and 1 was treated with
observation. Treatment for all but 1 recurrent ALT was surgical excision. Treatment of the vast majority of
recurrences, 91.89% (n=34), was surgical excision.
Conclusion: Our results suggest that a more selective approach to using MDM2 testing is warranted. The majority
of the Lipomas tested for MDM2 were negative, and of those that came back positive, only 4 resulted in
recurrence. Treatment of recurrent lipomas/ALTs was surgical excision whether or not the tumor was positive for
MDM2. MDM2 testing is not without financial cost, and in this cohort, testing provided little to no change to the
treatment options. Thus, we support the recent recommendations in the literature to limit testing for MDM2 to
recurrent lipomas, lipomatous tumors with equivocal cytologic atypia, and deep extremity tumors larger than 10cm
in patients over fifty.
Keywords: Lipoma, ALT, MDM2, Cytogenetics
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Abstract number: 111
Cell Surface Targeting in Large Cell Neuroendocrine Carcinoma
William Hasken; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
C. Allison Stewart; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Runsheng Wang; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Lixia Diao; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Kavya Ramkumar; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Lauren Averett Byers; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer
Center
B. Letitia Rodriguez; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Don L. Gibbons; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Jing Wang; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Carl M. Gay; Thoracic/Head & Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Pulmonary large-cell neuroendocrine carcinomas (LCNECs) comprise a subset of lung malignancies
that are difficult to address clinically because of their aggressive biology and lack of personalized therapeutic
strategies. Prior work has shown that subsets of LCNEC share genomic similarities with both NSCLC and SCLC
transcriptionally; however, LCNEC closely resembles SCLC immunohistochemically. As such, LCNEC patients
have traditionally been allocated similar treatment regimens as SCLC patients; but like SCLC, prognosis for these
patients remains unsatisfactory with bleak median survival rates. Recently, promising work has been done to
characterize LCNEC into two distinct genomic subgroups that allow them to be readily distinguished from other
NCSLCs and SCLCs. Here, we hypothesize that LCNEC represents a unique pulmonary malignancy with
distinctive protein signatures. To this point, we wish to show that targetable cell surface markers exist that may
provide more personalized treatment and clinical management of those diagnosed. Our goal is to identify cell
surface proteins that are uniquely expressed in LCNEC models. Subsequently, we aim to use these unique
surface markers to guide proven next generation therapeutic strategies such as antibody drug conjugates (ADCs)
or bispecific T-cell engagers (BiTEs).
Methods: Using RNAseq data from 69 LCNEC patient tumors and 18 LCNEC cell lines, we screened expression
of cell surface genes and identified AXL, ROR1, EPCAM, ANXA1, CEACAM5, DLL3, NCAM1, MUC16. We
verified expression of AXL, CEACAM5, and DLL3 protein levels by RPPA analysis. 20 LCNEC cell lines were
screened by flow cytometry and levels of cell surface expression ranged from 0-100% for these markers with
EPCAM, ROR1, AXL, DLL3 being the most abundant. Total protein lysate levels were verified by western blot
analyses.
Results: See methods
Conclusion: Our work suggests these cell targets may also be enriched in patients with LCNEC, suggesting
potential novel therapeutic targets that could be rapidly explored in the clinical setting. These experiments and
clinical trials highlight the importance of distinguishing targetable cell surface markers that LCNEC tumors
express preferentially; and furthermore, our study aims to elucidate further markers that may offer more
personalized therapies for patients with LCNEC. Further work that characterizes large cell neuroendocrine
cancers by the total amount of cell surface marker relative to non-malignant cell types may provide insight into
targeted therapeutic strategies that target these markers in patients with the disease.
Keywords: Large Cell Neuroendocrine Carcinoma
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Abstract number: 112
Incidence of Lymphedema in Inflammatory Breast Cancer Patients Following Trimodality Treatment
Shelby Irwin; Breast Surgical Oncology; University of Texas MD Anderson Cancer Center
Mediget Teshome; Breast Surgical Oncology; University of Texas MD Anderson Cancer Center; Morgan Welch
Inflammatory Breast Cancer Research Program and Clinic
Background: Lymphedema as a sequelae of breast cancer treatment is a major concern, especially with
improvements in survival outcomes. Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer and
trimodality treatment—neoadjuvant chemotherapy (NCT), modified radical mastectomy (MRM), and radiotherapy
(XRT)—remains the standard of care. Given this, IBC patients are at high risk to develop lymphedema. The
objective of this study is to evaluate the incidence of lymphedema in IBC patients following treatment.
Methods: Patients with stage III and stage IV IBC treated at MD Anderson Cancer Center between 2016-2019
were identified from a prospective database. Lymphedema measurements captured in the medical record were
reviewed. Patients were excluded if there were no lymphedema measurements available or they underwent
bilateral axillary surgery. Lymphedema was defined as a >10% increase in perometer readings in upper extremity
volumes comparing the baseline measurement to the highest reported volume. Patients with preoperative and
follow up lymphedema measurements were included in the analysis. Demographic, clinical and pathologic factors,
oncologic outcomes, lymphedema symptoms and objective lymphedema measurements were recorded for the
entire cohort and compared among patients who did and did not develop lymphedema.
Results: One hundred and seventy three patients with IBC were treated during the study period. Of this group,
124 (71.7%) had at least one lymphedema measurement recorded. Eight-four patients had a preoperative and at
least one follow up measurement recorded. Demographic and clinical and pathologic features are included in
Table 1. The incidence of objective lymphedema in this patient population was 47.6% (n=40). Subjective
symptoms of lymphedema such as a feeling of heaviness and swelling were reported at at least one time point by
85% of patients (n=34) and 100% (n=40) respectively in patients with objective lymphedema as compared to
43.2% (n=19) and 52.3% (n=23) in patients with no lymphedema.
Conclusion: Inflammatory breast cancer patients are at high risk for lymphedema, which impacts approximately
50% of patients with symptoms present in over 80%. Strategies to reduce the risk for lymphedema should be
considered in this high risk population.
Keywords: Inflammatory Breast Cancer, Lymphedema
Program Affiliation: First Year Medical Student Program
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Abstract number: 113
The association of oral and stool microbiome with bronchiolitis obliterans syndrome after hematopoietic
cell transplantation.
Breanna Jones; Pulmonary Medicine; University of Texas Rio Grande Valley
Luis Rocha; Pulmonary Medicine; Tecnologico de Monterrey
Amin Alousi; Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer Center
Lara Bashoura; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Muhammad H. Arain; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Laila Z. Noor; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Diana Montanez; Genomic Medicine; University of Texas MD Anderson Cancer Center
Rohtesh S. Mehta; Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer
Center
Uday Popat; Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer Center
Chitra Hosing; Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer Center
Elizabeth J Shpall; Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer
Center
Richard E Champlin; Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer
Center
Chia-Chi Chang; Genomic Medicine; University of Texas MD Anderson Cancer Center
Burton F Dickey; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Robert R. Jenq; Genomic Medicine; University of Texas MD Anderson Cancer Center
Ajay Sheshadri; Pulmonary Medicine; University of Texas MD Anderson Cancer Center Background:
Bronchiolitis Obliterans Syndrome (BOS) is an obstructive pulmonary disease and the primary manifestation of
graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT). Unfortunately, BOS is often
identified at a late stage, and airflow obstruction may often be irreversible upon diagnosis, leading to poor
prognosis. The use of more flexible criteria to diagnose BOS (BOS Stage 0p) leads to a high rate of false positive
diagnoses. Recent studies have shown lung microbiome depletion increases the risk of post-HSCT lung injury.
The purpose of this study is to determine whether oral and stool microbiota are associated with early BOS. By
identifying signatures that are associated with BOS, we hope to use a confirmatory microbiome signature to
improve the detection of early BOS using BOS stage 0p criteria.
Methods:: We conducted an observational study at MD Anderson Cancer Center in 36 allogeneic HCT recipients
with a new diagnosis of extrapulmonary GVHD and no pulmonary impairment, pre-BOS (BOS stage 0p with
irreversible impairment), and BOS. Each patient had provided oral and stool samples for microbiome analysis at
baseline and subsequently every three months for one year. We measured antibiotic use for 60 days prior to
enrollment and during the 12-month duration of the study. The pre-BOS patients were treated with inhaled
steroids per institutional protocol. We analyzed microbiome samples to measure abundance, α-diversity and βdiversity and compared pre-BOS and BOS patients to a combined control group of cGVHD and BOS stage 0p
with transient impairment.
Results: We report preliminary results from the first 22 HCT recipients with oral and stool samples. Analyses are
not yet corrected for antibiotic use. α-diversity and β-diversity did not vary significantly when comparing oral and
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stool microbiota from controls and combined pre-BOS/BOS groups. Oral microbiome results showed a significant
decrease in relative abundance between the combined pre-BOS and BOS groups when compared to controls.
The relative abundance of the gut microbiome had little to no changes. The pre-BOS subgroup analysis exhibits a
more pronounced difference in relative abundance as compared to the control.
Conclusion: We show that depletion of the oral microbiome is associated with diagnosis of early BOS, but
diversity was similar between BOS and controls. Future work from the complete cohort will analyze subgroup
effects, control for antibiotic use, and correlate with nasopharyngeal inflammation.
Keywords: Bronchiolitis Obliterans Syndrome, hematopoietic stem cell transplant, microbiome
Program Affiliation: First Year Medical Student Program
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Abstract number: 114
Evaluating the efficacy of AUCsymptom in predicting acute and late patient-reported outcomes for
oropharyngeal cancer patients treated with radiotherapy.
Elizabeth Klettke; Radiation Oncology; University of Texas Health Science Center - Houston, McGovern Medical
School
Lisanne Van Dijk; Radiation Oncology; University of Texas MD Anderson Cancer Center
Clifton Fuller; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Patients with head-and-neck cancer (HNC) undergoing radiotherapy (RT) may experience chronic
side effects, such as xerostomia and dysphagia, which severely impact quality of life. Recent quantitative
approaches have provided insight into these symptom trajectories. Van Dijk et al. [Cancer, 127(14): 2453-2464
(2021)] developed a measure of symptom burden over time, the area under the curve for a symptom
(AUCsymptom), which condenses symptom data over time into a single data point. While acute symptoms,
particularly xerostomia and dysphagia, have been shown to strongly predict late symptoms, this relationship for
the AUCsymptom has not been established. We hypothesize that acute AUCsymptom will be predictive of late
AUCsymptom; our objective for this study is to expand upon the work of Van Dijk et al. to determine the
predictive value of the acute AUCsymptom for late AUCsymptoms.
Methods: AUCsymptom data from 336 patients from a registry at MD Anderson Cancer Center of patients
evaluated for a suspected or confirmed diagnosis of oropharyngeal cancer (OPC), calculated by van Dijk et al.,
was used in the present study. AUCsymptoms were derived from patients’ responses to the MDASI-HN, a
validated, head-and-neck specific, 28-item symptom reporting tool in which patients rate symptoms from 0 (none)
to 10 (worst imaginable). Patient data was prospectively collected at baseline, RT weeks 1-7, and 6 weeks postRT (acute) and between 3-6 months and 18-24 months post-RT (late). Spearman’s rho correlations were
calculated between acute and late AUCsymptoms; correlations with p-values < 0.05 were considered significant.
The effects of treatment, TNM staging, age, and gender on acute and late scores will then be evaluated using a
non-parametric equivalent of linear regression.
Results: Correlations between acute and late AUCs have been initially calculated. At this early stage, acute AUC
appears to be significantly correlated with late AUC for several symptoms, notably dry mouth (r = 0.52, p <
0.0001) and drowsy (r = 0.43, p < 0.0001). The next step will be to assess the effects of treatment, staging, age,
and gender on these relationships.
Conclusion: Although this project is still ongoing, preliminary evidence suggests the AUCsymptom may have
utility for identifying patients that would benefit from individualized RT adaptation. We anticipate that this project
will demonstrate the validity of the AUCsymptom measure and encourage further study of its potential for
understanding RT side effects most important to OPC patients.
Keywords: AUCsymptom, patient-reported outcomes, oropharyngeal cancer, radiotherapy side effects, symptom
prediction
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Abstract number: 115
Differential responses of human and mouse lung epithelial cells in inducible resistance to viral infection
Shahid Manzar; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Michael Longmire; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Scott Evans; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Background: Respiratory infections are the leading cause of mortality globally and immunocompromised
individuals are at an elevated risk. The advent of the global SARS-CoV-2 pandemic has claimed over 4 million
lives and many more are suffering sequelae post-infection as of July 2021. The past year has shown us that there
is a pressing need for improved treatments and symptomatic management of viral respiratory infections. A
potential strategy is to induce protective host immune responses . One therapeutic is Pam2/ODN (Pam2CSK4
and ODN M362), a combination drug that has been shown to induce the formation of reactive oxygen species
(ROS), nonspecific mediators of antimicrobial defense. ODN has been shown to act through the toll-like receptor
(TLR) pathway which is required for inducible resistance in lung epithelial cells. Preliminary studies in HBEC3-KT
cells have demonstrated that this combination drug upregulates Keap1, an inhibitory regulator of Nrf2 mediates
antioxidant protection, resulting in overall increased ROS activity.
Methods: MLE-15 and HBEC3-KT cells were cultured and treated with or without Pam2/ODN for 4 hours prior to
viral challenge. The cells were inoculated with influenza A virus (H3N2) or mouse hepatitis virus (MHV-A59) at a
multiplicity of infection of 0.1 for 24 hours. Separately, uninfected cells were treated for 2, 4, and 6 hours with
Pam2/ODN (2.2 μM and 0.55 μM respectively) along with a group receiving only PBS as a negative control.
Expression of genes involved in the formation/attenuation of oxidative damage and viral burden was measured
using qPCR.
Results: Pam2/ODN treatment induced a protective phenotype in isolated lung epithelial cells and decreased
overall viral burden of influenza, however, MHV burden remained unchanged 24 hours post infection. We have
also observed a decrease in the expression of IκBα, an inhibitor of NF-κB in MLE’s treated with Pam2/ODN. In
HBEC’s, no change was observed in the expression of genes that promote antioxidants i.e. Nrf2, however, an
increase in the expression of genes that inhibit Nrf2 antioxidant pathways i.e. Keap1 was observed.
Conclusion: Pam2/ODN presents a novel means to combat viral respiratory infections. Prophylactic administration
markedly decreases influenza viral load and promotes oxidative damage. Overall, the net effect is a protective
phenotype observed in isolated cultures of MLE-15 and HBEC3-KT cells.
Keywords: Influenza, Coronavirus, Lung Epithelium, TLR Agonist, Human Bronchial Epithelial Cells
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Abstract number: 116
Differential responses of human and mouse lung epithelial cells in inducible resistance to viral infection
Shahid Manzar; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Michael Longmire; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Scott Evans; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Background: Respiratory infections are the leading cause of mortality globally and immunocompromised
individuals are at an elevated risk of mortality. With the advent of the global SARS-CoV-2 pandemic which has
claimed over 4 million lives and many more suffering sequelae post-infection as of July 2021. Anyone can agree
there is a pressing need for improved non-specific treatments and symptomatic management of viral respiratory
infections. One potential therapeutic option is Pam2-ODN (Pam2CSK4 and ODN M362), a combination drug that
has been shown in preliminary studies to induce the formation of reactive oxygen species (ROS). ODN has been
shown to act through the TLR pathway to bolster innate immunity. It has been shown in previous studies that TLR
signaling is required for inducible resistance in lung epithelial cells and ROS are general nonspecific mediators of
antimicrobial defense. Preliminary studies in HBEC3-KT cells have shown that this combination drug upregulates
Keap1, an inhibitory regulator of Nrf2 which regulated ROS generation, resulting in an increase in ROS overall.
Methods: MLE-15 and HBEC3-KT cells were cultured and treated with either Pam2-ODN or PBS (negative
control) for 4 hours prior to introduction of a viral burden. The cells were inoculated with Influenza A Virus (H3N2)
or Mouse Hepatitis Virus (MHV-A59) at a MOI of 0.1 for 24 hours. Separately, uninfected cells were treated for 2,
4, and 6 hours with Pam2-ODN (2.2 μM and 0.55 μM respectively) along with a group receiving only PBS as a
negative control. qPCR was used to measure gene expression and viral burden.
Results: It is shown that prophylactic Pam2-ODN treatment induces a protective phenotype in isolated lung
epithelial cells and decreases overall viral burden of influenza. We have also shown that Pam2-ODN decreases
the expression of IκBα, an inhibitor of NF-κB, which is we hypothesize is partially responsible for the protective
phenotype observed. A decrease in expression of genes that regulate ROS generation (Nrf2) was also observed
while the expression of pro-ROS genes (Keap1) was elevated.
Conclusion: Pam2-ODN presents a novel means to combat viral causes of respiratory infection. Prophylactic
administration shows a markedly decreased viral load and promotes the expression of ROS inducing proteins,
while decreasing the expression of genes that regulate ROS production. Overall, the net effect is a protective
phenotype observed in isolated cultures of MLE-15 and HBEC cells.
Keywords: H3N2, MHV-A59, Oligodeoxynucleotide, TLR Agonist
Program Affiliation: First Year Medical Student Program
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Abstract number: 117
Effect of MLC1 on Cell Viability and Invasion in U87 Glioblastoma Cell Line
Hui-Jean Ooi; Neurosurgery; University of Texas MD Anderson Cancer Center
Joseph McCarty; Neurosurgery; University of Texas MD Anderson Cancer Center
John Morales; Neurosurgery; University of Texas MD Anderson Cancer Center
Background: Glioblastoma multiforme (GBM) is one of the most common and aggressive brain tumors with high
recurrence rates. Previous studies have shown that the protein megalencephalic leukoencephalopathy with
subcortical cysts1 (MLC1) promotes glioblastoma stem cell growth and invasion, thus promoting its tumor
progression. In addition, primary human GBM tissue samples have been shown to express increased MLC1
mRNA levels that mainly localize to areas of invasive and infiltrative tumor growth. Therefore, here, we will
examine the effect of MLC1 expression on cell viability and invasion in vitro on the established GBM cell lineU87MG.
Methods: Expression of MLC1 was induced in U87 MG cells via lentiviral vector-mediated transgene expression.
As our empty vector control, the MLC1 gene was substituted with RFP within the vector. Infected cells were then
selected by fluorescence-activated cell sorting (FACS) and MLC1 expression will be confirmed via anti-MLC1
immunoblotting. Cell viability of U87MG cells that have been induced to express MLC1 (U87-MLC1) will be
measured via the CellTiter-Glo 2.0 Luminescent Cell Viability Assay. In addition, the cell invasion rate of U87MLC1 cells will be determined using the Matrigel Invasion Assay. Lastly, MLC1 immunohistochemistry was
carried out on sections of human glioblastoma brain tumor sections.
Results: U87-MLC1 cells expressed GFP fluorescence while U87-empty vector cells expressed both GFP and
RFP fluorescence. By anti-MLC1 immunoblotting, we anticipate U87-MLC1 cells to show significantly higher
MLC1 protein levels than U87-empty vector cells. We also anticipate that U87-MLC1 cells will show a significant
increase in luminescence (RLU) compared to U87-empty vector cells as time progresses. In addition, we
anticipate a greater invasion rate in the U87-MLC1 cells compared to the U87-empty vector control cells in the
Matrigel Invasion Assay. Lastly, immunohistochemistry staining of human glioblastoma brain sections for MLC1
protein showed localization of MLC1 in tumor cells surrounding cerebral blood vessels.
Conclusion: As we do not currently have results, we anticipate that an induced expression of MLC1 in U87MG
cells will increase cell viability and cell invasion rates compared to U87-empty vector cells as MLC1 knockouts in
glioblastoma stem cells have been shown to diminish cell proliferation and invasion. In concordance with previous
findings that MLC1 is localized to perivascular astrocytes, our findings also show that MLC1 is expressed in tumor
cells surrounding blood vessels in glioblastoma tumor sections.
Keywords: MLC1, glioblastoma, U87MG
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Abstract number: 118
Studying the effect of targeting STAT3 and PD-1 combination treatment of K-ras mutant lung cancer
Cody Chou; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Michael Clowers; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
T. Kris Eckols; Infectious Diseases, Infection Control, and Employee Health; University of Texas MD Anderson
Cancer Center
David Tweardy; Infectious Diseases, Infection Control, and Employee Health; University of Texas MD Anderson
Cancer Center
Background: Lung adenocarcinoma (LUAD) is an aggressive form of non-small cell lung cancer with erratic cell
proliferation and metastasis. 30% of LUAD patients have mutations in the Kirsten rat sarcoma viral oncogene (Kras). The K-ras mutation drives cellular proliferation and tumor malignancy, but direct targeting is often
unsuccessful as K-ras mutant lung tumors are resistant to most available targeted therapies. As a result, there is
a need to understand alternative strategies of targeting the downstream or co-occurring pathways of K-ras.
Transcription factor STAT3 is a major component of tumor associated inflammation in K-ras mutant tumors and
may serve as a potential therapeutic target. Previous work has shown that injection of the STAT3 inhibitor, TTI101, has led to a decrease in tumor burden in a K-ras induced lung cancer mouse model, CC-LR. In addition,
STAT3 has been shown to induce immunosuppression by up-regulating the immune checkpoint molecules PD1/PD-L1. Thus, a combination treatment of TTI-101 and anti-PD-1 will target two tumor promoting pathways in Kras mutant lung tumors and improve the outcomes.
Methods: In this study, we treated CC-LR mice with TTI-101 and/or anti-PD-1 from 10 to 14 weeks of age. With
the preliminary data acquired so far, we see a trend of decreased tumor area burden in the single and combined
treatment cohorts. With these samples, we will use qPCR to detect inflammatory markers in the tumor
environment, western blotting to detect apoptosis markers, H&E staining to determine tumor area percentage,
and immunohistochemistry staining to detect pSTAT3, measure proliferation, and angiogenesis.
Results: We predict the combined treatment, compared to a single treatment, will have a decrease in
inflammation-associated markers, pSTAT3, tumor size, multiplicity, grade, proliferation, and angiogenesis, while
seeing an increase in apoptosis markers, as well as an induction of anti-tumor immune response.
Conclusion: With the success of these predictions, we suggest that the treatment of K-ras mutant lung tumors by
the targeting of these two pathways, STAT3 and PD-1, could lead to a favorable outcome in mouse models. As a
result, we recommend further exploration in the use of TTI-101 and anti-PD-1 for clinical treatments in humans in
the future.
Keywords: K-ras, STAT3, TTI-101, LUAD, PD-1
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Abstract number: 119
Recombinant Thrombomodulin Has an Antitumor Effect and Enhances Treatment of Pancreatic Cancer
with Gemcitabine Through G-Protein Coupled Receptor 15
Kenei Furukawa; Surgery; The Jikei University School of Medicine
Paul Chiao; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Jianhua Ling; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Yichen Sun; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Yu Lu; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Jie Fu; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Nathan Nguyen; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Pranavi Garlapati; Molecular and Cellular Oncology; The University of Texas M. D. Anderson Cancer Center
Background: Pancreatic ductal adenocarcinoma (PDAC) is a detrimental disease, causing over 90% of pancreatic
malignancies with a 5-year survival rate under 8%. Due to PDAC’s high degree of therapy resistance, researchers
targeted alternative hallmarks of PDAC such as inflammation. Thrombomodulin (TM), a glycoprotein
anticoagulant, has anti-inflammatory and cytoprotective effects when interacting with G-protein coupled receptor
15 (GPR15). Since recombinant thrombomodulin (rTM) is approved to safely treat disseminated intravascular
coagulation in Japan, the path to clinical implementation for additional applications is less challenging. Leveraging
rTM's licensed status, the researchers investigated whether rTM's anti-inflammatory role in blood translated to
anti-inflammatory and anti-tumor effects in PDAC cells.
Methods: The goal of this study was to validate the Japanese study’s in-vitro results with 5 additional PDAC cell
lines of varying GPR15 expression, to examine the rTM/GPR15/NF-kB signaling axis in the regulation of PDAC
development. By exposing the cell lines with rTM and GEM, individually and combined, the researchers examined
the efficacy of rTM as a stand-alone and cocktail treatment for PDAC.
Results: A Japanese prospective study, which examined a PDAC patient-derived xenograft cell line PATC66 with
over-expression of GPR15, discovered that PATC66 cells treated with rTM plus gemcitabine (GEM) reduced cell
proliferation as compared to a single GEM treatment. Mechanistically, our study indicated that RTM plus GEM
significantly enhanced apoptosis and reduced the tumor burden in a subcutaneous xenograft model by inhibiting
NF-KB/p65 and ERK phosphorylation via GPR15.
Conclusion: The researchers concluded that rTM had anti-tumor effect and enhanced cytotoxic effect of GEM for
PDAC cells by inhibiting NF-KB and ERK activation via GPR15, suggesting that rTM is a highly applicable
therapeutic option for PDAC.
Keywords: recombinant thrombomodulin, gemcitabine, GPR15, pancreatic cancer
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Abstract number: 120
Automated Quantification of Mitotic Figures in Patients with Melanoma
Pranathi Pilla; Pathology; University of Texas MD Anderson Cancer Center
Phyu P. Aung; Pathology; University of Texas MD Anderson Cancer Center
Victor G. Prieto; Pathology; University of Texas MD Anderson Cancer Center
Background: Mitotic rate is an important factor with prognostic relevance in melanoma. In a number of tumors,
higher mitotic activity correlates significantly with reduced survival and is an important parameter in prognostic
models offering tailored predictions of prognosis for individual patients with melanoma. The quantification of a
proliferation index, an essential component of a pathology report, is traditionally performed by manually counting
mitotic figures on hematoxylin-eosin (H&E) stained slides. However, in addition to the time-consuming nature of
manual counting, there is interobserver and intraobserver variability. Computational pathology software based on
artificial intelligence and machine learning methods may serve fast, reproducible, and less error-prone index
computations for tumor regions.
Methods: In this project, we counted mitotic figures in 50 tissue samples from melanoma patients on H&E slides
from formalin-fixed, paraffin-embedded tissue. We used the standard method using optical microscope, in which
the area of the lesion containing the most mitotic figures (the ‘‘hot spot’’) is identified and mitotic rate is calculated
as a 1-mm2 region encompassing the hot spot. In our institution, we use 4½ high-power fields to approximate 1
mm2 under an Olympus BX43 microscope. Regarding the digital counting, we will count the entire available tumor
surface on the slides as well as 1 mm2 region encompassing the hot spot area (method previously reported [DOI:
10.5858/arpa.2020-0137-OA]) on whole slide images (WSI) visualized using the ImageScope viewer (Aperio)
and fixed-shape annotation with 500x500µm squares or circles.
Results: In this study, the measurements will include (i) a count of mitotic figures using standard method with light
microscope (completed) (ii) an overall measurement of the entire lesion (all melanoma cells in the slide) with the
algorithm to provide an average per mm2 (on going) (iii) a count of 1 mm2 limited the hot spot area marked by
two experienced dermatopathologists (on going) (iv) a count of 1 mm2 hot spot by using HALO from Indica Labs
after looking at the heat map of the mitotic figures (on going). We will compare the findings of all these four
measurements against clinico-histologic data.
Conclusion: This study will provide data to determine the feasibility of digital counting of mitotic figures in
melanoma and it will compare the results with standard, manual counting.
Keywords: Automated quantification, melanoma, mitotic figures
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Abstract number: 121
The potential role of miRNAs in SARS-CoV-2 infection prognosis: an in-silico approach
Joseph Quinlan; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Simone Anfossi; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
George Calin; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: SARS-CoV-2 is a novel coronavirus that results in COVID-19, a disease that has created an
unprecedented state of emergency at the global scale. The infection results in a wide range of symptoms affecting
the respiratory and cardiovascular systems that have been noted to differ across race, age, and sex. Because of
the differing outcomes of infection between groups, it is critical that biomarkers to determine the aggressiveness
of the infection prior to the onset of clinical symptoms. Single nucleotide polymorphisms (SNPs), which are
genetic variations of a single nucleotide amongst people, have been linked to involvement in the prognosis of a
COVID-19 infection. On a similar note, evidence of the non-coding genome having an impact on the progression
and outcome of COVID-19 infections suggests that other non-coding genes could potentially have a similar role.
For example, microRNAs (miRNAs) are small non-coding RNAs that are involved in the post-transcriptional gene
regulation by binding to target mRNA sequences, effectively silencing gene expression. MicroRNAs have been
identified as biomarkers for many other diseases, so there may be existing relationships with miRNAs and
COVID-19.
Methods: PubMed searches revealed papers on the significance of specific SNPs on the prognosis of patients
with COVID-19. The positions of the SNPs were compared to the positions of human miRNAs from miRBase
using the hg38 reference genome. SNPs were assigned to a miRNA if less than 100 kb or 1Mb away from the
start of the miRNA sequence. MiRNA target genes were identified using miRWalk 2.0, miRTarBase, miRecords,
and Tarbase V8. These targets were compared across miRNAs to identify similarities using RStudio, an open
source software for statistical analysis.
Results: Final results are pending. However, preliminary results reveal 114 human miRNAs in close proximity to
the SNPs. The confirmed targets for these miRNA will be studied using available databases to identify their
biological significance and possible relation to COVID-19.
Conclusion: In order to confidently determine whether or not the miRNAs could serve as potential biomarkers for
the prognosis and severity of COVID-19 infection, further wet-lab analysis of the specific miRNA concentrations in
control and patient samples is required.
Keywords: MiRNA, SARS-CoV-19, single nucleotide polymorphism, miRNA target
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Abstract number: 122
FaDu Human Squamous Cell Carcinoma Induces Hyperexcitability of Primary Sensory Neurons
Hannah Wani; Anesthesia and Pain Medicine; University of Texas MD Anderson Cancer Center
Uhelski, Megan L.; Anesthesia and Pain Medicine; University of Texas MD Anderson Cancer Center
Gorur, Aysegul; Anesthesiology and Perioperative Medicine; University of Texas MD Anderson Cancer Center
Li, Yan; Anesthesia and Pain Medicine; University of Texas MD Anderson Cancer Center
Dougherty, Patrick M.; Anesthesia and Pain Medicine; University of Texas MD Anderson Cancer Center
Cata, Juan P.; Anesthesiology and Perioperative Medicine; University of Texas MD Anderson Cancer Center
Background: Pain in patients with cancer constitutes the most prevalent symptom, accounting for significant
deterioration in their quality of life. Early in tumor development, the release of pro-inflammatory molecules leads to
the activation of receptors located on sensory neurons, promoting the sensitization of nociceptors. Currently,
cancer pain is viewed as a process orchestrated by the release of pro-nociceptive molecules (cytokines,
chemokines, growth factors) and the invasion of neural structures, known as perineural invasion. However, the
exact mechanisms of peripheral sensitization in the context of perineural invasion are still poorly understood. A
critical understanding of how early sensitization occurs represents a promising strategy for prevention, drug
development, and treatment of cancer pain.
Methods: Dorsal root ganglia (DRG) were co-cultured with FaDu squamous cancer cells or culture media only.
We have developed an in vitro model in which cancer cells are co-cultured with DRG neurons, enabling us to
study changes in neuronal activity that result from being in close proximity to FaDu cells. We performed whole-cell
patch-clamp electrophysiology experiments to measure the electrical membrane properties of dissociated DRG
sensory neurons to determine whether co-cultured DRG neurons are sensitized in the presence of FaDu cells.
We also evaluated the expression of pro-inflammatory cytokines in co-culture media and assessed the effects of
exosomes released by FaDu cancer cells.
Results: Co-culture with FaDu cancer cells sensitized rat DRG neurons. Co-cultured neurons from older adult
male rats demonstrated spontaneous activity (SA) and depolarizing spontaneous fluctuations (DSFs) more
frequently than media-only control neurons. Current thresholds were also lower in co-cultured neurons from older
adult male rats. Media collected after co-culture showed elevated levels of pro-inflammatory cytokines, which can
directly induce spontaneous activity in vitro. In addition, treatment with exosomes isolated from FaDu cancer cells
increased the frequency of SA and DSFs and decreased mean current thresholds in DRG neurons. FaDu
exosomes were also capable of producing mechanical allodynia after intraplantar or intrathecal administration.
Conclusion: Neuronal hyperexcitability, including lower current thresholds, SA, and large DSFs were observed
after incubation with FaDu cancer cells, which could indicate enhanced nociceptive activity following exposure to
FaDu cancer cells in vitro. These changes were accompanied by increased levels of pro-inflammatory cytokines
in co-culture media. We also observed neuronal sensitization and mechanical allodynia following treatment with
exosomes released by FaDu cancer cells. Further studies will advance understanding of the mechanisms of
peripheral sensitization and treatment and prevention of pain in patients with cancer.
Keywords: dorsal root ganglion, FaDu cells, exosomes, co-culture
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Abstract number: 123
ETP-ALL is an aggressive neoplasm with high tumor mutation burden
Matthew T. Ye; Hematopathology; University of Texas MD Anderson Cancer Center
Steliana Calin; Hematopathology; University of Texas MD Anderson Cancer Center
Yaling Yang; Hematopathology; University of Texas MD Anderson Cancer Center
Hua He; Hematopathology; University of Texas MD Anderson Cancer Center
M. James You; Hematopathology; University of Texas MD Anderson Cancer Center
Background: Early T-cell precursor lymphoblastic leukemia (ETP-ALL) is a recently recognized subtype of Tlymphoblastic leukemia/lymphoma with a unique immunophenotype and high rate of treatment failure. The
molecular genetic abnormalities and optimal therapeutic approaches of patients with ETP-ALL are poorly
understood.
Methods: We retrospectively collected a group of 32 patients with ETP-ALL seen at MD Anderson Cancer Center
from January 1, 2000 to July 30, 2020, and studied the morphologic and immunophenotypic features, molecular
genetic aberrations, treatment regimens and clinical outcome.
Results: The study group included 25 men and 7 women with a median age of 43 years (range, 16-71 years).
Twenty patients had lymphadenopathy and thirty patients had bone marrow involvement. The bone marrow was
hypercellular (median cellularity, 90%) with a median blast count of 65%, without significant dysplasia or
myelofibrosis. The blasts were positive for cytoplasmic CD3 and CD7, and negative for CD1a and CD8 in all
cases. Other markers expressed included CD34 (28/32, 88%), CD33 (23/32m 72%), CD117 (21/31, 68%), CD13
(18/31, 58%), CD5 (partial, 56%), CD2 (10/32, 31%), CD10 (8/32, 25%), CD56 (partial, 6/21, 19%), and CD4
(2/32, 6%). Cytogenetic analyses revealed diploid karyotype in 10, simple (1-2) abnormalities in 10, and complex
karyotype in 10 patients. Next-generation sequencing analyses were performed in 20 patients. All patients carried
gene mutations (median 4 mutations per patient). The most frequently mutated genes included WT1 (8/20, 40%),
NOTCH1 (6/20, 30%), NRAS (6/20, 30%), ASXL1 (4/20, 20%), DNMT3A (4/20, 20%), FLT3 (4/20, 20%), PFH6
(4/20, 20%), and TP53 (4/20, 20%). All patients except one received multi-agent chemotherapy, and 22 patients
additionally received stem cell transplantation. With a median follow-up of 20.5 months (range, 1-66 months), 19
patients died of disease, 11 patients achieved complete remission with negative minimal/measurable residual
disease status (among these 10 received stem cell transplantation), and two were alive with persistent disease.
Conclusion: We summarize that patients with ETP-ALL often carry high tumor mutation burden and have poor
clinical outcome. These patients may benefit from stem cell transplantation. The identification of recurrent gene
mutations may serve as novel therapeutic markers.
Keywords: ETP-ALL, WT1, NOTCH1, NRAS
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Abstract number: 124
USP48 inhibition as a potential therapeutic target for patients with T-acute lymphoblastic leukemia
Matthew T. Ye; Hematopathology; University of Texas MD Anderson Cancer Center
Yaling Yang; Hematopathology; University of Texas MD Anderson Cancer Center
Hua He; Hematopathology; University of Texas MD Anderson Cancer Center
M. James You; Hematopathology; University of Texas MD Anderson Cancer Center
Background: T-acute lymphoblastic leukemia (T-ALL) is a heterogeneous hematopoietic neoplasm of precursor
T-cells. Although the prognosis of T-ALL has improved with the advent of new intensified treatment protocols, the
outcome of the relapsed/refractory patients is still poor, and there is a need for new therapies that target signaling
pathways involved in T-ALL pathogenesis, such as PI3K/mTOR. Ubiquitin is a small protein with a posttranslational modification function, namely that when it is attached to a protein, it marks it for degradation at the
proteasome. Deubiquitinating enzymes (DUBs) are a family of enzymes that target ubiquitinated proteins and
remove the ubiquitin, allowing the deubiquitinated proteins to circumvent destruction. USP48 is one such DUBs
and is likely to be overexpressed in patients with T-ALL. BRCA1-associated ATM activator 1 (BRAT1) is a
regulator of mTOR that contributes to cell proliferation when present in excess. We aim to study if USP48 can
target BRAT1 and affect proliferation and apoptosis of T-ALL cells.
Methods: HBK-ALL cells, a T-ALL cell line, were treated with varying doses of PR-619 (0 uM, 1.25 uM, 2.5 uM,
5.0 uM), a DUB inhibitor. After an incubation period of 24 hours, a part of the cells was collected for flow
cytometry, by staining with PE Annexin V and 7-AAD, known markers of apoptosis. The remaining cells were
collected for Western blot to assess the presence of USP48 and BRAT1. Furthermore, another culture of HBKALL cells was infected in vitro with an shRNA, knocking down the gene that encodes for USP48. These cells as
well were collected for Western blot.
Results: Flow cytometry revealed that cells treated with PR-619 showed elevated levels of apoptosis compared
to control cells, in a dose-dependent manner. The PR-619-treated cells also showed decreasing levels of BRAT1
in conjunction with little to no USP48 expression by Western blot. The USP48 knockdown cells showed the same
results.
Conclusion: Our results suggest a positive relationship between USP48 and BRAT1. Inhibition of this DUB may
thus present new targeted therapies for patients with T-ALL.
Keywords: T-ALL, Deubiquitinating enzymes, USP48, BRAT1
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Abstract number: 125
Investigating BCLXL and BCLXS as Resistance Markers for BCL2 Inhibitors
Felipe Dantas; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Evelyn de Groot; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Cesar Augusto Ruiz Elizondo; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Y.N. Vashisht Gopal; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Cutaneous melanoma is the deadliest and most aggressive form of skin cancer. Current treatment
options are suboptimal with high relapse rates for both immunotherapies and single-agent targeted therapies.
Recent studies demonstrated that 70% of cutaneous melanoma patients have increased expression of BCL2
family proteins like BCL2, MCL1 and BCL-XL, which are all members of the family of apoptosis regulatory
proteins. Melanoma express high levels of BCL2, which may be a marker of treatment resistance and response to
BCL2 inhibitors such as Venetoclax and Navitoclax. However, the relevance of BCL-XL’s shorter, potentially
antagonistic isoform, BCL-XS, in these contexts are unknown. To investigate the link between BCLXL expression
and treatment resistance, we analyzed BCLXL-upregulated and the isoform BCLXS-upregulated melanoma cells.
BCLXS has not been investigated as a treatment marker for melanomas.
Methods: One BCLXL-upregulated cell line and one BCLXS-upregulated cell line were engineered from the lowBCL2-expressing cell line WM4257. Cell Titer Blue was used to investigate cell growth, and Cell Cycle Analysis
was used to investigate cell cycle regulation and apoptosis rates. The Cell Titer Blue was run on 5 separate days
with 10 replicates for each cell line plated. Plates were read 2.5 hours after adding dye. Cell lines were treated
with 1uM and 10uM dilutions of Navitoclax and Venetoclax followed by Cell Cycle Analysis performed in triplicate.
Results: In this study, we demonstrated that BCLXS-upregulated cells possessed greater rates of growth than
parental compared to BCLXL-upregulated cells. In cell cycle analysis, BCLXL-upregulated cells demonstrated
greater G1 phase than parental cells when treated with Navitoclax, while BCLXS-upregulated cells demonstrated
decreased S phase compared to parental lines when treated with Venetoclax. BCLXL-upregulated cells
demonstrated a greater growth rate after Navitoclax treatment as compared to parental and BCLXS-upregulated
cells, going against the currently known role of BCL-XS as described in literature. Venetoclax treatment did not
induce significant differences in cell-line growth rates.
Conclusion: Our results suggest that the apoptosis regulatory proteins BCLXL and BCL-XS may play differential
roles in cutaneous melanoma. Higher levels of BCL-XL have a negative effect on cell growth before treatment,
and a positive effect following treatment. Similarly, the pro-apoptosis protein BCLXS may have a positive effect on
cell growth before and after treatment. With neither cell line inducing greater apoptosis rates as compared to the
parental, research on high-BCL-X expressing cell lines is needed – which could be critical for improving the
efficacy of personalized melanoma therapies.
Keywords: Cutaneous melanoma, BCL2, targeted therapy, apoptosis regulation
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Abstract number: 126
Optimization of an Exploratory Oncology Panel for Immunoprofiling Tissues in the Tumor
Microenvironment via CO-Detection by indEXing (CODEX) Methodology
Davis John; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Saxon Rodriguez; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Edwin Parra Cuentas; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Salome McAllen; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Auriole Tamegnon; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Heladio Ibarguen; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Cancer immunotherapy is revolutionizing cancer treatment by aiding the natural ability of the
immune system to identify and defend against tumors. In order to better design cancer therapeutics and advance
clinical care, the immunoregulatory proteins involved in immune checkpoints and immunosuppression must be
immunoprofiled. Such analysis can provide key insight into understanding how tumors can evade inhibitory tumor
mechanisms. We used highly multiplexed tissue imaging technologies, such as CODEX (CO-Detection by
indEXing), which allows more than 40 antibody markers to be placed and analyzed on tissues. Herein, we
describe the optimization, validation and application of a 27-marker CODEX antibody panel used for
immunoprofiling cancer tissues.
Methods: The CODEX design involves staining the tissue section with antibodies that are conjugated to single
DNA strands (barcodes), then multiple cycles are performed in which complementary DNA bound to fluorophores
(reporters) are dispensed onto the tissue, bind to the barcodes, and revealed via fluorescence imaging. The
repetition of these cycles using a set of different reporters every cycle allows revealing the whole CODEX panel.
The 27-marker panel includes CD3e, Pan-Cytokeratin, Arginase-1, etc. Several consecutive positive control tonsil
tissues were prepared for antibody optimization via chromogenic immunohistochemistry (IHC) at antigen retrieval
pH 9. In parallel, similar consecutive positive control tissues and lung cancer cases were placed in cover slips to
start the optimization using the CODEX approach. After individual antibody optimization, the antibody cocktail was
prepared in order to stain the control tissues then a reporter solution was prepared. In order to remove
background noise, the first and last cycles are blank cycles- that is, no reporters are placed on the sample, so no
antibodies are exposed. In every other cycle however, three reporters are placed at a time onto the tissue (plus
DAPI), so we are revealing up to three markers per cycle.
Results: We successfully optimized the various markers to obtain similar staining patterns with both techniques,
chromogenic IHC and CODEX. As expected, PD-L1 expression was observed predominantly on the cell
membranes of epithelial cells from the tonsil crypts. Likewise, the other immune checkpoint markers were
observed in different immune cells with similar distribution patterns between chromogenic IHC and CODEX in
tonsil and other control tissues. In control tonsil, CK was expressed by epithelial cells, and among cells
surrounding the germinal centers, the T-cell marker CD3 was the most abundant, followed by CD8, Granzyme B,
CD45RO, and FOXP3. PD-1 was predominantly distributed in the germinal center of the tonsil tissues and with a
similar pattern on IHC and CODEX. We are continuing to test the other antibodies in the panel. We acquired a
multi-color overlay image from each cycle that depicts the various markers of interest in identical patterns to the
individual staining markers.
Conclusion: Multiplexed immunophenotyping approaches reveal key insight into identifying therapeutic
mechanisms. Traditional multiplex IHC is restricted by the few antibodies that can be utilized and other
multiparameter technologies, such as single-cell RNAseq, lack spatial context. The CODEX method overcame
these limitations as we demonstrated. A comprehensive immunoprofile will advance our understanding of how
various factors can determine disease progression, resistance and response to immunotherapies and facilitate
the development of new treatment approaches.
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Abstract number: 128
B-cell spatial proximity analysis in early stage non-small cell lung carcinoma
Jay Mehta; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Rossana Lazcano; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Pedro Rocha; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Edwin Parra; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Kasthuri Kannan; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Luisa Maren Solis; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: In recent years, B-cells have been recognized as important players in the anti-tumor immune
response, including that of lung cancer. However, their role in this response and their spatial relation to malignant
cells are not very clear. To better understand these concepts, we analyzed B-cells’ density and spatial proximity
to malignant cells in Stage I lung adenocarcinoma and correlated these data with patient clinicopathological
characteristics and other previously annotated immune phenotypes.
Methods: Twelve surgically resected Stage I lung adenocarcinoma tumor samples were obtained from the
archives of the University of Texas MD Anderson Cancer Center. The samples were processed for GeoMx digital
spatial profiling (DSP) using the morphology biomarkers cytokeratin, CD3, CD20, and Syto13 in addition to
NanoString DSP panels to assess 49 immune-oncology proteins. The images were exported for digital image
analysis using the software HALO v3.2 (Indica Labs). We quantified the number of B-cells (CD20+) in the
intratumoral area and obtained B-cell counts and B-cell-tumor spatial proximity analyses at 20, 40 and 60 µm. The
data obtained was analyzed with GraphPad Prism v9.0 to generate correlations with patient clinicopathological
characteristics and various immune cell phenotypes previously annotated.
Results: In this cohort, B-cell density positively correlated with tumor size (r = 0.587, p = 0.045). Spatial proximity
analysis showed a significantly higher number of B-cells in different distance intervals away from tumor (0 – 20,
20 – 40, 40 – 60, and 0 – 60 µm) in patients whose cancer had invaded the pleura compared to those whose had
not (p = 0.0162, p = 0.0040, p = 0.0040, and p = 0.0040, respectively). Furthermore, in the 0 – 20 µm interval, the
number of B-cells positively correlated with the densities of CD68+ and CD68+/PD-L1- macrophages (r = 0.5912;
p = 0.0429 and r = 0.7609; p = 0.0041, respectively) and with that of CD8-/FOXP3+/CD45RO- regulatory T-cells
(r = 0.6349; p = 0.0265).
Conclusion: Tumors more highly infiltrated by B-cells within 20 µm demonstrated higher macrophage and
regulatory T-cell infiltration. Thus, there appears to be evidence that tumoral B-cell infiltration may promote the
presentation of cancer antigens in an otherwise immunosuppressive tumor microenvironment. Explanations for
our observations regarding pleural invasion and tumor size are less obvious, however, and given that our cohort
is small, future studies with larger sample sizes are warranted. Analysis of the immune-oncology biomarkers is
ongoing.
Keywords: B-cells, spatial analysis, lung adenocarcinoma
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Abstract number: 129
The Hybrid Epithelial-Mesenchymal Cancer Cell State Exhibits Advantageous Plasticity through
Resistance to Apoptosis and the Co-localization of Cytokeratin and Vimentin Filament Proteins
Silmi Merchant; College of Natural Sciences; The University of Texas at Austin
Nick A. Kuburich; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Abhijeet P. Deshmukh; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Petra den Hollander; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Sendurai A. Mani; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: The epithelial-mesenchymal transition (EMT) is a developmental process activated during cancer
that allows cells to acquire invasive migratory capacities, stem cell properties, and increased metastatic potential.
Along the spectrum of EMT, there exists a hybrid E/M cell that exhibits plasticity, the ability to transit between
states, and adaptivity within the tumor microenvironment. Direct observation of this adaptivity is survival when
exposed to compounds that alter EMT states. Transforming growth factor-beta 1 (TGF-β1) is a potent EMT
inducer, which enhances ECM remodeling within tumor cells with plasticity. SB431542 inhibits the TGF-β1
signaling pathway, which pushes the tumor cells in the EMT state to undergo Mesenchymal-Epithelial Transition
(MET). However, not every cell possesses plasticity, and the cellular response to EMT-MET induction within
cancer cells with non-plasticity states is unknown. Another facet of hybrid E/M cells is their ability to express
epithelial and mesenchymal structural cellular markers, such as cytokeratin and vimentin respectively. The
putative interaction of these markers is not understood in hybrid E/M cells. We hypothesize that cells with
Epithelial-Mesenchymal plasticity (EMP) will be more resilient to stress relative to non-plastic cells, and they will
possess co-expression of vimentin and cytokeratin filaments.
Methods: To assess the nature of cell death when the EMT state is altered, we tested the response of cancer
cells with plasticity (D2.A1) and without plasticity (D2.OR) to TGF-β1 and SB431542. The induction of caspase
3/7, a marker of apoptosis, was examined using Incucyte Caspase-3/7 dye during live-cell imaging. The equation
(Caspase levels) ⁄ (Confluency) represents the relative calculation, in which a non-plastic cell (D2.OR) should
result in a value greater than or equal to 1 and a plastic cell (D2.A1) should produce a value less than or equal to
1. Western blot analysis on SUM159 is used to detect the expression of cytokeratin (Epithelial) and vimentin
(Mesenchymal) protein presence. Immunofluorescent staining and imaging on D2.A1 and D2.OR will determine
the co-localization of cytokeratin and vimentin.
Results: The IncuCyte data shows the difference in apoptosis regulation in regards to levels of plasticity within
D2.A1 and D2.OR. Moreover, immunofluorescent imaging reveals a potential co-localization of cytokeratin and
vimentin.
Conclusion: Data regarding apoptosis induction and co-localization of cytokeratin and vimentin within differing
cells on the E/M spectrum supports an understanding of the nature of structural plasticity. It will also determine
the components of a hybrid E/M cell that gives it advantageous flexibility compared to non-plastic cells.
Keywords: Epithelial-mesenchymal transition (EMT), Cancer stem cells (CSCs), Transforming growth factor-beta
1 (TGF-β1), Cytokeratin
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Abstract number: 130
Iron dynamics and microbiome dysbiosis during tobacco-associated lung adenocarcinoma development
Rhiannon Morris; Translational Molecular Pathology; The University of Texas at Austin
Warapen Treekitkarnmongkol; Translational Molecular Pathology; University of Texas MD Anderson Cancer
Center
Ansam Sinjab; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Katsuhiro Yoshimura; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Humam Kadara; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Our group has shown that loss of the airway lineage-specific G-protein-coupled receptor 5a
(Gprc5a-/-) leads to lung adenocarcinoma (LUAD) development particularly in animals exposed to the tobaccospecific carcinogen nicotine-derived nitrosamine ketone (NNK). Lipocalin 2 (LCN2), an immunomodulatory protein
that we showed to exert protective roles against LUAD development, is involved in iron homeostasis and prevents
non-commensal bacterial overgrowth that causes inflammation and potential carcinogenesis. LCN2 was shown to
bind to iron-laden siderophore proteins that are needed by non-commensal bacteria to thrive. However, interplay
between LCN2, iron dynamics, and lung microbiome changes in relation to LUAD development is yet to be
determined. Towards this, we probed iron and microbial changes during LUAD oncogenesis.
Methods: Bacterial microbiome profiling (both gut and lung) was performed by sequencing the 16S v4 region
using the Illumina platform. Analysis of changes in microbial alpha diversity were statistically examined using
Shannon diversity index. Temporal analysis of ferritin, an iron storing protein, and free iron levels (Fe2+ and
Fe3+) in sera and bronchoalveolar lavage fluid (BALF) from Gprc5a-/- mice seven months post-NNK exposure
were compared to baseline. Serum ferritin was also examined in wild type (WT), Gprc5a-/-, and Gprc5a-/-/Lcn2-/littermates four hours post lipopolysaccharide (LPS) injection. Data were plotted and two-tailed paired t-tests
were performed to determine significance.
Results: Diversity of the microbiome in the gut but not the lung increased with time in Gprc5a-/- mice. In contrast,
microbial diversity in both the gut and lungs of Gprc5a-/-/Lcn2-/- mice significantly decreased with time post-NNK
and during lung oncogenesis. BALF ferritin levels increased with time more significantly in Gprc5a-/- than WT
mice exposed to NNK. In contrast, blood serum ferritin significantly decreased with time in NNK-exposed Gprc5a/- mice. Post LPS stimulation, Gprc5a-/-/Lcn2-/- mice experienced diminished levels of ferritin compared to both
Gprc5a-/- and WT littermates.
Conclusion: Our findings point to changes in iron accessibility during lung oncogenesis concomitant with
alterations in microbial composition. Our preliminary study suggests that LCN2 is an important factor in
maintaining bacterial diversity in both the gut and the lungs of Gprc5a-/- mice and may play a significant role in
modulating ferritin levels during inflammation and oncogenesis. More studies are underway to elucidate the role of
LCN2-microbiome-iron chelation in LUAD development.
Keywords: Lung adenocarcinoma, microbiome, lipocalin 2, Gprc5a
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Abstract number: 131
Assessing Cell Signaling Factor Content in Snap-Frozen Mesothelioma Tumor Samples
Cole Ponsi; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Hsin-Yi Lu; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Carlos Ramos; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Jacqueline Oliva; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Katarzyna Tomczak; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Boris Sepesi; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Cara Haymaker; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Malignant pleural mesothelioma (MPM) is a rare form of thoracic cancer associated with exposure to
asbestos. Our group has found that, contrary to other tumor types, thin MPM tumors tend to have suppressed
immune responses and high T regulatory cell counts. In this study, we measured concentrations of 79 cell
signaling factors from frozen MPM tissue samples and compared these values to existing gene expression data.
This process was validated by testing two lysis buffers and three protein assays to maximize protein yield and
sample reading quality.
Methods: MPM tissue resections snap frozen in liquid nitrogen were lysed using two different detergents (T-PER
Tissue Protein Extraction Reagent and RIPA buffer) supplemented with protease and phosphatase inhibitors.
Sample dilutions ranging from 5x to 40x were prepared and analyzed using three different colorimetric assays—a
Lowry-based assay, a Bradford reagent-based assay, and a BCA protein assay—to determine the overall protein
concentration in each sample. Samples were assessed for their content of 79 cell signaling factors using a
Luminex-based approach. Optimal protein concentration for detection was assessed by testing overall sample
protein concentrations of 0.5 mg/mL, 1 mg/mL, and 2 mg/mL and comparing the read quality of each. The results
were compared with gene expression profiling using the Nanostring tumor signaling 360 panel of RNA extracted
from the same tumor tissue.
Results: The T-PER and RIPA reagents both demonstrated comparable protein recovery, however the T-PER
reagent samples showed higher read quality. Total protein concentration was found most consistently using a
BCA protein assay with a 5x or 10x sample dilution. One mg/mL total protein was found to be the optimal
concentration. In unpaired analysis, levels of Eotaxin and IL-2R were found to trend higher in MPM tumor
samples than in normal tissue samples, and IL-23 was found to be lower with a 90% confidence (p < 0.1). When
comparing paired samples, Eotaxin and MIP-3α levels were significantly higher and MCP-1 was significantly lower
(p < 0.05) in tumor samples. Additionally, sCD30 and VEGF-A measured higher while IL-1β, MCP-2, sCTLA4,
and sHVEM were lower with a 90% confidence.
Conclusion: We defined parameters for optimal detection of proteins within primary tumor tissue using a luminex
system. We identified immune-related proteins possibly associated with tumor tissue as compared to tumorassociated normal tissue. Analysis is ongoing to determine associations with cytokine presence and tumor
thickness as well as correlation with RNA expression as detected using Nanostring.
Keywords: malignant pleural mesothelioma, cytokines, chemokines
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Abstract number: 132
The 4T1 Cell Line Shows Increased Radiosensitivity When Treated With ATR Inhibitors and More so With
Protons Than Photons
Akanksha Acharya; Radiation Physics; University of Texas MD Anderson Cancer Center
Ilsa Quereshi; Radiation Physics; University of Texas MD Anderson Cancer Center
David Flint; Radiation Physics; University of Texas MD Anderson Cancer Center
Rishab Kolachina; Radiation Physics; University of Texas MD Anderson Cancer Center
Scott J. Bright; Radiation Physics; University of Texas MD Anderson Cancer Center
Simona F. Shaitelman; Radiation Oncology; University of Texas MD Anderson Cancer Center
Gabriel O. Sawakuchi; Radiation Physics; University of Texas MD Anderson Cancer Center
Background: The ataxia telangiectasia and Rad3-related (ATR) protein has several roles in DNA damage
response, including DNA double-strand break (DSB) repair through homologous recombination (HR) and cell
cycle checkpoint control at intra-S and G2 checkpoints. Combining ATR inhibitors (ATRi) with x-ray or proton
radiation could lead to synthetic lethality in cancer cells. In particular, protons may provide synergistic effects with
ATR inhibition due to their capacity to create more clustered DSB lesions, which require a relatively higher
contribution of HR, compared to less clustered DSB lesions induced by x-rays. In this work, we quantified the
effectiveness of an ATRi in sensitizing the 4T1 cell line, a murine triple-negative breast cancer cell line, to x-rays
and protons.
Methods: We performed clonogenic assays with 4T1 cells, treated with and without an ATRi (AZD6738). This was
completed at concentrations of 0.1 µM and 0.5 µM, with DMSO used as vehicle. The cells were then irradiated
with 6 MV x-rays or 9.9 keV/µm protons. At least 3 independent repeats were done for each condition. To quantify
drug sensitization at a given radiation quality we calculated the sensitization enhancement ratio, SER, as:
SER=D10%,DMSO/D10%,AZD6738, where D10% is the dose at 10% survival fraction.
Results: The SER value for the 4T1 at D10%, when treated with x-rays and ATRi (0.1 µM), was found to be 0.96 ±
0.16. With the higher concentration of the ATRi (0.5 µM), the SER value was found to be 1.17 ± 0.12. This
indicates that 4T1 cells are more radiosensitive at higher concentrations of ATRi. The SER value for the 4T1 cells
treated with the low concentration of the ATRi (0.1 µM) and 9.9 keV/µm protons was 0.88 ± 0.13 while the SER
value for the higher concentration (0.5 µM of AZD6738) was 1.26 ± 0.14.
Conclusion: With the higher concentration of ATRi (0.5 µM), 4T1 cells are more radiosensitive than the lower
concentration of ATRi (0.1 µM) and the vehicle for both x-rays and protons. We found that the ATR inhibitor is a
more effective radiosensitizer to protons than to photons likely because protons are more densely ionizing
resulting in more complex DNA breaks.
Keywords: Radiation Biology, Radiosensitizers, Inhibitors, Protons, DNA repair
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Abstract number: 133
Combination of ATR Inhibition and X-Ray Irradiation Radiosensitizes Cancer Cells
Nischal Ada; Radiation Physics; University of Texas MD Anderson Cancer Center
David Martinus; Radiation Physics; University of Texas MD Anderson Cancer Center
Gabriel Sawakuchi; Radiation Physics; University of Texas MD Anderson Cancer Center
Simona Shaitelman; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Efforts to suppress cancerous cells fail due to their ability to repair radiation-induced damage. One
pathway to repair double-strand DNA breaks is homologous recombination (HR). HR is assisted by Ataxia
telangiectasia and Rad3-related protein (ATR), which phosphorylates checkpoint kinase 1 (CHK1) upon exposure
to single-stranded DNA, which promote HR factors like Rad51. Combining ATR Inhibitors (ATRi) with radiation
sensitizes cancer cells by forcing them to find alternative pathways to repair DSBs such as non-homologous end
joining (NHEJ), which is not as faithful in DSB repair as HR. Thus, we experiment with the combined effect of xrays and ATRi on cancer cell DSB repair.
Methods: H1299 (lung cell carcinoma) and Panc1 (pancreatic cell carcinoma) cell lines were irradiated by 6 MV xrays with and without ATRi (0.1-1 μM, AZD6738). Immunofluorescent staining with the DSB-repair protein 53BP1
were then performed. Cells were then fixed at 4, 8, and 24 hour timepoints.
Results: 4 hours post-irradiation, increasing levels of ATRi were shown to decrease 53BP1 foci in both Panc1 and
H1299 cell lines. 8 hours post-irradiation, increasing levels of ATRi were shown to decrease 53BP1 foci in Panc1
but increase 53BP1 foci in H1299. However, at the 24-hour fixation, increasing levels of ATRi were shown to
increase 53BP1 foci for both cell lines.
Conclusion: Addition of ATRi radiosensitized Panc1 and H1299 cells by inhibiting DSB repair. Our results show
that, 4 hours post-irradiation, cells of either cell line with 1 μM concentration ATRi were hindered in their ability to
repair the DNA damage in comparison to cells with lower concentrations of ATRi and DMSO control. 24 hours
post-irradiation, early lesions of DSBs in these cancer cells lingered with higher concentration ATRi, forcing such
cells to find alternate DNA repair pathways to repair this damage. These results show that inhibiting ATR
sensitizes pancreatic and lung carcinoma to x-ray irradiation.
Keywords: Radiation Biology, Radiosensitizer, Double-strand break, DNA repair, Radiotherapy
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Abstract number: 134
Standardizing Clinical Trial Eligibility Using Natural Language Processing
Seth Chapman; Radiation Oncology; Abilene Christian University
Background: Clinical trials have varying formats, writing styles, and information presentation which can be
confusing for individuals trying to determine their eligibility. The goal of this project is to encode the information
from clinical trials that can then be used by natural language processing to write eligibility criteria in a more
standardized and clearer format.
Methods: The clinical trials were randomly chosen from the search criteria including breast, prostate, head and
neck, and pancreatic cancers. of active or active, recruiting trials. The random selection of trials was then
randomly divided among individuals to report on the chosen standard eligibility elements and record any
information that fell outside of those questions. Individuals would fill out these survey questions to provide
baselines for future work on the project.
Results: The results so far have shown that much of the information such as staging, metastasis, biomarkers, and
prior lines of therapy are the foundation of many of the listed requirements for clinical trial eligibility. It has also
shown that general health criteria such as neutrophil counts are regularly included as criteria and can be included
in future iterations. The various people filling out the surveys are providing data that can help the AI learning
process and can serve as a baseline to see how accurate the natural language processing is compared to a
group of educated individuals in understanding eligibility criteria, and it will help to show whether clarity and
understandability have improved because of the project.
Conclusion: The initial steps of encoding the data are nearing completion, and based upon the initial findings, it
appears that natural language processing is a viable option to help bring clarity to clinical trial eligibility criteria,
and it appears that further work on this project will be fruitful.
Keywords: radiation oncology, natural language processing, clinical trials
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Abstract number: 135
Glutaminase Inhibition is an Effective Radiosensitizer of Non-Small Cell Lung Cancer Cells to X-rays and
Protons
Rishab Kolachina; Radiation Physics; University of Texas MD Anderson Cancer Center
Scott Bright; Radiation Physics; University of Texas MD Anderson Cancer Center
Philip Jones; Applied Cancer Science Institute; University of Texas MD Anderson Cancer Center
Jeffrey Kovacs; Traction; University of Texas MD Anderson Cancer Center
Simona Shaitelman; Radiation Oncology; University of Texas MD Anderson Cancer Center
Gabriel Sawakuchi; Radiation Physics; University of Texas MD Anderson Cancer Center
Background: Glutamine is an essential amino acid required for cell proliferation. Cancer cells demonstrate
increased glutamine metabolism, controlled in part by oncogene-induced expression of Glutaminase-1 (GLS1).
GLS1 converts glutamine to glutamate. Glutamate can then be recycled in the TCA cycle to form glutathione
(GSH), an important cellular antioxidant, or nucleotides needed for DNA replication. Low GSH levels impair a
cell’s ability to prevent damage caused by reactive oxygen species (ROS), and failure to produce nucleotides can
induce replication fork stalling, both of which may intensify the effects of radiotherapy (RT). Here we examine the
impact of a GLS1 inhibitor (GLS1i) that is being used in a clinical trial (NCT03894540), on the radiosensitization of
non-small cell lung cancer cells to two forms of radiation, X-rays, and protons, which vary in their ability to
produce clustered DNA damage.
Methods: We performed clonogenic assays with H460 lung carcinoma cells exposed to 6 MV X-rays or 9.9
keV/µm protons with and without a GLS1i (IACS-6274; 0.1 and 1 µM). The cells were fixed 7-10 days postirradiation, and ImageJ macros were used to count the colonies. Radiosensitivity was represented using SF2Gy
(surviving fraction at 2 Gy). We also quantified the efficacy of GLS1i-+-protons by comparing the relative
biological effectiveness (RBE, the ratio of SF2Gy for X-rays divided by SF2Gy for protons) of vehicle vs GLS1i.
Results: H460 cells exposed to X-rays demonstrated a SF2Gy of 0.51±0.03 with vehicle. GLS1i minimally
sensitized cells with 0.1 µM (0.50±0.06) but strongly sensitized with 1 µM (0.41±0.07) concentration. H460 cells
exposed to protons exhibited a SF2Gy of 0.42±0.03 with vehicle. GLS1i showed strong sensitization at both 0.1
µM (0.164±0.016) and 1 µM (0.10±0.02) concentrations. Protons combined with vehicle had an RBE of 1.21±0.11,
whereas the RBE for protons combined with GLS1i had RBE values of 3.0±0.5 for 0.1 µM, and 4.0±1.0 for 1 µM
GLS1i.
Conclusion: GLS1 inhibition via IACS-6274 effectively radiosensitized H460 cells to X-ray and proton RT.
Interestingly, GLS1i appeared to be a more effective radiosensitizer for protons than X-rays, possibly due to
increased ROS production by protons and oxidative stress induced by GLS1i. Future analysis will investigate the
mechanism of radiosensitization and increased RBE, focusing on DNA damage response and cell cycle
progression.
Keywords: Radiobiology, Radiosensitizers, Radiation-induced cell death, Glutaminase Inhibition
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Abstract number: 136
Analyzing the effects of MG132 on tumor xenografts and HPK1 function
Mia Lee; Pathology; University of Texas MD Anderson Cancer Center
Rohan Moniruzziman; Pathology; University of Texas MD Anderson Cancer Center
Hua Wang; Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center
Background: The loss of hematopoietic progenitor kinase 1 (HPK1), a regulator of cellular response to stress,
proliferation, and apoptosis, is observed in >95% of pancreatic cancer cases, and is correlated with pancreatic
ductal adenocarcinoma (PDAC), a form of highly metastatic pancreatic cancer (Wang, 2014). According to the
CDC, pancreatic cancer was the third most common cause of cancer-related death in the United States in 2019,
and is often asymptomatic. This, combined with its high potential for early metastasis gives it a 5-year survival
rate of only 9% (Rawla, 2019). Pancreatic cancer is also highly resistant to chemotherapy, so identifying markers
of drug resistance is crucial to determine how different mutations affect receptivity to treatment.
Methods: This study investigated whether wild type tumor cells (HPK1 cells) would experience different mean
growth than kinase dead tumor cells (M46 cells) through xenografting onto mice. Tumor growth was assessed via
measurement of tumor volume every three days. In addition, the ability of proteasome inhibitor MG132 to restore
HPK1 function in both cell lines was assessed through Western Blot analysis. It was hypothesized that wild-type
HPK1 cells would experience lower mean tumor growth and respond more readily to treatment compared to the
kinase dead M46 cells.
Results: Preliminary results show that untreated wild-type HPK1 and kinase dead M46 xenografted mice showed
no significant difference in mean tumor growth (P > 0.05). Surprisingly, wild-type HPK1 xenografts appeared to
remain consistent in volume when treated with MG132, while kinase dead xenografts appeared to shrink under
the same treatment. However, further analysis and measurements are needed to finalize these conclusions, and
determine whether MG132 is able to restore HPK1 function.
Conclusion: Although this study is incomplete, it appears MG132 treatment is not more effective in wild-type
HPK1 cells compared to kinase dead cells. Currently, more measurements and analysis are being performed to
determine whether MG132 can restore HPK1 function. Further studies could include comparing xenografts of
wild-type HPK1 and kinase dead cell lines to ones with KRAS mutations to assess differences in response to
proteasome inhibitors, as well as immunohistochemical staining to examine differences in the composition and
structure of collected tumor tissue samples between xenograft cell lines.
Keywords: Pancreatic cancer, proteasome inhibitor, drug resistance
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Abstract number: 137
Is proton radiation more effective than photon radiation at inducing senescence?
Emma Moran; Radiation Physics; University of Texas MD Anderson Cancer Center
Mariam Ben Kacem; Radiation Physics; University of Texas MD Anderson Cancer Center
Gabriel Sawakuchi; Radiation Physics; University of Texas MD Anderson Cancer Center
Simona Shaitelman; Radiation Oncology; University of Texas MD Anderson Cancer Center
Cellular senescence is a state of permanent cell-cycle arrest, with associated phenotypic changes that can
influence the tumor microenvironment. It is classified into two categories: replicative senescence or stressinduced senescence. Cancer cells are characterized by a lack of replicative senescence, resulting in an infinite
lifespan. However, it is possible to cause stress-induced senescence in cancer cells via radiotherapy, which can
contribute to tumor control by permanently halting replication. The goal of this project is to determine which type
of radiation -- photons or protons - results in greater senescence. We hypothesize that protons will result in a
greater induction of senescence than photons due to protons’ higher linear energy transfer (LET) causing more
double-stranded breaks and thus greater replicative stress.
Senescence-associated beta-galactosidase (SA-βgal) is a biomarker of cellular senescence and can be used to
identify and quantify senescent cells. We focused our work on a human (HCC1937) and a murine (4T1) breast
cancer cell line. We used two methods to detect and compare SA-βgal activity after proton and photon irradiation:
1) histochemical assay to detect senescence in irradiated cells; and 2) flow cytometry to quantify the number of
senescent cells after irradiation. Beginning with the histochemical assay, we plated cells in a 6-well plate and
irradiated with 10 Gy protons (9.9 keV/µm) or photons (6 MV X-rays) when the cells were sub-confluent. Allowing
another 7 days after irradiation for senescence to develop, we then used the Invitrogen βgal Staining Kit. This kit
uses X-gal, a substrate of SA-βgal that releases an insoluble blue compound when cleaved to detect the
presence of senescent cells. Moreover, to quantify the proportion of senescent cells 7 days after irradiation, after
pretreatment with bafilomycin A1, we used C12FDG (5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside),
a SA-βgal substrate that fluoresces when cleaved and is detectable by cytometry.
The proportion of senescent cells is higher after proton irradiation compared to photon irradiation for 4T1 and
HCC1937. More data is being acquired and will be presented for the poster.
These results indicate that protons may be more effective at causing senescence in 4T1 and HCC1937 cell lines
and may result in better tumor control. Additional experiments are planned to further evaluate our in vitro results in
an in vivo setting.
Keywords: cellular senescence, radiobiology, ionizing radiation
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Abstract number: 138
Title: Assessment and comparison of physician-reported staging using the AJCC staging system in Head
and Neck Cancer
Laura Pareja; Radiology Oncology; Texas Woman's University
Andrea De Leon; Radiology Oncology; Houston Baptist University
Setareh Sharafi; Radiation Oncology; University of Texas MD Anderson Cancer Center
Travis Salzillo; Radiology Oncology; University of Texas MD Anderson Cancer Center
Vivian Salama; Radiology Oncology; University of Texas MD Anderson Cancer Center
Background: Head and neck cancers account for nearly 4% of all cancers in the United States. The staging of
these cancers is important for physicians to analyze and treat the patients. Furthermore, the American Joint
Committee on Cancer provides a comprehensive framework to guide physicians on staging these cancers. This
study explores both the staging of Oral Cavity and Oropharyngeal cancers, and the AJCC editions utilized
between three Oncology specialties--Head and Neck Surgery, Medical Oncology, and Radiology Oncology.
Methods: A cohort of 100 Head and Neck cancer patients with either Oral Cavity or Oropharyngeal cancers were
extracted from the EPIC electronic medical records system. The tumor stages and the edition of AJCC (7th
edition or 8th edition) utilized by the Head and Neck Surgeon, Medical Oncologist, and Radiology Oncologist were
collected and analyzed. The analysis is still ongoing. The mechanism utilized to obtain this data was through the
REDcap database. Furthermore, the effect of the AJCC staging criteria on survival was determined.
Results: AJCC edition usage for staging among the different oncology specialties was recorded. Descriptive
statistics were calculated for AJCC edition usage. Kaplan-Meier survival curves were produced demonstrating
differences in survival between the two AJCC criteria for each oncology specialty. Statistical analysis was
performed using ANOVA and follow-up t-tests. So far, the results show an inconsistency in the utilization of the
editions of AJCC by the physicians.
Conclusion: This work demonstrates the frequency of the staging data inputted by the physicians. Ongoing efforts
to assess the survival of the patients diagnosed with the 7th versus 8th edition AJCC are underway. The longterm goal of this work is to create an automated method for oncologists across specialties to consistently stage
head and neck cancers.
Keywords: Staging, Radiology Oncology, Oral Cavity Cancer, Oropharyngeal Cancer
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Abstract number: 139
Measuring Radiosensitization by ATR inhibitor (AZD6738) Using Phospho-Histone 3 Marker and Cell
Cycle Distribution
Tannistha Patra; Radiation Physics; University of Texas MD Anderson Cancer Center
Mandira Manandhar; Radiation Physics; University of Texas MD Anderson Cancer Center
Gabriel O. Sawakuchi; Radiation Physics; University of Texas MD Anderson Cancer Center
Simona Shaitelman; Radiation Physics; University of Texas MD Anderson Cancer Center
Background: Radiotherapy is widely used to treat various cancers. However, some cancer cells can develop
resistance to radiotherapy due to their ability to repair DNA lesions caused by radiation. Drugs that inhibit DNA
repair proteins combined with radiotherapy have the potential to enhance cell death in cancer cells. ATR (ataxia
telangiectasia and Rad3-related protein) is a DNA repair protein involved in double strand break repair as well as
cell cycle regulation. Our investigation sought to understand the effects of disrupting cell cycle arrest through ATR
inhibition on cancer cell lines that were irradiated with either X-rays or protons. Compared to X-rays, protons are
generally more effective at creating DNA lesions.
Methods: We studied the synergetic effect of DNA repair inhibition and radiation by analyzing the following:
phospho-histone 3 (pH3) population, and cell cycle distribution. ATR tends to arrest cells in G2 in order to allow
cells to repair themselves before going into mitosis. Phospho-histone-3 is a marker used to quantify mitotic
population. PANC-1 cancer cell lines were treated with DMSO and an ATR inhibitor (AZD6738, 0.1 μM and 1 μM)
1 hour before irradiation. Cells were then exposed to 5 Gy of 6 MV X-rays or 9.9 keV/µm protons before being
incubated for 24 or 48 hours. Cells were then fixed and stained for flow cytometry analysis. Flow cytometry was
used to evaluate a population’s cell cycle distribution (propidium iodide stain) and amount of cells in mitosis (pH3
marker). We performed at least 3 independent repeats for each condition and experiment.
Results: Our studies showed that ATR inhibition (1 µM) in combination with 6 MV x-rays or 9.9 keV/µm protons at
5 Gy dose inhibits cell cycle checkpoint at G2 compared to DMSO. A higher percentage of cells in mitosis was
observed with irradiated cells combined with 1 µM of ATR inhibitor compared to non-irradiated cells. The mitotic
population was significantly higher with protons compared to x-rays.
Conclusion: The combination of ATRi and radiation disrupts the cell cycle at G2, resulting in more damaged cells
going into mitosis. This increases genotoxicity and cytotoxicity in cells leading to more cell death.
Keywords: Proton, ataxia telangiectasia and Rad3-related protein, ATR, Phospho-Histone 3
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Abstract number: 140
Using Patient Reported Outcome Measure (PROM) to Manage Pain During Radiation Therapy
Sara Youssef; Radiation Oncology, Head and Neck Division; University of Texas, MD Anderson Cancer Center
Vivian Salama, MD.; Radiation Oncology, Head and Neck Division; University of Texas, MD Anderson Cancer
Center
Amy C. Morena, MD.; Radiation Oncology, Head and Neck Division; University of Texas, MD Anderson Cancer
Center
Clifton D. Fuller, MD., PhD.; Radiation Oncology, Head and Neck Division; University of Texas, MD Anderson
Cancer Center
Background: Pain severity is an important symptom to assess for head and neck cancer patients undergoing
radiotherapy (RT) due to its effects on the quality of life. Although radiation itself is painless, it induces an acute
postradiation reaction that can cause many side effects, with the most debilitating being oral mucositis. Due to the
subjective nature of pain, which can be difficult for health systems to measure, patient reported outcome
measures (PROMs) is a tool that can be used to better gauge and improve patient’s health experience. In this
study, we used an institution-based PROM, The MD Anderson Symptom Inventory (MDASI) for pain assessment.
The objective of our project is to determine the efficacy of pain management during RT using PROM.
Methods: Retrospective data was obtained for 500 oral cavity and oropharyngeal (OC/OPC) cancer patients,
treated with RT at the Radiation Oncology Department, MD Anderson Cancer Center in Houston, TX, USA. Pain
scores were collected during the weekly see visits utilizing MDASI, using a scale from 0 to 10 (0 =no pain, 10
=worst pain). Clinical data was collected using EPIC and Brocade software. Pain scores were compared to
mucositis intensities weekly (0 =none, 1 =mild, 2 =moderate, 3 =severe). Patients were divided into cohorts based
on age (19-33 =1, 34-48 =2, 49-64 =3, 65-78 =4, 79-98 =5). T-test and ANOVA test were used for statistical
analysis.
Results: MDASI pain scores reported during weekly see visits revealed a significant increase through the course
of RT (p <0.0001), with the highest severity of pain experienced at the end. Pain scores were tested across age
groups. There were no significant differences in pain scores between age cohorts, with a similar trend in each
week across the cohorts.
Conclusion: The aim of this study is to determine the efficacy of pain management during RT using PROM. Our
data revealed that pain levels consistently increased during RT. This suggests the pain management currently
implemented does not adequately control pain during the weeks of RT and is in need for improvement. This is
important to address due to the negative effect pain can have on patients’ quality of life. Future steps to take can
include analyzing which types of analgesics are given and at what point during RT. Stronger pain medications
may be needed earlier during the course to prevent high levels of pain seen towards the end of RT. Further
investigation is needed.
Keywords: pain, head and neck, radiation therapy, MDASI, PROMs
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Colorectal and Breast Cancer Screening in the U.S. during the COVID-19 Pandemic
Rosheem C. Browne; Health Services Research; University of Texas MD Anderson Cancer Center; 1University of
Texas Health Science Center at Houston – McGovern Medical School
Jiangong Niu, PhD; Health Services Research; University of Texas MD Anderson Cancer Center
Daria Zorzi, MD; Health Services Research; University of Texas MD Anderson Cancer Center
Sharon H. Giordano, MD, MPH; Health Services Research; Breast Medical Oncology; University of Texas MD
Anderson Cancer Center
Background: Colorectal (CRC) and breast cancer (BC) are two of the most diagnosed cancers in the United
States. Screening for these cancers is essential for the early diagnosis and improved prognosis of these
diseases. Despite its value, routine cancer screening had to be postponed to limit potential spread of the SARSCoV2 virus. We analyzed how the rates of CRC and BC screening varied over time and across patient
populations.
Methods: We identified CRC and BC screenings claims data from the OPTUM claims database using the
corresponding CPT/HCPCS/ICD-10 codes. We limited the study to 8,656,406 eligible colorectal cancer screening
patients and 5,116,717 eligible breast cancer patients between 01/01/2019 and 12/31/2020. Eligibility was defined
as patients fully insured during an entire quarter (Q) and eligible for screening according to the American Cancer
Society: ages 51-75 for CRC and women ages 46-74 for BC. The cancer screening rate was calculated per
quarter: the number of screenings over the number of eligible people in that quarter. We also analyzed the
change in screening rate by race. The change of screening rates over time was determined by the CochranArmitage trend test, and a comparison between the screening rates in Q4 2019 and Q2 2020 was made using the
Kruskal-Wallis test.
Results: We observed a declining trend in the overall CRC and BC screening rates from 2019 Q1 to 2020 Q2 over
six quarters (Q) (p<0.001 for both cancer sites), and in the rate of each CRC screening modality: colonoscopy,
sigmoidoscopy, CT colonography, fecal immunochemical test (FIT), fecal occult blood test (FOBT), and stool DNA
test (p<0.001 for all). We also observed a 47% decrease in overall CRC screening and a 50% drop in overall BC
screening in Q2 2020 compared to Q4 2019 (p<0.001 for both). A similar decrease was noted for each CRC
screening modality when comparing the same quarters. When stratified by race, the declining trend remained
consistent across Asian, Black, Hispanic, and White patients for overall CRC screening and each different
modality, and for overall BC screening.
Conclusion: There was a significant decrease in overall CRC screening, each CRC screening modality, and BC
screening from 2019 through 2020 across the United States. Screening rates dropped by approximately 50%
during Q2 2020 for BC and CRC.
Keywords: COVID-19, United States, breast cancer screening, colorectal cancer screening
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Abstract number: 142
Early Detection of Pancreatic Cancer by Hyperpolarization and Artificial Intelligence
Christopher Alducin; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Jose Enriquez; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Kang-lin Hseing; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Florencia McAllister; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Shayan Shams; School of Biomedical Informatics; University of Texas Health Science Center at Houston
Pratip K. Bhatacharya; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Background: In 2021, approximately 600,000 people will perish to cancer, and of those, 50,000 will be solely
pancreatic cancer. Pancreatic cancer is often deadly due to its late diagnosis and asymptomatic nature at early
stages. The high death toll showcases the pending need for non-invasive imaging markers that will help identify
pancreatic ductal adenocarcinoma (PDAC), making up more than 90% of all pancreatic cancer cases, before it
becomes fatal. Recently, there have been developments in hyperpolarized metabolic magnetic resonance (MRI)
and artificial intelligence (AI) on detecting early-stage biomarkers of pancreatic cancer and further, predict the
efficacy of therapy. The biomarker used, one of the most common, is the conversion of hyperpolarized pyruvate to
lactate and alanine. Implementing a deep learning algorithm to the AI allows us then to predict whether the
treatment is a viable solution by scanning the mice before and after, removing an uncertainty period of patient
observation where tumor growth is variable. :
Methods: Genetically engineered mice (GEM), models (P48Cre: LSLKrasG12D; LSL-p53R172H (KPC)) with preinvasive pancreatic intraepithelial neoplasia (PanIN) precursor lesions and control mice (P48:Cre or WT C57BL/6)
without pancreatic lesions metabolic process were analyzed using hyperpolarized 1-13C pyruvate magnetic
resonance spectroscopy (MRS). The dissolution dynamic nuclear polarization (DNP) operating at 3T was utilized
to hyperpolarize 1-13C pyruvate. The 13C MRS of hyperpolarized 1-13C pyruvate were acquired at a 7T MRI
scanner. The mice were imaged at three different timepoints. The biochemical development of alanine
transaminase (ALT) and lactate dehydrogenase (LDH) enzyme activity were assessed. Afterward, deep learning
(DL) techniques were implemented to develop a model and reveal hybrid biomarkers from the MRI and metabolic
imaging to predict early detection of pancreatic cancer. The model was developed through Bayesian DL
techniques and multi-modal data integration to allow uncertainty measurements and learn features from imaging
modalities to consider improving prediction accuracy. After training the model, the learned features from multiple
modalities to identify any correlation between MRI and metabolic imaging are explored that may lead to the
discovery of new hybrid biomarkers with predictive values for the early detection.
Results: Alanine-to-lactate signal ratio was found to decrease through progression from low to high-grade
PanINs. These results demonstrate that there are significant alterations of ALT and LDH activities through the
transformation from early to advanced PanINs lesions. The appropriate DL combining feature from the MRI and
metabolic imaging as complementary modalities can lead to proper prediction of early detection in this KPC GEM
model.
Conclusion: Findings from this emerging combination of DL and hyperpolarization-MRS techniques could
potentially be translated into clinics for detection of pancreatic premalignant lesion in high-risk populations through
early screenings.
Keywords: Early detection, pancreatic cancer, artificial intelligence, metabolic imaging, hyperpolarization.
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Creation and characterization of patient derived xenograft animal model of hereditary leiomyomatosis
associated renal cell carcinoma
Breanna Alonzo; Urology; University of Texas MD Anderson Cancer Center
Alberto Pieretti; Urology; University of Texas MD Anderson Cancer Center
Priya Rao; Pathology; University of Texas MD Anderson Cancer Center
Christopher Wood; Urology; University of Texas MD Anderson Cancer Center
Pavlos Msaouel; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer Center
Niki Zacharias Millward; Urology; University of Texas MD Anderson Cancer Center
Background: Hereditary leiomyomatosis is an autosomal dominant condition that results in mutations of fumarate
hydratase (FH), an enzyme required for the completion of the citric acid cycle. A defect in this enzyme results in
the buildup of fumarate, an oncometabolite that increases the risk for development of a rare and aggressive type
of renal cancer, type 2 papillary renal cell carcinoma (RCC). In hereditary leiomyomatosis associated renal cell
carcinoma (HLRCC) the expression of mutated FH is lower than in normal kidney or in other RCC tumor types. In
order to better understand the development of HLRCC, a patient derived xenograft (PDX) animal model was
generated in our lab. In addition to the animal model, we are also retrospectively determining the number of type
2 papillary RCC patients at MD Anderson that had reduced FH expression.
Methods: PDX models are made by directly implanting human resected tumor tissue into immunodeficient mice.
We implanted HLRCC resected tumor tissue from a 24-year old woman into NOD scid gamma (NSG) mice.
Tumors were harvested when they reached ≈ 1500 mm3 and resected tumor tissue was implanted/passaged into
another set of NSG mice. At the conclusion of the 2nd or 3rd passage, tumor tissue from the PDX model was
subjected to a series of analytical studies. Lysates from 3 HLRCC PDX tumors and 3 normal human kidney
tissue were compared by Western blot. Short tandem repeat (STR) DNA analysis was performed to confirm that
the PDX tumor tissue in the mice originated from the patient’s resected tumor. Tissue from the HLRCC PDX
model and the original HLRCC human tumor tissue were analyzed by histology.
Results: Histology and STR fingerprinting confirmed that the HLRCC PDX model is histologically and genetically
similar to the original resected HLRCC tumor. Higher expression of hypoxia inducible factors (HIF) HIF1- and
HIF2- was observed in the HLRCC PDX lysate versus normal kidney tissue. In addition, higher expression of
glutaminase 1 enzyme (GLS1) and lower expression of FH was observed in the HLRCC PDX tissue versus
normal kidney tissue.
Conclusion: We were able to create a PDX model of the rare cancer HLRCC. This model was similar to the
original patient resected tissue by histology and STR fingerprinting. We are now in the process of determining if
the expression of specific proteins in the PDX tissue (GLS1, HIF1-, HIF2-) can be used as therapeutic targets for
HLRCC.
Keywords: hereditary leiomyomatosis associated renal cell carcinoma, patient derived cancer animal model
Program Affiliation: Partnership for Careers in Cancer Science and Medicine

151

Abstract number: 144
Insertion of wrmScarlet11 into the cosa-1 gene in C. elegans using CRISPR
Jose Araujo; Genetics and Faculty Diversity, Equity and Inclusion; University of Texas MD Anderson Cancer
Center
Kenny Trimmer; Genetics; University of Texas MD Anderson Cancer Center
Swathi Arur; Genetics; University of Texas MD Anderson Cancer Center
Background: The revolutionary introduction of CRISPR in genome editing has proved to be a reliable way to
modify the DNA of organisms, in our case C. elegans. My goal was to visualize a meiotic crossover site on
chromosomes with live imaging. We chose COSA-1 as my crossover protein, which marks crossover sites where
chromosomes recombine. wrmScarlet is a fluorescent protein made up of 11 beta strands. When the 11th strand
(wrmScarlet11) is brought close to strands 1-10 (wrmScarlet1-10), the protein fluoresces. With CRISPR, we can
tag cosa-1 with the 11th strand into an animal that expresses wrmScarlet1-10 constitutively. This would allow
crossover sites to be labeled with fluorescence.
Methods: We performed CRISPR injections into a C. elegans germline carrying wrmScarlet 1-10. The injection
mix contained a repair template designed to insert wrmScarlet11 into the cosa-1 gene. We allowed the injected
mother to lay progeny and then tested for the insertion in the progeny by running a PCR on each one. A
successful insertion would show an increase in band size due to the insertion of wrmScarlet11. When we saw a
worm that appeared to be homozygous for wrmScarlet11 we checked for the presence of fluorescent protein, or
we waited for progeny of heterozygous parents to obtain a homozygous worm. Once fluorescence was confirmed
we would sequence and verify that wrmScarlet11 was inserted correctly.
Results: I injected 8 worms, of which two were successfully injected into the germline. This allowed me to follow
up the progeny of those two worms and screen them via PCR to see which ones had the insertion of
wrmScarlet11. From 84 worms that I screened, I was able to identify five heterozygous animals and one possible
homozygous one in the first generation (F1). I then took the progeny of these worms (F2) and looked for
fluorescence. None of them showed signs of fluorescence thus I screened the F2s from the heterozygous F1s via
PCR to identify multiple homozygous lines. I screened 53 F2 worms and obtained 4 lines with expected (648bp)
band sizes.
Conclusion: We could not detect fluorescence, therefore we will sequence the lines we identified to verify
whether the insertion occurred in-frame. We will send the PCR products for sequence verification. Sequencing
results and conclusions from them are going to be displayed in the poster.
Keywords: CRISPR, crossovers, fluorescence, C. elegans
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KDM4C is an oncogenic histone demethylase in pancreatic cancer
Laila Barkoudeh; Pancreatic Cancer; University of Texas MD Anderson Cancer Center
Mennatallah Shaheen, M.S; Pancreatic Cancer; University of Texas MD Anderson Cancer Center
Sarah Dhebat, M.S; Pancreatic Cancer; University of Texas MD Anderson Cancer Center
Anirban Maitra, M.B.B.S; Pancreatic Cancer; University of Texas MD Anderson Cancer Center
Bidyut Ghosh, Ph.D; Pancreatic Cancer; University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer is the third most common cause of cancer related deaths in the United States,
and its incidence is progressively rising. Understanding the molecular pathogenesis of this lethal cancer is critical
in order to identify potential therapeutic strategies and to stem the public health burden of this disease. In addition
to genomic alterations, epigenetic changes are a common mechanism of aberrant transcriptional activity in cancer
cells. Epigenetic changes include a variety of phenomena, such as methylation events at gene promoters and
enhancers, as well as modification of chromatin histone states through reversible post-translational modifications,
such as methylation or acetylation. Numerous chromatin-modifying proteins are aberrantly expressed in
pancreatic cancer, one of which is the histone H3 demethylase KDM4C, which demethylates lysine 9 residues
(H3K9 demethylase). Of note, KDM4C is expressed in embryonic stem cells, resulting in low levels of H3K9me,
facilitating cell division. KDM4C overexpression has been reported in lung, prostate, breast and brain cancers,
where its expression is linked to deregulation of wingless (wnt)/beta-catenin signaling. In contrast, KDM4C levels
are reduced in the adult pancreas. Prior studies in pancreatic cancer cell line models in our laboratory have
shown that KDM4C levels are overexpressed in cancer cells versus non-neoplastic control lines.
Methods: Therefore, we developed an immunofluorescence assay against endogenous KDM4C protein to
validate the aforementioned findings in primary pancreatic cancer tissues obtained from patients undergoing
surgical resection at MD Anderson.
Results: . In our pilot studies, KDM4C protein was found to be overexpressed in human and mouse pancreatic
cancers, but was minimally expressed in normal pancreas. We also assessed the expression level of Kdm4C
protein in a mouse model of pancreatic cancer which distinctly showed overexpression compared to normal
mouse pancreas. We then knocked out the KDM4C gene in a pancreatic cancer cell line (AsPC1) and performed
in vitro cell proliferation and colony formation assay in order to compare the growth of AsPC1-KDM4C-KO cells
versus wild type (WT) cells. This experiment confirmed significantly reduced growth of AsPC1-KDM4C-KO cells,
compared to contemporaneously AsPC1-KDM4C-WT cells. In another CRISPR mediated knocked out pancreatic
cancer line (MDA28-KDM4C-KO), we found the expression level of Wnt target genes significantly down regulated
compared to the MDA28-KDM4C-WT indicating an interplay of KDM4C and Wnt signaling pathway in the
pathogenesis of pancreatic cancer.
Conclusion: These foundational data form the basis for future studies that will examine the downstream effector
pathways of aberrant KDM4C expression in pancreatic cancer, including transcripts whose expression is altered
as a result of changes in the H3K9me levels in the corresponding regulatory regions. We anticipate these future
studies will also identify potential actionable pathways that might form the basis for reversing the oncogenic
effects of KDM4C in pancreatic cancer.
Keywords: KDM4C, Pancreatic Cancer, wingless (wnt)/beta-catenin signaling.
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Tracking plasticity-dependent cell cycle effects
Christian Beke Onana; Partnership for Careers in Cancer Science and Medicine; University of Texas MD
Anderson Cancer Center
Luigi Perelli; Genitourinary Oncology; University of Texas MD Anderson Cancer Center
Giannicola Genovese; Genomic Medicine; University of Texas MD Anderson Cancer Center
Background: Epithelial to mesenchymal transition is a type of cell plasticity with numerous implications both in
physiological and pathological conditions, such as cancer. The effects of epithelial to mesenchymal plasticity on
the cell cycle, however, are poorly understood. The cell cycle is a process by which a cell grows and proliferates.
The various phases of the cell cycle are tightly regulated. In this study, we are examining the impact of cell
plasticity on the cell cycle of pancreatic cancer cells.
Methods: Our hypothesis is that a cell dealing with chromosomal imbalances, such as aneuploidy, would require
to adjust the length of the phases of its cell cycle in order to modulate mounting DNA imbalance. Thus, we
compared epithelial and mesenchymal cells derived from a genetically engineered pancreatic cancer mouse
model exploiting CRISPR/Cas9 technology. The cells were infected with lentiviral particles enabling us to track
the degradation of two cell cycle markers, CDT1 and Geminin, via fluorescent reporters. Using confocal live
imaging microscopy, we followed up the fluorescence of random epithelial and mesenchymal cell lines and were
able to track the length of their various cell cycle phases.
Results: We observed that mesenchymal cells showed a prolonged G2/M phase compared to epithelial cells but a
relatively identical full cell cycle length. Mesenchymal cells are also subjected to catastrophic mitotic events
whereas epithelial cells are not. This, therefore, confirms that there is a correlation between epithelial to
mesenchymal plasticity and aneuploidy.
Conclusion: Our findings provide us with insight into the mechanisms behind epithelial to mesenchymal transition,
highlighting a novel regulatory pathway of the cell cycle. In summary, these data provide us with a deeper
understanding of the mechanisms of the metastatic cascade and progression of pancreatic tumors.
Keywords: Cell plasticity, epithelial-to-mesenchymal-transition, cell cycle, pancreatic cancer, aneuploidy
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Abstract number: 147
The role of depressive symptoms on cancer risk factors of smoking and physical activity among AfricanAmericans
Belinda Busogi; Health Disparities Research; University of Texas MD Anderson Cancer Center
Nga Nguyen; Health Disparities Research; University of Texas MD Anderson Cancer Center
Alba Calzada; Health Disparities Research; University of Texas MD Anderson Cancer Center
Lorna H. McNeill; Health Disparities Research; University of Texas MD Anderson Cancer Center
Background: Our mental health greatly dictates the way we think, feel, and act. Recent statistics illustrate that
African Americans are prone to having higher rates of depressive symptoms compared to other race and ethnicity
groups (Ettman, C. et. al., 2020). In a number of studies, depressive symptoms have been linked to poor health
outcomes, such as cancer (Wing, R. R. et. al., 2002). African Americans are disproportionately affected by
cancer, with attention to having the highest mortality rate for all cancers amalgamated among all ethnic and racial
demographics in the United States. This study seeks to explore the associations between depressive symptoms
with cancer risk factors of smoking and physical activity among African-Americans. The hypothesis is that as
depressive symptoms increase, the risk for cancer (smoking and physical activity) increases.
Methods: The participants analyzed in this study are from a church-based cohort of African Americans in
Houston, TX recruited between 2008-2013 from Windsor Village United Methodist Church (mean age = 45.19
years, STD= 12.87; 74.64% female). The participants completed a computer-based survey, which included selfreported descriptive characteristics (i.e., age, sex, and chronic conditions), self-reported depressive symptoms
(CES-D), self-reported smoking frequency, and self-reported physical activity. The hypothesis was tested using
multiple logistic regression, while controlling for the descriptive characteristics (Table 1).
Results: Higher score of depressive symptoms was associated with increased odds of smoking (OR=1.049, 95%
CI=(1.012-1.087), p-value=0.008). While, higher score of depressive symptoms was associated with increased
odds of being inactive (OR=1.028, 95% CI=1.003-1.053, p-value=0.028).
Conclusion: Depressive symptoms (CES-D score) were positively associated with the known cancer risk factors
of smoking and physical activity. There needs to be more interventions and awareness on mental health,
specifically in the African American community.
Keywords: African Americans, Depressive Symptoms, Smoking, Physical Activity
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Deciphering how mutant p53 suppresses innate immune response by Toll-like receptors in a triplenegative breast cancer model.
Alejandra Carmona; Genetics; University of Texas MD Anderson Cancer Center
Denada Dibra; Genetics; University of Texas MD Anderson Cancer Center
Guillermina (Gigi) Lozano; Genetics; University of Texas MD Anderson Cancer Center
Background: The innate immune system initiates immune responses by pattern‐recognition receptors. Virus‐
derived nucleic acids are sensed by 3 different mechanisms: (1) the retinoic acid‐inducible gene I (RIG‐I)‐like
receptor (RLR) family, (2)the toll‐like receptor (TLR) family as well as (3) the DNA sensor cyclic GMP‐AMP
(cGAMP) synthase (cGAS). These receptors activate IRF3/7 and NF‐κB signaling pathways to induce the
expression of type I interferons (IFNs) and other cytokines firing antiviral responses within the cell. Bulk RNA
sequencing experiments comparing tumors with mutant p53 and mutant p53 deletion suggest that mutant p53
deletion impacts all three mechanisms; yet only the third mechanism has been described in the literature.
Therefore, the hypothesis of the project will be to determine if mutant p53 affects any or all three different
pathways and to what degree.
Methods: To test this hypothesis, two cell lines with or without mutant p53 were treated with TLR1-9 agonists at
different concentrations, and endpoints are type 1 cytokine production (ELISA) or downstream pathways
activation (via western blot).
Results: Levels of secreted TNF-α in the supernatant in both cell lines were below detection level via ELISA,
suggesting that more cells per well are needed.
Conclusion: We are currently testing cytokine expression with RT-PCR as well and downstream pathway
activation via western blots.
Keywords: Toll-like receptors, p53, ELISA, Western Blot, RT-PCR
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Targeting Cathepsin G in Solid Tumors
Nicole Dawson; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer Center
Amber Gibson; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer Center
Pariya Sukhumalchandra; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer
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Background: Polymorphonuclear Neutrophils (PMNs) are the most abundant type of leukocytes circulating in the
blood. PMNs contain granules of serine proteases that are released upon PMN activation. One of these serine
proteases is Cathepsin G (CG), which functions to kill off pathogens. Prior research has shown that some serine
proteases, after being released from PMNs, can be taken up into malignant cells. The peptide derived from CG,
CG1, can then be presented on the surface of malignant cells to become immunotherapeutic targets. Here, we
hypothesize that CG can be taken up by osteosarcoma (OS) cells and non-small cell lung cancer (NSCLC) cells
and become immunotherapeutic targets.
Methods: NSCLC and OS cell lines were cultured as per standard protocol with appropriate media. The U937
(histiocytic leukemia) and T2 (multiple myeloma) cell lines were used as our controls. For Reverse Transcription
Polymerase Chain Reaction (RT-PCR), purified RNA was extracted, and cDNA was synthesized as per protocol.
Tumor cells were co-cultured in appropriate medium and pulsed with irradiated PMNs/PMN lysate. After coincubation, cells were permeabilized and stained intracellularly. Analysis for CG uptake in NSCLC and OS cell
lines were performed by standard flow cytometry methods. To expand CG1-specific lymphocytes for cytotoxic
assay, dendritic cells (DCs) were matured from peripheral blood mononuclear cells (PBMC) from buffy coats.
PBMCs and PMNs were isolated after a single or double density gradient separation, respectively. CG1-CTLs
were co-cultured with target cells and percent killing was analyzed with a Cytation Imaging Reader.
Results: RT-PCR showed no mRNA expression of CG in NSCLC/OS cells lines. To assess CG uptake, SaOS2
(OS) cells were pulsed with irradiated PMNs at a ratio of 7:1. Flow cytometry analysis showed a two-fold increase
in the CG-mean fluorescence intensity (MFI) (vs. non-pulsed cells). After pulsing the H1650 (NSCLC) cells with
irradiated PMNs at a ratio of 10:1, flow cytometry analysis showed a 1.25-fold increase in the CG-MFI (vs. nonpulsed cells). Cytotoxicity assay showed non-specific killing of both control (T2) and pulsed cells.
Conclusion: Our results indicate that both OS and NSCLC do not endogenously express CG but do show CG
uptake. Though the results from the cytotoxicity assay were inconclusive, it is likely due to a much higher
concentration of CTLs which nonspecifically killed all cells. We are still in the preliminary stages; however, in the
future, we hope to see a steady progression towards the efficacy in cancer cytotoxicity that stems from targeting
CG.
Keywords: Cathepsin G, Uptake, Cytotoxicity, Immunotherapy
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Impact of Hispanic Ethnicity on Colorectal Cancer Surveillance Outcomes and Management in an
Institutional Longitudinal Cohort of Lynch Syndrome Patients
Gabriel del Carmen; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Laura Reyes-Uribe; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Kyera Evans; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
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Background: Lynch Syndrome (LS) patients are at an elevated risk for the development of colorectal cancer
(CRC) during their lifetime. Despite this well-documented risk, variance in symptom presentation and
management are not well understood. Therefore, there is a need for prospective patient registries that map realtime clinical and demographic information. Similarly, there exists a need to document and understand disparities
in LS management for racial/ethnic minorities. In this study, our aims were (1) to characterize and report CRC
screening outcomes for the LS patient cohort; and (2) to document any differences in clinical presentation by
Hispanic ethnicity for these patients.
Methods: Data from our prospectively maintained REDCap database of patients with LS was the primary source
of clinical information on our cohort. Data on clinic visits, endoscopic procedures, surgeries, and biopsy
procedures were used for our analysis.
Results: From November 1997 to March 2020, a total of 177 LS patients (59.9% female) were enrolled in our
study. In terms of ethnicity, 87% of the patient cohort self-identified as non-Hispanic compared to 13% who
identified as Hispanic. On univariate analysis, LS patients in our cohort had an average of 4.8 visits (range 1-23
visits), with a median interval between visits of 12 months. The median age at first colonoscopy was 45.5±13.0
years (range 17-73 years). The patient population had an average of 4.8 colonoscopies (range 1-23). A total of 25
CRCs were present in our cohort with 6 stage III at the time of diagnosis. At first colonoscopy, 14.7% of patients
had tubular adenomas and 5.5% had advanced adenomas. On bivariate analysis, Hispanics with LS were
younger at clinic visits compared to non-Hispanics (M=46.8, SD=12.4; M=51.6, SD=13.7, respectively; p<0.001).
We also found Hispanics were significantly younger at their first colonoscopy when compared to non-Hispanics at
their first colonoscopy visit (39.5 years ± 11.5; 51.2 years ±13.5, respectively; p<0.001). However, at initial
colonoscopy, Hispanic patients were not found to be at higher risk for a tubular or advanced adenoma compared
to non-Hispanic patients, Χ2(2, N = 163)=.29, p=0.867.
Conclusion: The maintenance of a robust database of patients is necessary to better meet the needs of this
patient cohort. While we found that Hispanic patients are younger than non-Hispanic patients at their initial
colonoscopy and subsequent visits, we did not find any disparities in outcomes presentation in our institutional
cohort. Our findings provide support to the successful implementation of screening and surveillance guidelines.
Keywords: Lynch syndrome, colorectal cancer, disparities, colonoscopies
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Developing REST as a therapeutic target in DIPG
Haibatou Diallo; Pediatrics; University of Texas MD Anderson Cancer Center
Shavali Shaik; Pediatrics; University of Texas MD Anderson Cancer Center
Vidya Gopalakrishnan; Pediatrics; University of Texas MD Anderson Cancer Center
Background: Diffuse Intrinsic Pontine Glioma (DIPG) is an oligodendroglial tumor of childhood, and, typically
patients do not survive their disease. Current treatment involves radiation. Chemotherapy does not have efficacy
and surgery is not an option given the location of the tumor. This underscores the urgent need for new
therapeutics. DIPGs are characterized by a somatic mutation in H3F3A and HIST1H3A genes, encoding histones
H3.3 and 3.1, respectively. This mutation, which occurs in 80% of DIPGs inhibits the activity of the Polycomb
repressive complex 2 (PRC2), which promotes the H3K27trimethyl (me3) mark on chromatin and an increase in
the activating H3K27acetyl (ac) mark. The resultant activation of oncogenic pathways drives tumorigenesis in the
context of additional “hits”. We propose that the RE1 silencing transcription factor (REST), may play such a role in
DIPG genesis. Consistent with this hypothesis, REST expression is upregulated in H3K27M DIPG tumors and
DIPG cell lines. REST knockdown blocks tumor growth. Thus, we propose that targeting REST is a therapeutic
approach. REST is a DNA binding protein, and requires the activity of the chromatin remodelers: G9a, lysinespecific demethylase 1 (LSD1), and histone deacetylase 1/2 (HDAC1/2) to function. We postulate that targeting
these enzymes alone or in combination with blocking gene activation by H3K27ac in DIPGs will be a novel
treatment approach.
Methods: DIPG cell lines (DIPG-IV, -VII, and -XIII) expressing the H3.1K27M, wildtype (WT), and H3.3 K27M,
respectively were seeded in 96 well plates and treated with G9a inhibitor-UNC0638 alone or JQ1-a drug that
inactivates the K3K27Ac, for up to 120 hrs. Isogenic cells engineered to express higher-REST levels were also
used. DIPG response to drug treatment was determined using the ATP lite assay kit.
Results: A dose-dependent and significant decrease (>50%) in the growth of H3.1K27M and H3.3K27M DIPG
cells was observed following JQ1 treatment at 1 µM. Only a small decrease in the growth of WT-H3 DIPG cells
was noted. REST elevation in DIPG-IV cells caused an increase in the sensitivity to UNC0638, but not with JQ1.
However, the combination of UNC0638 (0.25 µM) and JQ1 (0.1 µM) showed a synergistic effect in decreasing the
growth of DIPG-IV-GFP-REST cells to 38% compared to just 1% with DIPG-IV-GFP cells.
Conclusion: DIPG cells are sensitive to UNC0638 and JQ1 treatment as single agents. UNC0638 and JQ1
promote a synergistic reduction in the growth of H3.1K27M DIPG cells in a REST-dependent manner.
Keywords: DIPG, H3K27M, REST, UN0638, JQ1
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IRF2BP1 regulation of MHC-I in breast cancer cell lines
Abigail Fajardo; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Arseniy E. Yuzhalin; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Yohei Saito; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Dihua Yu; Molecular and Cellular Oncology; University of Texas MD Anderson Cancer Center
Background: Brain metastasis is one of the dangerous consequences of breast cancer and is responsible for
most deaths from this disease. Aberrant function of protein kinases permits the uncontrolled outgrowth of cancer
cells. We previously observed that cyclin-dependent kinase 5 (CDK5) promotes metastasis growth in
experimental mouse models of brain metastasis through affecting the antitumor immunity. Another protein of
interest is Interferon Regulatory Factor 2 Binding Protein 1 (IRF2BP1). While there is not much known about this
yet, a similar protein, Interferon Regulatory Factor 2 Binding Protein 1 (IRF2BP1) has been known to be an
important factor in the immune system.
Methods: Breast cancer cells (4T1, T11) were cultured at 37°C under humidified conditions. These cancer cells
were cultured in two different groups with two conditions each; cells inoculated with a lentivirus with either a
shCdk5 or shIrf2bp1 gene knockdown as our experimental groups and cells inoculated with a blank lentivirus as
our controls. RNA was extracted from both groups using TRI reagent (MRC), followed by cDNA Synthesis using
iScript gDNA Clear cDNA Synthesis Kit (Bio-Rad). Protein was also extracted from these cells using a lysis buffer
and immunoblots were performed on the shCdk5 and control group using Mini-PROTEAN Tetra system (Bio-Rad)
and monoclonal antibodies. Quantitative PCR was run on the shIrf2bp1 and control group.
Results: In cultured 4T1 and T11 cells, genetic knockdown of Cdk5 resulted in a reduced phosphorylation of
IRF2BP1 as evidenced by reduced intensity of bands on a PhosTag Gel. Further shRNA-mediated knockdown of
Irf2bp1 demonstrated a dramatic reduction of key immune-related genes, in particular those associated with the
class I major histocompatibility complex.
Conclusion: CDK5 may alter MHC-I expression through IRF2BP1 phosphorylation.
Keywords: Brain metastasis, Breast cancer, CDK5, IRF2BP1
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Abstract number: 154
Study of Levonorgestrel Intrauterine Device (IUD) Alone or in Combination with an mTORC1 Inhibitor
(everolimus) to Overcome Progesterone Resistance in AH or Stage Ia Grade 1 EEC
Ernesto Flores; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Tina Alvarado; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Gaby Granda; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Sara Hull; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer Center
Larissa Meyer; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Melinda Yates; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Shannon Westin; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Background: Endometrial cancer is the most common gynecologic cancer in the United States with over 66,000
women diagnosed in 2020. The standard of care for early stage disease is complete surgical resection. The
average age for women diagnosed with endometrial cancer is 60 years, however, 25% of patients are
premenopausal and many are still of childbearing age. Thus, surgical resection may not the ideal course of action
for young women who want children in the future or women who are unable to have the surgery performed due to
medical co-morbidities. The levonorgestrel intrauterine device (IUD) releases a consistent dose of progesterone
into the uterine cavity for five years. IUD has been used in lieu of a surgical resection for atypical hyperplasia (AH)
and grade 1 endometrioid endometrial carcinoma (EEC) with response rates for 85% and 65%, respectively, but
resistance to progesterone can be observed. One proposed mechanism of action of resistance is through the
PI3K/AKT pathway. This trial will study the levonorgestrel intrauterine device (IUD) alone or in combination with
an mTORC1 inhibitor (everolimus) to overcome progesterone resistance in AH or stage Ia grade 1 EEC. In
addition, we will assess clinical, pathologic, and molecular factors associated with progesterone resistance.
Methods: This multicenter study is a two-stage, randomized phase II trial of the LIUD alone or in combination with
everolimus for the treatment of patients with AH or stage Ia, grade 1 EEC. Patients will have adequate organ and
bone marrow function. Well controlled diabetes is permitted on study. In the first stage , patients without prior
treatment with have LIUD placed at the time of confirmatory dilation and curettage. Biopsy will be obtained after 3
months of treatment. Those patients that have residual disease are deemed progesterone resistant and proceed
to the second stage. Patients with LIUD in place for at least 3 months prior to study that have residual disease
are deemed progesterone resistant will progress immediately to second stage. In stage 2, patients will be
randomized to either the LIUD alone or in combination with everolimus. Approximately 270 women with AH or
grade 1 EEC will participate in the first stage of the study. We will randomize 80 patients in the second stage to
achieve adequate power to detect difference in response. For translational objectives, tissue is obtained at
baseline, 3 months, and 6 months. Molecular factors, including baseline and change in gene/protein expression in
relevant pathways such as PI3K/AKT, estrogen-regulation, and Wnt signaling, will be associated with response
and resistance to therapy.
Results: There have been 57 patients have been treated with the LIUD during the first stage of this ongoing study.
18 patients continued into stage 2 of the study with 9 being treated with LIUD alone and 9 with the combination of
LIUD and everolimus. To date, tissue has been collected from 16 patients at all three time points.
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Conclusion: Tissue collection is feasible in a multicenter study. Analysis of the data collected on study is ongoing.
Keywords: endometrial cancer, everolimus, progesterone, levonorgestrel
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Abstract number: 155
Characterizing infiltrating monocytes in anti-PD-1/CTLA-4 immunotherapy resistant NSCLC tumors
Karina Flores; Thoracic/Head and Neck Medical Oncology; Careers in Cancer Science and Medicine, The
University of Texas MD Anderson Cancer Center
B. Leticia Rodriguez; Thoracic/Head and Neck Medical Oncology; University of Texas MD Anderson Cancer
Center
Jessica M. Konen; Thoracic/Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Don L. Gibbons; Thoracic/Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Lung cancer is the leading cause of cancer-related mortality in the world cancers because of its
propensity to metastasize and its late stage diagnosis. Small-cell and non-small-cell lung cancer (NSCLC)
represent over 80% of lung cancer cases. NSCLC treatment options include chemotherapy, radiation therapy,
hormone therapy, biological therapy, and immunotherapy. Instead of targeting the tumor cells, immunotherapy
directly targets a host’s immune system by mobilizing immune cells to recognize and eliminate tumor cells.
Because of primary and acquired resistance to immunotherapy we investigated the potential immune cells that
may be contributing to resistance.
Methods: Human cell lines, THP-1 and U937, were cultured in RPMI 1640 with 10% fetal bovine serum. Male or
female wild-type 129/sv mice were sacrificed and their spleen and femur bone marrow were collected.
Manufacturer recommendations were followed to isolate total RNA from cultured cells or purified mouse
monocytes with TRIzol. SYBR green PCR master mix was used for QPCR and was repeated twice for each gene
in each cell line. Each gene’s specific primer was validated before use. L32 was used to normalize expression for
ddCt, GAPDH was used to normalize expression across genes per plate. 7500 Fast Real Time PCR systems
were used for QPCR reactions.
Results: Using the 344SQ KP mouse model we observed that combination anti-PD1/CTLA-4 was initially
responsive but develops resistance over time due to T-regulatory cells, neutrophils, MDSC, and monocytes. We
found that resistance was due to infiltrating monocytes; therefore, we hypothesized that targeting monocyte
populations in immunotherapy-resistant tumors could change tumor sensitivity to immunotherapy. Using Zilionus
et al. 2019 scRNA sequence analysis, we found that Ly6C+ monocytes in mice belong to monocyte cluster 1 and
are equivalent to human monocyte cluster 1. Human cell lines THP-1 and U937 were chosen for further cluster
analysis via QPCR. Mouse monocytes were analyzed and found to belong in cluster 1. We also found that the
THP1 cells could differentiate into dendritic cells and macrophage cells. Differentiation of mouse monocytes was
confirmed for dendritic cells, M1 macrophage, and MDSC.
Conclusion: Cluster analysis of THP-1 and U937 had varied expression. Due to the large variability in expression
between genes additional genes will need to be queried for further confirmation of cluster. Identification of the
monocyte clusters will contribute to help understand how they are able to differentiate and how they are
contributing to immunotherapy resistance.
Keywords: Immunotherapy, resistance, monocytes, NSCLC, word 1.
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Abstract number: 156
Study of protein arginine methyltransferase 6 in medulloblastoma
Sarah Grandinette; Pediatrics; University of Texas MD Anderson Cancer Center
Ajay Sharma; Pediatrics; University of Texas MD Anderson Cancer Center
Yanwen Yang; Pediatrics; University of Texas MD Anderson Cancer Center
Donghang Cheng; Pediatrics; University of Texas MD Anderson Cancer Center
Vidya Gopalakrishnan; Pediatrics; University of Texas MD Anderson Cancer Center
Background: Medulloblastoma is the most common malignant brain tumor in children and a major cause of cancer
related childhood mortality. Current treatments have drastic side effects that can last throughout a patient’s
lifetime. The search for new treatments requires a better understanding of medulloblastoma biology. The sonic
hedgehog (SHH) subgroup of medulloblastomas overexpress RE1-silencing transcription factor (REST), which
represses neuronal differentiation genes and drives tumorigenesis. REST elevation in cerebellar granule
progenitor cells (CGNPs) increased proliferation and decreased telomere length. The latter is a trigger for
senescence and apoptosis; however, these cells escape both processes. To better understand these
mechanisms, we performed a gain of function screen with a library of epigenes. Protein arginine
methyltransferase 6 (PRMT6) was identified as a high-priority REST-interacting protein. PRMT6 is known to
regulate the expression of genes involved in senescence. The availability of PRMT6 specific inhibitors for
evaluation in pre-clinical studies was an added criterion for our focus on PRMT6. Our hypothesis is that PRMT6
prevents senescence in REST-driven SHH medulloblastomas.
Methods: Published transcriptomic databases were mined for PRMT6 and REST expression and survival curves
were generated. The brain sections of mice harboring patient derived xenografts (PDX) were stained with
hematoxylin and eosin to confirm that tumors were present. Immunohistochemistry will be performed to study the
expression of PRMT6 in DAOY and DAOY high REST tumors. PRMT6 was knocked down in medulloblastoma
cell lines using siRNA and cell viability was measured using MTT assays. qPCR will be done to confirm reduction
of PRMT6 expression. In pre-clinical studies, MTT assays were performed to determine the IC50s of PRMT6
inhibitors (Licochalcone A, EPZ020411, and MS117) against a panel of medulloblastoma cell lines.
Results: Elevated REST and PRMT6 in human SHH medulloblastomas were associated with poor prognosis.
H&E staining located tumors in the brains of mice xenografted with human medulloblastoma cell lines.
Experiments are ongoing to evaluate the expression of PRMT6 in tumors and the effect of PRMT6 knockdown on
cell viability. MTT assays revealed the cytotoxicity of PRMT6 inhibitors in medulloblastoma cells in vitro.
Conclusion: We have identified a novel genetic interaction between REST and PRMT6 in medulloblastoma. If
PRMT6 knockdown significantly decreases cell viability and parallels our findings from pharmacological studies
with PRMT6 inhibitors, we will have provided the foundation for further mechanistic and pre-clinical studies
focused on investigating the role of PRMT6 in REST-driven SHH medulloblastomas and the feasibility of targeting
it for treatment.
Keywords: PRMT6, medulloblastoma, REST, SHH, therapeutics
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Abstract number: 157
Neuroinflammatory Response in Human Derived Cerebral Organoids to Proton FLASH and Conventional
Radiotherapy
Talia Hall; Experimental Radiation Oncology; MD Anderson Cancer Center
Lawrence Bronk; Experimental Radiation Oncology; MD Anderson Cancer Center
Sanjay Singh; Neurosurgery; MD Anderson Cancer Center
Julianna Bronk; Radiation Oncology; MD Anderson Cancer Center
Fredrick Lang; Radiation Oncology; MD Anderson Cancer Center
David Grosshans; Radiation Oncology; MD Anderson Cancer Center
Background: FLASH radiotherapy (FLASH-RT) refers to the delivery of radiation at ultra-high dose rates.
Preliminary data has suggested that there is a reduction in radiation-induced toxicity and preservation of
surrounding normal tissue when radiation is delivered at FLASH dose rates compared to conventional dose rates;
however, the mechanisms behind this phenomenon are unknown. Using human-induced pluripotent stem cellderived cerebral organoids (COs) as a 3D in vitro model of normal human brain tissue, we investigated the effects
of proton FLASH and conventional dose-rate RT on microglia, the innate immune cells of the central nervous
system, as chronic neuroinflammation following RT including microglial activation has been correlated with normal
tissue damage.
Methods: COs were used to determine the number of activated microglia following exposure to conventional or
FLASH-RT. Samples to assess microglia development within the CO model at 1 and 2 months of maturation were
also prepared. After six months of maturation, COs were irradiated to 2, 5, and 9Gy at the MD Anderson Proton
Therapy Center with FLASH and conventional-dose rates. One month following irradiation, COs were fixed,
sectioned, and immuno-stained with markers for activated microglia, Iba1, and CD68. Slides were imaged on a
Vectra Polaris and analyzed using the QuPath software package. The percentage of activated microglia cells was
defined as cells with positive expression of both CD68 and Iba1 divided by the number of all Iba1 positive cells.
Results: The number of microglia cells detected at 1, 2, and 7 months of maturation was found to increase (76,
89, 344) while the percentage of activated microglia detected decreased (11, 6, 3%). A significant increase in the
percentage of activated microglia cells was detected at 2Gy FLASH (37%) followed by a decrease at 5Gy and
9Gy (5, 1%). For COs irradiated at conventional dose rates, the percentage of activated microglia at 2Gy (4%)
was approximately the same as the control but was higher at 5Gy and 9Gy (19, 10%).
Conclusion: Our results begin to characterize the long-term maturation of microglia cells within the CO model.
Irradiated COs display dose-rate dependent differential effects in neuroinflammation markers where FLASH
appears to result in reduced microglial activation for higher doses compared to conventional RT. These findings
motivate further investigation into the mechanism behind the sparing of the neuroinflammatory response of
normal brain tissue at FLASH dose-rates and the clinical applications of FLASH-RT to improve radiation-related
toxicity in patients receiving RT for brain tumors.
Keywords: proton FLASH therapy, microglia, cerebral organoids
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Abstract number: 159
Statically Analysis of Spinal Cord Radiology Reports
Kristin Huntoon; Neurosurgery; University of Texas MD Anderson Cancer Center
Madeline Garibay; Neurosurgery; Rockhurst
Background: Using the Radiology reports of patient who have undergone Spine Stereotactic Radiosurgery
(SSRS) and comparing to see the differences from the Local Control (LC) to determine the significant difference
of the different genes.
Methods: Looking over patient charts in the radiology department specifically in the spinal cord seeing there MRI’s
from the different fractures that got radiated. To then be able to use One Way ANOVA to see what the significant
difference are is between the different genes. Comparing genes to the SRSS minus the LC date if there were
multiple fractions that got radiated, then take the average number use it as the dependent. Making each type of
DNA that was being used as the factor. In order to get the significant difference, standard deviation and compare
how many mutations there where using the One-Way ANOVA Post hoc Tukey Alpha (0.05) was the best way to
see those results.
Results: In the studied there were a total of 169 people in the records that showed their average age to be about
61 and their average survival rate to be a year and 5 months. From this studied there were 79 women and 90
men that were shown in their charts to be of that gender. The top proportions consisted of Breast 7.69%, Lung
19.53%, Melanoma 11.83%, Prostate 2.96%, Renal 12.43%, Thyroid 19.53, and Colon at 5.92%. From the top 10
shortest survival rate Lung made almost half of the days and one of the lowest numbers being 28. While out of the
top 10 longest survival rates was Thyroid making almost half of the days and being the third longest number being
3251. In the analysis of the different genes such as TP53 p =.035, EGFR p =.024, and Gender p = .034, showed
significant difference while KRAS, MET, KIT, PIK3CA, BRAF, APC, ATM, NRAS, CDKN2A, SMAD4, STK11,
CTNNBI, IDH1, KDR, VHL, FGFR2, HRAS, PTEN, MLL2 ARIDIA, GNAS, and JAK3 did not show significant
difference.
Conclusion: TP53 had the best outcome since it showed to have a longer date from when it progressed by almost
double the amount since when there were no mutations it lasted 624.2665 compared to 385.7766.
Keywords: One Way ANOVA; Genes; Spinal Radiology
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Abstract number: 160
The Effect of Cigarette Smoke on Acute Myeloid Leukemia
Amenda Khoei; Pediatrics - Research; University of Texas MD Anderson Cancer Center
Joya Chandra; Pediatrics - Research, Department of Epigenetics and Molecular Carcinogenesis; University of
Texas MD Anderson Cancer Center
Mary Figueroa; Pediatrics - Research; University of Texas MD Anderson Cancer Center
Background: Modifiable behaviors, such as smoking, can increase cancer risk; data shows that smoking
influences survival in acute myeloid leukemia (AML) patients. Understanding the molecular effect of smoking on
cancer biology is essential for tailoring treatment to patients. Smoking increases the levels of reactive oxygen
species (ROS), which damage cells. Little is known about the mechanism by which smoking impacts cancer
treatment or the expression of proteins that regulate redox reactions. Our lab has shown that cigarette smoke
exposure of AML-bearing mice had increased Heme Oxygenase 1 (HO-1) expression in spleens and that
cigarette smoke condensate (CSC) treatment of AML cells in vitro had increased glutathione and superoxide
levels. HO-1 is a heat shock protein and antioxidant that eliminates ROS and aids AML cell survival. We
hypothesize that CSC treated leukemia cells would increase HO-1 expression, and lead to resistance to
chemotherapeutic treatments which could be reversed by an HO-1 inhibitor.
Methods: We treated human AML MOLM13 and MOLM14 cells with CSC to chemically mimic cigarette smoke
exposure or with dimethyl sulfoxide (DMSO) as the control for two weeks. Daunorubicin is a chemotherapeutic
drug and an anthracycline used to treat AML patients. We visualized cell proliferation from Daunorubicin treated
cells with an alamarBlue assay. We also introduced Brusatol, a HO-1 regulator, to CSC and DMSO treated cells.
We assessed HO-1 expression by western blot analysis. We analyzed cell death with Propidium Iodide (PI)
staining and flow cytometry.
Results: No significant changes in cell proliferation between DMSO and CSC treated AML cells were seen.
However, two of the three replicates showed that HO-1 expression increased in CSC treated cells and one
showed a decrease in HO-1 expression in CSC treated cells with Brusatol. We found a trend of increased HO-1
with Brusatol treatment in CSC, little cell death at low concentrations, and an increase in ROS levels at higher
concentrations.
Conclusion: Despite previous in vivo experiments indicating enhanced proliferation with cigarette smoke
exposure, this was not the case for our in vitro experiments. Our setting does not encompass the tumor
microenvironment, which may be contributing to AML growth from smoking. Therefore, it may be necessary to
use in vivo models to mimic human smoking. The low cytotoxic effects of Brusatol indicate it could be used in
patients. Additional research must be done to understand the role of redox changes from lifestyle factors, such as
smoking, and their role in AML.
Keywords: Acute Myeloid Leukemia, Cigarette smoking, Heme Oxygenase-1 (HO-1), Brusatol, Daunorubicin
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Abstract number: 161
Associations between social support and depression, stress, and fruit and vegetable consumption among
African American adults in Houston
Edom Kidane; Health Disparities; University of Texas MD Anderson Cancer Center
Nga Nguyen; Health Disparities; University of Texas MD Anderson Cancer Center
Alba Calzada; Health Disparities; University of Texas MD Anderson Cancer Center
Lorna H.McNeill; Health Disparities; University of Texas MD Anderson Cancer Center
Background: Lack of social support has been associated with increased risk for psychological distress, such as
depression and stress, obesity, and other diseases. Recent studies have shown that patterns of social support
vary depending on race/ethnicity. (Yang, T. C. et. al., 2019). One study stated that African American adults tend
to experience greater psychological distress and consume fruit and vegetables at a lower rate than other
racial/ethnic populations due to variations in social support. (O'Neal, C. W. et. al., 2014). This study seeks to
explore the relationship between social support and depression, stress, and fruit and vegetable consumption
among a population-based sample of African American adults.
Methods: Participants of this study are from a church-based cohort of 1,827 African Americans recruited between
2008-2013. Participants were asked to come into the church to complete a computer-based survey, which
included self-reported descriptive characteristics (age, sex, and chronic conditions), self-reported depressive
symptoms using the Epidemiological Studies-Depression (CES-D) scale, social support using the Interpersonal
Support Evaluation List (ISEL) scale, perceived stress using the Perceived Stress Score (PSS) scale, and selfreported fruit and vegetable consumption.
Results: Greater social support was associated with lower scores of depressive symptoms (estimate= -0.29,
SE=0.02, p-value<.0001). Greater social support was also associated with lower scores of perceived stress
(estimate= -0.15, SE=0.01, p-value< .001). There was no significant association found between social support
and fruit and vegetable consumption (estimate= 0.02, SE= 0.01, p-value< 0.06).
Conclusion: The results indicate a negative correlation between social support and depression and social support
and stress. As examined in numerous studies, there is a pattern in African-American adults concerning higher
rates of psychological distress compared to other racial/ethnic groups. (Williams D. R., 2018). Social support can
help buffer the effects of stress and depression in African Americans and future interventions should consider
interventions to increase social support.
Keywords: African-Americans, Social Support, Psychological Distress, Fruit and Vegetable Consumption
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Abstract number: 162
The auditions for Kruppel Like Factor 5 interacting proteins
Johnny Lin; Cancer Biology; University of Texas MD Anderson Cancer Center
Yejing Ge; Cancer Biology; University of Texas MD Anderson Cancer Center, Robin Neustein Laboratory of
Mammalian Development and Cell Biology, Howard Hughes Medical Institute, The Rockefeller University, New
York, NY 10065, USA
Background: The Ge lab is interested in stem cell functionalities in normal skin development, tissue regeneration,
and diseases. We are also looking into the molecular mechanisms regulating stem cell plasticity, and how it goes
awry in skin diseases such as chronic wounds or skin cancer. My project involves the transcription factor KLF5,
Kruppel Like Factor 5, and its role in skin wound repair and cancer. Transcription factors and epigenetic
regulators are known to be critical in all living organisms. KLF5 in particular, is found in both humans and mice,
and known as an important regulator of tissue development in the gut(McConnell, B.B., 2011), heart(Drosatos, K.,
2016), lung(Wan, H., 2008), eyes(Kenchegowda, D., 2011), bladder(Bell, S.M., 2011), muscle, etc. In the skin,
KLF5 is known to be important for tumorigenesis and wound repair (Ge et al., 2017). What is unclear is KLF5
targets and how it regulates skin function.
Methods: To find out how KLF5 executes its function, I set out to examine KLF5 interacting proteins in the lab.
First, we harvested wounded tissues and cells. Then, we immunoprecipitated KLF5 using a KLF5-specific
antibody. Next, we performed mass spectrometry to identify the proteins extracted from the samples. From this,
we created a list of putative KLF5 interacting proteins. To validate these proteins, we followed-up with a designed
Co-IP strategy and western blots.
Results: We tested around 40 genes, most of them were nuclear proteins including epigenetic regulators,
transcription factors, and regulators of RNA stability. Among all 40, we found 30 were successfully expressed,
and 24 interacted with KLF5 in the CoIP assay. We repeated this assay twice, and 20 consistently interacted with
KLF5.
Conclusion: KLF5 potentially interacts with 20 proteins to regulate wound repair.
Keywords: Kruppel-Like Factor 5, Wound Repair, Transcription
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Abstract number: 163
The deciphering of medical jargon
Maria Maldonado-Barreno; Radiation Oncology; University of Texas MD Anderson Cancer Center
Michael Rooney; Radiation Oncology; University of Texas MD Anderson Cancer Center
Dr. Clifton David Fuller; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Clinical trials are medical research involving real patients used to evaluate the safety and efficacy of
new experimental trials.ClinicalTrials.gov is a database available to the public that disseminates clinical trial
information and assists researchers with participant recruitment. Because there is such a large variety of syntax
and readability, it might be difficult for non-experts to identify whether patients are eligible for specific trials. The
public's understanding of the clinical trial eligibility criteria used for participation is unknown, and the requirements
can be hard to decipher.
Methods: Using the eligibility NCI survey on Redcap, we will decode 100 clinical trials on lung cancer from
clinicaltrials.gov. The survey asks a series of questions about eligibility to determine which patients are eligible for
the study. The comprehensibility of the eligibility criteria is assessed using categorical and numerical measures
about cancer stage, metastatic role, biomarkers, therapies, age, gender, and performance status.
Results: As a high school student, I found biomarkers and the role of metastases to be the most difficult to
comprehend because of my lack of scientific expertise. I used the internet to learn about medical language and
terminology, intricate human anatomy, and biological molecules found in lung cancer. I also read a few lung
cancer-related medical publications.
Conclusion: If you do not have an extensive scientific background, clinical trials on clinicaltrials.gov can be
arduous to comprehend. If patients want to be part of clinical trials, the website needs to be improved because it
is hard to understand with little to no deep scientific understanding. To keep the eligibility criteria section simple:
medical jargon should be avoided.
Keywords: comprehension, no science degree, ClinicslTrials.gov, readability, clinical trials,
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Abstract number: 164
Inhibition of p38 Renders Mesenchymal-like Cancer Stem Cells Sensitive to TGF-β1 or TGF-β Inhibitor
Kelsey Medina; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Micaela Morgado; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Sanduri Mani; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Epithelial to Mesenchymal Transition (EMT) is an embryonic program that is critical for development.
Cancer cells can also undergo EMT which endows the cells with migratory and stem cell properties, increased
metastatic capacity, and resistance to cancer treatment. FOXC2, a forkhead transcription factor, plays a critical
role in EMT through various signaling pathways, however, since it is a transcription factor it is difficult to target.
We previously discovered that p38 kinase phosphorylates FOXC2 at the serine 367 position. This phosphorylation
leads to the activation and translocation of FOXC2 to the nucleus, rendering it active and able to transform
epithelial cells to mesenchymal-like cancer stem cells and making them more metastatic and resistant.
Methods: This study focuses on the inhibition of p38 using the small molecule inhibitor SB203580. This will inhibit
the downstream effects of FOXC2 leading to the inhibition of EMT. The impact of p38 inhibition on cell
morphology, proliferation, expression of mesenchymal markers, and stem cell properties were assessed. D2A1
and 4T1 mouse syngeneic breast cancer cell lines are known to have a hybrid phenotype expressing epithelial
and mesenchymal markers (E/M cells) were used. Unpublished observations in our lab have shown that
treatment of these cells with either TGF-β1 or TGF-β Inhibitor (SB 431532) did not seem to influence the induction
of a mesenchymal or epithelial phenotype. These cells are harder to treat due to their plasticity. We hypothesized
that inhibiting p38 will sensitize these cells to TGFβ1 or SB 431532 transitioning them to a more mesenchymal or
epithelial state respectively sensitizing them for treatment.
Results: Cell morphology, proliferation, and stemness were disrupted by the inhibition of p38 alone and more so
with the combination of either TGF-β1 or SB 431532. A change in epithelial and mesenchymal markers is
expected. Data so far shows that the inhibition of p38 on the resistant hybrid E/M cells disrupts their stemness
and proliferative potential, allowing them to switch to a more epithelial or mesenchymal state. * Additional results
will be included as they are generated
Conclusion: p38 plays a major role in regulating the plasticity of metastatic cancer cells in breast and prostate
cancer. Inhibition of p38 in E/M-like cells will prove to be vital in the clinical setting as we can use the plasticity-like
nature of the cells to manipulate them to our advantage and transition them into a more stable state rendering the
cells sensitive to a standard of care.
Keywords: Breast Cancer, Epithelial to Mesenchymal Transition (EMT), cell plasticity, p38 Inhibitor (SB203580),
FOXC2
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Abstract number: 165
Using Finite Element Analysis to Quantify the Brain Shift that Occurs during Tumor Resections
Rael Memnon; Imaging Physics; University of Texas MD Anderson Cancer Center
Anne-Cecile Lesage Ph.D; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Neuronavigation has been used for many years to guide neurosurgeons in the resection of tumors.
However, when the brain is cut open, a brain shift occurs due to the intracranial pressure changes and partial
cerebrospinal fluid drainage. It is imperative that neurosurgeons are able to predict the brain shift (brain
deformations) that occurs with tumor resections to minimize the possible fatal effects and maximize the tumor
removal. The goal of this project therefore is to use 200 patients’ data and FEA deformations to accurately
produce an AI model to predict brain shifts that enables surgeons to minimize damages to health tissues of the
brain.
During this project, we first started to compile patients from the ADNI database, the PACS database(patients from
MD Anderson), and the BITE patient data. For this portion of my project, 15 MD Anderson patients were used.
The images that were downloaded from each patient included 90+slides of T1A, T1B, and T2 (pre-op and
postop). Afterwards, the patients whose data were collected from PACS, we contoured the patients’ tumor and
the ventricles on the preop T2. This will allow us to build a 3D model of the brain.Next, we placed POI on a couple
of images (points of interest) that were on the gray matter of the sulci on T1A intraop and found the similar points
on T1B intraop. This allowed us to measure the brain deformation that occurred once the skull was cut open. We
then contoured the cerebellum and the brain stem on the T1A portion of the brain. Again, this was done to allow
us to build a 3D model of the brain. We also contoured the ventricles Next for these patients, For the ADNI
patients, we had to download their data and convert them from nifty files into dicom, using command line. The
same was done for the 14 BITE patients. The next step will be to skull strip the patient's brain from the T1A brain
images. Skull stripping is done to remove any extra meningeal tissues and only the outline of the brain
remains.Skull stripping is done using the PuTTy software in conjunction with the command line prompt. It will be
done for all patients, as it betters the brain segmentation required to diagnose brain related diseases and pinpoint
brain deformations.
Results: The results of the skull strip are still being worked on. The next step of this project is to complete a library
of finite element models from these 3-D brain models. From there, an AI (artificial intelligence) predictor can be
made where the brain shift can be predicted.
Conclusions: In conclusion, there are huge brain shifts that occur during the surgery that can bring the original
plans of surgery to a demise. The goals of this project are to produce a database from which an AI (artificial
intelligence) pipeline can predict the finite element methods result.
Keywords: Ray station, Brain shift, skull stripping, neuronavigation, 3-D brain, artificial intelligence, finite element
method, finite element analysis,
Program Affiliation: Partnership for Careers in Cancer Science and Medicine

174

Abstract number: 166
Protein purification of SETD8: a structure and inhibition study
Fabian Mendoza; Epigenetics and Molecular Carcinogenesis; University of Houston-Downtown
John R. Horton; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Xiaodong Cheng; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Background: SETD8 is the only lysine methyltransferase that is known to target and monomethylate lysine 20 in
histone H4 (H4K20). H4K20 methylation by SETD8 hinders DNA replication by blocking acetylation in G1 phase,
suppresses p53 activation in cancer cells. SETD8 overexpression in many types of cancer is associated with poor
prognosis and is an attractive cancer drug target. There are limited known inhibitors that specifically bind and
inhibit SETD8. Inhibitors may bind to the cofactor, substrate, or allosteric sites. We will use the “fragment drug
discovery” method to structurally analyze the binding mode of small compounds (fragments) that have been
confirmed to bind SETD8 with low affinity by our collaborator. Combining fragments that binds to different sites of
SETD8 could potentially lead to better inhibitors that could be used in cancer treatments.
Methods: We will be testing several binding compounds that bind SETD8 to find their binding location (cofactor,
substrate, or another site). Differential Scanning Fluorimetry (DSF) and Surface plasmon resonance (SPR) have
been used to confirm that small fragment compounds binding to SETD8 in high micro-molar range (KD > 220µM).
The binding location information can be used to optimize new generation inhibitors. We will use protein
crystallography and x-ray diffraction by cocrystallization of SETD8 with binding compounds to create protein
structures that will help us locate the binding location of the compounds.
Results: We first expressed and purified SETD8 catalytic domain (residues 232-380), which was missing 13
residues at C-terminus. We used an expression plasmid induced with Isopropyl β-d-1-thiogalactopyranoside
(IPTG) to induce SETD8 expression. For purification, we used Nickel affinity and size exclusion chromatography
to prepare the protein for crystallization. No apo-crystals were formed using this construct nor with three inhibitors
of the highest binding affinity we have. Next, we used a longer construct with complete C-terminus, residue 232393 of SETD8. We are screening the crystallization conditions of many commercial screen kits. Once crystals are
produced, data can be obtained from x-ray diffraction and the binding location of each of the binding compounds
will be determined.
Conclusion: As we continue forward, further testing is required to know the exact binding location. Crystallization
of the SETD8 along with the different binding inhibitors is crucial to get data from x-ray diffraction. Using this data,
we will better understand the binding location of possible inhibitors that may someday lead to new drugs for
cancer treatment.
Keywords: SETD8 methyltransferase, crystallography, X-ray diffraction, inhibitors
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Abstract number: 167
Investigating Chromatin Organization Around Prominent Oncogenes Through Hi-C Analysis
Kristy Mendoza Rangel; Neurosurgery; Barnard College
Kadir Akdemir; Neurosurgery; University of Texas MD Anderson Cancer Center
Background: Three-dimensional-chromatin organization is critical for proper gene expression and communication.
Chromosome Conformation Capture methods, such as Hi-C, allows scientists to investigate chromatin
interactions and organization on a genome-wide scale. Hi-C contacts maps are then created to analyze chromatin
interactions within cell types. Hi-C shows squares displaying interaction frequencies, depicted by color intensity,
between pairs of loci. TADs are prominent features in Hi-C maps that are high self-interacting regions that are
conserved among cell types. Within TADs, other features include loops, stripes, and sub-TADs. Although our
understanding of chromatin organization within non-cancerous cell types is expanding substantially, what remains
questionable is how chromatin organization differs in cancer cells from normal cells, especially around the
prominent oncogenic regions. Therefore, studying the chromatin organization in cancer cells could identify
potentially important non-coding regulatory regions.
Methods: To investigate chromatin organization within normal and cancer cells, we used two main data
visualization tools: HiGlass and Juicebox. We looked at the chromatin organization of several oncogenes genes
such as c-MYC and STAT3 using these visualization browsers and compared them to different cell lines. Our
control cell line was a normal lymphoblastoid cell line, GM12878. We compared each gene’s chromatin
organization to other non-cancerous cell lines like HMEC, HUVEC, IMR90. We also compared it to cancerous cell
lines representing such as leukemia, adult and child brain tumors, sarcoma, melanoma, lung cancer, esophageal
cancer, and colon cancer types.
Results: Analyzing the CD274 gene (PD-L1), differences in chromatin organization were observed between the
GM12878 cell line and the sarcoma cell line. In sarcoma, the TAD in which CD274 is located has stripes that go
beyond the CTCF-mediated loops meaning that the TAD may be having interactions with nearby loci. In sarcoma,
the TAD also seems to be part of a bigger domain compared to the GM12878 cell line. Examining the Hi-C data of
c-MYC gene, there were vast differences within all cancerous cell lines. Both the adult brain tumor cell line and
colon cancer cell line show that c-MYC is being amplified and overexpressed potentially caused by a mutation. In
child brain tumors, there seems to be less sub-TADs and has a much simpler chromatin organization.
Conclusion: Our study revealed that certain oncogenic regions exhibit differential chromatin organization in a
cancer specific manner. Further investigation of these altered chromatin organization will reveal potential noncoding elements driving the oncogene expression.
Keywords: 3D-chromatin organization, oncogenes, Hi-C
Program Affiliation: Partnership for Careers in Cancer Science and Medicine

176

Abstract number: 168
The tumor immune microenvironment of chronic lymphocytic leukemia
Patricia Montes; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Priyanka Khare; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Ronghua Zhang; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Sheighlah McManus; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Maria Teresa S. Bertilaccio; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
Background: Chronic lymphocytic leukemia (CLL) is a B cell malignancy characterized by the overexpression of
CD5+ B-cells. These cells have been shown to have high levels of proliferation that is facilitated through
interactions with the surrounding microenvironment. The immune microenvironment is populated by several cell
types of the lymphoid and myeloid lineage. Including regulatory and memory T cells, monocytes, tumor
associated macrophages (TAMs), and myeloid derived suppressor cells (MDSCs). Currently, there are
therapeutic agents such as BTK inhibitors (e.g.Ibrutinib) that target CLL cells by inhibiting the Bruton’s tyrosine
kinase, which is involved in the growth and proliferation of leukemic cells. One major setback from the use of
these therapies is the immune suppression that results. Some patients that undergo treatment are prone to
serious fungal infections and other immune dysfunctions. This evidence opens the door for the possibility that
these therapies could interfere with non-neoplastic immune cells as well as CLL cells. There is a gap in
knowledge that exists about the current state of immune cells that interact with CLL cells. It is important to
analyze the microenvironment of CLL in order to be able to correctly identify how to repair immune dysfunction
that is a common feature of patients with CLL. We hypothesize that the tumor immune microenvironment of CLL
includes dysfunctional memory T cells, but also lymphoid and myeloid cells with pro-tumor function.
Methods: In order to examine the immune microenvironment, we isolated peripheral blood mononuclear cells
(PBMCs) from patients with CLL. Once the PBMC samples were obtained, 8-color flow-cytometry phenotype
analysis of human myeloid cells and 10-color flow-cytometry phenotype analysis of human lymphoid cells were
performed using LSR Fortessa X-20 (BD Biosciences). Samples were analyzed with FCS Express 6 FlowCytometry Software (De Novo Software).
Results: We successfully identified and characterized through multi-color flow cytometry a number of cell types of
the lymphoid and myeloid lineage. As hypothesized, some of these cell types have pro-tumor phenotype/function
and include immunosuppressive regulatory CD4 cells (TREG), tumor associated macrophages (TAM) and
monocytic-MDSCs. In addition, naïve, effector and central memory CD4+ and CD8+ T cells were identified.
Conclusion: The characterization of the cellular tumor immune microenvironment will pave the way toward future
studies aimed at repairing the function of some immune cells, but also at depleting immune cells with
immunosuppressive function.
Keywords: CLL, Microenvironment, Immune Cells
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Abstract number: 169
Generation of Anti-Müllerian Hormone (AMH) knockout chickens by CRISPR/Cas9 Genome Editing to
Study Sex Development
Selene Nanez; Partnership for Careers in Cancer Science and Medicine (PCCSM), Houston, TX; MD Anderson
Cancer Center
Rachel D. Mullen; Genetics; University of Texas MD Anderson Cancer Center, Houston, TX
Richard R. Behringer; Genetics; University of Texas MD Anderson Cancer Center, Houston, TX
Background: Anti-Müllerian Hormone (AMH) is a Transforming Growth Factor-β family member responsible for
Müllerian Duct (MD) regression during male development in vertebrates. The MD is the precursor of the uterus,
oviduct, cervix, and upper vagina and the Wolffian Duct is a precursor of the seminal vesicles, vas deferens, and
epididymis. These ducts form within the mesonephros of both males and females. In males, the embryonic
gonads differentiate into testes with Sertoli and Leydig cells. Sertoli cells produce AMH and signal AMH receptors
in the mesenchyme adjacent to the MD to induce MD regression in males. If MD regression is interrupted, a male
will be born with male reproductive tract organs and a uterus and oviducts, a condition known as Persistent
Müllerian Duct Syndrome. AMH loss in teleost fishes resulted in male-to-female sex reversal and germ cell
overproliferation in females. The evolutionary relationship of AMH signaling across vertebrate species is currently
unknown. Studying AMH signaling across vertebrate species should reveal how the function of this pathway
regulates germ cell development and sex development. In chickens, testes express AMH during early
development. We hypothesize that AMH is required for Müllerian Duct regression in male chickens. Primordial
Germ Cells (PGCs) give rise to oocytes and sperm depending on the sex of the embryo. PGCs circulate in the
embryonic blood before settling in the gonads. Thus, PGCs can be isolated from the blood of chicken embryos for
in vitro culture and expansion for genetic manipulation. Genetically-manipulated PGCs can then be returned to
the circulation of embryos to generate germline chimeras that can transmit the genetic alteration to progeny.
Methods: Three target sequences for CRISPR/Cas9 genome editing within exon 1 of the chicken AMH gene were
identified using Benchling. Oligonucleotides with these target sequences were annealed and phosphorylated to
generate guide RNA inserts to be cloned into the pX459v2 plasmid. PGCs were isolated from Rhode Island red
chickens (Gallus gallus domesticus). The three plasmids will be transfected into male chicken PGCs using
lipofectamine. Following transfections, cells will be selected for two days using puromycin. Isolated Clonal cell
lines are genotyped and confirmed by PCR and TA cloning.
N/A
Conclusion: Molecular cloning is currently ongoing. Post cloning, future directions include transfection and embryo
microinjections. Studying AMH signaling in chickens is important to determine whether AMH signaling is a
conserved evolutionary mechanism across vertebrate species. This study will shed light on its role in chicken sex
development.
Keywords: AMH, CRISPR/Cas9, Sex Development, Chicken
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Abstract number: 170
Immune Checkpoint Inhibitor Myocarditis: Concomitant Coronary Artery Disease and Heart Failure
Praise Oderinde; Cardiology; University of Texas MD Anderson Cancer Center, Houston, Texas; University of
Houston Downtown
Samat Kabani MD; University of Texas Health Science Center
Marilyne Daher MD; Baylor College of Medicine
Cezar Iliescu MD; University of Texas MD Anderson Cancer Center
Anita Deswal MD MPH; Cardiology; University of Texas MD Anderson Cancer Center
Nicolas L. Palaskas MD; Cardiology; University of Texas MD Anderson Cancer Center
Background: Despite promising cancer results from immune checkpoint inhibitors (ICI) several immune related
adverse events (irAE) have been observed, including myocarditis. Despite ICI myocarditis having a low incidence,
0.5 to 1%, it is the most fatal irAE with a reported mortality of 25 to 50%. The diagnosis of ICI myocarditis is
dependent on a combination of clinical presentation, biomarkers, cardiac imaging, and endomyocardial biopsy.
The clinical presentation of myocarditis is often equated with heart failure despite the majority of patients
presenting with normal left ventricular ejection fraction (LVEF). In addition, current practice guidelines suggest to
first rule coronary artery disease (CAD) prior to making a diagnosis of myocarditis.
Methods: A single center retrospective cohort study of all patients who had endomyocardial biopsy for suspected
ICI myocarditis between January 2018 and January 2020 was performed. Manual electronic medical record
review was performed to collect demographics, oncologic history, laboratory values, catheterization data, and
cardiac imaging data. Clinical parameters and right heart hemodynamics were compared using Chi-square test.
Results: During the study period, 52 patients had endomyocardial biopsy for suspicion of ICI myocarditis. The
mean age was 68 years and the majority were male (75%). By the Bonaca criteria 42 (81%) patients had definite,
probable, or possible myocarditis and the remaining were considered negative for myocarditis. Of those with
myocarditis, LVEF <50% was observed in 47% of patients and pulmonary capillary wedge pressure (PCWP) >12
mmHg was observed in 47% of patients however elevated PCWP and LVEF <50% were not correlated (p=0.78).
In addition, 47% presented with dyspnea however presenting symptoms of dyspnea and elevated PCWP were
not associated (p=0.09). Of the 8 patients presenting with dyspnea but with normal PCWP, 3 (38%) had
concomitant myositis, myasthenia gravis, or guillian barre irAEs. Significant CAD was found on left heart cath in
26% of patients presenting with myocarditis but the presence of CAD was not associated with having elevated
PCWP (p=0.14).
Conclusion: ICI myocarditis has varied clinical presentations including heart failure however only half may actually
have heart failure this may be present in those with both normal and depressed LVEF. When patients present
with dyspnea but have normal filling pressures on echocardiogram then concomitant muscular/neuromuscular
junction irAEs should be considered. Cancer and CAD have shared risk factors and up to a quarter of patients
presenting with myocarditis may have concomitant CAD therefore the presence of CAD should not rule out
myocarditis.
Keywords: Myocarditis; Immune checkpoint inhibitors; Heart failure; Coronary artery disease
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Abstract number: 171
Analyzing Disease Mutations in Proteins Involved in Liquid-Liquid Phase Separation
Wendy Olivares; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Sueda Cetinkaya; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Raymond Zou; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Sairahul Pentaparthi; Oncology; Livestrong Cancer Institutes, Dell Medical School, The University of Texas at
Austin
Stephen Yi; Oncology; Livestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin
Nidhi Sahni; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Background: Liquid-liquid phase separation (LLPS) is the natural process where a liquid separates into two
distinct phases and this leads to the formation of membrane-less organelles in cells. These condensates can be
formed from intrinsically disordered regions, multiple folded domains, and other physical properties of proteins.
High concentration and overexpression can also lead to condensate formation concentration which can trigger the
formation of aggregates or signaling clusters. Mutations can impact the structural features of proteins or their
expression levels, consequently altering phase separation. The dysregulation of LLPS is associated with the
occurrence of certain cancers and neurodegenerative diseases and there is a greater need for understanding the
role that mutations play in this scenario. Additionally, there is growing evidence of the implications of LLPS in
such diseases. which is why we analyzed disease related mutations in genes related to LLPS to ultimately
understand the roles of LLPS in disease development and the relationship between genotypes and phenotypes.
Methods: ClinVar presents data on human variation and phenotype and the Human Gene Mutation Database
(HGMD) presents mutations associated with human disease. We first curated a list of experimentally validated
LLPS genes using LLPS protein databases. This gene list was used to filter out the mutation databases for our
analyses. The interactions in protein-protein interaction regions depend on the edgotype of the mutations, or the
effect of mutations on molecular interaction. Using previously established edgotype data for HGMD mutations we
noted the distribution of mutation edgotypes across LLPS genes. We then filtered out the HGMD and ClinVar data
for pathogenic clinical significance and single nucleotide variants in LLPS genes and used published data labeling
HGMD mutations as gain-of-function (GOF) or loss-of-function (LOF). Here we present the findings from our
systematic analysis of these mutation databases filtered for LLPS genes.
Results: We found no significant differences between edgotype characterization of LLPS and non-LLPS gene
mutations in HGMD. We generated a list of diseases that are significantly enriched with LLPS gene mutations
which includes relevant LLPS diseases like parathyroid carcinoma, frontotemporal dementia, and melanoma.
Additionally, some of the genes enriched for GOF/LOF mutations include tumor suppressor genes and oncogenes
like PTEN and CDKN2A.
Conclusion: Overall, we observe significant data associating cancer and neurodegenerative diseases with
mutations in LLPS genes and acquired promising data in our systematic analyses for further investigating the
impact of mutations on protein structure and properties to understand the roles of LLPS in diseases.
Keywords: Liquid-liquid phase separation, Edgotype, Mutations, GOF/LOF, Diseases
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Abstract number: 172
Preclinical Evaluation of APR-246, a p53 reactivator in Head and Neck Squamous Cell Carcinoma
Charles Osamor III; Head and Neck Surgery; University of Texas Health Science Center McGovern Medical
School
Mason Bartels; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Dr. Jeffrey Myers; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Dr. Abdullah Osman; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Background: Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer type in the
world. The cure rate for patients with advanced HNSCC remains in the 25-40% range due to resistance to
standard therapy, primarily consisting of platinum-based chemoradiation therapy. Mutation of the TP53 is the
most common aberration in head and neck cancer and often associated with poor survival and treatment
resistance. Therefore, novel therapeutic approaches to overcome this resistance are urgently needed. As WT p53
protein is a known potent inducer of apoptosis and senescence when expressed in tumor cells, reactivation of
some level of WT function in mutant TP53 bearing cells is an attractive therapeutic strategy. APR-246, a
methylated PRIMA-1 analog, is a small molecule that selectively induces apoptosis in TP53 mutant cancer cells.
Mechanistically, APR-246 covalently binds to the cysteine residues in mutant p53 causing more stable functional
conformation. The goal of this study is to examine whether APR-246 restores wildtype p53 activity in HNSCC
expressing mutant p53.
Methods: To examine the in vitro susceptibility of mutant TP53 HNSCC cell lines to APR-246 as a single agent
and in combination with cisplatin, western blotting, clonogenic survival assays, and immunostaining were
performed. For clonogenic assay, cells were seeded at predetermined densities and treated with various doses of
the drugs as indicated. Colonies were then visualized with crystal violet. The IC50 of the drugs was determined by
GraphPad prism software and the combination therapy effects were evaluated by the Talalay-Chow method. To
examine reactivation of the wildtype p53, cells were treated with the drugs and subjected to western blot analysis
using appropriate antibodies. Immunostaining was performed with antibodies that recognize mutant and WT p53
forms to test for the correct conformational changes.
Results: APR-246 treatment induced p21 levels indicating p53 wildtype reactivation in the cells tested.
Additionally, APR-246 caused apoptosis as determined by PARP-1 cleavage. Furthermore, the clonogenic
survival assay produced an IC50 of 2.43 µmol/L and 1.07 µmol/L for the APR-246 and cisplatin respectively.
Addition of APR-246 synergized with cisplatin in the cells (CI = 0.764). Lastly, immunostaining suggested
conformational changes in the mutant p53 cell tested following treatment with APR-246.
Conclusion: APR-246 restored wildtype activity and synergized with cisplatin in vitro in the p53 mutated HNSCC
cell lines. Future experiments will be performed to evaluate the degree of the p21 induction and apoptosis in the
cells following treatment with combination therapy.
Keywords: wild type, p21, TP53, mutant, APR-246
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Abstract number: 173
A novel small molecule targeting oncogenic miR-10b in gastric cancer
Paola Rausseo; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Iman Sahnoune; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
George A. Calin; Translational Molecular Pathology; University of MD Anderson Cancer Center
Background: Gastric cancer is a frequent cause of death worldwide. It is linked to environmental factors that differ
worldwide; in the United States, risk factors vary from processed foods to H. pylori bacteria. Gastric carcinomas
are heterogeneous and therapy-resistant, making it difficult to establish a unified therapeutic approach. MiRNAs
are small non-coding RNAs implicated in gene expression. One miRNA in particular, miR-10b, has been found to
be oncogenic, with overexpression linked to proliferation, migration, and metastasis and associated with poorer
overall survival. The limited treatment options around miR-10b have led the laboratory to develop a novel
therapeutic binding miR-10b. This study reports on the effect of Compound 25, a derivative of the FDA-approved
therapeutic linifanib. This compound was developed in collaboration with the Institute for Applied Cancer Sciences
at MD Anderson. We hypothesize that miR-10b drives cancer through binding tumor suppressor genes and that
Compound 25 decreases binding of miR-10b. Therefore, high miR-10b expression in gastric cancer cells will be
impacted by the compound, leading to malignant cell death.
Methods: To gain a strong foundation on my project, I reviewed over 50 papers on miRNAs and miR-10b in
PubMed. After my first week in the laboratory, I performed cell culture, and by the second week, I was maintaining
seven cell lines across three tissue types. I shadowed senior colleagues on RNA extraction, cDNA preparation,
Western blots, and PCR techniques. I then learned to plate cells, use the microscope, and start new cell lines. By
the sixth week, I did my own PCR to generate data for an ongoing publication. Afterward, I was taught to evaluate
and analyze the data. Compound 25 was tested across established laboratory techniques in our gastric cell
lines, including RNA expression, microscopy, and evaluating cell lines and patient samples to validate our
findings.
Results: We used microscopy to assess morphological changes within two gastric cancer cell lines and one
normal cell line. There were minimal differences to the normal cell line, validating that the compound targets
cancer cells. Using PCR, we tested miR-10b expression in our cell lines and inpatient samples from a collaborator
at MD Anderson. We identified a reduction of miR-10b after the treatment with Compound 25 in the cancer cells.
Conclusion: Oncogenic miR-10b is upregulated in gastric cancer cells. Compound 25 targets miR-10b in cancer
and has the potential for translational application in gastric cancer.
Keywords: MiR-10b, Gastric Cancer
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Abstract number: 174
Assessing Tumor Mutational Burden of Patients with Pancreatic Cancer using Cell Free DNA (cfDNA)
Brianna Resendiz; Radiation Oncology; University of Texas MD Anderson Cancer Center
Daniel Lin; Radiation Oncology; University of Texas MD Anderson Cancer Center
Bret Stephens; Radiation Oncology; University of Texas MD Anderson Cancer Center
Cullen Taniguchi; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer (PDAC) lacks indicative biomarkers for early detection, prompting late diagnosis
and poor prognosis. Cell free DNA (cfDNA) from liquid biopsies presents possibilities for early detection,
predicting cancer recurrence, and monitoring the effectiveness of cancer therapy in a minimally invasive manner.
Previous studies have shown that cfDNA from the blood displays the same genetic alterations from the primary
tumor, such as KRAS and TRP53. Here, we present a sample processing pipeline which can be used to isolate,
purify, amplify, and sequence cfDNA from whole human blood.
Methods: Blood was collected before, during, and following ablative radiation from 6 patients with unresectable
pancreatic cancer on an institutional trial (2017-0606). Whole blood was centrifuged to separate components into
three layers: plasma, buffy coat, and erythrocytes. Germline DNA was isolated from peripheral blood
mononuclear cells (PBMC) found in buffy coat using the Qiagen DNeasy Blood & Tissue Kit to use as a control
sequence template. cfDNA was isolated from the patient plasma by QIAmp Circulating Nucleic Acid Kit,
isopropanol precipitated, then quantified by Qubit to measure DNA concentration before proceeding to
sequencing library preparation. Ligation-based library preparation was then performed to prepare the DNA for
sequencing which involves a series of DNA fragmentation, end-repair, ligation, PCR-based amplification, and
barcoding. DNA quality was analyzed using TapeStation D1000 assessing average base pair size with a target of
300-400 base pairs.
Results: Average germline DNA concentration after using the DNeasy Blood & Tissue kit was 48.2±26.2 ng/μl.
Average DNA concentration after cfDNA isolation from patient plasma at baseline, during treatment, and following
treatment was 9.0±7.3, 6.3±3.6, and 4.3±2.4 ng/μl, respectively. DNA concentrations following library amplification
increased initial concentrations by 3, 10, 21, and 37-fold with average concentrations of 152.8±64.5, 90.9±88.1,
132.1±66.5, and 157.0±83.8 ng/μl for germline, baseline, during treatment, and post-treatment, respectively.
Average base pair size for germline, baseline, during treatment, and post-treatment were 339±15, 365±35,
362±13, and 358±17 indicating successful molecular-barcode insertion during library preparation.
Conclusion: The methodology presented demonstrates that this facile sample processing pipeline is capable of
producing high quality DNA in quantities sufficient for targeted next generation DNA sequencing. Downstream
DNA sequencing with a custom targeted panel focused on detecting key mutational sequences associated with
pancreatic cancer can help to personalize cancer treatments and possibly predict and improve patient outcomes.
Keywords: cell free DNA, pancreatic cancer, liquid biopsy
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Abstract number: 175
Combination therapy of natural killer cells and oncolytic viruses.
Ehulises Rodriguez; Stem Cell Transplantation and Cellular Therapy Research; University of Texas MD Anderson
Cancer Center
Katy Rezvani; Stem Cell Transplantation and Cellular Therapy Research; University of Texas MD Anderson
Cancer Center
Xin Ru Jiang; Stem Cell Transplantation and Cellular Therapy Research; University of Texas MD Anderson
Cancer Center
Background: Cancer is a disease that affects the immune system, one of our body’s organ systems. The immune
organ system specializes in the protection against illnesses and restoration of the human body.The immune
system is split into two branches: the innate and the adaptive. I will be focusing on the innate immune system.
The innate immune system is considered as the “nonspecific” immune system due to its first response
mechanism that attacks any foreign substance that enters the body. It is carried out by different cells: scavenger
cells, proteins, and natural killer (NK) cells. For the purposes of my project, I will be focusing on NK cells. Natural
killer cells are, as the name implies, killers. They primarily kill virally infected cells and tumor cells. They
accomplish this through inspecting cells and changes to their surfaces; if any anomaly is detected they destroy
the cell. . However, NK cells have only been proven to treat blood tumors because solid tumors have a
suppressive tumor microenvironment and inhibits NK killing. To overcome this, we are using a certain type of
virus, known as oncolytic viruses, to infect tumors and reverse the suppressive microtumor environment to aid NK
killing. My project revolves around the combination of oncolytic viruses and NK cells in an attempt to find a union
that best helps combat cancer cells.
Methods: The use of the xCELLigence instrument is essential to my project as it enables the monitoring of cell
killing in real time. The xCELLigence machine works in a way that measures the adherence of cells to an
xCELLigence plate that emits electric currents. These electric currents flow from one end of the plate to the other
and by measuring their distortion we are able to tell cells’ quality of adherence and number of adherent cells.
Adherence is important because it allows us to know whether our NK and oncolytic viruses are killing our cancer
cells. To explore and find out what combination of NK and OV works the best, I split my plate into sections that
exhibit different MOI’s (multiplicity of infection) and ET ratios (effector to target cells). Essentially, combining a
different number of virus cells with a different number of NK cells in an attempt to find the best results in
comparison to a control.
Results: Collection of the data from this project is still in progress.
Conclusion: Analysis of the data is still in progress.
Keywords: Natural killer cells, innate immune system, oncolytic virus, xcelligence
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Abstract number: 176
Radiobiology Behind Dose Fractionation in Ewing Sarcoma
Rebeca Rodriguez; Pediatrics Research; Wellesley College
Bella S. Guerrouahen; Pediatrics Research; University of Texas MD Anderson Cancer Center
David Flint; Radiation Oncology; University of Texas MD Anderson Cancer Center
Keri L. Schadler; Pediatrics Research; University of Texas MD Anderson Cancer Center
Background: Ewing sarcoma (ES) is an aggressive bone and soft tissue sarcoma that most frequently occurs in
adolescent patients. The multimodal treatment for ES consists of chemotherapy, radiation, and surgery.
Unfortunately, >10% of patients have recurrent disease, indicating room for improvement in radiation efficacy.
Radiation creates reactive oxygen species that cause double strand breaks (DSB) to tumor cell DNA in the
presence of oxygen. Thus, increasing oxygenation of tumors may enhance radiation efficacy. Exercise improves
tumor vascular function which enhances oxygenation. We hypothesize that exercise will enhance RT efficacy in
an A673 ES murine model. To test this, we first determined the radiosensitivity of ES cells in vitro.
Methods: We performed clonogenic assays, the gold standard in measuring radiosensitivity, on A673 Ewing
tumor cells in increasing seeding densities (100, 200, 300, 500, 1000, 1500, 2000, 3000) in 6 well plates. Plates
were irradiated at 2, 4, 5, and 7Gy with a clinical linear accelerator (6MV photon beam), the same machine used
to treat patients. Backscatter and buildup material were used to place the cells at a water-equivalent depth of 10
cm during irradiation mimicking the location of a tumor in the human body. After 8-14 days, colonies (50 cells)
were stained using Crystal Violet 0.5%, and counted using ImageJ. The plating efficiency (PE) and survival
fractions (SF) were calculated and the dose-survival curves were generated by plotting the SF as a function of the
dose on a semi-logarithmic scale (Prism Software) and fitted using linear quadratic model.
Results: We first determined the appropriate seeding density at 0Gy (100, 400, 800). After 12 days, colonies were
overlapping for seeding densities of 400 and 800. For the irradiation experiment, we proceeded with a lower
seeding density of 100 and 200 at 0Gy. We expect to reach at least 10% survival with the selected 4 doses. We
expect to calculate the metrics which include the alpha/beta ratio, where the alpha components corresponds to
non-repairable lethal damage and beta to repairable DSB, and Biological Effective Dose (BED).
Conclusion: The alpha/beta ratio and BED will be used to design a fractionation protocol to be used in
combination with treadmill exercise in mice studies.
Keywords: Ewing Sarcoma; Radiobiology; Clonogenic assay; exercise; A673 cells
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Abstract number: 177
Exploring the mechanisms of PHF20/PHF20L1 within the NSL complex
Daniela Ruiz; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Peter Harkins; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Background: Targeted DNA is frequently observed for its characterization and role in specific protein complexes.
Chromatin consists of DNA and a protein called histone. Histones support and organize the DNA by coiling and
changing their shape to assist in the formation of chromosomes. Chromatin aids in processes like transcription
and DNA repair by its ability to condense and uncondense DNA. The ChIP assay allows for selection of protein
bound to DNA through antibody specificity which allows for quantification of bound DNA through qPCR. Previous
studies have shown the NSL complex expressing PHF20 gene which is related to non-small cell lung cancer and
has a paralog PHF20L1. The presence or absence of proteins can repress or enhance the process of
transcription. To better understand the role on the molecular mechanism of the NSL complex a knockdown of
PHF20 and PHF20L1 were created in U2OS cells. Protein complexes can be studied through crosslinking,
immunoprecipitation, and western blotting.
Methods: PHF20 and PHF20L1 single knockdown efficiency was assessed through western blot. Single
knockdown for PHF20 and PHF20L1 cell lines were cross linked binding the DNA to protein using formaldehyde.
Sonication testing sheered the chromatins and a comparison of non-sonicated and sonicated fraction was
obtained to compare DNA levels. IgG antibodies and sepharose beads were utilized during chromatin
immunoprecipitation (ChIP) for DNA clean up. Washing and eluting of the beads bound to the antibodies removed
non-specific proteins and other unrelated cellular material. Phenol chloroform extraction continued the purification
of DNA. Quantification of DNA was observed by qPCR.
Results: Western blot analysis displayed a knockdown of PHF20L1 and PHF20 demonstrating the effectiveness
of these mutants. The cross-linkage of a single knockdown in PHF20 demonstrated at the NSL3 complex the
amount of purified DNA in PHF20-4 increased drastically compared to the empty vector.
Conclusion: Through ChIP assays, we prepared these mutants for chromatin immunoprecipitation and ran a
qPCR that expressed the PHF20-4 cell line with an increased amount DNA compared to the empty vector. PHF20
and PHF20L1 proved successful single knockdowns as observed through the amount of protein signal in the
western blots. Studying molecular mechanisms can help progress or change targeted cancer therapies. Creating
knockdowns of PHF20 and PHF20L1 and performing ChIP assays will help us understand these cells lines
specific role within the NSL complex.
Keywords: ChIP, NSL Complex, Protein-DNA interaction
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Abstract number: 178
Implementation and testing of an enzyme linked immunosorbent assay for the detection of circulating
SARS-CoV-2 receptor binding domain antibodies
Emilly Sanchez; Faculty Diversity, Equity & Inclusion; University of Texas MD Anderson Cancer Center
Eleonora Dondossola; Genitourinary Medicine Oncology; University of Texas MD Anderson Cancer Center
Sarah B. Johnson; Surgical Oncology; University of Texas MD Cancer Center
Pranoti V. Sahasrabhojane; Genomic Medicine; University of Texas MD Anderson Cancer Center
Khalel Imanbayev; Genomic Medicine; University of Texas MD Anderson Cancer Center
Manoj Chelvanambi; Surgical Oncology; University of Texas MD Anderson Cancer Center
Michael G. White; Surgical Oncology; University of Texas MD Anderson Cancer Center
Nadim J. Ajami; Genomic Medicine; University of Texas MD Anderson Cancer Center
Jennifer A. Wargo; Surgical Oncology; University of Texas MD Anderson Cancer Center
Background: The coronavirus disease 2019 (COVID-19) pandemic has caused over 4 million deaths worldwide
and is a major ongoing public health concern. COVID-19 is caused by the highly contagious severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 uses a virally encoded surface spike protein (S)
to attach and enter ACE-2+ cells. The critical neutralizing domain (CND) is contained in the receptor-binding
domain (RBD) of the S protein and leads highly potent neutralizing antibody response conferring effective
protection against subsequent severe disease, hospitalization, and death. Therefore, the detection of anti-RBD
antibodies in serum (i.e., seroconversion) is considered predictive of immune protection from severe COVID19.
Here, we implement and test an enzyme linked immunosorbent assay (ELISA) adapted from the protocol
developed by Dr. Florian Krammer (Icahn School of Medicine at Mount Sinai) to detect serum antibodies against
the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
Methods: We tested the antigenicity of a cloned and purified RBD through an indirect enzyme linked
immunosorbent assay (ELISA). Briefly, multi-well microtiter plates were coated with the cloned RBD and probed
for using serial dilutions (1:1000 to 1:256,000 in 2-fold increments) of a commercially available rabbit anti-human
RBD antibody. RBD detection was visualized using a colorimetric OPD substrate that was catalyzed by an antirabbit secondary antibody conjugated to the enzyme horseradish peroxidase (HRP). Successful detection of RBD
by anti-RBD antibody was identified by quantifying absorbance of colorimetric product at 490nm.
Results: Serial dilutions of the anti-human RBD antibody demonstrated a dilution-dependent decrease in OD490
absorbance suggesting successful recognition and antigenicity of the cloned RBD protein. Importantly,
nonspecific negative control antibodies when used at the highest concentration tested failed to impart any color to
corresponding experimental wells highlighting the accurate diagnostic value of this workflow thanks to low nonspecific reactivity.
Conclusion: Taken together, the implementation of the RBD ELISA presents a specific and accurate assay to test
for presence of anti-RBD antibodies in specimen sera. This validated workflow will be instrumental in future
studies seeking to identify seroconversion, neutralization, and subsequently dissect anti-COVID19 immune
responses in large human cohorts.
Keywords: ELISA, COVID-19, RBD, antibody
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Abstract number: 179
Killed in cold blood: An exploration of the efficacy of oncolytic adenoviruses in metastatic breast cancer
Taylor Southward; Neuro-Oncology; Howard University
Sagar Sohoni; Neuro-Oncology; University of Texas MD Anderson Cancer Center
William Symmans; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Dong Ho Shin; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Juan Fueyo; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Candelaria Gomez-Manzano; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Background: Despite advances in cancer treatment and prevention, metastatic breast cancer remains the most
frequent form of cancer in women. Given the lack of targeted therapies and high mortality rates for metastatic
breast cancer patients, there is a demand for newer, more effective approaches. Our lab focuses on adenovirusbased virotherapy for treatment of solid tumors. In a recently concluded phase 1 clinical trial, we showed that
patients with glioblastomas treated with Delta-24-RGD exhibit increased long-term survival rates, as 20% of
patients survived more than three years. Our current study uses a derivative of Delta-24-RGD, called Delta-24RGDOX, armed with immune co-stimulatory ligand OX40L. Previously, we have shown that this virus triggers
CD4+ T-cell specific immune response against the tumor. In this study, we hypothesize that oncolytic virotherapy
will elicit a robust antitumor immune response, which will exert abscopal effects and eradicate primary tumors and
metastatic niches in metastatic breast cancer models.
Methods: Prior to in vivo experiments, infectivity, replication, and expression of the costimulatory ligand OX40L
were studied in vitro. Human and murine breast cancer cell lines were treated with various amounts of virus and
monitored over a period of seven days. OX40L expression was assessed with flow cytometry. Female BALB/c
mice were intratumorally administered Delta-24-RGDOX, and tumor growth and metastasis was monitored with
BLI imaging. Changes in the tumor microenvironment after treatment were examined with flow cytometry.
Results: In vitro analysis of cell lines indicates successful infection of viruses across all cell lines. Within seven
days, the cell populations decreased over 97% after day zero of infection, as compared to the control population.
In vivo 4T1 primary breast tumors exhibited a strong anti-tumor immune response characterized by increased
CD8+/CD4+ ratio and decrease in exhausted T-cells in tumor microenvironment (ANOVA p<0.001) as well as
decreased tumor growth and metastasis.
Conclusion: Our data indicates that this common-cold virus, Delta-24-RGDOX, shows great efficacy infecting and
killing breast tumor cells in vitro. As observed in murine models, treatment with armed oncolytic viruses increases
T-cell specific anti-tumor responses, and thus controls primary tumor growth and metastasis. This development of
oncolytic viruses has introduced a paradigm shift in our approach to cancer treatment. Our data may constitute
the basis for the development of virotherapy in patients with metastatic breast cancer.
Keywords: adenovirus, metastatic breast cancer, virotherapy, oncolytic virus
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Abstract number: 180
Qualitative Analysis of Focus Group Data for Liver Cancer Prevention Program Planning
Jordan Swan; Behavioral Science; University of Texas MD Anderson Cancer Center
Background: Texas currently has the highest reported age-adjusted incidence rate of hepatocellular carcinoma
(HCC) in the nation. Minority communities tend to have a higher incidence rate of HCC compared to non-Hispanic
Whites. Individuals with a past medical history of fibrosis, cirrhosis, and alcoholic and non-alcoholic fatty liver
disease – all of which are potentially preventable – are known to be at greater risk for developing HCC. Early
detection of HCC is known to improve survival rates; however, rates of screening for risk factors and timely
detection are low. Improved efforts are, therefore, required to educate minority communities on prevention of risk
factors that may lead to development of HCC. The HOPE Clinic is a community based 501(c)(3) that aims to
provide culturally competent healthcare to all Greater Houston Area. The aim of this analysis is to determine
characteristics of an effective and retentive intervention program that would be attractive to and serve the Greater
Houston Area using focus group data from HOPE Clinic patient participants.
Methods: Patients were recruited from the HOPE Clinic to participate in focus groups. A total of five focus group
interviews were conducted in English, Vietnamese, and Spanish and translated for analysis to determine patient’s
knowledge of risk factors of liver cancer, barriers to lifestyle changes, and health management efforts. Focus
group data was analyzed using qualitative methods of analysis. Atlas.ti 8 for Windows was used to assign labels
(codes) to focus group data, determine frequency of codes, and aid in organization of recurring themes across all
interviews.
Results: The results of this qualitative analysis found themes of health barriers, motivating factors, willingness to
participate in intervention programs, program needs, knowledge of liver health, suggested protective efforts, and
past program involvement.
Conclusion: Participants often pointed out their awareness of important health behaviors such as nutrition, alcohol
consumption, and physical activity while also acknowledging barriers such as time constraints due to overworking,
accessibility of physical activity, and culturally specific diets. Fear of illness and aging were prominent motivational
factors. Program format should include tailored scheduling with the option of virtual, in person, and asynchronous
participation. Content of the program should include objectives such as healthier recipes and food preparation,
recipe adaptation, time management skills, and physical activity for beginners. Overall, there was a consensus
that interventions should promote positive health behaviors in both younger and older age groups.
Keywords: hepatocellular carcinoma, liver health, community-based intervention, qualitative analysis
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Abstract number: 181
Role of Soluble E-cadherin in the Epithelial to Mesenchymal transition of Inflammatory Breast Cancer
Fikir Tadesse; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Dr.Bisrat Debeb DVM, Ph.D; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Xiao Ding Hu; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Emilly Schlee Villodre; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Breast cancer is one of the most common cancers in women, and the second leading cause of
cancer death in women. The majority of deaths occur due to metastasis. Inflammatory breast cancer (IBC) is a
highly aggressive and rare form of breast cancer with a high propensity to metastasize. IBC is known to have
worse prognosis than other types of breast cancer. The epithelial to mesenchymal transition (EMT), where the
epithelial features in carcinoma cells are converted to mesenchymal phenotype, increases cells motility and
invasion thereby confer metastatic properties upon cancer cells. Various markers and regulators associated with
EMT have been reported in breast cancer patients. The purpose of this study is to determine the role of soluble Ecadherin (sEcad), an 80-kDa extracellular proteolytic fragment of full-length E-cadherin, in regulating EMT.
Methods: The level of expression of EMT markers and regulators was compared between Control and sEcad
overexpressing SUM149 cells using Immunoblotting and Real time-PCR.
Results: Gene set enrichment analysis (GSEA, Hallmark) of RNA Seq from SUM149 control and overexpression
sEcad groups showed enrichment of the EMT pathways in the sEcad-overexpressing versus control cells. The
genes upregulated in this pathways included FBN, Vimentin, NNMT and FN1. We use real-time PCR to validate
our RNA-Seq results. The results showed higher relative gene expression of Vimentin, NNMT, and Ecadherin in
sEcad-expressing cells. However, the expression of Snail, Twist, FN1, and Slug was lower in sEcad
overexpressing SUM149 cells. By western blot, we observed that EMT markers such as Vimentin, Slug, Twist and
E-Cadherin were upregulated in sEcad overexpressing SUM149 and SUM190 cells, with no change in FN1.
Conclusion: We found that sEcad overexpression affects the expression of some of the known EMT markers such
as Vimentin, Slug, Twist and E-cadherin. Additional experiments are warranted to evaluate how sEcad regulates
the expression and function of EMT inducing transcription factors.
Keywords: Soluble E-Cadherin, sEcad, EMT, Inflammatory Breast Cancer
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Abstract number: 182
Theragnostic Nanoparticles for Magnetic Resonance Imaging and Phototherapy of Cancer
Ha Thach; Imaging of Physics; Texas A&M University
Background: The purpose of this research is to develop a nanostructure that can induce localized photothermal
therapy (PTT) in solid tumors and guide the therapy under magnetic resonance imaging (MRI) simultaneously.
Gold nanoshells have numerous advantages, including multiplexing, theragnostic, and multimodal signal
capabilities. Furthermore, they are biocompatible, optically tunable, and efficient in converting near-infrared (NIR)
light to heat. Since gold nanoshells have shown a promising clinical result in the photoablation of prostate cancer,
our research could further simplify the treatment and improve the therapy outcome for cancer by providing MRIactive nanoshell (NS) that induce MRI-guided PTT under NIR illumination.
Methods: We have synthesized an MRI-active nanoshell (NS) with ~95 nm in diameter mesoporous SiO2 doped
with ~ 2 nm in diameter Gd2O3 particles as a T1-MRI contrast agent. The final structure was sealed with gold
shell (20-30 nm) and functionalized with polyethylene glycol to prevent aggregation and improve circulation time
in vivo. This robust structure reduces the biotoxicity of Gd by preventing it from seeping out into the patient’s
bloodstream. Gd is known for being a T1-contrast agent, having various side effects that can be intercepted by
the shell design, which confines the Gd ions inside.
Results: With prior research on the use of gold nanoshells, we put it to use and found that a shell thickness of
22.7nm give high r1 and r2 relaxivity rates of 17 1/(Mm*s) and 122 1/(mM*s), which are 4-fold and 25-fold higher,
respectively, than the FDA-approved Gd-based contrast agent (Magnevist) at 4.7 T. Promising results were also
obtained through PTT under MRI guidance, which provided higher intensity, and a more illuminated visual.
Graphing our “Normalized Longitudinal Magnetization vs. Recovery Time (sec)” also showed us that the more Gd
we had, the shorter the T1 and T2 relaxation time, which is the kind of trend we expected to see. This is crucial
information that further proves the effectiveness of such nanoparticles, and how they play a significant role in
cancer treatment.
Conclusion: Nanoshells have many unique properties that are valuable to our research. We hope to facilitate
further experiments with these properties by pairing them with diagnostic and therapeutic applications. This will
provide a more expedient outcome by being a one-stop shop for patients, improve the development of multimodal
nanoparticles, and even take part in surgical resection. In short, nanoparticles are very promising in preclinical
and clinical environments. Although many aspects should be considered, including standard of care, toxicity, and
more, there is no doubt that extensive studies will lead us to improve the “See and Treat” approach towards
cancer.
Keywords: Nanoshells, MRI, PTT, Gd, Cancer
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Abstract number: 183
Theragnostic Particles for MRI Imaging and Phototherapy of Cancer
Ha Thach; Imaging Physics; Texas A&M University
Background: The purpose of this research is to observe the properties of gold nanoshells, using photothermal
therapy (PTT) under MRI guided localized PTT. Gold nanoshells have numerous advantages, including
multiplexing, theragnostic, and multimodal signal capabilities. Furthermore, they are biocompatible, tunable, and
efficient in light to heat conversion in the NIR. Since gold nanoshells have strong magnetic resonance imaging
(MRI) and near infrared (NIR) optical properties, our research of its occurrence in solid tumors could further
improve patient treatment for cancer.
Methods: To utilize gold nanoshells for our research, we doped the Gd-nanomatryoshka (Gd-NM) particles with
T1-weighted MRI contrast agent (Gd-DOTA). We then designed a tunable MRI-active nanoshell (NS) with 110 nm
mesoporous SiO2 surrounded by 10 nm Au shell. This limits the biotoxicity of Gd by preventing it from seeping
out into the patient’s body. Gd is known for being a T1 based contrast agent, having various side effects that can
be intercepted by the shell design, which confines the Gd ions inside.
Results: To utilize gold nanoshells for our research, we doped the Gd-nanomatryoshka (Gd-NM) particles with
T1-weighted MRI contrast agent (Gd-DOTA). We then designed a tunable MRI-active nanoshell (NS) with 110 nm
mesoporous SiO2 surrounded by 10 nm Au shell. This limits the biotoxicity of Gd by preventing it from seeping
out into the patient’s body. Gd is known for being a T1 based contrast agent, having various side effects that can
be intercepted by the shell design, which confines the Gd ions inside.
Conclusion: Nanoshells have many unique properties that is truly valuable to our research. We hope to facilitate
further experiments with these properties by pairing them with diagnostic and therapeutic applications. This will
provide a more expedient outcome by being a one-stop shop for patients, improve the development of multimodal
nanoparticles, and even take part in surgical resection. In short, nanoparticles are very promising in preclinical
and clinical environments. Although many aspects should be considered, including standard of care, toxicity, and
more, there is no doubt that extensive studies will lead us to improve the “See and Treat” approach towards
cancer.
Keywords: Nanoshells, Gd, MRI, PTT, NIR
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Abstract number: 184
Gene Essentiality and Related Functions
Jennifer Ton; Bioinformatics and Computational Biology; University of Texas MD Anderson Cancer Center
Background: Between 1973 and 2015, the number of cancer cases has risen by 30%. In addition to being one of
the leading causes of death worldwide, it is crucial to explore and expand the knowledge surrounding cancer.
Determining gene essentiality can potentially help to treat cancer in a universal manner. Essential genes are a
necessity that cells need in order to thrive and reproduce. Removal of essential genes results in a cell’s loss of
function or fitness. Identifying genes that are essential in cancerous cells but not in somatic cells will enable us to
target those essential cancerous genes without harming the healthy somatic cells of a patient. This study also
examines similarities in the functions related to the essential genes.
Methods: In order to attain a set of essential genes to compare their associated cellular functions, a data set of
roughly 17,000 genes. This data included 808 cell lines and each gene had an essentiality score. Using Cohen’s
D statistic, these genes were filtered and narrowed down to just the “always essential” genes. Cohen’s D statistic
is the appropriate effect size found by comparing two means. A d-score of greater than 2 was determined to be
essential genes. This new set of always essential genes was then inputted the GORILLA program (Gene
Ontology Enrichment Analysis and Visualization Tool) as the target list and another set of genes (n = 18,828) as
the background list. The ontology option of “Function” was also chosen. The GORILLA program created a table of
enrichment values. Those with an enrichment value equal to or less than 2 were removed from the data set. Pvalues and FDR q-values were then analyzed.
Results: Of the 17,000 genes in the first data set, it was determined that 717 genes were always essential. When
inputted into the GORILLA program as a single ranked list, 697 of those genes were recognized and only 696 of
them were associated with a GO term. With the data set of 18,828 genes, 18,041 of those genes were
recognized. 707 of the genes in the list were duplicates and thus removed from the set. Additionally, only 16,985
were associated with a GO term.
Conclusion: As expected, some functions such as RNA binding, polymerase activity, and nucleic acid binding had
high enrichment factors (4.81, 14.91, and 2.58 respectively). This was expected since it is known these functions
are essential and the basis for cell growth and reproduction.
Keywords: gene essentiality, cell functions
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Abstract number: 185
Predicting Tumor-Related Liver Failure in Unresectable Intrahepatic Cholangiocarcinoma Patients
through the Development of an Imaging-Based Deep Learning Neural Network Model
Arie Van Wieren; Radiation Oncology; University of Texas MD Anderson Cancer Center
Brian De; Radiation Oncology; University of Texas MD Anderson Cancer Center
David Fuentes; Imaging Physics; University of Texas MD Anderson Cancer Center
Milind Javle; Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center
Eugene Koay; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Intrahepatic cholangiocarcinoma (ICC) is an uncommon, aggressive bile duct cancer. Two-thirds of
ICC tumors are surgically unresectable at diagnosis and prognosis for these patients is poor, with median survival
time of 2.5-7.5 months in absence of treatment. More than half of unresectable ICC patients die from tumorrelated liver failure (TRLF). Ablative radiotherapy (ART) has been shown to effectively mitigate TRLF and improve
survival, but fewer than 1 in 6 ICC patients likely to develop TRLF receive this treatment. This stems from the
difficulty of prospectively identifying this subgroup of patients. To enable automated identification of ICC patients
likely to develop TRLF, we are developing a model applying the predictive ability of deep convolutional neural
networks (CNNs) to an institutional database and pretreatment computed tomography (CT) scans for patients with
unresectable ICC. We predict that intratumoral and peritumoral imaging features of ICC along with
clinicopathologic features can be used by a CNN to accurately predict TRLF.
Methods: We will construct a large institutional database that includes manually segmented CT scans, molecular
data, and treatment data to train, validate, and test a CNN that can accurately predict whether a patient will
develop TRLF. To construct an institutional database for training of the CNN, we will review records of 700+
patients with ICC.
Results: Currently, we have analyzed 175 patients who underwent radiotherapy. TRLF was found to be the cause
of death in 13 of 83 patients with a known cause of death. Median age was 66 years (range, 25-89). One-year
Overall Survival (OS) was 73% [65-81]. American Joint Committee on Cancer 8th Edition stages were I, II, III, and
IV in 12%, 22%, 37%, and 29%, respectively. Median tumor size was 7.3 cm (range, 1.7 -18.4). 71% of tumors
were located centrally while 29% were located peripherally. The most common mutations were in IDH1 (24%),
TP53 (21%), ARID1A (21%), FGFR2 (13%), BAP1 (12%), IDH2 (12%), and PIK3CA (11%). Radiotherapy median
dose was 67.5 Gy (range, 33-100) in a median 15 fractions (range, 10-33) for a median BED10 of 98 Gy (range,
44-144 Gy).
Conclusion: Our preliminary data indicate a range of outcomes for patients and variables that may be useful to
develop a CNN to predict TRLF. Looking forward, we will expand on our efforts to annotate patient data as well as
manually segment CT scans of these patients for training of the CNN models.
Keywords: Intrahepatic Cholangiocarcinoma, Tumor-related Liver Failure, Convolutional Neural Network
Program Affiliation: Partnership for Careers in Cancer Science and Medicine

194

Abstract number: 186
Analyzing the Effect of HADH Overexpression on Response to ICB
Danielle Wills; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer Center
Jielin Liu; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer Center UTHealth Graduate
School of Biomedical Sciences
Padmanee Sharma; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Immune checkpoint blockade (ICB) is a developing immunotherapy which targets regulators of the
immune system and mounts an anti-tumor response from CD8 T cells. However, cancer cells can be resistant to
ICB due to tumor intrinsic and extrinsic factors. Our lab performed a screen to identify genes that have a possible
role in regulating the response to ICB. HADH was identified as a target gene for improving response to ICB.
HADH is a protein encoding gene that catalyzes the third step in beta oxidation of fatty acids. Beta oxidation is
important because it reduces accumulation of lipids, which cancer cells use for cellular membrane synthesis and
other functions. We hypothesize that HADH expression affects response to immune checkpoint blockade (ICB) by
affecting beta oxidation, production of ROS, lipid peroxidation, and CD8 T cell induced ferroptosis. Increased
HADH activity would reduce resistance to immune checkpoint blockade by making an unstable environment for
cancer cells.
Methods: The aim of the experiment is to overexpress HADH in tumor cells in order to improve response to
immune checkpoint blockade. Tumor cells with HADH overexpression (HADHOE) were generated by introducing
an HADHOE plasmid to MB49 cells through transfection. In order to verify HADHOE, qPCR was first performed to
evaluate the transcription level of HADH. The translation level of HADH was evaluated by Western blot. After
verification of HADHOE, mice were injected with either HADHOE tumor cells or wild type tumor cells. The two
groups of mice were split into two more groups and given three doses of either IgG/PBS or anti-PD-1. Tumor
growth was monitored every three days to analyze the response to treatment with anti-PD1 and IgG/PBS.
Results: qPCR analysis of HADHOE showed that the HADHOE cell line had a 16 fold change in transcription level
compared to wild type cells, suggesting successful establishment of the HADHOE. The result was confirmed by
Western blot. Currently, we are monitoring the growth of tumors in the different groups of mice. Mice injected with
HADHOE tumor cells and treated with anti-PD1 have slower tumor growth rate compared to the control group.
This observation infers decreased resistance to ICB because of HADH overexpression.
Conclusion: A cell line with HADHOE was successfully created. More experiments can be conducted to further
understand the role of HADH in ICB. Understanding the relationship between ICB and expression of genes is
important for improving efficiency.
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Abstract number: 187
ATR Inhibitor BAY 1895344 Inhibited Proliferation of Triple-Negative Breast Cancer Cells In Vitro by
Arresting Cell Cycle Progression and Inducing Apoptosis
Mylah Wilson; Breast Medical Oncology; University of Texas MD Anderson Cancer Center, Houston, Texas
Xuemei Xie; Breast Medical Oncology; University of Texas MD Anderson Cancer Center, Houston, Texas
Jangsoon Lee; Breast Medical Oncology; University of Texas MD Anderson Cancer Center, Houston, Texas
Huey Liu; Breast Medical Oncology; University of Texas MD Anderson Cancer Center, Houston, Texas
Naoto T. Ueno; Breast Medical Oncology; University of Texas MD Anderson Cancer Center, Houston, Texas
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer with high recurrence and
mortality rates. Given that replication stress, caused by DNA damage, leads to genetic instability in cancer, an
attractive option for cancer treatment is targeting ataxia telangiectasia and Rad3-related protein (ATR), a key
sensor of DNA damage and replication stress. Following DNA damage, several events driving TNBC
pathogenesis increase reliance on ATR signaling. Therefore, targeting ATR can be a therapeutic option for TNBC.
Here, we evaluated the ATR inhibitor BAY 1895344 for its antitumor efficacy in TNBC cells.
Methods: We first treated TNBC cells MDA-MB-231 and BCX-010 with BAY 1895344 for 72 hours and then
assessed cell viability using the CellTiter-Blue and sulforhodamine B assays. The cells were also treated for 10
days and then assessed for long-term treatment effects using a clonogenic assay. Next, to identify targets
involved in BAY 1895344’s anti-proliferation activity, we treated the cells for 48 hours and then performed
Western blotting to assess expression of H2A histone family member X (H2AX), an ATR substrate that
contributes to DNA repair. Last, to understand BAY 1895344’s action mechanism, we performed FACS to
determine the inhibitor’s impact on cell cycle progression and apoptosis.
Results: BAY 1895344 effectively inhibited proliferation of both MDA-MB-231 (IC50 = 0.44 µM) and BCX-010
(IC50 = 0.14 µM) cells in vitro. Compared to the DMSO control, BAY 1895344 (0.01 µM) suppressed colony
formation by 1.35-fold (P < 0.05) in MDA-MB-231 cells and 26-fold (P < 0.0001) in BCX-010 cells. In MDA-MB231 cells, BAY 1895344 had no effect on expression of H2AX but increased its phosphorylation (Ser139); in BCX010 cells, BAY 1895344 decreased H2AX expression but did not affect its phosphorylation, indicating that BAY
1895344 operates through differential signaling in these different cells. We then looked into BAY 1895344's effect
on cell cycle progression and apoptosis. Compared to the DMSO control, BAY 1895344 (0.1 µM) induced G2/M
(2.87% in MDA-MB-231, 9.39% in BCX-010) and intra-S (5.91% in MDA-MB-231, 6.77% in BCX-010) checkpoint
arrest, along with apoptosis (2.24-fold increase in MDA-MB-231, 1.00-fold increase in BCX-010). These findings
demonstrate BAY 1895344's therapeutic potential in TNBC
Conclusion: BAY 1895344 suppressed TNBC cell growth by inducing cell cycle arrest and apoptosis. According to
our findings, targeting ATR can be an effective strategy for TNBC. Future in vivo studies investigating BAY
1895344’s effectiveness are warranted.
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Abstract number: 188
Med12 is a novel regulator of peripheral myelination
Kayla Young; College of Arts and Sciences; Howard University
Fatma Betul Aksoy Yasar; UTHealth Graduate School of Biomedical Sciences; MD Anderson Cancer Center
Jian Hu; Cancer Biology; MD Anderson Cancer Center
Background: Demyelination describes a process in which the myelin sheath, a protective lipid-rich layer
surrounding axons, is eroded away. This loss of myelin is accredited to the development of many
neurodegenerative diseases in humans, as the ability for cells to send and receive signals efficiently is greatly
hindered. Med12 is a subunit of the general transcriptional mediator complex, and its mutations lead to diseases
including: FG Syndrome, Lujan-Fryns Syndrome and Odho Syndrome, all of which show myelin abnormalities.
This current research study explores the role of the Med12 protein in nervous system myelination, and what role it
has in myelin development and maintenance.
Methods: To conduct this research, a mouse model was previously generated in the lab, using a Cre-lox
recombination system which enables conditional and induced deletion of Med12 gene in myelinating glia. Upon
subcutaneous injection with Tamoxifen at postnatal day 7, the mice that did not have the Cre recombinase
enzyme and/or Med12 floxed allele were placed into the Med12 WT group, which retained Med12 allele upon
injection. Their littermate which had Cre-loxP sites as well as the floxed Med12 allele, on the other hand,
constituted the knockout mutants, Med12 iCKO group.The animals underwent routine physical evaluations to note
any differences in their phenotypes at various time points after the injection. Following the duration of the physical
monitoring, the mice were then harvested to have their brains and other nervous system organs collected, stained
and quantified. The main staining focuses were fluoromyelin, a dye that binds to lipids on the myelin, and MBP,
myelin basic protein, both of which allowed for visualization and investigation of the myelin integrity.
Results: For the phenotypic outcomes of the research, there were significant differences between the physical
performances between Med12 iCKO and Med12 WT groups. The iCKO groups had a very distinctive clasping of
their hind legs which prevented them from performing well on their physical tasks. This was indicative of PNS
myelin deficiencies. The myelin staining results showed that there were no significant differences between the
CNS organs, specifically the corpus callosum, in terms of both myelin lipids and major myelin proteins. However,
there were noticeable differences noted in the PNS myelin, which supports the phenotypic differences observed.
Further experiments are needed to explain this phenotypic change.
Conclusion: This study affirms that Med12 is an important regulator of peripheral myelin synthesis and
maintenance.
Keywords: demyelination, neurodegenerative, Med12, myelin-lipids, corpus callosum
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Abstract number: 189
The role of radiotherapy in the management of massive intrahepatic cholangiocarcinoma
Humberto R. Nieves-Jimenez; Radiation Oncology; University of Texas MD Anderson Cancer Center
Joseph Abi Jaoude; Radiation Oncology; University of Texas MD Anderson Cancer Center
Eugene J. Koay; Radiation Oncology; University of Texas MD Anderson Cancer Center
Ethan B. Ludmir; Radiation Oncology; University of Texas MD Anderson Cancer Center
Cullen M. Taniguchi; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Intrahepatic cholangiocarcinoma (IHCC) is the second most common primary liver malignancy, and
often presents as large tumors with limited role for local therapy. Higher radiation therapy (RT) doses may
improve outcomes in this patient population. Here, we present our experience with RT treatment in patients with
large IHCC.
Methods: We performed a retrospective review of patients with IHCC treated with RT at the University of Texas
MD Anderson Cancer Center. Patients with a gross tumor volume (GTV) of 800cc or more were eligible for
inclusion in our study. Patients were treated with conformal RT using either intensity-modulated radiation therapy
(8, 66.7%) or proton therapy (4, 33.3%). The main outcomes were overall survival (OS), local progression(LPFS), and distant metastasis- free survival (DMFS) from the beginning of RT. Treatment toxicity was assessed
by regularly documented CTCAE criteria during on-treatment visits and follow-ups.
Results: The study consisted of 12 patients (8 males and 4 females) with a median age of 60. The median RT
dose was 67.5Gy delivered over a median of 15 fractions. The median GTV was 1277.7cc (IQR 900.0-1929.4),
and the median largest tumor diameter was 14.1 (IQR 12.6-15.8). Median OS from time of diagnosis was 27
months. Median OS, LRFS, and DMFS from beginning of RT was 20, 20, and 11.3 months, respectively. Only 2
patients (16.7%) died from tumor-related liver failure. The main adverse events noted were grade 1 fatigue (9,
75.0%), nausea (6, 50.0%) and abdominal pain (6, 50.0%). No patient developed grade 2 or higher toxicity.
Conclusion: In our study, patients with large IHCC showed excellent clinical outcomes in response to high dose
RT, within minimal toxicity. Future prospective studies are needed to better define the role of RT and possibly
systemic treatments in this patient population.
Keywords: Intrahepatic cholangiocarcinoma, liver tumor, radiation therapy, overall survival, toxicity
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Abstract number: 190
Segmentation for assessment of lumbar muscle mass metrics using quantitative analysis
Esther Soyebo; Radiation Oncology; McGovern Medical School
Chrissherra Mills; Radiation Oncology; Meharry Medical College
Clifton Fuller; Radiation Oncology; University of Texas MD Anderson Cancer Center
Abdallah Mohamed; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Sarcopenia is the decrease of lean body mass usually due to either loss of muscle cells or as a
result of cachexia. Most cancer patients experience this life-altering side effects post chemoradiotherapy, some
of which includes loss of lean body mass, cancer therapy-induced nutritional compromise, and systemic effect of
chemoradiotherapy. Previous experiments in our lab have shown that the onset of sarcopenia during
chemoradiotherapy was associated with reduced survival and cancer control in head and neck cancer patients.
However, these data were from HPV + patients who received feeding tubes which showed a correlation between
toxicity, sarcopenia, and oncologic outcome. The aim of our project is to predict the development of post-therapy
sarcopenia and define what effects, if any, systemic agent selection might have upon resultant late toxicity.
Methods: The CT scans prior to radiation treatment from 30 patients were pulled from EPIC. Cross-sectional
imaging was manually segmented first using Velocity software , and then auto-segmented with an AI model. Both
softwares were used to extract lean body mass (LBM), subcutaneous fat, and intra-abdominal fat body mass
alterations from baseline, and stratified using the skeletal muscle index (SMI) in the third lumbar level to to assess
pre-treatment levels on lean body mass in each patient.
Results: Manual and auto-segmentation of LBM, subcutaneous fat, and intracutaneous fat body mass is
underway. Statistical analysis will assess the association between delta-LBM, subcutaneous fat, and
intracutaneous fat body mass from pre-treatment and MDASI-HN overall score, multi-variable effects of
chemotherapy variables, and sarcopenia, and construction of toxicity prediction nomograms.
Conclusion: After conducting the segmentation part of the project, we aim to predict post-radiotherapy sarcopenia
and define what effects, if any, systemic agent selection might have upon resultant late toxicity. This will improve
patient’s care because it will allow physicians to be able to change treatments if needed to prevent cancer
induced sarcopenia based on the prediction. It would also allow physicians to administer appetite stimulants as a
preventive measure.
Keywords: sarcopenia, radiotherapy, lean body mass,
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Abstract number: 191
Standardization of Clinical Trials Eligibility Through Language Comprehension
Mohan Murari; Radiation Oncology; University of Texas Dallas
Background: Patient enrollment in clinical trials is the cornerstone of medical research. However, there are still
existing disparities in patient enrollment for clinical trials, particularly impacting geriatric and transgender patients.
We hypothesized that the un-standardized nature of eligibility criteria in clinical trials are contributing to these
disparities and should be assessed.
Methods: To do so, we assigned 70 clinical trials to non-expert educated students and tested their comprehension
of the eligibility criteria through REDCAP surveys. The clinical trials were randomly selected using the search
criteria (breast, prostate, head and neck, and pancreatic cancers, etc.) of active, recruiting trials. The selected
trails were then randomized again and split up into sets of 70 for each of the 12 students who volunteered to
analyze the trails. In addition, each student has about 2 clinical trials that will be coded into REDCAP by
themselves and another student, making it so that each trial will have been read by 2 students. Furthermore, each
survey entry is screened by a one-up medical student in order to detect any discrepancies between each
student's understanding of a single trail. For example, if, for a certain trial, the 2 students who read it come to
different conclusions about what qualifies as eligibility criteria, then the medical student who is in charge of
reading all the collected data will see this discrepancy. This discrepancy being that, hypothetically, language was
comprehended differently among the students . With a total of 12 different students, including ourselves, we were
able to analyze 800 clinical trials for language comprehension. This is still an ongoing process, with students still
finishing answering the REDCAP surveys. Once the data is compiled, however, we aim to analyze clinical trial
comprehension by comparing the differences in eligibility criteria understanding among these student non-experts
and measure the readability of the criteria.
Results: While this project is currently still being researched, our current data suggests that there are multiple
readability discrepancies among student non-experts reading eligibility criteria. Many of which center around
biomarker recognition, HIV status of the patient, the patient’s gender, and metastatic criteria. We predict more
discrepancies will emerge as the study continues, and thus believe our hypothesis was correct.
Conclusion: With our prediction we would encourage that eligibility criteria be standardized in order to improve
enrollment of qualified patients in clinical trials. In addition, we hope to potentially use our natural language
processing algorithm to streamline the standardization of clinical trials to improve readability/accessibility in the
future.
Keywords: Standardize, Criteria, Language, Algorithm, Discrepancy
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Abstract number: 192
The Use of Chemotherapy and Targeted Therapy During Radiotherapy and Its Effects on Patients Pain
Levels
Jacari Tate; Radiation Oncology; University of Texas MD Anderson Cancer Center
Vivian Salama; Radiation Oncology; University of Texas MD Anderson Cancer Center
Clifton Fuller; Radiation Oncology; University of Texas MD Anderson Cancer Center
Radiation treatment (RT) used during head and neck cancer can cause many side effects, such as acute
mucositis, oral candidiasis, xerostomia and etc; that can lead to a lot of pain. In order to combat these side effects
physicians will use different drugs, such as mild opioid combination agents and analgesic, and methods of pain
management to ease these side effects; but there is no standardized-automated method for pain prediction. This
project's main goal is to create an algorithm that can be used by clinicians to help figure out exactly which actions
need to be used in pain management, but this poster will only highlight one part of this project. The hypothesis of
this poster is that the patients who receive targeted therapy during radiotherapy will have a lower level of pain
during their overall radiotherapy treatments.
Using a detailed survey that asks about pain severity, treatment data( Dose, Fx/Dose, duration), clinical features (
type of cancer: Oropharyngeal or Oral, ECOG performance, Karnofsky Performance Status), and pain
assessment ( intensity, score, location and orientation) data will be collected from 110 patients. The sources
where the data was collected from are Epic, Barcode, and MDASI-HN. This data will then be used to compare the
pain score over the course of all the weekly see visits to whether or not a patient received chemotherapy or
targeted therapy during radiotherapy using a scatter plot chart. Then linear regression was used in order to
establish a trend line.
The data showed that when a patient is being treated with chemotherapy or targeted therapy they tend to have
lower pain scores throughout their radiotherapy treatment. The data also showed that when a patient is being
treated with chemotherapy or targeted therapy during radiotherapy their pain scores tend to always be less than 5
and those patients who don’t receive either one of these tend to have pain scores above 5.
Conclusion: In conclusion the use of chemotherapy or targeted therapy during radiotherapy tends to lead to a
patient having overall less pain.
Keywords: Pain Management , Head And Neck Cancers, Radiotherapy, Chemotherapy
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Abstract number: 193
Towards High-quality prostate MRI: Frequency and reasons for repeated and extra sequences in prostate
MRI examinations
Yu An Lin; Abdominal Imaging Department; William Carey University College of Osteopathic Medicine
Hyunjung Lim, MD; Abdominal Imaging Department; University of Texas MD Anderson Cancer Center
Jingfei Ma, PhD; Imaging Physics; University of Texas MD Anderson Cancer Center
Priya Bhosale, MD; Abdominal Imaging Department; University of Texas MD Anderson Cancer Center
Janio Szlaruk, MD, PhD; Abdominal Imaging Department; University of Texas MD Anderson Cancer Center
Tharakeswara K Bathala, MD; Abdominal Imaging Department; University of Texas MD Anderson Cancer Center
Background: Magnetic resonance imaging (MRI) plays an essential role in both the assessment of clinically
suspected prostate cancer, and in follow-up evaluation during and after treatment. However, MRI can be
expensive, and it is susceptible to artifact, which can lead to poor-quality images and thus the need for repeated
sequences. Repeated sequences increase the cost and duration of the procedure, contributing to a general
decrease in diagnostic performance. By identifying the most commonly repeated sequences and the reasons for
their repetition, we aim to help guide sequence optimization, quality improvement initiatives, and operational
standardizations to improve the general quality of care of our patients.
Methods: We retrospectively reviewed 770 consecutive patients who underwent pelvic MRI examinations at MD
Anderson from January to April 2020. We identified sequences done in addition to our standard institutional
protocol and the reasons for these repeated sequences.
Results: Of the 770 patients, 94 had at least one repeated sequence (12.21%); 1 patient had 3 repeated
sequences (0.13%), 11 had 2 repeated sequence (1.43%) and 82 had 1 repeated sequence (10.64%). In
significantly greater fractions of patients, those who underwent prostate cancer staging (n = 669) had one or more
repeats in comparison with those who underwent brachytherapy assessment (n = 101), 12.71% vs. 8.91% (p <
0.05). The most commonly repeated sequence was prostate sagittal T2-weighted MRI in 5.88% of patients (n =
765). The second most commonly repeated sequence was prostate axial T2-weighted MRI in 2.92% of patients (n
= 686). When segregating each case by risk group, 11.11% of low risk group patient (Gleason score 6, n = 117),
13.46% of intermediate risk group patient (Gleason score 7 or 8, n = 327), 14.15% of high risk group patient
(Gleason score 9 or 10, n = 212), and 6.14% of pre-biopsy patient had one or more repeats (n = 114).
Conclusion: For both prostate cancer staging and prostate brachytherapy assessment procedures, sequences
were most often repeated due to motion artifact. The reasons for patient motion often arise from anxiety,
drowsiness, or intolerance to coil. Endorectal coil repositioning is the second most common reason for repeated
sequence for both prostate cancer staging and prostate brachytherapy assessment.
Keywords: Prostate Imaging, MRI, Quality improvement, Artifact
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Abstract number: 194
Optimizing Dual-Energy CT Virtual Monochromatic Energy and Contrast Timing to Maximize Brain
Metastasis Conspicuity
Brian Nan; Neuroradiology; University of Texas MD Anderson Cancer Center
Abhi Rashiwala; Neuroradiology; University of Texas MD Anderson Cancer Center
Apollo Krayyam; Neuroradiology; University of Texas MD Anderson Cancer Center
Ethan Wang; Neuroradiology; University of Texas MD Anderson Cancer Center
Halyna Pokhylevych; Neuroradiology; University of Texas MD Anderson Cancer Center
Jason Johnson; Neuroradiology; University of Texas MD Anderson Cancer Center
Background: Brain metastases (BM) have been reported to occur in up to 40% of patients with cancer. At present,
gadolinium-enhanced MRI is considered to be the imaging technique of choice in patients suspected of BM;
however, CT is cheaper, more widely available, and does not suffer from geometric distortion as seen with MR
imaging. Prior studies have shown superior conspicuity of brain malignancy with delayed imaging times. We
sought to optimize CT parameters for BM conspicuity in a prospective trial.
Methods: Twenty-three patients (12 women, 58.4±14.6 years) with 4.4±2.5 BM were scanned on a DECT scanner
(Somatom Force, Siemens, Malvern, USA) at 90 seconds, 5 minutes, 10 minutes, and 20 minutes following the
injection of 123±8.0 ml of iohexol (GE Healthcare, Chicago, USA). The primary cancer was melanoma (7), lung
(7), breast (5), genitourinary (3), and gastrointestinal (1). Circular ROI was drawn on axial QC (conventional
polychromatic) images where the largest BM (16.0±6.3 mm diameter) had the largest cross-sectional diameter.
BM with necrosis also had an ROI placed to cover the area of maximal enhancement while avoiding tissue
outside of the BM and the necrotic (non-enhancing) region. A ROI was also placed in the contralateral normalappearing brain (NAB and in the air (“noise” measurement). A ROI was obtained at each imaging time point. For
lesions with necrosis, the “hot spot” was used for SNR/CNR. A single-tail Students T-test was used for
comparative statistics. DE virtual monochromatic reconstructed (VMR) images were created using Syngo
(Siemens, Malvern, USA). ROI were placed as above in both lesion and NAB. The HU were recorded for each
energy between 40 and 190 keV. VMR lesion and NAB data were used to calculate SNR and CNR at each
energy.
Results: At 90 sec, the mean BM HU was 85.3±12.0, SNR 27.0±10.0, CNR 12.8±4.7. (Figure 1) At 5 min, the
mean BM HU was 80.4±13.3, SNR 25.3±10.5, CNR 11.9±5.9. At 10 min, the mean BM HU was 77.2±12.0, SNR
22.5±6.7, CNR 10.0±3.5. At 20 min, the mean BM HU was 74.0±9.8, SNR 23.4±7.1, CNR 10.4±3.7. CNR was
greatest at 90 sec, and this difference was statistically significant (P < 0.05) compared to 10 and 20 min. CNR at 5
min was also statistically significantly greater than later time points (P < 0.05). A negative linear relationship was
observed between SNR/CNR and Kev with lower VMR energies resulting in the highest SNR and CNR and higher
VMR showing the lowest SNR and CNR (see Figure 1).
Conclusion: Despite prior reports demonstrating greater conspicuity for brain malignancy using later time points,
our results show that earlier time points show objectively greater conspicuity. Although lower energies result in
higher VMR noise, the increased iodine conspicuity at lower energies resulted in the highest SNR/CNR at lower
VMR. Additional work remains to verify that earlier times and lower VMR energies lead to a difference in
radiologist detection rate and confidence.
Keywords: Dual-Energy CT, Brain Metastasis Conspicuity, CT parameters, Virtual Monochromatic Energy,
Contrast Timing
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Abstract number: 195
CAR-T cell generation (Chimeric Antigen Receptor)
Baleigh Cavalier; Lymphoma/Myeloma; University of Texas at San Antonio
Background: Recent studies with Chimeric antigen receptor (CAR) T cells have shown a new emergence of
cancer immunotherapies. CAR T cells are constructed by harvesting mononuclear cells, usually from a patient’s
blood, subsequently stimulating, altering the T cells to express a transgene encoding a tumor-specific CAR, thus
permeating the CAR T cells into the patient. The development of CD27-CARs to target CD70 shows promising
increased safety for CAR- T cell immunotherapy.
Methods: We tested the efficacy of CD27- CARs to target CD70. Through the transformation of 27CAR plasmids
in a competent E-coli cell. CD27 functional activity was assessed through the generation of 27- CAR viral particles
by transfection. The measurement of viral titration was examined through green fluorescence expression.
Following, the isolation of CD70 plasmid DNA from selected clones allows for the desired plasmid to be confirmed
through RE (restriction enzyme) digestion. Thus, allowing for a ligand/ receptor communication between CD27
and CD70 and the generation of CAR T cells.
Results: CD27-CARs are highly expressed in T-cell Lymphoma and leukemia, such as AML (acute myeloid
leukemia).The insertion of the gene GFP (green fluorescent protein) in a vector permits the quick collection of
effective transduced cells. The construction of lentiviral vectors includes plasmids into 293T cells and transfection.
The measurement of the viral titration showed MOI (multiplicity of infection) to be at its highest at 48 hours. Bifunctional CAR-T cells show increased safety for CAR- t cell immunotherapy and enhanced movement against
cancer target antigens to promote tumor eradication.
Conclusion: The immunotherapeutic treatment of immunocompromised patients with CAR T cells is one of the
utmost reassuring adoptive cellular therapy tactics. Promoting the progression of CAR therapies will further
selectively destroying of cancerous tissue
Keywords: CD27: Protein-coding gene, co-stimulatory immune checkpoint, member of tumor necrosis factor
receptor CD70: protein in humans encoded by CD70 gene, CD70 is a ligand for CD27 CAR-T: Chimeric antigen
receptor; genetically modified T- cells plasmid DNA: the
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Abstract number: 196
Factors associated with pain in oral and oropharyngeal cancer patients during radiation therapy
Jaime Chen; Bioengineering; University of Illinois at Urbana-Champaign
Vivian Salama; Radiation Oncology; University of Texas MD Anderson Cancer Center
Amy C. Moreno; Radiation Oncology; University of Texas MD Anderson Cancer Center
Clifton D. Fuller; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Oral and oropharyngeal cancer (OC/OPC) is estimated to affect 54,000 people annually in the
United States. Radiation therapy is often standard of care for OC/OPC patients, but it is known to cause
significant pain for patients. There are various factors that can contribute to pain severity, and if identified, these
could help physicians with pain management techniques. The objective of this study is to assess the effect of
concurrent chemotherapy, cancer type, and gender on pain profiles at the last weekly visit for OC/OPC patients
who receive radiation therapy.
Methods: We limited analysis to patients with pathological confirmation of non-metastatic OC/OPC who were
treated at MD Anderson from 2016 to 2021. The patients received radiation therapy, defined as 6000-7000 cGy,
with curative intent for 6-7 weeks. Patient profiles, treatment information, and pain scores were collected. An
unpaired t test was performed to compare pain scores of patients with concurrent chemotherapy vs. no
chemotherapy, OC vs. OPC, and male vs. female patients to see if these are factors significantly associated with
pain.
Results: A total of 267 patients were included in this study with 137 diagnosed with OC and 130 with OPC. The
pain scores collected at the weekly visits ranged from 0 to 10 where scores of 0 indicate no pain, 1-4 is mild pain,
and 5-10 is moderate to severe pain. There was significant difference in the pain scores from week 1 to 7 as p <
0.05. The mean pain score for concurrent chemotherapy was 4.90 and 4.76 for no chemotherapy (p = 0.80). The
mean pain score for OC was 4.79 and 4.89 for OPC (p = 0.92). Finally, in observing the role of gender in pain
severity, the mean pain score for females was 4.64 and 4.93 for males (p = 0.42).
Conclusion: The results demonstrate that neither concurrent chemotherapy, cancer type, nor gender play a
statistically significant role in predicting patients’ pain severity during radiation. However, these factors do still
result in mild to moderate pain, so additional pain prevention measures could be explored to further decrease
patients’ pain during radiation therapy treatment. Future directions for this study include exploring other clinical
features such as tumor characteristics and a patient’s social history (smoking, alcohol, and drug use) as
predictors of increased pain severity.
Keywords: radiation therapy, pain, oral and oropharyngeal cancer
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Abstract number: 197
Spatially resolved transcriptomics identified distinct tumor-stroma crosstalk networks associated with
chemoresistance in ovarian cancer
Mansi Diwanji; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Jianting Sheng; Systems Medicine and Bioengineering; Houston Methodist Cancer Center
Ying Zhu; Systems Medicine and Bioengineering; Houston Methodist Cancer Center
Rita Siu Fee Cheng; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson
Cancer Center
Stephen T. Wong; Systems Medicine and Bioengineering; University of Texas MD Anderson Cancer Center
Samuel C. Mok; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Sammy Ferri-Borgogno; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson
Cancer Center
Background: As one of the leading causes of ovarian cancer related death, high-grade serous ovarian cancer
(HGSC) is currently treated with cytoreductive surgery before or followed by platinum- and taxane-based
combination chemotherapy. A majority of patients respond to this first line treatment; however, in a subset of
patients, tumors recur within 6 months after the last cycle of treatment developing chemoresistance. Ovarian
cancer progression is often dictated by strategically located activity of cells and proteins in the tumor
microenvironment (TME) that allow for sustenance of the tumor through crosstalk signaling networks established
between cancer and stromal cells. Substantial efforts have been made recently to develop gene expressionbased molecular signatures and biomarkers from these cells to predict chemoresistance in HGSC. However, a
transcriptome-based signature that can predict chemoresistance in HGSC is still lacking.
Methods: Spatial transcriptomics (ST) is a cutting-edge technology capable of providing a rich spatial context to
gene expression by generating thousands of spatially resolved transcriptomes on a single tissue section with a
resolution of 10-50 cells. We successfully developed an ST pipeline that was able to characterize tumor and
stroma subclusters as well as the stromal-tumor interface to determine several significant ligand-receptor pairs in
treatment-naïve advanced-stage chemoresistant tumors (progression free survival, PFS < 6 months) and
chemosensitive tumors (PFS >24 months).
Results: Multiple rounds of subclustering showed high levels of heterogeneity in both tumor and stroma regions,
as well as in chemoresistant compared to chemosensitive samples. Furthermore, crosstalk signaling network
analyses of certain cell populations from stroma and tumor spots located at the stromal-tumor interface of each
stroma and tumor cluster in each patient sample identified relevant ligand-receptor pairs associated with
chemoresistance. Finally, multiplex immunofluorescent (mIF) staining of tumor sections validated that cluster
defining markers CD36 and periostin in the stroma and CDK1 and LRG5 in the tumor were preferentially
expressed in chemoresistant tumors. In the same manner, increased expression of spatially resolved ligandreceptor pair biomarkers CD47 and THBS2 was validated in chemoresistant tumors.
Conclusion: These findings suggest that a new class of biomarkers based on spatial intratumoral heterogeneity
and spatially resolved transcriptomic analyses can be used to develop predictive models for chemoresistance.
The implications are that novel therapeutic strategies can be developed to target not only tumor and stromal cells,
but also the ligand-receptor crosstalk networks established between cancer and stromal cells, which may result in
improving survival rates for HGSC patients with chemoresistant diseases.
Keywords: Spatial transcriptomics, ovarian cancer, chemoresistance, tumor microenvironment
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Abstract number: 198
Genetic Interactions with Transcription-coupled Nucleotide Excision Repair
Travis Dowd; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Rui Wang; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Junjie Chen; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Transcription-coupled nucleotide excision repair (TC-NER) is a subpathway of the nucleotide
excision repair pathway that repairs DNA lesions on actively transcribed genes. There are two major TC-NER
repair proteins: Cockayne Syndrome Type A (CSA) and Cockayne Syndrome type B (CSB). CSB initiates TCNER by direct interaction with RNA polymerase II (RNAPIIo), while CSA drives RNAPIIo ubiquitination. The DNA
repair mechanisms that replace dysfunctional TC-NER remain largely unknown. However, CRISPR-Cas9 genetic
screens provide a revolutionary method to identify possible backup candidate pathways for future study. To
ensure adequate CRISPR library coverage throughout such screens, we evaluated drug sensitivity and
cumulative genotoxicity of 293A CSA-/-, CSB-/-, and wild type (WT) cells to the chemotherapeutic drug Illudin-S,
which introduces DNA lesions repaired almost exclusively by TC-NER.
Methods: CSA and CSB knockout cells were created by transient transfection of 293A cells using plasmids
expressing Cas9 with sgRNA targeting the CSA or CSB gene. Knockout cells were subjected to validation by
Western blotting and sanger sequencing. Independent Illudin-S screens were conducted in CSA-/-, CSB-/-, and
their parental 293A cells. Each two technical replicates were tested with four different Illudin-S concentrations.
The number of viable cells was used as the readout.
Results: Western blot results showed a 33% homozygous knockout efficiency for the CSA gene and at least 25%
for the CSB gene. Drug screening targeted a percentage of consistent cell survival around 80%, or a lethal dose
to 20% of cells (LD20), to maintain adequate library coverage in future CRISPR screens. Even the lowest 0.5
µg/ml concentration demonstrated excessive cell toxicity. By day 9 of the screening, 64.2% of CSA-/- cells
survived this lowest dose. The 0.5 µg/ml concentration killed approximately 10% of CSB-/- and WT cells in
preliminary passages but reached 20% lethality by the screen’s end, making this concentration a possible LD20
candidate. CSA-/- cells were considerably more sensitive to Illudin-S at each dose than CSB-/- and WT cells.
Conclusion: Decreased cell viability in CSA-/- cells following Illudin-S treatment suggests a more crucial role than
previously thought for CSA in dealing with the damages induced by illudin-S. CSA-/-, CSB-/-, and WT cells all
demonstrated large percent survival drop-offs at concentrations above 0.5 µg/ml. Lower drug concentrations than
those tested are thus appropriate for CRISPR screens of cells with an efficient or deficient TC-NER pathway.
Future screening studies will examine lower Illudin-S concentrations to determine an LD20 for 293A.
Keywords: Transcription-coupled nucleotide excision repair, Cockayne Syndrome type A, Cockayne Syndrome
type B, Illudin-S
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Abstract number: 199
A Novel Second-Generation MELK specific inhibitor targets triple negative inflammatory breast cancer
(TN-IBC)
Hector C. Gonzalez; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Moises J. Tacam; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Mohd Mughees; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Juhyeon Lee; Chemistry; University of Texas at Austin
Kevin N. Dalby; Chemistry; The University of Texas at Austin
Chandra Bartholomeusz; Breast Medical Oncology; University of Texas MD Anderson Cancer Center
Background: In 2021, there were about 281,550 cases of breast cancer in the U.S. At least 20% of breast cancers
are “triple-negative” (TNBC), defined as negative for receptors to estrogen and progesterone and HER2. TNBC is
often associated with poor prognosis and high metastasis. Inflammatory breast cancer (IBC), another highly
aggressive breast cancer, accounts for 1-5% of all breast cancers, but causes about 8-10% of U.S. breast cancer
deaths and approximately one-third of cases of IBC are also TNBC. Patients with TN-IBC are treated with the
standard-of-care multimodality therapy, which has thus far resulted in poor outcomes. Therefore, there is an
urgent need to develop new strategies to treat TN-IBC. We previously showed that MELK knockdown in TNBC
cells using genetic manipulation reduced CSC phenotype, reversed epithelial-mesenchymal transition (EMT), and
blocked invasion and metastasis. Therefore, we hypothesized that suppressing MELK with a selective, potent
MELK inhibitor will reduce tumorigenicity, cancer stemness, and invasiveness of TN-IBC.
Methods: We studied the effect of a second-generation kinase MELK-specific inhibitor, MELK-In-30e, in the triple
negative inflammatory breast cancer cell line SUM149. We used standard assays including cell proliferation,
colony formation, soft agar, migration, and flow cytometry.
Results: We first treated SUM149 with MELK-In-30e and examined the effects on cell proliferation using the Cell
Titer Blue viability assay. We found that MELK-In-30e exhibited high cytotoxicity (IC50 = 0.53μM) against
SUM149. In colony formation we tested in vitro cell survival and its ability to form colonies. We showed a
significant decrease in clonogenic growth at 0.5μM concentration (DMSO 100% vs MELK-In-30e 3.7%) (P<
0.0001) and anchorage-independent growth, an indicator of in vivo tumorigenicity (DMSO 100% vs MELK-In-30e
51.58%). We next examined the effects of MELK-In-30e on cell motility. MELK-In-30e (1μM) strongly inhibited
migration of SUM149 cells (DMSO 43.4% vs MELK-In-30e 17.3%) (P<0.0001). These results indicate the
capability of MELK-in-30e to suppress metastasis of TNBC cells. Interestingly, MELK-In-30e (1μM) also reduced
the proportion of CD44+/CD24- cells (DMSO 75.2% vs MELK-In-30e 63.4%) and that of ALDH1+ cells (DMSO
12.3% vs MELK-In-30e 4.8%), suggesting the potential of MELK-In-30e to inhibit MELK-mediated cancer
stemness.
Conclusion: Together this study highlights the potential for MELK-In-30e, the second-generation MELK-specific
inhibitor, as an approach for TN-IBC targeted therapy. Further studies will be conducted to determine the
molecular mechanisms of MELK-In-30e and its therapeutic efficacy in a TN-IBC xenograft mouse model to pave
the way for this promising target to be translated for clinical use.
Keywords: Maternal embryonic leucine zipper kinase (MELK), TNBC, IBC, CSC
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Abstract number: 200
Role of CARM1 in Regulating Qki-mediated Brain Cholesterol Biosynthesis
Yannie Guo; Bioengineering; Rice University
Seula Shin; Cancer Biology; University of Texas MD Anderson Cancer Center
Jianji Chen; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Mark Bedford; Epigenetics and Molecular Carcinogenesis; University of Texas MD Anderson Cancer Center
Jian Hu; Cancer Biology; University of Texas MD Anderson Cancer Center
Background: Cholesterol-rich organs such as brain and eye lens depend extensively on de novo cholesterol
biosynthesis, in which quaking (Qki) serves as a master transcription regulator. During studies of brain and eye
lens early development, Qki deficient mice displayed myelination defects and cataracts caused by substantial
reduction of cholesterol biosynthesis [1,2]. Therefore, studying mechanisms underlying the enhancement of Qki
activity can aid in developing potential therapeutic targets to treat demyelinating diseases and cataracts.
However, the key upstream regulators of Qki’s role in gene transcription remain unclear. As Qki expression is
most abundant in the brain, we used neural stem cells (NSCs) to investigate epigenetic regulation of Qkimediated cholesterol biosynthesis. One class of epigenetic regulators, protein arginine methyl transferases
(PRMTs), is known to regulate gene expression through methylation of transcription regulators. Previous human
PRMT interactome mapping showed that PRMT4 – also known as CARM1 – interacts with Qki [3]. However, how
this interaction affects Qki’s role in regulating cholesterol biosynthesis is not well understood. We hypothesize that
Qki methylation by CARM1 downregulates the gene expression of Qki-mediated cholesterol biosynthesis.
Methods: For Qki methylation assay, recombinant wild type and arginine mutant Qki proteins were purified. The
in vitro methylation reactions containing these Qki proteins, CARM1, and S-adenosyl-L-[methyl-3H]-methionine
(SAM) were followed by gel electrophoresis and radiolabeled film exposure. The effect of CARM1 inhibition on
Qki activity was investigated using NSC culture treated with TP-064, a CARM1 specific inhibitor. The protein
expressions of Qki targets (Hmgcs1, Hmgcr, and Fdps) were analyzed using immunoblotting. To further test how
putative CARM1 methylation sites on Qki affect gene expression of Qki targets, we plan to generate NSCs
bearing Qki plasmids mutated on these arginine residues using lentiviral transfection system.
Results: CARM1 directly methylates Qki specifically on its C-terminus domain by CARM1. We are in the process
of testing purified Qki proteins with mutations on putative arginine methylation sites in in vitro methylation assay.
Inhibition of CARM1 leads to increased expression of cholesterol biosynthesis genes such as Hmgcs1, Hmgcr,
and Fdps in a dose-dependent manner, suggesting that CARM1 downregulates expressions of Qki target proteins
involved in cholesterol biosynthesis.
Conclusion: We found that methylation of Qki by CARM1 negatively regulates Qki-mediated cholesterol
biosynthesis. To continue this project, it would be valuable to use immunofluorescence co-staining of CARM1 and
markers for neural cells such as oligodendrocytes, astrocytes, and neurons in brain tissues to investigate the
types of cells that CARM1-Qki axis affects. References: [1]
Shin S, Zhou H, He C, Wei Y, Wang Y, Shingu
T, et al. Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency. Nat
Commun. 2021;12(1):3005. [2] Zhou X, Shin S, He C, Zhang Q, Rasband MN, Ren J, et al. Qki regulates
myelinogenesis through Srebp2-dependent cholesterol biosynthesis. Elife. 2021;10:e60467. [3] Weimann M,
Grossmann A, Woodsmith J, Özkan Z, Birth P, Meierhofer D, et al. A Y2H-seq approach defines the human
protein methyltransferase interactome. Nat Methods. 2013;10(4):339–42.
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Abstract number: 201
Radiopaque Polycaprolactone Scaffolds for Localized Drug Delivery
Amy Mu; Interventional Radiology; University of Texas MD Anderson Cancer Center
Jossana Damasco; Interventional Radiology; University of Texas MD Anderson Cancer Center
Joy Perez; Interventional Radiology; University of Texas MD Anderson Cancer Center
Marites Melancon; Interventional Radiology; University of Texas MD Anderson Cancer Center
Background: Failures in vascular interventions are often attributable to inflammation and the subsequent
development of neointimal hyperplasia (NIH). Localized delivery of drugs from polymeric devices may offer a
viable solution by limiting pathologic smooth muscle proliferation, while still allowing for endothelialization over
time. Simultaneously, the incorporation of nanoparticles can confer radiopacity to the device for easy monitoring
with imaging modalities. In this study, we fabricated polymeric polycaprolactone (PCL) nanofibrous scaffolds,
loaded with the immunosuppressant drug rapamycin and radiopaque agent bismuth nanoparticles (BiNP). These
polymeric scaffolds were evaluated in vitro for their efficacy as bioresorbable perivascular wraps.
Methods: Scaffolds were made by first dissolving PCL and BiNP at 12% w/v in a solvent mixture of 8:3 toluene to
methanol and then adding 40 mg/mL rapamycin. Solutions were electrospun into nanofibrous scaffolds using
Avecta’s Spraybase system under the following parameters: 0.5 mL volume, 20-gauge needle, 4 mL/hr feed rate,
10 cm spray distance, 12 kV voltage, and 18-gauge collector spun at 230 rpm. Tensile strength, radiopacity, and
drug-release kinetics of the scaffolds were monitored over the course of 7 weeks. To determine biocompatibility,
scaffolds were also tested for cell attachment and proliferation over the course of 7 days using mesenchymal
stem cells (MSCs), endothelial cell line RF-24, and smooth muscle cell line MOVAS.
Results: PCL scaffolds were shown to withstand maximum stress at 11.89 mPa. Micro-computed tomography
(mCT) imaging confirmed sufficient radiopacity of BiNP-PCL scaffolds was maintained over the 7-week period.
Proliferation of RF-24, MSCs, and MOVAS seeded on the PCL and BiNP-PCL scaffolds for 7 days showed no
significant toxicity to any of the cell lines tested. Rapamycin-loaded PCL and BiNP-PCL scaffolds both
demonstrated controlled and steadily increasing drug release over the course of 7 weeks. BiNP-PCL scaffolds
achieved a cumulative release of 15.22% based from the prepared solutions, while PCL scaffolds without BiNP
achieved a cumulative release of 17.85%.
Conclusion: Rapamycin-eluting BiNP-PCL scaffolds demonstrate sustained drug release, radiopacity, and in vitro
biocompatibility with endothelial and smooth muscle cells with minimal in vitro degradation over 7 weeks. As such,
these materials show promise as radiopaque, bioresorbable drug eluting perivascular wraps that can prevent
inflammation and formation of NIH which is critical for vascular access interventions.
Keywords: Radiopacity, Nanoparticles, Polymeric Scaffolds, Inflammation, Neointimal Hyperplasia
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Abstract number: 202
How Lactobacillus Iners Affects Cisplatin Sensitivity in Cervical Cancer Cell Lines
Noah Que; Radiation Oncology; University of Texas MD Anderson Cancer Center
Erica Lynn; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: In an attempt to better treatment methodology for cervical cancer patients who are at higher risk for
responding poorly to standard forms of treatment, research is being conducted to develop more targeted
approaches to improve chances of recovery. A potential factor worth investigating is the tumor microenvironment
and how the diversity or presence of particular bacterium may affect tumor response to treatment. Lactobacillus
Iners has been identified as a species that may hinder a successful response of a tumor to chemoradiation
treatment (CRT). This project seeks to investigate the validity of this specific effect.
Methods: In order to observe the effect Lactobacillus Iners has on the ability of cervical cancer cells to repair DNA
damage induced by treatment, two cervical cancer lines (HeLa and SiHa) will be treated with supernatants from
three different strains of Lactobacillus Iners and compared with both a full negative media control and a negative
bacteria control (Lactobacillus Crispatus, another species present in the vaginal microbiome that is not associated
with response to CRT). Damage will be prompted by applying varying doses of cisplatin treatment and DNA
damage repair assays will be performed to assess differences between cells treated with Lactobacillus Iners and
the various control groups. The primary aim will be to perform clonogenic survival assays that give a broad
indication of cells’ ability to recover after cisplatin treatment. Lactobacillus Iners supernatant is expected to
decrease the cancer cells’ sensitivity to treatment.
Results: Colony formation of cells exposed to Lactobacillus Iners exhibited a smaller percent survival in
comparison to cells treated with the negative media control, NYCIII. However, this slight trend is inconclusive as
overlapping standard deviations suggest that the presence of L. Iners may not have a significant effect on cell
recovery post treatment.
Conclusion: The sole presence of Lactobacillus Iners in the tumor microenvironment does not seem to have its
hypothesized effect on the ability of cells to successfully respond to standard chemoradiation treatment. Cells
treated with Lactobacillus Iners supernatant did not have a more pronounced recovery when compared to its
negative media control. Future experimentation is needed to compare the difference between the presence of
Lactobacillus Iners and Lactobacillus Crispatus in the tumor microbiome in addition to increased cell exposure to
higher doses of cisplatin.
Keywords: Lactobacillus Iners, Cisplatin, Cervical, Clonogenics
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Abstract number: 203
Obesity-associated immune environment changes in the endometrium as potential contributors to cancer
development
Alexandria Roy; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Brenda Melendez; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Nisha Gokul; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Elizabeth Whitley; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Karen Lu; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer Center
Melinda Yates; Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer
Center
Background: Endometrial cancer (EC) occurs in the lining of the uterus and is the most common gynecological
cancer in the United States with 66,570 new cases and 12,940 deaths expected this year. Contrary to other
cancer types, the incidence and mortality rate of EC continue to rise, paralleling the rise of obesity in the US.
Nearly 20% of women diagnosed with EC are obese or overweight. While the link between obesity and EC is well
established, the underlying molecular mechanism is not well understood. To better understand the relationship
between obesity and inflammation, we investigated the long-term effects of a high-fat diet on the immune
environment of normal endometrium.
Methods: To model lifestyle obesity, immunocompetent (C57BL/6J) mice were fed either a low-fat diet (n= 20,
10% fat) or high-fat diet (n= 20, 60% fat) starting from 8 weeks of age. At 12 months, reproductive organs were
collected. Hematoxylin and eosin staining was performed for pathology and estrus cycle assessment (n=11). The
epithelial cell height of the endometrial lumen was measured using the Aperio system by Leica. The uterine
immune environment was characterized using immunohistochemistry (IHC). IHC stainings were analyzed using
the Aperio system. Markers for NK cells (NK1.1), macrophages (F4/80), immune checkpoint (PD-1) and arginase1 (Arg-1) were evaluated. Two-sample unpaired t-test with Welch’s correction or Mann-Whitney test were used,
as appropriate, to determine differences between groups.
Results: After 12 months, mice fed with a HFD (n=5) had a 1.79-fold (p<0.0001) increase in weight compared to
mice fed with a LFD (n=6). HFD-mice showed signs of dysfunction in estrus cycling, with 80% found in the
metestrus phase and 20% in proestrus. In comparison, 16.67% of LFD-mice were in metestrus phase, 16.67% in
proestrus, 33.33% in estrus and 33.33% in diestrus. HFD-mice also had a 1.49-fold increase in epithelial lumen
cell height compared to LFD (p=0.025). We found no statistical difference in the infiltration rates of NK cells
(p=0.646), macrophages (p=0.191), or PD-1+ cells (p=0.536). There was a 2.86-fold increase in Arg-1+ cells
(p=0.049) in HFD-mice.
Conclusion: In our mouse model, long-term obesity did not affect infiltration rates of certain innate immune cells
such as NK cells or macrophages. However, increase in Arg-1+ cells in HFD-mice suggests that obesity may
induce immune cell dysfunction in normal endometrium which could potentially contribute to EC carcinogenesis.
Future studies will expand the immune cell characterization to a larger sample size and focus on the quantification
of Arg-1 producing cells.
Keywords: endometrial cancer, obesity, inflammation
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Abstract number: 204
Filipin Staining
Dylan Salters; Pain Management & Anesthesiology; University of Texas MD Anderson Cancer Center
Background: A complication that cancer victims and cancer treatment doctors are faced with today is suffering
from neuropathic pain associated with nerve compression. The initial part of my research consisted of becoming
familiar with TLR Pathways, which are “toll- like receptors” that play a critical role in immune responses.
Significant receptor channels that directly affect pain within the body consist of: TLR4, Nav1.7, Cav3.2, TRPV1,
HCN1, and HCN2. Despite channel activity being suppressed by an increase in membrane cholesterol, Na
channels and TRP channels which pain receptors travel through are inhibited by cholesterol depletion. The
reason rats are common vehicle used in this lab is to diagnose primary pain receptors and develop methods of
desensitizing those channels so that pain is subsided. Lipid rafts, which are partially composed of cholesterol are
vital to the research since they play a role in regulation trafficking and act as activation signals to other cells.
Based on cholesterol’s drastic effect on ion channel signaling, I formulated a proposal on how this phenomenon
could potentially combat neuropathic pain. My hypothesis states since paclitaxel induces an uptake in cholesterol,
this activity indirectly causes Filipin clusters to be visible under UV fluorescence due to presence of excited
neurons, which induces neuropathic pain in the ganglia of cancer patients.
Methods: Filipin slides were conducted under consecutive PBS “phage buffer washes”. Primary solution 1 was
formed while HCN1 was extracted from Human DRG samples who had cancer and exhibited either normal or
pain tissue. After slide application, filipin stains were mounted and prepared for microscopy and imaging under
FITC, TRITC, UV, and CY5 fluorescence. Roughly four images per slide were captured to give proper magnitude
of neuron activity, tissue presence, as well as fat. Blinded clinical experiment to some degree because I was
oblivious to some DRG samples being absent of pain receptor sensitivity, thus meaning no neuropathic pain
present.
Results: Of the four cancerous Human DRG stained for Filipin, normal tissue exhibited sparse neuron activity
while pain tissue exhibited an abundance of illuminated neurons under UV fluorescence. A good indicator of
neuropathic pain cells were large amounts of neurons in Patient 60, with minimal fat present, and three entire
columns of neurons in Patient 72 despite low FITC fluorescence—who likely was victim to extreme neuropathic
pain. Patient 64 appeared to signify no neuropathic pain as there was scarce activity and merely tissue presence
which was not to be mistaken for neuron activation. Lastly, patient 91 exhibited a left side dominance of neurons
only, which can be deduced to some neuropathic discomfort.
Conclusion: Based on the results achieved from the Filipin staining, bright illumination under UV imaging indicates
that Paclitaxel induces an uptake in cholesterol activity, which directly supports the hypothesis stated. One error
that persisted within the experimentation was the lack of correlation and regard to sexual dimorphism and ethnic
influence—two factors that could influence the results. Because we are only seven weeks into a ten-week
laboratory, this remains an open conclusion and require further tests and lab work to increase scientific validity.
Keywords: Chemotherapy, neuropathy, Cholesterol, filipin
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Abstract number: 205
Improving equity and access to Pathways fertility preservation decision aid
Adam Warren; Oncofertility Program; University of Texas MD Anderson Cancer Center
Terri Woodard; Oncofertility Program; University of Texas MD Anderson Cancer Center
Aubri Hoffman; Oncofertility Program; University of Texas MD Anderson Cancer Center
Background: According to the American Society of Clinical Oncologists women of reproductive age diagnosed
with cancer should be referred to a fertility specialist after diagnosis, however, less than 5% receive referrals and
only 12-26% of women recall discussing fertility before starting treatment. Financial barriers to fertility
preservation have been reduced in recent years but the barriers to awareness and access remain. Pathways: a
fertility preservation patient decision aid for women with cancer is a website that gives women the information,
support, and resources they need to be prepared to have discussions with their providers. Previous studies have
shown Pathways to be highly effective at reducing women’s decisional conflict, however, currently Pathways
exists only in English and is ready to be translated and adapted into the next two most spoken languages by MD
Anderson Cancer Center patients: Spanish and Arabic.
Methods: In collaboration with Strategic Communications, we will recruit up to 10 eligible patients and replicate
the video testimonial content available in the English version. Participants will be female cancer survivors from the
Oncofertility Clinic aged 18-45 years-old when diagnosed and able to read, speak, and understand both English
and either Spanish or Arabic. Participants will be asked testimonial discussion prompts and will respond in their
chosen language. Completed recorded interviews will be reviewed by the Bilingual Advisory Panel and added to
Pathways. These same participants will also be asked to review the Spanish and Arabic versions of Pathways
and use the Ottawa Acceptability Scale to rate acceptability.
Results: Given already established efficacy and acceptability of Pathways in English, and the fact we are only
translating the language and making minor adjustments for cultural acceptability, we expect for greater than 80%
of participants to give greater than 80% favorable responses which is the threshold for acceptability. Open-ended
questions are incorporated in the study so we also expect specific suggestions from participants that we will
review and incorporate into the website.
Conclusion: Spanish and Arabic versions of Pathways would not only address the need at MD Anderson to serve
non-English speakers, but would also increase dissemination of Pathways to other institutions, as is the plan as
studies on the platform continue. Successful adaptation of Pathways has further significance because studies
show compounded disparities for non-native English speakers because they are often not told about fertility
preservation options at all because patient information is only available in English.
Keywords: Oncofertility, Fertility, Decision-Aid
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Abstract number: 206
cGAS localization in the Nucleus in Response to Mitochondrial Stress
Eduardo Cardona-Rodriguez; N/A; University of Puerto Rico, Medical Sciences Campus
Sunetra Roy, P.h.D.; Cancer Biology; University of Texas MD Anderson Cancer Center
Eszter Dombi, P.h.D.; Cancer Biology; University of Texas MD Anderson Cancer Center
Katharina Schlacher, P.h.D.; Departmen of Cancer Biology; University of Texas MD Anderson Cancer Center
Background: Resected mitochondrial DNA (mtDNA) has emerged as a prominent inducer of inflammation through
the cGAS/STING pathway associated with chemoresistance. This pathway can also detect microbial and selfDNA in the cytosol and activate an immune and inflammatory response. In the nucleus, cGAS has an
independent role in replication fork protection, which is a genome stability pathway critical to chemoresistance.
We hypothesized that mitochondrial stress could activate cGAS in the nucleus making cancer cells resistant to
chemotherapy.
Methods: RAD51C mutant (R258H) and WT complemented cells were plated in 8-well slides and treated with
various mitochondrial damaging agents such as ddC and MtOx. These drugs were picked because both stress
the cell’s mitochondria using a different mechanism. MtOx stalls mitDNA replication by causing oxidative damage
after exposure to light and ddC stalls mitDNA replication by inhibition of chain elongation. After treatment, a SIRF
assay was performed, which detects proteins bound to nascent DNA, to visualize cGAS bound to replicating
nuclear DNA.
Results: We found a high number of cGAS-SIRF signals in cells treated with ddC and MtOx compared to when no
mitochondrial stress is induced. These signals peak at the 24-hour after damage. We also saw a high number of
signals localized in the nucleus, conmsistant with cGAS localization in the nucleus by mitochondrial stress. Cells
treated with aphidicolin show fewer PLA signals given that this drug affects DNA replication and not the
mitochondria. Rho cells demonstrated fewer PLA signals given that they lack mtDNA. Cells treated with a
combination of aphidicolin (APH), which stalls nuclear but not mitochondrial forks, show considerably less SIRF
signals.Rho cells which lack mtDNA lacked cGAS-SIRF signals. Cells treated with a combination of APH and
MtOx presented the most signals compared to those treated with APH or MtOx only.
Conclusion: The data suggests nuclear localization of cGAS is induced with mitochondrial stressors.
Keywords: cGAS/STING, RAD51C, mitDNA, inflammation, chemotherapy
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Abstract number: 207
Validation of a New and Efficient Version of an Assay for Galectin-3 Ligand, A Blood-Based Marker for
Colorectal Cancer
Paola Cruz Rivera; School of Medicine; The University of Puerto Rico School of Medicine
Robert Bresalier; Gastroenterology, Hepatology and Nutrition; University of Texas MD Anderson Cancer Center
Background: The Bresalier laboratory previously described galectin-3 ligand, an aberrantly glycosylated
haptoglobin glycoform produced by neoplastic cells in the colon, which is a promising blood-based biomarker for
detection of colorectal neoplasia. Due to its size and charge, sialic acid may cause cancer-associated
carbohydrate sequences to be masked or “cryptic”. As detection of galectin-3 ligand with labeled galectin-3 or the
lectin ECL requires prior removal of sialic acid, a mild acid hydrolysis has been used for removing sialic acid in a
mild acid-based assay, the standard assay for detecting the galectin-3 ligand. The laboratory also developed an
alternative assay for galectin-3 ligand which uses sialidase from Clostridium perfringens to remove sialic acid. Our
aim is to compare the standard mild acid-based assay to the new sialidase-based assay to determine its
effectiveness for detecting galectin-3 ligand in serum from normal individuals and those with colorectal neoplasia.
Methods: Serum samples from NCI’s Early Detection Research Network (n=279) were included in initial studies
using the mild acid- and the sialidase-based assays. A subset of 28 normals and 28 cancer specimens were
randomly chosen for examination in a blinded fashion after storage at -80oC for 4 to 6 years. A sandwich ELISA
for galectin-3 ligand was performed using anti-haptoglobin (captures both normal and cancer-associated
glycoforms) as catcher and biotinylated ECL lectin as probe (detects cancer-associated glycoform). Binding of
biotinyl-lectin in 96-well plates was detected with ABC and ABTS substrate, read at 405 nanometers.
Results: Both assays performed equally well in differentiating normal individuals from those with colorectal
neoplasia with a high degree of correlation. The ability to detect galectin-3 ligand and differentiate normal
individuals from those with cancer persisted after up to 6 years of storage of sera at -80oC with ROC curves
generating AUCs of 0.764 for the mild acid-based assay and 0.756 for the new sialidase-based assay. Galectin-3
ligand differentiated normal individuals from those with colorectal neoplasia (AUCs versus normal for original mild
acid-based assay include 0.80 for all cancers, 0.77 for stages I + II, 0.84 for stages II + IV, and 0.78 for advanced
adenomas).
Conclusions: The new sialidase-based assay is similar in performance to the original mild acid-based assay, and
offers the possibility of automation and multiplexing. Cancer-associated galectin-3 ligand is stable to long-term
storage in both assays.
Keywords: Colon cancer, biomarkers, glycoproteins, galectin-3
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Abstract number: 208
Quaking is an Essential Regulator of Mature Myelin Maintenance in Peripheral Nerves
Francisco A. Del Valle Díaz; N/A; University of Puerto Rico - Medical Sciences Campus
Joseph A. Barnes-Vélez; Cancer Biology; MD Anderson Cancer Center UTHealth Graduate School of Biomedical
Sciences University of Puerto Rico - Medical Sciences Campus
Jian Hu, PhD; Cancer Biology; University of Texas MD Anderson Cancer Center
Background: Myelin is a multilaminar lipid-rich membrane that ensheaths axons and is essential for proper nerve
signaling. It is synthesized and maintained by Schwann cells in the peripheral nervous system (PNS), and its
disruption is known to elicit neuropathies in the PNS that can extend to life-threatening conditions. For decades,
the consensus has been that myelin is metabolically inert with a low turnover rate. Recently, however, our lab
demonstrated that myelin lipids are highly dynamic in the brain with a rapid turnover enabled by Quaking (Qki)dependent lipid-synthesis pathways in brain-specific myelinating glia. Whether myelin lipids in the PNS exhibit
comparable metabolic activity and whether Schwann cells are dependent on similar pathways for myelin
maintenance remain unknown. Given the abundant expression of Qki in adult Schwann cells, we hypothesize that
similar to the central nervous system, Qki is a critical regulator of myelin lipid turnover and maintenance in the
PNS.
Methods: Using an inducible Cre-lox system, Qki was conditionally depleted in Schwann cells in MpzCreERT2/QkL/L mice (iCKO) starting at 8-10 weeks of age. The mTmG reporter allele was used to verify lineage
specificity for the Cre transgene. Following tamoxifen injection, iCKO mice were monitored for survival and signs
of peripheral neuropathy. Sciatic nerves were extracted and interrogated for myelin loss using electron
microscopy and immunohistochemistry. To elucidate Qki-dependent pathways in Schwann cells, RNA extracts
from sciatic nerves were submitted for RNA-sequencing.
Results: Immunofluorescence for GFP+ cells in Mpz-CreERT2/mTmG reporter mice demonstrated effective and
specific recombination in the PNS with minimal GFP reactivity detected in the brain. Relative to control littermates,
iCKO mice exhibited several signs of significant neuropathy, including impaired coordination, muscle weakness,
and abnormal hindlimb clasping starting as early as 2 weeks post-injection. Additionally, up to 40% of iCKO mice
developed severe paralysis and morbidity, surviving for less than 6 weeks post-injection. Electron microscopy
demonstrated extensive demyelination of the sciatic nerve. RNA-sequencing and assessment of myelin-markers
through immunohistochemical analysis are currently ongoing.
Conclusion: Our research demonstrated that Qki mediates an essential role in the maintenance of PNS myelin
and that disturbance to this system incites neuropathic manifestations comparable to those seen in severe
polyneuropathies. Ongoing RNA-sequencing analysis will help decipher the underlying mechanisms of Qkidependent myelin maintenance. Future directions include assessment of inflammatory infiltrates for further
characterization of quaking-related demyelination, and lipidomic assessment to interrogate the contribution of
myelin lipid metabolism in Schwann cells to myelin maintenance.
Keywords: Schwann cells, myelin-maintenance, neuropathy, Quaking
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Abstract number: 209
Mechanisms of HIF2-dependent crosstalk between macrophages and cancer-associated fibroblasts in
the pancreatic tumor microenvironment
Iancarlos Jimenez; N/A; University of Puerto Rico, Medical Sciences Campus
Carolina Garcia Garcia; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Yanqing Huang, PhD; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Cullen Taniguchi MD-PhD; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immunotherapy due to its extensive
desmoplastic stroma, which suppresses anti-tumor immunity and impairs drug delivery. One of the major
components and producers of stroma are alpha smooth muscle actin-expressing (SMA+) cancer-associated
fibroblasts (CAFs), which are often peritumoral and hypoxic. Our lab has previously shown that loss of the
hypoxia-inducible factor 2 (HIF2) in CAFs improves survival in a PDAC mouse model via a reduction in protumoral M2 macrophages. Here, we aimed to recapitulate and characterize this in vivo phenotype in an ex vivo
model using CAF lines with a conditionally null HIF2 allele.
Methods: We established CAF lines from a dual recombinase mouse model containing floxed Hif2α alleles and
αSMACreERT2/+ within autochthonous tumors driven by Pdx1-FlpO, FSF-KrasG12D/+, and Trp53 frt/frt via
outgrowth methods. Individual fibroblast clones were obtained, and genotypes were verified by PCR of genomic
DNA. Gene expression signature for CAF identity were verified with quantitative RT-PCR. Conditioned media
(CM) from CAFs was obtained from CAF with intact or abrogated HIF2 expression. Murine macrophages were
then incubated with this conditioned media to examine macrophage polarization markers as well as migration via
transwell assays.
Results: We verified αSMACreERT2-driven Hif2α recombination on isolated genomic DNA from all CAF clones.
Moreover, we found that most CAFs were enriched for fibroblast markers including Acta2 and Ctgf compared to
epithelial cell controls. Conversely, the CAF lines expressed low levels of the epithelial markers Epcam and Krt19.
Conditioned media from CAFs stimulated migration of murine macrophages, and the effect was abrogated with
the addition of PT2399, a clinical HIF2 inhibitor. Moreover, conditioned media from hypoxic CAFs upregulates
macrophage Arg1 expression and migration in a HIF2-dependent manner. Furthermore, PT2399 failed to reduce
macrophage polarization independently of CAF conditioned media.
Conclusion: Taken together, our results suggest that we have an ideal ex vivo CAF model, that recapitulates in
vivo CAF biology, to investigate the role of CAF HIF2 signaling in their crosstalk with immunosuppressive
macrophages. Additionally, HIF2 may dictate phenotypic changes in CAFs that promote the formation of one
functional CAF type over others. Furthermore, these CAFs lines can be used to study the HIF2-dependent
mechanisms that can contribute to the progression of PDAC in its hypoxic microenvironment, paving the way for
new therapeutic targets for this disease.
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Abstract number: 210
Elucidating the role of bacterial extracellular vesicles in the development of circulating microbiome
María A. Limardo-González; Medicine; University of Puerto Rico- Medical Sciences Campus, San Juan, PR
Golnaz Morad DDS, PhD; Surgical Oncology; University of Texas MD Anderson Cancer Center, Houston, TX
Jennifer Wargo MD, MMSc; Surgical Oncology; University of Texas MD Anderson Cancer Center, Houston, TX
Background: Microbiota is an ecosystem consisting of trillions of microorganisms including bacteria, viruses, and
fungi, predominantly residing in the gut and on epidermal and mucosal surfaces. Microbiota has a broad impact
on systemic immunity and different pathologies including cancer. Understanding the mechanisms underlying
these effects will facilitate the discovery of novel preventive, diagnostic, and therapeutic strategies. Recent
studies have identified bacterial genes circulating within the blood, which was previously considered a sterile
environment. However, the mechanism(s) underlying the development of this circulating microbiome and its
association with the gut microbiota is unknown. Extracellular vesicles (EVs) are nanoscale vesicles that originate
from various cell types including bacteria and can transfer proteins and genetic material to provoke changes in
other cells via intercellular communication. Given the ability of bacteria to transfer their genetic material through
bacterial EVs (BEVs) to distant sites, we sought to address the hypothesis that BEVs released from the gut
microbiota into the blood can contribute to the development of the circulating microbiome.
Methods: To evaluate the association between the circulating and gut microbiome, C57BL6 mice were treated
with a broad-spectrum antibiotic regimen to deplete the gut microbiota, and bacterial gene load in blood and stool
were measured through 16S rRNA gene PCR. To determine the presence of BEVs in the blood, BEVs were
isolated from human plasma samples through size exclusion chromatography followed by density gradient
ultracentrifugation. BEVs were characterized by electron microscopy and nanoparticle tracking analysis. Lastly,
to understand the contribution of BEVs to the circulating microbiome, EV-containing and EV-depleted fractions of
the plasma were evaluated for bacterial genes by PCR.
Results: Consistent with our hypothesis, gut microbiome depletion in mice led to an increase in the circulating
bacterial gene load, suggesting a relationship between the gut and the circulating microbiomes. BEVs were
present in plasma, demonstrating a round shape with a lipid bilayer membrane and were within a size range of
30-150 nm. Bacterial genes were detected in both EV-containing and EV-depleted fractions of the plasma,
suggesting that BEVs contribute to the circulating microbiome but are not the only source of bacterial genes found
in the blood.
Conclusion: Our findings support the hypothesis that BEVs can contribute to the development of the circulating
microbiome. Ongoing studies in the Wargo Lab will evaluate the correlation of bacterial gene signatures in BEVs
and the circulating microbiome and will elucidate the mechanistic role of the circulating microbiome in cancer.
Keywords: Microbiome; circulating microbiota; extracellular vesicles.
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Abstract number: 211
Live Long and Prosper: Assessing Cervical Cancer Incidence in the United States (2001-2018) to Address
Geographical Health Disparities in Women
Kevin J. Ortiz-Ramos; Biostatistics and Epidemiology; University of Puerto Rico, Medical Sciences Campus
Haluk Damgacioglu; Management, Policy and Community Health; UTHealth School of Public Health
Ashish A. Deshmukh; Management, Policy and Community Health; UTHealth School of Public Health
Elizabeth Y. Chiao; Epidemiology; University of Texas MD Anderson Cancer Center
Background: Cervical cancer is the fourth most common gynecologic malignancy affecting women in the world
and one of the leading causes of death worldwide. Although preventable, thanks to guidelines by national
recognized professional organizations, new trends in incidence and burden have been observed indicating
possible geographical health disparities in the continental United States (US). We evaluated the trajectory of the
incidence and burden of cervical cancer by state and birth year to conduct a retrospective cohort study of the
incidence of cervical cancer across the US from 2001 through 2018 using the SEER dataset.
Methods: Cervix malignancies were filtered using diagnosis codes (C53.0-C53.9) and morphology type ICD-O-3
codes (8010-8671, 8940-8941). All cases were microscopically confirmed. Age-adjusted incidence rates per
100,000 persons were calculated using SEER*Stat software. The Jointpoint Regression Program (version 4.9.0.0)
was used to compare temporal trends by states and to estimate annual percent change. The National Cancer
Institute Age Period Cohort online tool was used to fit birth cohort models with 1954 as the reference year (1953
for Nevada).
Results: From 2001 to 2018, 218,660 cervical cancer cases were diagnosed in the US. The incidence of cervical
cancer per 100,000 person-years has decreased from 8.7 (95% CI, 8.5-8.8) in 2001 to 7.1 (95% CI, 7.0-7.3) in
2018. However, a significant rise in the incidence of cervical cancer has been noted in Indiana, Kentucky, and
Nevada. Cervical cancer incidence declined significantly in Nevada from 2001 to 2011 (APC= -2.8%, 95% CI= 0.9% to -3.1%) and then significantly increased from 2011 to 2018 (APC= 5.2%, 95% CI= 0.7% to 9.8%).
Likewise, in Kentucky, cervical cancer incidence decreased significantly from 2001 to 2008 (APC= -3.4%, 95%
CI= -6.5% to -0.2%) and then significantly increased from 2008 to 2017 (APC= 1.8%, 95% CI= -0.2% to 3.8%).
Indiana had a similar trend having a significant decrease in cervical cancer incidence from 2001 to 2008 (APC= 2.9%, 95% CI= -4.7% to -1.1%) and a significant increase from 2008 to 2018 (APC= 1.2%, 95% CI= 0.1% to
2.4%).
Conclusion: This study reveals possible geographical health disparities, which might indicate the underutilization
of preventative care in these states and have implications for future cancer prevention campaigns. Additional
research is needed to assess screening and vaccination rates by state to determine cervical cancer incidence
trends.
Keywords: Cervical cancer, Epidemiology, Health disparities, Cancer prevention
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Abstract number: 213
Immune Monitoring in Cancer Patients with COVID-19
Ismael Perez-Martinez; N/A; University of Puerto Rico - Medical Sciences Campus
Yuwei Zhang Ph.D.; Immunology; University of Texas MD Anderson Cancer Center
Fei Duan Ph.D.; Immunology; University of Texas MD Anderson Cancer Center
Padmanee Sharma M.D., Ph.D.; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer
Center
Background: Coronavirus disease 2019 (COVID-19) infected people exhibit different clinical manifestations and
disease severities, which can range from asymptomatic to critically ill. This can be even more challenging when
managing vulnerable populations, such as cancer patients. They are often in a systemic immunosuppressive
state due to tumor growth or the effects of anti-cancer treatments. Additionally, cancer patients may face
increased risk of exposure to COVID-19 following frequent hospital visits. The relationship between immune
responses to COVID-19 and severity in cancer patients is not clear. This emphasizes the importance of
understanding the immune profile in cancer patients with COVID-19, which will help risk management and
effective treatments for these patients.
Methods: Longitudinal blood samples of normal donors (ND, n=15) and cancer patients with COVID-19 (n=155)
were collected post COVID-19 diagnosis. Human peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll from whole blood samples. Cells were stained with 41 intracellular and extracellular antibodies for
phenotyping of immune cells. Data were obtained using Cytometry by Time of Flight (CyTOF). Unsupervised
Clustering analysis of CyTOF data was performed on CD45+ cells using FlowSOM algorithm. Cell frequencies
were analyzed with Prism 8 to compare ND, mild COVID-19 and severe COVID-19 patients at each time point.
Results: Unsupervised clustering of CyTOF analysis of 155 COVID-19 cancer patients identified a subset of
CD45RA+CD86+ monocytes. The frequency of this monocyte subset was significantly lower in cancer patients
with severe COVID-19, compared to patients with mild COVID-19. Notably, while the frequency of this subset of
monocytes barely showed changes over the time in cancer patient with mild COVID-19, it decreased dramatically
during the first week of diagnosis and remained low, for at least five weeks, in patients with severe COVID-19.
Conclusion: Lower frequency of CD45RA+CD86+ monocyte was associated with severity of COVID-19 in patients
with cancer. This subset of monocytes might have an anti-inflammatory or protective role in cancer patients with
COVID-19.
Keywords: COVID-19, CyTOF, immune profiling, cancer, monocytes
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Abstract number: 214
Evaluating BET inhibition as a potential therapy in PRC2 mutant malignant peripheral nerve sheath
tumors
Francisco Rivera Emanuelli; N/A; University of Puerto Rico, Medical Sciences Campus
Sharon M. Landers; Surgical Oncology; University of Texas, M.D Anderson Cancer Center
Veena Kochat; Surgical Oncology; University of Texas, M.D Anderson Cancer Center
Angela D. Bhalla; Surgical Oncology; University of Texas, M.D Anderson Cancer Center
Keila E. Torres MD, PhD; Surgical Oncology; University of Texas, M.D Anderson Cancer Center
Background: Sarcomas are rare cancers that can arise from soft tissues. Malignant Peripheral Nerve Sheath
Tumors (MPNST) are sarcomas that develop from the nervous system. MPNSTs are difficult to study since
sarcoma is 1% of cancer and MPNST is only 3-5%. \MPNSTs are usually fatal because of their high recurrence
and metastasis rates and their resistance to chemotherapy and radiation therapy. Another characteristic is
mutations of the Polycomb Repressive Complex 2 (PRC2) is present in 70 to 92% of MPNSTs. These PRC2
mutants lack the necessary molecular machinery to methylate histone 3 at lysine 27 and therefore cannot silence
certain genes. Ongoing work has shown that in addition to having lower levels of methylation, PRC2 mutants also
have higher levels of acetylation. Therefore, we would like to test the effectiveness of BRD4 inhibition in MPNST
cell lines of varying PRC2 status.
Methods: Immunohistochemistry (IHC)- Used to observe the presence of methylation marks, acetylation marks,
and general histological characteristics of MPNST tumor models. Proliferation assay (MTS)- We used MTS to see
which PRC2 mutant cell lines are susceptible to BRD4 inhibition by I-BET 762 treatment and IC50. Western blot
(WB)- Western blots were used to verify tumor and cell line status for proteins of interest. Cell Culture- Cell lines
were cultured in xx DMEM supplemented with 10% FBS, drug was added on day 1 and changed on day 4.
Results: We established that two new models of MPNST developed in the lab, MPNST0910 is a PRC2 mutant,
and MPNST 0764B which is a PRC2 wild type. The Western blot results demonstrate that the PRC2 mutant
model lacks SUZ12 and H3K27me3. We confirmed the status of SUZ12 in the M724 (Knock-Out), M007 (Under
expressed), S462 (Overexpressed) cell lines through Western blot showing that the modifications of SUZ 12
expressions in the cell lines were working as intended. Afterwards we performed an MTS proliferation assay for
the modified cell lines and their unmodified controls.
Conclusion: PRC2 mutants respond better to I-BET 762 treatment possibly due to their heightened acetylation
levels which sensitize the cell lines to BRD4 inhibition. The inhibition of BRD4 could lead to a decrease of
unwanted transcription and cell death in the MPNST cells. Cell lines could be tested in vivo to generate mouse
models for more generalizable findings.
Keywords: MPNST, PRC2, I-BET 762, Sarcoma, Epigenetics
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Abstract number: 215
A LONG NON-CODING ULTRACOSNERVED RNA CONTRIBUTION TO CLL
Natalia Roa Vidal; School of Medicine; University of Puerto Rico Medical Science Campus
Swati Mohapatra; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
George Calin; Translational Molecular Pathology; University of Texas MD Anderson Cancer Center
Background: Ultra-conserved regions (UCRs) are genomic segments highly conserved between orthologous
regions of human, rat and mouse. Many UCRs are transcribed into noncoding RNAs which have been seen to
have altered expression in cancer. A previous study, Ultraconserved Regions Encoding ncRNAs Are Altered in
Human Leukemias and Carcinomas (Calin et al., 2007), found 19 UCRs significantly involved in Chronic
Lymphocytic Leukemia (CLL). CLL is the most frequent leukemia in adults that is characterized by expansion of
B-cells. An earlier functional screening in our lab led to identify an oncogenic UCR named UC. 206 which was
found to be transcribed into a novel long noncoding RNA, TRUC-16, found to be overexpressed in CLL patients
and harbor a mutation G324A. TRUC-16 overexpression has shown decreased p16 protein levels. Subsequently
decreased p16 relates to decreased CDK inhibition and increased E2F expression which promotes proliferation.
Methods: To further characterize the effects of TRUC-16 in CLL the lab developed B-cells specific overexpressed
TRUC-16 mice, both wildtype and G324A mutated with CRISPR-CAS9. Dissection was performed on mice 6 to 9
months old from both the cohorts along with age-matched wildtype littermates, and organs were harvested.
Protein and RNA was isolated from spleen, liver, kidney, lungs, brain and lymph nodes, B-cells were also isolated
from the spleens through negative selection. qPCR was performed to check the TRUC-16 expression levels in the
above-mentioned organs. Immunoblotting was performed using p16, E2F and GAPDH antibodies.
Results: Real-time quantitative PCR showed overexpression of TRUC-16 in spleens, B-cells and lymph nodes of
heterozygous and homozygous transgenic insert wildtype and insert mutant mice. Meanwhile, immunoblotting
showed decreased p16 expression but increased E2F expression in spleens in B-cells and lymph nodes of
heterozygous and homozygous transgenic insert wildtype and insert mutant mice.
Conclusion: CLL is an uncurable disease with a heterogenous course and variable progression. Identification of
new parameters and targets such as TRUC-16 brings new opportunities for therapy and better understanding of
the transformation into aggressive lymphoma known as Richter Syndrome.
Keywords: CLL, UCRs, long non-coding RNA, TRUC-16
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Abstract number: 216
Knocking in CD32 and CD64 into Double Knockout U937 Cells
Valeria Rodríguez-González; Medical Science Campus; University of Puerto Rico
Rolando Vedia; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer Center
Sijie Lu; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer Center
Anna Sergueeva; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer Center
Jeffrey Molldrem; Hematopoietic Biology and Malignancy; University of Texas MD Anderson Cancer Center
Background: Acute Myeloid Leukemia (AML) is a clonal disorder of the hematopoietic progenitor cells. In elderly
patients, chemotherapy cures less than 10%, due to their low resistance to the treatment. 8F4, a T cell receptor
(TCR)-like monoclonal antibody (mAb), has been developed to potentially treat patients and has demonstrated a
high activity against AML cells, including HLA-A2 transfected U937 cell line, in vivo. 8F4 binds with high affinity to
a conformational epitope of PR1/HLA-A2 via its Fab region. Previous experiments have demonstrated that 8F4
also binds to Fc Receptors (FcR) on AML cells. Binding of AMLs through 8F4 via the Fab region and FcR is
hypothesized to be the cause of their mutual destruction, aka fratricide. To further validate the role of
FcγRI(CD64) and FcγRII(CD32) in the mechanism of action of 8F4, double knockout (DKO) cells were previously
developed through CRISPR/Cas9 to test AML cells’ susceptibility to 8F4.
Methods: To exclude a possible off-target effect of CRISPR/Cas9 KO and verify that the observed phenotype is
due to gene knockout, FcγRI or FcγRII cDNAs were re-expressed into the DKO U937 cells. Human CD32 and
CD64 sequences were engineered into plasmids and transformed into a bacterial system to upscale plasmid
production. Plasmids independently bearing CD32 and CD64 were sequence verified and packaged into retroviral
expression systems which were then transduced into DKO U937 cells. Flow cytometry was used to confirm the
efficiency of the transduction. For isolation of transduced cells, cell sorting was done.
Results: Flow cytometry staining demonstrated that 24% of CD64-transfected cells were CD64 positive and 3.4%
of CD32-transfected cells were CD32 positive on day two of the transduction. Flow cytometry also exhibited that
0.87% of CD32/CD64-transfected cells were CD32/CD64 positive, 12.7% of CD32/CD64-transfected cells were
CD64 positive and 2% of CD32/CD64-transfected cells were CD32 positive on day two of transduction. Cells were
sorted on day three post-transduction and positive cells were collected for expansion.
Conclusion: Successful transductions produced DKO U937 cells that expressed CD32, CD64 and CD32/CD64.
Ongoing in vivo experiments have preliminarily demonstrated that DKO U937 cells exhibit a decreased
susceptibility to 8F4. Further experiments must be done in vivo to test transduced DKO U937 cells’ susceptibility
to 8F4 in comparison to DKO U937 cells. These experiments could disregard errors in CRISPR/Cas 9 and could
further validate FcR’s (FcγRI and FcγRII) role in the mechanism of action of 8F4.
Keywords: Acute Myeloid Leukemia, 8F4, FcγRI, FcγRII
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Abstract number: 217
The characterization of a novel cSCC mouse model to advance immunotherapy treatments
Alanis Enid Rodriguez-Rosario; University of Puerto Rico-Bayamon
Roberto Rangel, Ph.D.; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Jeffrey N. Myers, M.D., Ph.D.; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Background: Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common malignancy diagnosed
in Caucasians with an incidence of about one million cases per year. TP53 and p16 are the most common
mutated genes in cSCC and head and neck SCC (HNSCC). Previous studies have shown that patients with
cSCC with p53 and p16 mutations have lower survival rates. There are currently no syngeneic mouse preclinical
models to accelerate the efficacy of immunotherapy combinations to treat cSCC. Our laboratory has generated
several genetically engineered mouse models (GEMMs) containing tissue-specific p53 and p16 gene mutations,
both genes are the main cancer drivers of cSCC in human patients. Recently, we have immortalized three murine
cSCC cell lines (cSCC-5690, cSCC-8006, and cSCC-8271) derived from spontaneous skin tumors from GEMMs.
The aim of this study is to characterize and establish a new syngeneic preclinical mouse model of cSCC.
Methods: First, western blots and quantitative PCR validated the expression of p53 and p16 in the three cell lines.
To evaluate the stem cell population and tumorigenicity of the cell lines, we performed sphere and soft agar
assays, respectively. Then, we evaluated the chemosensitivity with cisplatin through clonogenic assays. To
further study the tumorigenicity of cells, we evaluated in vivo tumor growth on C57BL/6J immunocompetent mice
by injecting subcutaneously the tumor cell lines.
Results: Interestingly, all cell lines expressed different levels of keratin 14, but cSCC 5690 and 8006 expressed
high levels of mesenchymal markers as well genes related to oncogenic pathways. The cell line cSCC-5690
expressing mutant p53 R172H with p16 gene deletion, showed an enhanced sphere, and colony tumor formation
and both tumorigenic cell lines (cSCC-5690, 8006) showed different sensitivity to cisplatin treatment. We
observed a higher tumor growth rate with cSCC-5690 compared to cSCC-8006, while with cSCC-8271 there was
no tumor growth. Next, immunohistochemistry studies demonstrated that both cSCC-5690 and 8006 tumors
expressed vimentin but only cSCC-5690 expressed keratin-14 protein. Briefly, quantitative PCR of cytokines and
immune checkpoints inhibitors (ICIs) revealed markers related to tumor-associated macrophages type 2 and
immunosuppressive cytokines. Finally, to evaluate the anti-tumor efficiency of anti-PD1, anti-CD47 antibodies,
and STING-agonist, we selected the most aggressive syngeneic tumor model (cSCC-5690). We observed a
significant tumor respond only to STING agonist (c-di-GMP) which acts to activate the innate and adaptive
immune response.
Conclusion: Thus, we have characterized and established a new mouse model of cSCC as a relevant platform for
preclinical studies.
Keywords: Cutaneous squamous cell carcinoma, p53, p16, immunotherapy, mouse model
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Abstract number: 218
Spatial temporal map of glioma cancer cells
Angelica Romero-Vega; Neuro-Oncology; University of Texas MD Anderson Cancer Center
John F. de Groot; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Veerakumar Balasubramaniyan; Neuro-Oncology; University of Texas MD Anderson Cancer Center
Background: Glioblastoma (GBM) is the most aggressive, lethal brain tumor in adults. GBM tumor is highly
heterogeneous and disease progression is attributed to several factors including the tumor microenvironment,
perturbation in signaling pathways, metabolic alterations, and epigenetic modifications. The objectives of this
study is to determine the cellular phenotype and expression levels of ETV5, an important glial lineage
transcription factor that plays a role in tumor growth. In addition, we also aimed to determine the signaling
pathways affected by MEK inhibition (indirectly blocking ETV5) in mouse xenograft tumors.
Methods: We performed single antibody IHC analysis on FFPE human glioma tissue sections using specific
antibodies directed against ETV5, SOX9, CD44, pERK, GFAP and OLIG2. We standardized single antibody IHC
in mouse xenografts tumors to determine the expression of pERK, pAKT and Ki-67. Lastly, we examined marker
expression in mouse xenograft tumors treated with and without MEK inhibitor trametinib.
Results: Conditions for optimal staining were determined for most cellular phenotype markers such as SOX9 and
ETV5 as EGFR positive cancer cell markers, general astrocyte marker GFAP. To discriminate between glioma
molecular subtypes, we optimized olig2 as proneural and CD44 as mesenchymal . Furthermore, we optimized the
staining conditions for proliferative and signaling markers for mouse xenograft tumors. Ongoing studies will
establish the use of these antibodies to develop a panel of cellular phenotype markers to determine the cellular
composition of glioma tissues.
Conclusion: The development and standardization of a panel of multiplex immunofluorescence techniques allows
us to construct a spatial and temporal map of glioma cancer cells and their cellular composition in a single tissue
section.
Keywords: Glioblastoma, Neural Stem Cells, immunohistochemistry, multiplex immunofluorescence
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Abstract number: 219
Targeting dopamine signaling on NK cells to enhance cytolysis of DIPGs
Yarelis Roque Reyes; University of Puerto Rico, Rio Piedras Campus
Juan Bournat; Pediatrics; University of Texas MD Anderson Cancer Center
Donghang Cheng; Pediatrics; University of Texas MD Anderson Cancer Center
Vidya Gopalakrishnan; Pediatrics; University of Texas MD Anderson Cancer Center
Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive CNS tumor and the leading cause of
pediatric brain cancer-related deaths. Increasing evidence has established that natural killer (NK) cells have
cytotoxicity against DIPG cells in vitro. Importantly, dopamine (DA) has an inhibitory effect on human NK cells. DA
binds and signals through the dopamine receptor 2 (DRD2). ONC201 is a DRD2 antagonist that has the potential
to block DA-mediated neural and immune cell signaling. In previous studies, ONC201 was cytotoxic to DIPG cells
in vitro and in vivo, and is currently in clinical trials for DIPG. This knowledge led us to hypothesize that ONC201
might reverse DA’s inhibitory effect on NK cells and thus reduce DIPG progression.
Methods: We examined whether DA inhibits NK cell-mediated DIPG cell cytotoxicity. Human NK cells (NK-18 or
NK-19) were pre-treated with varying concentrations of DA for 48 hours and then were co-cultured with a panel of
vehicle- of ONC201-pre-treated DIPG cells (DIPG-4, 7, and 13). We then evaluated NK cell cytotoxicity using
DIPG-luciferase (LUC) reporter lines.
Results: We observed that pre-treatment with DA in NK cells caused a 1.5- to 6-fold increase in DIPG-LUC
bioluminescence, indicating that DA reduced DIPG cell cytolysis by NK cells. We also found that DIPG-LUC cells
had an ONC201-dependent reduction in bioluminescence, potentially indicating a direct cytotoxic effect on DIPG
cells. Therefore, ongoing experiments will evaluate if the combination treatment of ONC201 with DA in NK cells
would reverse the inhibitory effect of DA on NK cell-mediated cytolysis of DIPG cells.
Conclusion: Our data confirm that DA has an inhibitory effect on the cytolytic capacity of patient-derived NK cells.
Future directions include exposing NK cells simultaneously to ONC201 and DA to assess their cytolytic activity
against DIPGs and testing this combination in mouse models. Further research into DA-mediated NK and DIPG
cell crosstalk could provide additional mechanistic insight that could guide ONC201-based combinatorial
therapies with NK cell infusions in DIPG and strengthen its therapeutic potential.
Keywords: DIPGs, NK cells, ONC201, Dopamine, DRD2
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Abstract number: 220
Cephalothin Analogs Inhibit GD3 Synthase and Target GD2+ Breast Cancer Stem-like Cells in Triple
Negative Breast Cancer
Zoe Arvanitis; Leukemia Department; Augustana College; University of Texas MD Anderson Cancer Center
Appalaraju Jaggupilli Ph.D.; Leukemia Department; University of Texas MD Anderson Cancer Center
Vivek Anand Ph.D.; Leukemia Department; University of Texas MD Anderson Cancer Center
V.L. Battula Ph.D.; Leukemia Department; University of Texas MD Anderson Cancer Center
Background: Annually, around 44,000 women die from developing breast cancer. Triple negative breast cancer
(TNBC) is the most aggressive among all breast cancer subtypes. Breast cancer stem-like cells (BCSC) comprise
a small section of the primary tumor, which are highly tumorigenic, metastatic, and resistant to conventional
cancer treatments. However, there are no specific drugs that target BCSCs. Our lab identified that Ganglioside
GD2 expression identifies BCSCs in TNBC cell lines and patient samples. Moreover, we found that GD3
Synthase (GD3S), an enzyme that produces the precursor molecule (GD3) for GD2 biosynthesis is highly
upregulated in GD2+ cells. We have reported that genetic or pharmacological inhibition of GD3S expression in
TNBC cells significantly inhibited their stem-cell function and inhibited tumor growth in vivo. Here, we hypothesize
that targeting GD3S enzyme activity using small-molecule inhibitors inhibits tumor growth and metastasis in
TNBC.
Methods: Using a structural homology modeling approach, we identified cephalothin (an FDA-approved
antimicrobial agent) as a potential inhibitor of GD3S. TNBC cell lines including MDA-MB-231 and SUM159 cells
were treated with cephalothin and its analogs at different concentrations for 72hrs and GD2 expression was
analyzed by flow cytometry. Moreover, TNBC cell lines treated with cephalothin and its analogs were subjected to
BCSC functional assay including mammosphere assay. Finally to determine effect of cephalothin and its
derivatives on GD3S mRNA expression, we performed real-time qRT-PCR.
Results: Treatment with cephalothin and its structural analog (Cefixime) decreased the percentage of GD2
expression by 2- to 6-fold within 72hrs in a concentration dependent manner in SUM159 and MDA-MB-231 cells.
In addition, cephalothin and cefixime inhibited mammosphere formation in SUM159 and MDA-MB-231 cells by
10-fold. To demonstrate that cephalothin and cefixime inhibit GD2 biosynthesis by inhibiting GD3S activity, but not
by inhibiting mRNA expression, we treated SUM159 and MDA-MB-231 cells with these compounds at different
concentrations and measured mRNA expression of GD3S by qRT-PCR. We found no significant effect on the
gene expression of GD3S in both cell lines tested. Next to further enhance the GD3S inhibitory activity, we
identified 6 additional cephalothin analogs (A1-A6) and tested their effect on GD2 expression in TNBC cell lines.
Interestingly A3 and A4 compounds significantly inhibited GD2 expression in a concentration dependent manner
suggesting that these compounds inhibit GD3S enzyme activity.
Conclusion: Collectively, this data indicates that cephalothin is a potent lead compound inhibiting GD3S enzyme
activity. Functional characterization of its structural analogs is currently ongoing.
Keywords: GD2, GD3 Synthase (GD3S), Cephalothin, Breast Cancer Stem-like Cells (BCSC)
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Abstract number: 221
RE1 Silencing Transcription Factor (REST) and DNA Methyltransferase 1 (DNMT1) Interaction in
Medulloblastoma
Jouwana Bzal; Departments of Pediatrics; Augustana College
Tara Dobson; Departments of Pediatrics; University of Texas MD Anderson Cancer Center
Jyothishmathi Swaminathan; Departments of Pediatrics; University of Texas MD Anderson Cancer Center
Shinji Maegawa; Departments of Pediatrics; University of Texas MD Anderson Cancer Center
Vidya Gopalakrishnan; Pediatrics and Molecular and Cellular Oncology; University of Texas MD Anderson Cancer
Center
Background: Medulloblastoma (MB) is the most common tumor of the central nervous system in children with
high metastasis rate and ineffective therapies. We previously found the upregulated expression of the RE1
Silencing Transcription Factor (REST), a repressor of neurogenesis, to be associated with poor survival in
patients with Sonic Hedgehog (SHH) subgroup of MBs. Through a loss of function screen, we identified DNA
methyltransferase 1 (DNMT1) as a high-priority candidate that is critical for the viability of tumor cells in the
context of REST elevation in SHH-MBs. Thus far, the mechanism of REST-mediated tumorigenesis has not been
well understood.
Methods: To detect the effects of REST upregulation on DNA methylation status and the overall survival, we
analyzed a publicly available database and divided the SHH-MBs into REST-high and REST-low patients.
Volcano plots were generated to identify differential methylation between low- and high-REST expressing human
medulloblastoma tumors in different genomic locations. Locations that were hypermethylated in high-REST cells
in CpG island (CGI) sites at the promoter were chosen for pathway analysis and further analysis using DNA
methylation and RNA-seq data in mouse neural progenitors from RESTTG and wild type (WT) mice and for
validation at target genes by bisulfite pyrosequencing assay and quantitative reverse transcription PCR in three
SHH-MB cell lines (DAOY, UW426 and UW228).
Results: We observed SHH-MBs patients that had high REST levels were associated with lower overall survival
rate. Volcano plots of publicly available DNA methylation datasets of human MBs revealed genome-wide
differences in DNA methylation in the context of REST elevation. We found that CpG sites in CGIs to be more
hypermethylated when REST levels are high than in shore, shelf and non-CGI (4.3% vs 3.9% and 1.7%
respectively; p<0.05; DNA met diff> |10%|. The pathway analysis performed on hypermethylated genes in CGIs at
the promoter showed their involvement in cancer.
Conclusion: REST elevation in SHH-MBs is associated with poor survival. REST elevation promotes tumor cell
proliferation and the knockdown of DNMT1 blocks REST-dependent cell growth. Compared to tumors with low
REST expression, samples with higher REST expression exhibit hypermethylation at the promoter, gene body
and intergenic locations. Hypermethylated genes play a role in development and differentiation processes. The
consequence of these differences to REST-dependent cell proliferation are being investigated.
Keywords: REST, DNMT1, Medulloblastoma, DNA methylation.
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Abstract number: 222
Quality vs Quantity of Social Relationships in Ovarian Cancer Survival
Jeffrey Flinchem; Behavioral Science; University of Texas MD Anderson Cancer Center
Susan Lutgendorf; Psychological and Brain Sciences, Obstetrics and Gynecology, Urology, and Holden
Comprehensive Cancer Center; University of Iowa
Bryan Fellman; Biostatistics; University of Texas MD Anderson Cancer Center
Anil Sood; Gynecologic Oncology, Cancer Biology, and Center for RNA Interference and Noncoding RNA;
University of Texas MD Anderson Cancer Center
Eileen Shinn; Behavioral Science; University of Texas MD Anderson Cancer Center
Background: Ovarian cancer is the most lethal gynecologic cancer, with 5-year relative survival of 48% across all
stages. Anecdotally, cancer patients tend to attribute survival to strong social support (SS). However, research
examining the impact of SS on mortality in cancer patients is conflicting: out of 27 prospective studies, 15
reported a positive impact. Inconsistency in the measurement of SS may contribute to the field’s lack of
consensus. SS measures tend to focus on either perceived quality of social relationships or the quantity of
available SS resources. Just one study has assessed the impact of SS on mortality in ovarian cancer. Our study
investigated whether SS affects survival in ovarian cancer, controlling for demographic and disease covariates.
Methods: Newly-diagnosed patients with stage III-IV ovarian/ peritoneal cancer were eligible if they were at least
18 years old, spoke English, had performance status < 3, and were in their first 2 cycles of chemotherapy. SS was
measured using the Medical Outcomes Study (MOS) Social Support Survey. All-cause survival, disease
information, smoking and alcohol use were abstracted from medical records. Cox proportional hazards regression
analysis adjusted for age, stage, histological grade, cytoreductive status, smoking, and alcohol use.
Results: Eighty-seven ovarian cancer patients had complete data for this study. The median follow-up was 36.9
months. MOS SS did not independently predict survival outcome in univariate or multivariate regression analyses
(Hazard ratio [HR], 0.99; 95% CI, 0.97- 1.01; p=0.203). Age, lifetime smoking history of > 1 packs of cigarettes,
alcohol use at time of diagnosis, and suboptimal debulking status were univariately associated with survival. In a
multivariable model including age, alcohol use, smoking history, grade and suboptimal debulking, smoking and
debulking status remained significant (HR, 0.45; 0.25- 0.71; p=0.006; HR, 1.97; 1.13-3.42; =0.016, respectively).
Conclusion: Suboptimal debulking and smoking history, but not SS, were associated with overall survival. The
field’s 15 positive studies tended to characterize SS in terms of quantity, e.g., network size, number of confidants,
and/or number of group memberships, whereas the MOS measures patients’ perceived quality of social support.
Additionally, when comparing our study to positive SS studies (median sample size= 185), our sample size was
much smaller. Unlike most of the positive studies, our study limited inclusion to late-stage disease and carefully
characterized factors known to impact survival. These factors, along with an emphasis on network size, may
prove important for future research in this area.
Keywords: epithelial ovarian cancer, social support, survival, newly diagnosed
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Abstract number: 223
Role of REST in altering PRMT5 expression in Chronic pain
DiAngelo Gonzalez; Genetics; UT MD Anderson Cancer Center
Biji Chatterjee; Genetics; UT MD Anderson Cancer Center
Ashok Subedi; Genetics; UT MD Anderson Cancer Center
Sadhan Majumder; Genetics; UT MD Anderson Cancer Center
Background: Chronic neuropathic pain originates from the damaged sensory nervous system and remains a
major clinical challenge despite multiple clinical and preclinical studies. The existing knowledge suggests an
altered expression of pain associated genes (PAGs) following nerve injury and involves epigenetic modifications
in dorsal root ganglion (DRG). The protein arginine methyltransferase 5 (PRMT5) is predominantly expressed in
neuronal cells and it catalyzes arginine methylation of histones and many non-histone proteins. However, it
remains unclear if such arginine methylation events also occur after nerve injury and pain sensation. Earlier
reports suggest an increased expression of the repressor element1–silencing transcription factor (REST) in DRGs
after nerve injury which contributes to transcriptional repression of various genes, resulting in chronic pain
development. Given that PRMT5 is a potential REST target, we hypothesized that chronic pain involves RESTinduced silencing of the PRMT5 mechanism. As a first step of this mechanism, we aimed to explore the alteration
in the PRMT5 expression with concurrent role of REST in the mouse DRG after nerve injury.
Methods: The L3-L4 DRGs and spinal cord tissues obtained from wild type (WT) and REST conditional knock out
(cKO) mice before and after spared nerve injury (SNI) on the left hind limb were used for quantitative real time
PCR (qPCR) and western blotting. The REST binding site on the mouse PRMT5 promoter was predicted by
MatInspector (Genomatix).
Results: The initial qPCR results suggested an above 3.5-fold increase of REST mRNA with concurrent reduction
in PRMT5 mRNA levels in the SNI compared to uninjured DRGs. The reduction of PRMT5 expression with
increased levels of REST in DRGs after SNI was also confirmed by Western Blotting. In the REST cKO mice, SNI
did not affect PRMT5 protein level, suggesting a role of REST in regulating PRMT5. The predicted binding site of
REST in the mouse PRMT5 promoter was located at the -369 to -339 region proximal to the transcription start
site.
Conclusion: Our findings suggest a potential role of REST in negatively regulating PRMT5 expression in the
DRGs after SNI. As a potential binding site is observed in the promoter, further validation of its binding is needed.
Further, elucidating the role of PRMT5 downregulation in epigenetic alteration of PRGs could unravel a novel
mechanism of arginine methylation in chronic pain development.
Keywords: Chronic pain; Epigenetics; DRG; PRMT5; REST
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Abstract number: 224
Addressing Existential Suffering and a Loss of Self in Terminal Cancer Patients: A Phenomenological
Approach
Rosalie Looijaard; Integrated Ethics; Augustana College
Background: A terminal cancer diagnosis can cause existential suffering, a loss of self, and anxiety towards
death. Every patient experiences these symptoms differently, but it inhibits their quality of life and can prevent
them from finding peace with death. In caring for the whole person, it is important to ensure that these symptoms
are addressed to facilitate a good death. Establishing an ontology of terminal illness can help identify what these
patients need.
Methods: A literature review was conducted to identify qualitative studies regarding patient experiences with
existential suffering, a loss of self, and anxiety towards death. These sources were analyzed through a
Heideggerian phenomenological approach that centers the patient experience from a first-person perspective to
establish the ontology of living with illness. This ontology was used to deduce strategies for alleviating existential
suffering and identify implications for clinical practice. Conversations were also held with healthcare providers to
identify how existential suffering appears in patients and what practical solutions have proven effective.
Results: One of the most fundamental and impactful symptoms of existential suffering is a loss of self. While
every patient is different, it was found that preventative and psychosocial measures were consistently effective in
building resilience to existential suffering. Encouraging projects that help connect the patient to values and social
roles and helping the patient focus on quality over quantity at the end of life was also found to help bolster a
sense of self and facilitate a good death.
Conclusion: While a good death is different for every patient, much can be done preventatively to ease existential
suffering and anxiety toward death by helping patients maintain meaning and regain their sense of identity. In
order to implement this in clinical practice, providers must practice realism and clinical empathy. Home hospice
should be encouraged where appropriate, and non-beneficial treatment should be discouraged. The inevitability of
death should be acknowledged, and patients should receive resources to cope and the opportunity to reinvent
themselves to regain their sense of self. Above all, an understanding of the existential state of each patient’s
relationship with illness can help identify further palliative measures specific to them.
Keywords: End of life, phenomenology, terminal diagnosis, death, existential suffering
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Abstract number: 225
Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study
Lisa Lowenstein; Health Services Research; University of Texas MD Anderson Cancer Center
Van Thanh T Nguyen; Health Services; Augustana College
Background: Active surveillance is a treatment plan that is recommended for men with low-risk prostate cancer.
However, for older patients whose cancer has not progressed, it is important to understand the needs of patients,
caregivers, and clinicians on when to have shared decision-making about when to de-escalate the intensity of
monitoring for cancer progression.
Methods: Mixed methods study of older active surveillance patients and their caregivers recruited from MD
Anderson Cancer Center. Administered surveys assess the patient level of regret regarding active surveillance,
uncertainty about the prostate cancer diagnosis, and fear of progression. After the survey, patients and caregivers
will be asked if they are willing to participate in a semi-structured interview to evaluate the patient's responses on
the three factors above.
Results: 21 men with an average age of 70 and 4 years on active surveillance possessed varied opinions
regarding their decisions on active surveillance. The reasons for all the patients to start on active surveillance are
varied. However, the majority of patients and caregivers show the unwillingness to stop active surveillance
completely and would like to continue on active surveillance as long as they can. Patients and caregivers indicate
that they would only be willing to reduce the frequency of active surveillance either with the recommendation of
clinicians or fail health conditions and old age that forbid them from living independently.
Conclusion: A decision aid is essential in facilitating a shared conversation among patients, caregivers, and
clinicians on when to de-escalate the intensity of monitoring for cancer progression. This shared conversation
about modifying the active surveillance protocol in the absence of disease progression would help improve the
quality of cancer care and maintain the quality of life for many older men with low-risk prostate cancer and their
caregivers.
Keywords: low-risk prostate cancer, shared decision making
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Abstract number: 226
Development and characterization of STAT3 Y705H mutated breast cancer lines for genetic validation of
the mechanism of action of STAT3 inhibitor TTI-101
Matt MacArthur; Infectious Diseases, Infection Control and Employee Health; University of Texas MD Anderson
Cancer Center
Background: STAT3 signaling has been shown to play a role in almost all aspects of cancer biology. There is a
large amount of clinical and preclinical data supporting STAT3 as a therapeutic target. TTI-101, currently in phase
1 clinical trials, is a STAT3 inhibitor that competitively inhibits STAT3 activation. It directly targets the Yphosphopeptide binding pocket within the SH2 domain of STAT3, thus blocking key steps in its activation
process. In this work, we generated and characterized the breast cancer cell line MDA-MB-468 to be used in the
validation of the mechanism of action of TTI-101. Hypothesis: Our primary hypothesis is that the genetic
inactivation of STAT3 by mutating the key Y705 residue to H705 will elicit changes in the transcriptome of breast
cancer cell lines similar to those observed with STAT3 inhibitor TTI-101.
Methods: 15 MDA MB breast cancer cells were cultured in DMEM, 10% FBS at 37°C with an atmosphere of 5%
CO2. Protein expression was analyzed with western blots as well as Luminex assay. Immunofluorescence
microscopy was used to visualize nuclear translocation. qPCR was utilized to measure the effect of TTI-101
exposure on the expression of STAT3 dependent genes: CCL2, IL8, MUC1, SOC3, and Cyclin D1.
Results: Three different types of MDA MB 468 cell lines were generated: STAT3 knockout (KO), STAT3 Y705H
mutants and STAT3 WT controls. We show the absence of STAT3 protein expression in knockout clones and lack
of response to IL6 stimulation in STAT3 Y705H edited cells. Optimal conditions for IL6 stimulation and TTI-101
treatment were determined. The results show that maximum STAT3 phosphorylation was achieved after 15min of
100ng/ml IL6 treatment. TTI-101 at a concentration of 33uM was shown to reduce IL6 dependent phosphorylation
by more than 90% after 4 hours of pretreatment. Importantly, levels of tSTAT3 and β-actin remained unchanged
at this concentration. Immunofluorescence data showed that the Y705H mutation inhibited STAT3 nuclear
translocation in response to IL6 stimulation, showing that nuclear translocation is dependent on phosphorylation
at Y705.
Conclusion: Analysis of MDA MB 468 cells subjected to CRISPR-Cas9 editing show successful knockouts and
mutation at the Y705 site. Optimal experimental treatment conditions of IL6 exposure and TTI-101 concentration
were identified. These conditions will guide future experiments on MDA MB 468 cells. Y705H mutants were found
to behave similarly to those treated with TTI-101 in the presence of IL6 stimulation. Although, future experiments
are needed to determine the exact changes ongoing in the cells.
Keywords: STAT3, TTI-101, IL6, tumorigenesis, CRISPR-Cas9
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Abstract number: 227
Identification of CD74 Isoforms that Complex with CD44
Kalli Majewski; Melanoma Oncology; Augustana College
Suhendan Ekmekcioglu; Melanoma Oncology; University of Texas MD Anderson Cancer Center
Yasunari Fukuda; Melanoma Oncology; University of Texas MD Anderson Cancer Center
Background: The protein CD74 (Cluster of Differentiation 74) is a transmembrane molecule that acts as a
receptor for macrophage migration inhibitory factor (MIF). The interaction between MIF and CD74 initiates
oncogenic signaling in cancer to control the growth of a tumor. CD74 alone does not function to signal these
pathways but does so with help of others including CD44, a non-kinase transmembrane glycoprotein, acting as a
transducing co-receptor. Although, since CD74 has several isoforms, it is unclear which isoform makes this
complex with CD44. In this proposal, we aim to identify the CD74 isoform that makes the complex with CD44 to
initiate the oncogenic signaling pathways.
Methods: Our group has previously shown that autocrine MIF-CD74 interactions in response to interferon-γ (IFNγ) induced oncogenic pAKT pathway and tumor progression in cutaneous melanoma. However, we have not
shown whether the interaction between MIF and CD74/CD44 binding induces the oncogenic signaling. In our
current study we used malignant melanoma cell lines, A-375 and SB2. Induction of the cell surface CD74 was
done by using IFN-γ. We have shown upregulation of CD74 expression under IFN-γ stimulation by real-time
quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting for p33, p35, and
p41 isoforms of CD74. In addition, our flow cytometry analyses revealed that IFN-γ induced cell surface CD74
expression. We have then incubated our cells with recombinant MIF in different time points of 0, 10, 30, and 120
minutes, with or without IFN-γ to test the difference on pAKT expression which regulated by cell surface CD74.
We have then prepared the lysates from the cell cultures from previously decided time points experiments to
analyze pAKT expression by western blotting.
Results: Our results show that when cells are pre-treated with IFN-γ to induce CD74 expression, pAKT
expression was remarkably upregulated by recombinant MIF. Then the change in AKT signaling will be evaluated
with knocking down of CD74 and CD44 (as single and double) by RNA interference.
Conclusion: Finally, in order to reveal the exact isoform of CD74 that complexes with CD44, we will perform coimmunoprecipitation followed by western blot analyses. By completing this final step, we hope to reveal IFN-γ’s
differential effect on MIF/CD74/CD44 complex to regulate inflammation in tumor microenvironment.
Keywords: Protein CD74 isoforms, interferon-γ (IFN-γ), pAKT pathway, tumor microenvironment.
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Abstract number: 228
Development and validation of a high-throughput 3D cytotoxicity assay to predict CAR T cell efficacy in
solid tumors
Sara Mazrimas; Pediatrics; University of Texas MD Anderson Cancer Center
Amer Najjar, PhD; Pediatrics; University of Texas MD Anderson Cancer Center
Background: Chimeric antigen receptor (CAR) T cell therapy has been shown to be highly effective against
leukemia and lymphoma. However, its efficacy in treating solid tumors has been limited due to several factors that
include tumor antigen heterogeneity, immunosuppressive microenvironments, and nutritional constraints.
Therefore, development of effective cellular therapies for solid tumors requires adjuvants that can help T cells
overcome these intrinsic barriers. Rapid determination of these factors requires high-throughput screening of
combinatorial libraries of cytokines and checkpoint inhibitors in a representative in vitro setting that can accurately
predict CAR T cell function in solid tumors. Spheroids are three-dimensional (3D) cell cultures that can effectively
mimic solid tumor microenvironments. To this end, we have utilized a rapid 3D bioprinting method to produce a
large array of spheroids in 384-well plates to rapidly identify optimal conditions that maximize CAR T cell
infiltration and cytotoxicity in a 3D setting.
Methods: We used magnetic 3D bioprinting to produce a large array of spheroids composed of U87 glioma cells
expressing green fluorescent protein (GFP) in a 384-well plate. CAR T cells, labeled with Hoechst stain for
fluorescent visualization, were added to the spheroid cultures in the presence of cytokines and checkpoint
inhibitors to determine optimal combinations for T cell function. Time-lapse fluorescence microscopy was used to
visualize and measure tumor spheroid viability (GFP intensity) and T cell infiltration by acquiring images over a
48-hour time period.
Results: Spheroids created by this magnetic bioprinting method were highly consistent in density and size,
averaging about 525 µm in diameter. Clear infiltration of the glioma spheroids by CAR T cells was revealed and
quantified over time in the blue channel (405 nm) within regions-of-interest (ROI) drawn around the perimeter of
the spheroids. Correlative glioma cell death was simultaneously measured within the same ROIs in the green
fluorescence channel (525 nm). Plotting fluorescence intensities of both channels provided an objective and
visual measure of CAR T cell infiltration coupled with a gradual and correlative anti-tumor response.
Conclusion: This high-throughput assay can facilitate large-scale screening of therapeutic configurations that
optimize CAR T cell cytotoxicity in a 3D environment that mimics solid tumors. The use of a fluorescent
microscope for image acquisition in the assay provides an object quantification of T cell infiltration and anti-tumor
response at microscopic and macroscopic levels. The degree of T cell infiltration can be further stratified by
creating intra-tumoral zones to assess depth of infiltration over time.
Keywords: CAR T cell therapy, magnetic 3D bioprinting, spheroid, cytotoxicity assay, fluorescence microscopy
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Abstract number: 229
Preliminary Reliability and Literature Review of the Dynamic Imaging Grade of Swallowing Toxicity
(DIGEST) Method in a Multi-Site Study
Brooklynn Schelling; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Carly Barbon; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Katherine Hutcheson; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Background: Dysphagia, or difficulty swallowing, is common after treatment for head and neck cancer (HNC) and
requires reliable use of clinical measures to characterize and grade swallowing impairment. The Dynamic Imaging
Grade of Swallowing Toxicity (DIGEST) is a clinician-rated method used to grade the safety and efficiency of the
pharyngeal stage of the swallow. DIGEST was developed for use in HNC patients with validity and reliability
established among trained raters at the developing institution, but the reliability of the tool in external raters is
uncertain. The aims of the current study are (1) to review and summarize reliability of DIGEST in the published
literature and (2) explore rater reliability, patterns of use, and training needs among speech-language pathologists
(SLPs).
Methods: For Aim 1, a literature review was completed to obtain reliability information on DIGEST published
between 2016 and 2021. 20 articles reporting use of DIGEST were identified, among which, 8 articles including
reliability statistics on DIGEST were summarized according to Cohen’s conventions. For Aim 2, 18 SLPs from
seven institutions blindly DIGEST graded three rounds of 20 re-keyed MBS videos. Rounds one and two
established a baseline and intra-rater reliability, and the third round determined the efficacy of a written training
manual after self-study. 18 raters completed a 27-item user survey after the round three training condition.
Preliminary results were descriptively summarized.
Results: Within the current literature, inter-rater reliability ranged from substantial to almost perfect (k = 0.67-1.0),
while intra-rater reliability was almost perfect (k = 0.82-1.0). These studies took place at various institutions
among HNC patients as well as other populations, such as ALS. Survey results have demonstrated that 94%
(17/18) raters found the DIGEST manual helpful or very helpful in their grading of pharyngeal dysphagia. The
median of overall rater confidence increased significantly from 7 at baseline to 9 after reading the manual.
Conclusion: Clinical measures must be reliable for health professionals to obtain a clear representation of
swallowing ability. Increasing diagnostic ability and easing communication among providers should improve
patient outcomes. Early data show promise that provider training may be useful to ensure consistency and
reliable implementation of DIGEST among SLP clinical users.
Keywords: dysphagia, DIGEST, swallowing measures, patient outcomes
Program Affiliation: University Outreach– Augustana College

239

Abstract number: 230
Synthesis and purification of cyclic peptide autophagy inhibitor 4B1W and its target LC3a
Iva Vucic; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Brian J. Engel; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Joshua P. Gray; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Steven W. Millward; Cancer Systems Imaging; University of Texas MD Anderson Cancer Center
Background: Autophagy is a conserved cellular process involving the recycling of damaged or misfolded proteins
and organelles. It serves as a survival mechanism that can lead to treatment resistance in a variety of cancer
types. Finding ways to decrease treatment resistance by inhibiting autophagy remains challenging, since unique
cellular contexts dictate whether an induction or inhibition of autophagy leads to tumor survival. Within autophagy,
LC3 proteins serve as scaffolding components during the formation of autophagosomes, and thus are appropriate
targets for inhibiting autophagy. Accordingly, LC3 proteins have been widely studied and used as molecular
biomarkers for autophagocytotic activity. Previously, we developed a small cyclic peptide inhibitor, 4B1W, that
binds strongly to recombinant GST-LC3a, a protein variant of LC3 bound to glutathione S-transferase. Thus, we
focused our current efforts on large-scale synthesis of 4B1W and recombinant GST-LC3a to be used in future in
vivo experiments.
Methods: Linear 4B1W was synthesized via solid phase synthesis (SPPS) on an automated peptide synthesizer,
deprotected and cleaved with trifluoroacetic acid, purified via HPLC, then identified via mass spectrometry.
Cyclization of linear 4B1W was performed with disuccinimidyl glutarate followed by HPLC and mass
spectrometry. Recombinant GST-LC3a was induced in BL21 E. coli cells with isopropylthio-β-galactoside (IPTG)
for 3 hours at 37°C. Cells were lysed with lysozyme and tip sonication. GST-LC3a was purified by affinity
chromatography using glutathione agarose resin. SDS-PAGE analysis determined GST-LC3a purity and BCA
assay quantified GST-LC3a yield.
Results: Linear 4B1W peptide was synthesized at a 6.46%-25.7% yield. Mass spectrometry confirmed product
identity at 1450.0 [M+H]+ (expected 1449.70 [M+H]+). Cyclization reactions and purifications are ongoing.
Recombinant GST-LC3a protein was purified at 11.6 mg/L E. coli culture. SDS-PAGE gel analysis confirmed a
band of the expected 49 kDa size.
Conclusion: 4B1W peptide and recombinant GST-LC3a proteins were produced at high yield and purity. Cyclic
4B1W will be incorporated into in vitro cell assays and mouse models to determine the utility of autophagy
inhibition in these assays. Recombinant GST-LC3a protein will be used as a target for further improvement of
peptide inhibitors of autophagy.
Keywords: autophagy, LC3a, solid phase peptide synthesis, protein purification
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University Outreach– Baylor University
Abstract number: 231
Determination of Optimal Cell and Plasmid Concentration for Transfection of I-SceI in DR-GFP Cells
Madison Ambrose; Clinical Cancer Prevention; Baylor University and University of Texas MD Anderson Cancer
Center
Xueqian Cheng, Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center; Clinical Cancer
Prevention; University of Texas MD Anderson Cancer Center
Lulu Wang; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Guang Peng; Clinical Cancer Prevention; University of Texas MD Anderson Cancer Center
Background: Cancer development is known to have both environmental and genetic factors. There are several
ways DNA can be damaged and mutated, including nucleotide mismatch and thymine dimers. However, instead
of repairing the mutations, cancer treatments, such as chemotherapy, induce more DNA damage to force the cell
into apoptosis. One way the DNA damaged is created is through interstrand cross-links (ICLs). ICLs are a result
of two separate strands of DNA becoming connected by a covalent bond. These ICLs are cytotoxic, causing
several metabolic processes and DNA replication to be halted, eventually resulting in apoptosis. When ICLs occur
in the cell, homologous recombination (HR) is employed by the cell as a repair mechanism to alleviate the cell of
ICLs. HR repairs double-stranded DNA damage by using the identical sister chromatid as a template for repair.
Due to the effectiveness of HR, drugs are being developed to inhibit HR, therefore keeping the ICLs and helping
to make chemotherapy treatment more effective.
Methods: In the following study, direct repeat green fluorescent protein (DR-GFP) was used to measure the HR
rate in cells. Specifically, the I-SceI plasmid was used to transfect DR-GFP cells. Various cell concentrations and
plasmid concentrations were used to determine the most effective transfection rate.
Results: The results indicated that a cell concentration of 1x10^5 cells/mL produced a transfection rate of 14.0%.
Further, at the concentration of 1x10^5 cell/mL, the 1.5ug of plasmid produced a transfection rate of 16.1%.
Conclusion: This information can be used in the future to better understand the elements of the HR repair
mechanism and help determine the correct drug concentrations for HR inhibitors for cancer treatment.
Keywords: interstrand cross-links, homologous recombination, I-SceI, flow cytometry, transfection
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Abstract number: 232
Clonal Interdependency Between Wild-type and Mutant p53 AML Abrogates BCL-2 Inhibitor-Mediated
Apoptosis Induction.
Atreyu Balasundaram; Leukemia, Molecular Hematology Therapy Andreeff Lab; University of Texas MD
Anderson Cancer Center
Yuki Nishida; Leukemia, Molecular Hematology Therapy Andreeff Lab; University of Texas MD Anderson Cancer
Center
Background: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. In most patients, the
exact triggering event(s) is unknown, but a genetic origin is strongly implicated. Of the genetic factors, around
13% of AML patients have abnormal p53 mutant expression which results in the arrest of normal myeloid
differentiation and proliferation. These cause the most devastating form of AML irrespective of mutation
variances. Of these, there are 2 key p53 mutations, namely the KO and the R248Q mutation. Recently
Venetoclax (VEN), a potent and selective Bcl-2 inhibitor that disrupts the dysfunctional apoptotic pathway of AML
has been approved by the FDA. Although many patients with AML have a response to induction chemotherapy
relapse represents the major cause of treatment failure. Here, we describe the concept of inter-clonal dependency
between wild-type and key p53 mutations under the stress-induced conditions of Venetoclax treatments.
Methods: We used AML MOLM-13 cell line for all experiments. The wild-type (WT) cells and mutant were
transfected with GFP and BFP respectively. First, we treated WT-GFP, KO-BFP, and 248-BFP cells alone and
then mixed in an 8:2 (WT: Mutant) ratio with 100 nM of VEN over 9 days. Concurrently we used the supernatant
of these and cultured fresh cells with them to record levels of cells death. We used Annexin V/ PI staining to
analyze the growth/death of cells using flow cytometry methods in intervals of 3 days
Results: After 3 days of treatment the wild-type, KO, and R248Q cells cultured alone had worse survival (p <
0.005) than those in the co-cultures. Interestingly, by day 6 the difference in survival we had observed on day 3
was less significant (p > 0.05) The WT-cells cultured with WT-KO and WT-248 supernatant showed lower levels
of Annexin-V, a marker of cell death, than those cultured in the WT-Only supernatant. Similarly, KO and 248 cells
cultured with the co-culture supernatant showed lower levels of cell death when compared to being cultured in
KO-only and 248-only supernatant respectively.
Conclusion: Our observations of the cocultures indicate that mutants confer some drug resistance to WT cells and
that the supernatant plays a role in communication. In the clinical perspective, it indicates the consequences of
administering non-lethal doses of the drug on treatment success and relapse. Future studies could look toward
using RNA sequencing of the cells treated to determine if there are changes to major apoptotic pathways.
Keywords: AML, p53, Clonal-Interdependency, BCL2 Inhibitor, Apoptosis
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Abstract number: 233
Synthesis and Analysis of novel PROTACs to Degrade YAP1 Proteins
Sudili Fernando; Genomic Medicine; University of Texas MD Anderson Cancer Center
Praveen Barrodia; Genomic Medicine; University of Texas MD Anderson Cancer Center
Kunal Rai; Genomic Medicine; University of Texas MD Anderson Cancer Center
Background: YAP1 is a transcriptional co-activator and downstream effector in the Hippo signaling pathway.
YAP1 is a highly potent oncogene that plays a major role tumorigenesis and metastasis in various types of
cancer. This gene is overexpressed in 10% of all cancers and seen in many solid tumors either by genetic copy
number amplification or by unknown pathways. While a well-known oncogene, the YAP1 protein does not have
targetable enzymatic activity, making novel blocking strategies essential for potential treatment. Since YAP1 has
been shown to be regulated by proteasomal mediated degradation, we reasoned that it may be possible to
identify chemicals that promote YAP1 degradation. To achieve this, we performed a high-throughput chemical
screen to identify compounds/PROTACs that could degrade YAP1 proteins.
Methods: To identify small molecules that could selectively degrade YAP1 proteins, we used OVCAR5-mCherry
cells stably expressing YAP1-GFP. The ChemBridge drug library (~ 50,000 compounds) was consulted and the
efficacy of selected drug was determined at three different concentrations (1μM, 3μM, and 10μM). Drugs that
reduce the expression of YAP1-GFP compared to untreated/DMSO treated cells were further analyzed by
western blotting. We then synthesized SAR products/PROTACs and verified the activity of these compounds in
several YAP1 dependent or independent cell lines through western blot analysis. The cells were treated with each
compound individually at 20nM and 100nM concentrations for 4- and 24-hour periods, after which cells were lysed
and probed with YAP1 antibody. The band intensity of each target was quantified using ImageJ in comparison to
the DMSO treated cells. To further understand the effects of these drugs, the inhibition of cell growth after
treatment was evaluated by live cell monitoring using the IncuCyte ZOOM System.
Results: Primary screening followed by secondary validation identified about 32 molecules with potential reduction
of GFP levels tagged to the YAP1 protein. Some hits were further validated by YAP1 western blot which
suggested that some of the identified compounds degraded YAP1. We saw reduction in YAP1 protein at 20nM in
YAP1 dependent and independent cell lines after 4 hours of treatment with PROTACs CIDD-0150877, CIDD0162266, CIDD-0162288 and CIDD-0162289. Simultaneously, we saw reduced proliferation of YAP1-dependent
cell lines in vitro, suggesting functional activity.
Conclusion: Our data reveal novel molecules and chemical structure that can significantly reduce YAP1 protein
levels and can be potentially useful agents to target YAP1-dependent cancers.
Keywords: YAP1, Cancer, Inhibitor, PROTAC
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Abstract number: 234
Continuing Provider Education through Project ECHO (Extension for Community Healthcare Outcomes)
Sarah Jones; Gynecologic Oncology; University of Texas MD Anderson Cancer Center
Background: Project ECHO (Extension for Community Healthcare Outcomes) is a telecounseling and
telementoring partnership between MD Anderson Cancer Center specialists and providers in rural and
underserved communities with the goal of demonopolizing knowledge. With an ever-changing demographic of
ECHO participants from various health professions, surveys of participant satisfaction were used to gauge the
effectiveness of the current educational program. Areas tested by the survey included educational opportunities,
overall program satisfaction, and the ease of translating information learned into practice.
Methods: Surveys of provider satisfaction were conducted through REDCap (Research Electronic Data Capture)
and demographics were analyzed through SAS. Responses to provider education prompts were then analyzed
across professional designation (MD, PA, RN, APRN, or Other). Significant findings were then discussed, leading
to the development of additional educational materials.
Results: Differences in professional training proved to be statistically significant in relation to provider confidence
and overall satisfaction with the ECHO program, with the greatest professional differences being seen in the
responses to questions regarding previous education.
Conclusion: Additional educational opportunities on case presentations and gynecologic terminology will be
offered to ECHO participants to further improve participant satisfaction and participation. These materials would
serve to reduce educational disparities throughout all the allied health professions represented at these events.
Keywords: Gynecologic Oncology, Continuing Education, Provider Training, Project ECHO
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Abstract number: 235
Anti-tumoral activity of Acetogenins derived from Soursop Fruit (Annona muricata L.) in High-Grade
Serous Ovarian Cancer
Efigenia Montalvo-González; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Paola Amero; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Andrés E. León-Fernández; Integral Laboratory of Food Research; National Technological Institute of Mexico
Yasmin M. Attia; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Abdelrahman M. Elsayed; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Roberto Cárdenas-Zuñiga; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Roger T. Neuberger; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Gabriela Aguilar-Hernández; Integral Laboratory of Food Research; National Technological Institute of Mexico
Luis G. Zepeda-Vallejo; Departamento de Química Orgánica; Escuela Nacional de Ciencias Biológicas-IPN
Gabriel López-Berestein; Experimental Therapeutics; University of Texas at MD Anderson Cancer Center
Cristian Rodríguez-Aguayo; Experimental Therapeutics; University of Texas MD Anderson Cancer Center
High-grade serous ovarian cancer (HGSOC) constitutes the most prevalent malignancies of ovarian carcinoma.
Despite improvements in treatment outcomes in the last several years, patients relapse at a high rate, in turn
leading to drug resistance. There is a growing need for novel therapeutic strategies for ovarian cancer care, with
many interested in traditional natural dietary compounds. In this study, we characterized the biological and
therapeutic effect of acetogenins (ACGs) in HGSOC.
We isolated and characterized ACGs derived from soursop fruit pulp. HGSOC (OCAR5 and OVCAR8) cell lines
were used for in vitro and in vivo experiments using ACGs alone or in combination with cisplatin to determine their
therapeutic potential. Assessments of cytotoxicity, cell proliferation, invasion, migration and apoptosis were
conducted by functional assays, showing that ACGs inhibited cell growth, migration, and the expression of
NOTCH1, as well as reduced the phosphorylation of ERK1/2, caused cell cycle arrest, and promoted apoptosis in
vitro.
In vivo, ACGs significantly reduced tumor burden in OVCAR5 and OVCAR8 xenograft murine models compared
to the control. The greatest reduction, however, was observed when ACGs were used in combination with
cisplatin. These changes correlated with increased apoptosis as well as a reduction of angiogenesis and tumor
cell proliferation.
These findings provide new insights into the anti-tumoral effect of ACGs, associated with significant downregulation of the Notch signaling pathway, posing ACGs as an attractive therapeutic approach in HGSOC.
Keywords: Ovarian cancer, Acetogenins, Notch1, Annona muricata L.
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Abstract number: 236
Topoisomerase II inhibition in human papillomavirus-positive oral and vaginal cancers induces antigenspecific immune activation via pyroptosis
Elizabeth Reesman; Thoracic Head and Neck Medical Oncology; University of Texas MD Anderson Cancer
Center
Pragya Sinha; Thoracic Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Tuhina Mazumdar; Thoracic Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Venkatesh Hegde; Thoracic Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Faye M. Johnson; Thoracic Head and Neck Medical Oncology; University of Texas MD Anderson Cancer Center
Jagannadha Sastry; Thoracic Head and Neck Medical Oncology; University of Texas MD Anderson Cancer
Center
Potential therapeutic targets for human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) include DNA
replication pathways, which are overexpressed in HPV-positive OPCs compared to HPV-negative OPCs.
Topoisomerase II, which generates transient double-strand DNA breaks for processes including replication and
transcription, is upregulated in HPV-positive OPCs and HPV-negative OPC cells engineered to express HPV E6
and E7 oncogenes. One topoisomerase II inhibitor, etoposide, was shown to exert greater cytotoxicity in HPVpositive than HPV-negative OPCs. Another, amsacrine (mAMSA), induced a higher response rate in OPCs (which
are more frequently HPV-positive) than other head and neck cancers. Moreover, topoisomerase II inhibition can
stimulate anti-tumor immune activity by inducing pyroptosis—gasdermin-mediated cell death involving release of
immune stimulants, including high mobility group box 1 (HMGB1), which activates dendritic cells, subsequently
leading to anti-tumor T cell activity. Topoisomerase II inhibition with etoposide was found to induce immunogenic
cell death in melanoma, but it is unknown whether it induces antigen-specific anti-tumor immune activity. We
hypothesize that topoisomerase II inhibition in HPV-positive OPCs will induce pyroptosis, leading to increased
HPV-antigen-specific anti-tumor immune activity. We tested this hypothesis using two well-established preclinical
murine models for HPV-positive oral and genital cancers, mEER and TC-1, respectively.
Cells were treated with etoposide, mAMSA, or DMSO (vehicle control), then cells and conditioned media were
harvested and probed for markers of pyroptosis using Western blotting. Splenocytes from mice immunized with
E6 and E7 peptides were cocultured with conditioned media, and immune activation was measured with flow
cytometry.
Topoisomerase II inhibition with etoposide and mAMSA lead to pyroptosis in HPV-positive cancers, as indicated
by higher levels of cleaved gasdermin E, cleaved caspase 3, and HMGB1 than the vehicle control. Ongoing
experiments are testing whether cell death induced by topoisomerase II inhibition increases antigen-specific
immune activity as demonstrated by E7-antigen-specific T cell activation in splenocytes cocultured with
conditioned media from treatment with etoposide and mAMSA than DMSO.
The findings of this investigation validate the murine tumor models for studies of the mechanism of cell death
induced by topoisomerase II inhibition in HPV-positive OPCs. Further, it will show how topoisomerase II inhibitioninduced cell death affects the tumor immune microenvironment, specifically HPV-antigen-specific CD8 T cells.
Future in vivo studies using immunocompetent and CD8-depleted mice implanted with HPV-positive tumors, and
E6/E7 knockdown in these tumors could demonstrate whether antigen-specific immune activation by
topoisomerase II inhibition-induced cell death leads to tumor regression and establish causality.
Keywords: HPV-positive cancer, Topoisomerase II inhibition, pyroptosis, antigen-specific immunity
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Abstract number: 237
Lymphatic endothelial cell secretions’ effect on inflammatory breast cancer cell growth
Kara Smeltzer; Radiation Oncology; University of Texas MD Anderson Cancer Center and Baylor University
Wintana Balema; Radiation Oncology; University of Texas MD Anderson Cancer Center
Jessica Li; Radiation Oncology; University of Texas MD Anderson Cancer Center
Richard Larson; Radiation Oncology; University of Texas MD Anderson Cancer Center
Wendy Woodward; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Inflammatory breast cancer (IBC) is a rare form of cancer that is highly life-threatening. A hallmark of
IBC is lymphatic dermal invasion. Lymphatic cells may change how breast cancer cells act, possibly increasing
growth and metastatic ability. This project determines how lymphatic endothelial cells (LECs) influence IBC cell
growth and vice versa. It is hypothesized that LEC conditioned media (CM) will cause increased IBC3 cell growth
in a lipocalin-2 dependent manner.
Methods: Normal breast cells, IBC3 cells, IBC3 cells with short hairpin RNA to inhibit lipocalin-2 (LCN2), and
LECs were cultured. Colony assays were performed to assess IBC3 cells’ ability to divide repeatedly. The first
was completed with IBC3 cells with 25% LEC CM. The second seeded IBC3 and IBC3 with shLCN2 cells and
added 10% LEC CM. Cells were irradiated (0, 2, 4, 6 Gy) and maintained at 37C for 14 days. Plates were fixed
and stained with crystal violet and colonies assessed using Fiji. Lastly, cells were plated to assess proliferation at
24 hours, 48 hours, and one week using a plate reader. Group 1 was a control with LECs in LEC media. Group 2
was LECs in IBC3 wild-type CM. Group 3 was LECs in CM from IBC3 LCN2 knockout cells.
Results: Two images were captured from each well in the first colony assay and imaged using two methods.
Image 2 was a more magnified image and captured more data. Method 1 used "Find Maxima" on Fiji with
prominence set to 20. Method 2 used "Analyze Particles" on Fiji with threshold set to 80. Analysis on image 1
produced non-significant results. Using image 2 and method 1, the average number of IBC3 colonies was 4377 in
control with standard deviation 385 and 5183 in LEC CM with standard deviation 298. P = 0.046. With method 2,
the average was 2834 in control with standard deviation 443 and 3641 in LEC CM with standard deviation 273.
P=0.051. Remaining plates are still incubating.
Conclusion: The first colony assay yielded significant results using the second image, which is logical considering
image 2 is more representative of the data. Adding LEC CM to IBC3 cells caused them to increase in colony
formation. Consequently, an abundance of lymphatic vasculature may increase IBC metastasis and severity.
Identifying patients with increased lymphatics may be helpful in determining prognosis.
Keywords: Inflammatory Breast Cancer, Lymphatic Dermal Invasion, Lipocalin-2, IBC3 Cell Line, Lymphatic
Endothelial Cells
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Abstract number: 238
CHD1-JMJD2 axis regulates histone methylation in prostate cancer
Kaitlyn Tremble; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Haoyan Li; Experimental Radiation Oncoloy; University of Texas MD Anderson Cancer Center
Di Zhao; Experimental Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: Chromodomain-helicase-DNA-binding protein 1 (CHD1) is an ATP-dependent chromatin remodeler
involved in gene transcription and organismal development [1]. Homozygous CHD1 deletion leads to genomic
instability and cell phenotypic alterations and is commonly found in human prostate cancer (PCa) [2, 3]. JMJD2
protein family are histone demethylases that target H3K9 and H3K36 [4]. High expression of JMJD2s promotes
tumorigenesis, including prostate cancer [5]. ML324 is a small-molecule selective inhibitor of JMJD2s which
reduces PCa cell proliferation [6-8]. Here, we study the crosstalk between CHD1 and JMJD2 in PCa.
Methods: Epigenetics compound library screening was performed using LnCaP WT cell and isogeneic CHD1
knockout cell, which were treated with compounds at 10uM for 72h, cell viability was then measured using
CellTiter-Glo Luminescent Cell Viability Assay. The small compounds were ranked based on the sensitivity in WT
versus CHD1 knockout cells. For top candidates, the inhibitory concentration (IC50) was determined by
measuring cell viability in multiple PCa cell lines. Protein expression and histone mark was assessed by Western
Blot and immunohistochemistry.
Results: Through epigenetics compound library screening, ML324, a small-molecule selective inhibitor of JMJD2,
ranked #1 of compounds that are sensitive in WT versus CHD1 knockout LNCaP cells. IC50s analyses in multiple
PCa cell lines with or without CHD1 deletion confirmed that CHD1 loss makes PCa cells less sensitive to JMJD2
inhibitor ML324. Mechanistically, we found CHD1 depletion reduces the expression of JMJD2A and JMJD2D both
in vitro and in vivo; while it enhances the trimethylation of H3K9 in cancer cells.
Conclusion: As a chromatin remodeler, CHD1 was found involved in transcription regulation by reading
H3K4me3. Here, our study uncovered a novel function of CHD1 on modulating histone methylation at H3K9 via
regulating JMJD2A and JMJD2D. Future studies will focus on the identification of target genes and downstream
pathways of CHD1-JMJD2 axis, as well as understanding of their biological function in PCa development and
progression.
Keywords: CHD1, JMJD2, histone methylation, prostate cancer
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Abstract number: 239
Mass Spectrometry Imaging Characterization of Ethiodized Oil, a Radiopaque Hydrophobic Multipurpose
Liquid Used in Cancer Therapy
Shubhneet Warar; Interventional Radiology; Baylor University
Danielle Stolley; Interventional Radiology; University of Texas MD Anderson Cancer Center
A. Colleen Crouch; Interventional Radiology; University of Texas MD Anderson Cancer Center
Erik Cressman; Interventional Radiology; University of Texas MD Anderson Cancer Center
Background: The incidence and mortality of liver cancer are both increasing, and there is no curative medical
treatment. One promising treatment option utilizes ethiodized oil (iodinated ethyl esters from poppy seed oil) in
combination with drugs to disrupt tumor arterial supply. The oil is an ideal radiopaque contrast agent for computed
tomography (CT) imaging due to its iodination. Characterization of ethiodized oil with mass spectrometry
imagining (MSI) is currently unknown but vital to map drug distribution in tissue. Herein, we describe our efforts to
characterize ethiodized oil using matrix-assisted laser desorption ionization (MALDI)-MSI.
Methods: Three matrices were tested on ethiodized oil (Guerbet LLC) by spotting a 1:1 ratio of solution to matrix
on a standard MALDI well plate as follows: for positive ion mode, 2,5-dihydroxybenzoic acid (DHB) and alphacyano-4-hydroxycinnamic acid (CHCA); for negative ion mode, 9-aminoacridine hydrochloride (9AA). Samples
were analyzed using a Waters Synapt G2-Si instrument and MS/MS was done with optimized transfer collision
energies for selected peaks to characterize features further. Ethiodized oil was spotted on tissue, and matrix was
applied uniformly across by a robotic sprayer. Results were analyzed with HDImaging software.
Results: In positive ion mode, distinct MS peaks were seen at m/z 320.25 and 412.32. For precursor ion m/z
320.25, MS/MS analysis showed fragment peaks at 72.08 and 208.13. For precursor ion m/z 412.32, fragment
peaks were seen at 72.08, 91.05, 208.13, and 320.26. In negative ion mode, distinct peaks were seen at m/z
344.71, 436.68, and 508.58. For both precursor ions m/z 344.71 and 436.68, only a fragment peak at 126.90 was
seen. For precursor ion m/z 508.58, fragment peaks were seen at 126.90, 169.46, 210.83, and 316.74. The peak
at m/z 126.90 [M]- was assigned to iodide. Mass spectra of spotted tissue showed similar precursor peaks but
with weaker intensity, as endogenous lipids were of higher intensity.
Conclusion: Ethiodized oil is a common clinical contrast agent, but exact structures of the mixture are not
reported. To determine chemical composition, MS peaks can be analyzed and compared to endogenous peaks in
tissue. The mass spectra were consistent with the oil being a mixture of compounds with iodinated long-chain
fatty acid esters. Compounds were determined to have between 1-3 iodines per structure. By characterizing MS
peaks, researchers can now track distribution of ethiodized oil in tissues. By detecting the oil in tissue, other drugs
dissolved in the oil could be more easily traced.
Keywords: Mass spectrometry imaging, cancer therapy
Program Affiliation: University Outreach– Baylor University

249

University Outreach– Nova Southeastern University
Abstract number: 240
Effects of Combined Inhaled TLR Agonists on House Dust Mite Related Asthma in Mice
David L. Goldblatt; Pulmonary Medicine; University of Texas MD Anderson Cancer Center; Howard Hughes
Medical Institute
Gabriella Valverde Ha; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Shradha Wali; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Vikram V. Kulkarni; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Ana Maria Jaramillo; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Tazifer F. Purresh; Pulmonary Medicine; University of Texas MD Anderson Cancer Center; Howard Hughes
Medical Institute
Rosha P. Chittuluru; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Adrienne Fouts; Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Margarita Martinez-Moczygemba; Microbial and Molecular Pathogenesis; Clinical Science and Translational
Research Institute; Texas A&M Health Science Center
Jonathan T. Lei; Clinical Science and Translational Research Institute; Texas A&M Health Science Center
David P. Huston; Department of Microbial and Molecular Pathogenesis; Clinical Science and Translational
Research Institute; Texas A&M Health Science Center
Michael J. Tuvim; Department of Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Burton F. Dickey; Department of Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Scott E. Evans; Department of Pulmonary Medicine; University of Texas MD Anderson Cancer Center
Background: Allergic asthma is a chronic inflammatory respiratory disease associated with eosinophilic infiltration,
increased mucus production, airway hyperresponsiveness (AHR), and airway remodeling. Lung airway epithelial
cells express a myriad of pattern recognition receptors such as Toll-like receptors (TLRs), enabling them to sense
and respond to a variety of external triggers. The epithelial-derived cytokines IL-33, TSLP, and IL-25 are widely
recognized as alarmins produced in response to house-dust mites (HDM). These cytokines activate several
leukocytes involved in allergic inflammation, such as eosinophils. We have shown that a combination of
Pam2CSK4 (“Pam2”, TLR2/6 ligand) and a class C oligodeoxynucleotide ODN M362 (“ODN”, TLR9 ligand) when
delivered together by aerosol (“Pam2ODN”) synergistically activate an innate immune response in the lung
mucosa. To further study the immunomodulatory effects of Pam2ODN, we have developed allergic models to
show that Pam2ODN attenuates an allergic immune response to HDM.
Methods: Mice were sensitized with 100 μg HDM extract at day 0, followed by 6 daily challenges of 10 μg HDM
from day 7 to 12. Evaluation of allergic inflammation was done with differential cell counts of leukocytes in
bronchioalveolar lavage fluid on day 15. To evaluate synergy, Pam2 and ODN were aerosolized individually or in
combination.
Results: When mice were treated with a single Pam2ODN treatment 7 days before HDM sensitization, we
observed strong reductions in leukocytes collected in lung lavage fluid, compared to HDM/HDM mice. Pam2ODN
treatments similarly showed efficacy when administered 30- and 15-days before sensitization, with a trend toward
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less efficacy when the treatment-sensitization interval was further increased. When Pam2ODN treatment was
administered any day after HDM sensitization, the treatment effect was completely absent. Neither Pam2 nor
ODN exhibited any significant efficacy when administered alone, but they exhibited a synergistic efficacy when
delivered together.
Conclusion: Strong immunomodulatory agents have been a longstanding therapeutic goal for allergic disease
without significant breakthroughs to date. This study shows that Pam2ODN is an immunomodulatory agent
capable of attenuating allergic disease in mice. Furthermore, we have uncovered important parameters
underlying the success of immunomodulation protocols, such as optimal treatment window, which might guide
clinical use. Clinical studies with Pam2ODN have shown the drug to be well tolerated in humans (NCT02124278,
NCT02566252), and results from this study provide proof of concept for Pam2ODN in the allergic disease setting.
Keywords: innate immunity, lung epithelium, Toll-like receptor ligands, asthma, immunomodulation
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Abstract number: 241
RET Promotes Osteoblastic Bone Metastases in Medullary Thyroid Carcinoma
Lucia Martinez; Endocrine, Neoplasia and Hormonal Disorders; MD Anderson Cancer Research Center
Gabriel M. Pagnotti; Endocrine, Neoplasia and Hormonal Disorders; MD Anderson Cancer Research Center
Trupti Trivedi; Endocrine, Neoplasia and Hormonal Disorders; MD Anderson Cancer Research Center
Jade A. Martinez; Endocrine, Neoplasia and Hormonal Disorders; MD Anderson Cancer Research Center
Theresa A. Guise; Endocrine, Neoplasia and Hormonal Disorders; MD Anderson Cancer Research Center
Rozita Bagheri-Yarmand; Endocrine, Neoplasia and Hormonal Disorders; MD Anderson Cancer Research Center
Background: The protooncogene RET (rearranged during transfection) is a driver oncogene in medullary thyroid
carcinoma (MTC), encoding the transmembrane tyrosine kinase receptor. Somatic missense RET mutations
occur in 50% of sporadic MTC. The mutations result in constitutive activation of the receptor as a result of
dimerization or alteration in the tyrosine kinase substrate specificity. The most frequent RET mutations are at
codons W634R and M918T. Bone metastases are common in MTC; the lesions can be osteolytic, osteoblastic, or
mixed. However, the role of RET mutations and their specific substrates or effectors in formation of different types
of bone lesions is unknown. Our study evaluates the relationship between RET mutation or expression in the
development of different types of bone lesions
Methods: We used MZCRC1 and TT cell lines. TT cells carry a mutation in exon 11 at codon 634 (W634R), and
MZCRC1 cells have a mutation in exon 16 at codon 918 (M918T). Cultured TT, MZCRC1, and MZCRC1-RETshRNA were injected into the femurs of SCID mice. Tumor growth in bone was assessed using radiography and
histology. Decalcified bones were used for histology and histomorphometry analysis using BIOQUANT OSTEO
software. In vitro experiments were performed using MC3T3-E1 preosteoblast cells. Cells were cultured in
differentiation medium containing ascorbic acid (100 mg/ml) and β-glycerophosphate (10 mg/ml) in the presence
or absence of conditioned media of TT cells. The cells were stained for alkaline phosphatase activity. RNA was
extracted and analyzed by qRT-PCR for bone markers.
Results: Radiographic images show that intrafemoral inoculation of TT cells carrying RET- W634T mutation
formed osteoblastic bone lesions. M918T mutation in MZCRC1 cells caused increase in cortical thickness,
porosity, and sclerotic areas which were reduced in MZCRC1- RET knockdown cell-inoculated bones. In vitro
results indicate that conditioned media of TT cells is associated with increased osteoblast differentiation and
expression of osteogenic markers ALP, Cola1, RUNX2
Conclusion: These results suggest an association between bone metastases phenotype in MTC and the type of
RET mutation. Both mutations are associated with osteoblastic bone metastases, but the type of osteoblastic
lesions is different with each mutation. Histology analyses will show MTC-tumor interaction and could provide
insight into pathophysiology associated with MTC-associated bone metastases. Our in vitro data provides a
potential mechanism where RET may promote osteoblastic phenotype through the increase of osteoblast
differentiation. The understanding of RET-induced osteoblastic bone metastases will promote the development of
new therapies for treating MTC bone metastases.
Keywords: MTC, Bone Metastases, RET, Osteoblast
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Abstract number: 242
Combination therapy of DNA repair inhibitors and ionizing radiation to enhance DNA damage in 4T1
murine cell lines and H1299 Non-small cell human lung carcinoma
Vijay Patel; Radiation Physics; University of Texas MD Anderson Cancer Center
Broderick X. Turner; Radiation Physics; University of Texas MD Anderson Cancer Center
Scott J. Bright; Radiation Physics; University of Texas MD Anderson Cancer Center
David B. Flint; Radiation Physics; University of Texas MD Anderson Cancer Center
Simona F. Shaitelman; Radiation Physics; University of Texas MD Anderson Cancer Center
Gabriel Sawakuchi; Radiation Physics; University of Texas MD Anderson Cancer Center
Background: Cancer treatments are often non-selective or nor tailored to the tumor cell line. Current treatment
plans use both radiation and drugs independent of each other, but an intentional combination could potentially
yield more effective and synergistic treatment. Both radiation types, protons and photons, deliver double strand
DNA breaks, but protons administer clustered damage and is difficult to repair. The addition of DNA repair
inhibitors to radiation prevents radiation-induced damage from being undone and could ultimately improve
treatment efficiency. Here we wanted to investigate the combination of DNA-repair inhibitor treatment as well
various radiotherapies to elucidate greater damage to tumor cells. PARP and ATR are DNA-repair proteins that
are prominent in DNA damage repair signaling and homologous recombination, respectively. Since protons inflict
greater DNA damage, they yield the most damage to cells when paired with a DNA repair inhibitor.
Methods: Cells were grown and seated at a density of 200,000 per condition and treated with 1uM of either
DMSO control, ATR inhibitor Ceralasertib (ATRi), or PARP inhibitor Olaparib (PARPi), and incubated for 1 hour
prior to irradiation with 5Gy of photons or protons. After 24 hours, an alkaline Comet Assay was performed to
quantify DNA damage. Damaged DNA in Cells were stained with sybr gold staining solution and imaged using
Cytation5. Cells were analyzed using Comet Score, and the quantity of DNA in the tail (DNA%) and tail moment
(DNA%*tail length) were recorded.
Results: The non-small cell carcinoma H1299, there was a significant increase in the percentage of DNA damage
present in the comet tails. 5Gy protons+ATRi was 1.27x more effective compared to 5Gy photons+ATRi
(p=0.0385). Additionally, the combination of 5Gy protons+ATRi outperformed all other treatment groups (p all
<.05). In the murine breast cancer cell line 4T1, similar trends were observed using both ATRi and PARPi. 5Gy
Proton+ATRi was 1.14x more effective than 5Gy PARPi, though more data needs to be collected to evaluate for
significance.
Conclusion: The combination of radiation and DNA repair inhibitors showed increased DNA damage to both 4T1
and H1299, with protons being more effective than photons. This may be due to the increased damage protons
cause through clustered double strand breaks and an inability of tumor cells to repair the damage dealt. Due to
the similarities of trends between cell lines, it is plausible that DNA repair inhibitors could be used in synergy with
radiation therapy, particularly with proton therapy over photons. The type of DNA repair inhibitor could
theoretically be tailored to the mechanisms the cell line is capable of. Future research aims to test the efficacy in
animal models for these cell lines and ultimately human trials.
Keywords: Proton, 4T1, DNA Repair inhibitors, H1299, X-ray, Comet Assay
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Abstract number: 243
Effect of Trophon Machine on Endorectal Coil viability
Vidhi Raval; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Magnetic resonance imaging is a powerful tool that can be used to visualize different types of
cancer, including prostate cancer. However, with each tool comes limitations. For example, with prostate cancer,
it can be difficult to visualize precise matters due to distractions from other body parts. With the use of the
endorectal coil, however, it may be easier to image the prostate more clearly. It is also extremely important to use
high level disinfection techniques when working with the endorectal coil to avoid contamination and transfer of
foreign bodies. The purpose of this experiment was to determine if a high level disinfection cycle from the
Trophon machine was able to disinfect the coil properly and if it impacted the MRI signals sent out.
Methods: The MRI machine was used to determine the signals from the endorectal coil with different samples milli-Q water and saline sample (50% saline solution, 50% milli-Q water). After data collection, the endorectal coil
was placed in the Trophon machine for 100 cycles to undergo high level disinfection. Once the cycles were
completed, the endorectal coil was assessed again to ensure that the Trophon disinfection did not impact the
signals from the MRI. Afterwards, to determine if the disinfection cycles thoroughly got rid of the bacteria, four
strains of bacteria were inoculated onto the coil and run through the machine. Pre and post agar plates were used
to determine bacterial growth.
Results: Results indicated that the Trophon cycles did not impact the signal to noise ratio for the coil. The signal
to noise ratio was observed over time and there was no downward trend shown. Additionally, plates with bacteria
inoculated onto the trophon showed no growth after the cycle.
Conclusion: Though there are still more experiments that need to be done to bring this to clinical use, the
endorectal coil holds much promise for improving diagnostic imaging procedures.
Keywords: imaging physics, prostate cancer, diagnostic, endorectal
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Abstract number: 244
Effects of inactivating Arid1a mutation on the tumor microenvironment in response to immune
checkpoint therapy
Hawraa Al Janabi; Genitourinary Medical Oncology; University of Notre Dame
Seanu Natarajan; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer Center
Sangeeta Goswami; Genitourinary Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Although Immune checkpoint therapy (ICT) provides durable clinical benefit in many types of
cancers, only a subset of eligible patients respond to treatments. While biomarkers like PD-L1 were being
developed as predictive biomarkers, clinical data highlighted the difficulty of using it as a single biomarker by the
varying responsiveness of patients. To identify additional biomarkers for the immune checkpoint therapy,
Goswami et al. found that inactivating Arid1a mutation predicted responses to immune checkpoint therapy in
metastatic urothelial carcinoma. Arid1a is a chromatin remodeling complex and inactivating mutation of Arid1a is
highly prevalent in various tumor types. To develop mechanistic understanding on how Arid1a modulates tumor
microenvironment and responsiveness to ICT, we will explore the effects of Arid1a in a pre-clinical model of
urothelial cancer.
Methods: Using shRNA gene silencing, we created the Arid1a knockdown MB49 cells. The scramble and Arid1a
knockdown MB49 cells were grown in vitro. Then, tumor cells were subcutaneously injected into wild type mice
(n=20). Mice injected with the Arid1a knockdown cells or the scramble were also divided into treatment groups
(anti-PD-1) and control groups (PBS). The Arid1a knockdown and scramble treatment groups received the
treatments via an intraperitoneal injection of anti-PD-1 on days 3,6, and 9. On day 14, the tumors were collected
from the mice. To explore differences in tumor microenvironment due to the Arid1a knockdown, mass cytometry
(CyTOF) was performed.
Results: The tumor weight data was collected for Arid1a knockdown and scramble, including anti-PD-1 treatment
and control groups. We noted that Arid1a knockdown tumor treated with anti-PD-1 therapy had a smaller tumor
compared to Arid1a- scramble tumor treated with anti-PD-1 therapy (P≤ 0.01), suggesting improved sensitivity to
anti-PD-1 in absence of Arid1a. To explore the baseline effects of Arid1a knockdown in comparison to the
scramble (control) in the tumor microenvironment, mass cytometry (CyTOF) data was compared. Compared to
the scramble (control), Arid1a knockdown had higher infiltrating CD8+ GZMB+ cells (P ≤ 0.01), which was further
increased following anti-PD-1 therapy demonstrating an inflammatory tumor microenvironment in absence of
Arid1a.
Conclusion: We show that knockdown of Arid1a in MB49 bladder cancer cell lines enhances sensitivity to antiPD-1 therapy by increasing cytotoxic CD8 T cells in the microenvironment in a murine model of urothelial cancer.
Future studies will aim at understanding the pathways of increased T cell infiltration. Further, a clinical trial testing
Arid1a mutation as a predictive biomarker is currently ongoing.
Keywords: Arid1a knockdown, Immune checkpoint therapy
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Abstract number: 245
Rimiducid’s Effect on T Cell Development and Differentiation
Brian Dineen; Hematopoietic Biology and Malignancy; MD Anderson Cancer Center
Dan Li; Hematopoietic Biology and Malignancy; MD Anderson Cancer Center
Qing Ma; Hematopoietic Biology and Malignancy; MD Anderson Cancer Center
Background: Chimeric antigen receptor modified T cells (CAR-T cells) have been found to be effective antitumor
agents when treating chronic lymphocytic leukemia and acute lymphoblastic leukemia. However, attempts to treat
other types of leukemia, as well as solid tumors, with CAR-T cells have been less successful. One of the major
barriers to widespread use of CAR-T cells is the toxicity of these cells. CAR-T cells cause cytokine release
syndrome, on-target off-tumor toxicity and neurological toxicities. Several deaths in clinical trials have been
attributed to these. The addition of a “suicide gene” encoding the caspase-9 protein to CAR-T cells has been
proposed as a method to decrease their toxicity. This strategy uses rimiducid (AP1903), a drug that causes
dimerization of the caspase-9 protein. Dimerization of caspase-9 domains leads to CAR-T cell death and thereby
prevents inflammation and off-tumor toxicity. Rimiducid’s effect on the development and differentiation of native T
cell populations has not yet been studied.
Methods: Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat by layering with
HISTOPAQUE-1077 and centrifugation. PBMCs were divided into three time points (days three, five, and seven)
and three treatments. The control group was not treated. The stimulation group was treated with CD3 and CD28.
The rimiducid group was treated with CD3 and CD28 as well as either 20μL or 80μL of 10μM rimiducid. Cells
were mixed with antibodies for various markers of T cell development and differentiation and were analyzed using
flow cytometry.
Results: Rimiducid treated groups contained a lower proportion of central memory and naive CD4+ T cells as well
as a higher proportion of effector memory CD4+ T cells and terminally differentiated T cells at the end of seven
days. An increase in the prevalence of effector memory and terminally differentiated CD8+ T cells was also seen
on day seven. Rimiducid did not appear to have any influence on the development of double negative T cells or
any groups prior to day seven. There was no significant difference between samples treated with the higher and
lower dose of rimiducid.
Conclusion: These results point to rimiducid effecting T cell development by promoting differentiation to effector
memory and terminally differentiated cells. However, the effect sizes and sample size were too small to
confidently say anything about rimiducid’s effect on the development of cells in the immune system.
Keywords: Rimiducid, Suicide gene, Cytokine Release Syndrome
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Abstract number: 246
Immunosuppression By Recruitment and Polarization of MDSC's by CAFs
Patrick Gaffney; Immunology; University of Texas MD Anderson Cancer Center
Arthur Liu; Immunology; University of Texas MD Anderson Cancer Center
Background: Despite the clinical success of immunotherapy, immunosuppression mediated by the tumor stroma
remains a major barrier in refractory tumors. Cancer-associated fibroblasts (CAFs) make up a large portion of the
pancreatic tumor microenvironment and can play a role in promoting the immunosuppressive TME. The goal of
these experiments is to identify CAF-associated paracrine factor(s) responsible for the suppressive polarization of
tumor infiltration of myeloid cells, which can directly inhibit antitumor CD8 T cell function. Identifying a CAFassociated soluble factor would be crucial in providing a target to disrupt CAF conditioned myeloid cell recruitment
and reversing immunosuppression.
Methods: To determine whether CAFs polarize myeloid cells, bone marrow (BM) progenitors were cultured for 96
hours in normal fibroblast or CAF conditioned media. Flow cytometry assessed the suppressive capacity of
fibroblast conditioned myeloid cells. Suppression of T cells by CAF conditioned myeloid cells was determined by
co-culturing myeloid cells with T cells for 72 hours. To assess the effect of CAF mediated myeloid polarization in
vivo, mice were challenged with pancreatic tumor cells and then left untreated or treated with DMEM, normal
fibroblast CM, or CAF CM.
Results: We found that CAFs can recruit myeloid progenitors. Macrophages (Macs) differentiated from BM
progenitors cultured in CAF CM showed significant increases in PD-L1 expression. Granulocytic myeloid-derived
suppressor cells (grMDSC) showed similar results, as well as an increase in arginase expression. These data are
corroborated by another CAF cell line, mPSC, which promotes PD-L1 expression in grMDSCs and Macs. T cells
co-cultured with myeloid cells conditioned with CAF CM, showed decreased proliferation compared to their
normal fibroblast conditioned counterparts. Mice challenged with pancreatic tumors showed increased tumor
volume in the CAF CM and DMEM groups compared to that in the normal CM and untreated groups. Mice
injected intratumorally with mPSC showed higher expression of immunosuppressive markers in tumor-associated
macrophages and granulocytes.
Conclusion: Our results indicate that CAFs can recruit myeloid cells and influence their suppressive function.
CAFs promote suppressive markers on myeloid cells, including PD-L1 and arginase. mPSC CM also increased
PD-L1 expression, corroborating our CAF data. We found that CAF conditioned myeloid cells reduce T cell
proliferation, and that in vivo, CAF CM promotes tumor growth. In addition, intratumoral treatment with mPSC CM
led to increased PD-L1 expression on macrophages and granulocytes. Our results suggest that disrupting the
CAF-induced recruitment and polarization of myeloid cells may present an effective strategy for reversing
immunosuppression.
Keywords: cancer-associated fibroblasts, myeloid-derived suppressor cells, pancreatic cancer, immunotherapy
resistance, T cells
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MRI-Based Therapy Guidance for Ultrasound Neuromodulation
Marie Gerges; Imaging Physics; University of Texas MD Anderson Cancer Center
Wayne Goodman; Psychiatry and Behavioral Sciences; Baylor College of Medicine
Junqian Xu; Radiology; Baylor College of Medicine
Xuefeng Zhang; Psychiatry; Baylor College of Medicine
Joo-won Kim; Radiology; Baylor College of Medicine
Richard Bouchard; Imaging Physics; University of Texas MD Anderson Cancer Center
Background: Focused ultrasound (FUS) is a form of ultrasound in which sound waves from a transducer converge
at a small target in the body. Because FUS offers the possibility to alter brain function non-invasively, the
technology has been studied to treat a range of neurological diseases. One application of FUS is
neuromodulation, the inhibition or enhancement of neural activity. MRI is often used in conjunction with FUSdriven neuromodulation to obtain real-time information on the temperature and function of the brain during
treatment. We aimed to calculate the position and orientation of an ultrasound target for a given position and
orientation of the transducer, as well as determine whether the transducer would be flush against the subject’s
head at different locations on the head.
Methods: An FUS transducer (BrainSonix) was strapped to the side of a healthy subject’s head above the ear.
The subject then underwent MRI (Siemens MAGNETOM Prisma) at 3 T. MRI data from the subject were
analyzed using MATLAB’s Image Processing Toolbox. The image was cropped to show only the region of the
skull where the transducer was located, and a polynomial surface fit was calculated for this region of the skull.
Results: Using the surface fit for the skull and linear static analysis, the position and orientation of the ultrasound
beam in the brain were calculated for a given position of the transducer on the head. The normal vectors at
different points on the surface were also calculated to determine whether the transducer would be flush against
the subject’s head at a specified position.
Conclusion: Knowledge of the location of the ultrasound beam in the individual’s brain is an important first step in
using FUS for neuromodulation.
Keywords: Focused ultrasound, FUS, neuromodulation, MRI, transducer
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Mathematical modeling of the CA19-9 response to chemotherapy in patients with pancreatic cancer
Lauren Hollmer; Radiation Oncology; University of Texas MD Anderson Cancer Center
Connor Thunshelle; Radiation Oncology; University of Texas MD Anderson Cancer Center
Tasadduk Chowdhury; Radiation Oncology; University of Texas MD Anderson Cancer Center
Eugene Jon Koay; Radiation Oncology; University of Texas MD Anderson Cancer Center
Background: CA19-9 is the most widely used biomarker for pancreatic cancer, and multiple studies have
demonstrated that normalization of CA19-9 is associated with a good prognosis. However, there is currently no
method to predict normalization early during chemotherapy to determine treatment efficacy.
Methods: 732 patients with resectable, borderline resectable, or locally advanced pancreatic cancer between
2015-2019 were identified. Patients were selected from this group if they met all of the following criteria: No
CA19-9 normalization prior to therapy, normal bilirubin prior to therapy(<2.0 mg/dL), no metastasis, uninterrupted
FOLFIRINOX or Gemcitabine/nab-paclitaxel for 6 months, and at least two CA19-9 measurements in addition to
the baseline. Normalization was defined as CA19-9 levels below 40 U/mL at any point during chemotherapy.
CA19-9 data were fit to an exponential decay model (Y[t]=alpha*exp(beta[t]); where Y was the CA19-9 level at
time t, and alpha and beta were model parameters describing the shape of the response curve to predict the
presence or absence of normalization within 6 months. If CA19-9 levels increased to time “T” within the first 60
days but then decreased, data was fit to a piecewise curve with magnitude for the rate of increase equivalent to
the rate of decrease and the turning point at t=T. Model predictions were compared to ground truth CA19-9,
followed by an assessment of misclassifications, progression trends, and ROC analysis.
Results: 86 patients (34 normalizers and 52 non-normalizers) met all inclusion criteria, resulting in accurate
classification for 73 patients (AUC=.866). Normalizers had a lower baseline CA19-9 (median 148.55 U/mL [range
43.6-1562]) compared to non-normalizers (median 600.8 U/mL [range 53.2-8815], ANOVA, p=0.0016). Eight
patients were misclassified as non-normalizers: 7 exhibited a “bidirectional to normalization” change in CA19-9
and 1 demonstrated an inconsistent rate of change. Five patients were misclassified as normalizers: 2
demonstrated a “U-shaped” change in CA19-9 and 3 decreased without normalization. The model predicted
longer survival from chemotherapy start date for normalizers (Median 870 days [95% CI 544-1090]) compared to
non-normalizers (Median 611 days [95% CI 472-892], Log Rank Test, p=.2441). Ground truth normalizers
survived significantly longer (Median 1037 days [95% CI 550-1037]) than non-normalizers (Median 544 days
[95% CI 472-800], Log Rank Test p=.0115).
Conclusion: Describing the change in CA19-9 levels during chemotherapy and applying a mathematical model to
predict 6-month normalization can provide insight into a subset of patient responses and outcomes. Ongoing work
will characterize and model responses for other subsets.
Keywords: CA19-9, Pancreatic cancer, Mathematical modeling
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Analysis of the relationship between neural landscapes and functional and survival outcomes in head
and neck cancer
Margaret Kurop; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Tongxin Xie; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Jennifer Covello; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Moran Amit; Head and Neck Surgery; University of Texas MD Anderson Cancer Center
Background: Oropharyngeal cancer is a type of head and neck cancer in which cancer cells are found within a
specific area of the throat known as the oropharynx. Over 90% of oropharyngeal cancers are squamous cell
carcinomas (SCC), with the cancer arising from the flat surface cells that line the mouth and throat. Treatments
such as radiation therapy can produce adverse effects, causing oropharyngeal cancer patients to often have
trouble with speech or swallowing. Studies have examined the effects of oropharyngeal cancer and radiation
therapy on the muscular systems in the oropharynx, however, there is little known about the implications of this
form of cancer and radiation on nerves. Understanding the neural environment is imperative to alleviating
symptoms of oropharyngeal cancer as nerves often have nociceptive receptors and pain is the most common
presenting symptom in oral SCC. Therefore, the goal of this study is to correlate the neural landscape with
function and survival measures of patients with oropharyngeal cancer.
Methods: Epithelium samples affected by oral SCC of 22 oropharyngeal cancer patients treated at MD Anderson
Cancer Center were obtained. Tissues were fixed with 4% paraformaldehyde (PFA), dehydrated, embedded in
paraffin, and cut into 5 μm segments. Sections were labeled with neural and cancer markers using RNAscope
Multiplex v2 Assay combined with Immunofluorescence. Images of the fluorescent histologic sections were
analyzed for nerve quantification, phenotype, and location using custom automated applications in Visiopharm’s
image analysis system. This information was compared with patient’s clinical data from the MD Anderson Speech
Pathology division in the Department of Head & Neck Surgery. This included objective and semi-objective data
such modified barium swallow (MBS) and endoscopy results and self-reported questionnaires (MDASI, MDADI,
PSSHN, and EQ5D).
Results: Data from this study is still being currently obtained. Upon nerve quantification and phenotyping, these
results will be statistically compared with the clinical data. Using reported data from MDASI, MDADI, PSSHN, and
EQ5D questionnaires and MBS test results, significant differences will be examined through t-tests. It is
hypothesized that the number of tumor-invaded and injured nerves will correlate with poorer functional and
survival outcomes in patients.
Conclusion: The results of this study provide an enhanced understanding of cancer pain and its association with
neural landscapes. Further research on these topics will not only provide relief from oropharyngeal cancer pain
and adverse radiation effects, but also improve patient functional and survival outcomes.
Keywords: oral cancer, nerves, digital histology
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Characterizing the Abraxas/BRCA1 Interaction in the Control of DNA Double Strand Breaks
Grace Murphy; Genetics; University of Texas MD Anderson Cancer Center
Xiao Wu; Genetics; University of Texas MD Anderson Cancer Center
Shengfeng Xu; Genetics; University of Texas MD Anderson Cancer Center
Bin Wang; Genetics; University of Texas MD Anderson Cancer Center
Background: Genomic instability is a hallmark of cancer. Upon DNA damage, multiple repair mechanisms exist,
one of which being the highly mutagenic break-induced replication (BIR). The BRCA1-A complex is a collection of
proteins that repair dsDNA breaks. Two crucial proteins of this complex are BRCA1, a tumor suppressor, and
Abraxas, a scaffold protein. When DNA is damaged, ATM signaling induces ubiquitination of lysines conjugated at
the damage site. RAP80 binds to the polyubiquitin chain of lysine 63, recruiting BRCA1. Abraxas then dimerizes
and stabilizes BRCA1 at the site. It has been shown that DNA end resection as a result of camptothecin (CPT), a
topoisomerase inhibitor, damage is inhibited by Abraxas, limiting BIR. Abraxas and BRCA1 interact at two
important points when they form the BRCA1-A complex: S406 and S404. S406 is phosphorylated in response to
DNA damage. S404 is crucial for BRCA1 accumulation at damage sites. Its phosphorylation is required for
dimerization of BRCA1-BRCT/Abraxas. The aim of my project is to test if Abraxas S404A S406A double mutant
affects Abraxas’s function in inhibition of DNA end resection and BIR in response to CPT damage, and it was
shown to have no significant effects.
Methods: Using the Single Molecule Analysis of Resection Tracks (SMART) assay, I tested the length of ssDNA
in response to CPT treatment in complemented WT Abraxas and S404A S406A double mutant into Abraxas KO
U2OS cells (ULF3). Three other cells lines were analyzed: untreated U2OS, treated U2OS, treated ULF3. The
cells were treated with 1μM CPT for 1 hour. The DNA was extracted and molecular combing stretched the DNA
fibers onto coverslips. The fibers were stained with BrdU, causing them to fluoresce green when imaged using the
80i microscope. The fiber length was then measured using Image J. Data was plotted as mean length and
statistically analyzed using ANOVA.
Results: The statistical analysis showed a non-significant difference in mean fiber length between the treated
U2OS and the ULF3 double mutant cells.
Conclusion: Based on these preliminary findings, the interaction of BRCA1 and Abraxas at these interaction
points is not crucial in the function of the BRCA1-A complex in repairing DNA double strand breaks.
Keywords: DNA double strand breaks, BIR, BRCA1-A complex, SMART
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Abstract number: 251
Targeting EF2K in Pancreatic Cancer Cells with Thymoquinone
Chelsea Popoola; Experimental Therapeutics; University of Notre Dame
Background: Thymoquinone has served as a novel drug in inhibiting EF2K, a kinase that serves a role in cell
proliferation, in breast cancer. My goal is to prove the hypothesis that Thymoquinone can also serve as a novel
drug in inhibiting EF2K in Pancreatic Cancer.
Methods: In an attempt to prove the hypothesis, several clonogenic assay and Western blots were set up in order
to review the role of Thymoquinone in inhibiting EF2K. In the clonogenic assay, the cells are seeded and left to
proliferate for 24-48 hours, after the time set, Thymoquinone of varying concentrations were added to the cells
and left for 7-10 days for the colonies to form. For the western blot, cells are seeded and left for 24-48 hours and
then Thymoquinone is added. 24 hours after the Thymoquinone drug is added, the cells are collected and the
proteins in the cell are separated through gel electrophoresis and transferred onto a membrane and read.
Results: Western Blot On reading the membrane gotten from the gel electrophoresis, the hypothesis was seen
to be true. With increased concentration of Thymoquinone, the expression of EF2K was seen to decrease. This
shows that Thymoquinone could possibly serve as novel drug in combatting pancreatic cancer by decreasing its
proliferation by EF2K.
Clonogenic Assay After staining each well of the plate, it was seen that with increasing
concentration of Thymoquinone, colony formation decreased. This experiment also proves the hypothesis that
Thymoquinone inhibits cell proliferation in Pancreatic Cancer.
Conclusion: Following the above experiments, it is shown that Thymoquinone can also inhibit EF2K in Pancreatic
cancer. Though, there are many more steps to go before Thymoquinone can finally be used as a drug in fighting
Pancreatic Cancer but a few steps closer in making cancer history.
Keywords: EF2K, Thymoquinone, Proliferation, Pancreatic
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Abstract number: 252
Anti-B7H3 monoclonal antibodies induce natural killer cell- mediated apoptosis in triple negative breast
cancer
Kathryn Robinson; Leukemia; University of Notre Dame, University of Texas MD Anderson Cancer Center
Anudishi Tygagi; Leukemia; University of Texas MD Anderson Cancer Center
Venkata Lokesh Battula; Leukemia; University of Texas MD Anderson Cancer Center
Background: Immune checkpoint blockade (ICB) therapies have shown promising results in treating a variety of
cancer types; however, the median duration of progression free survival with these treatments in triple negative
breast cancer (TNBC) is very low. A new protein B7 homolog 3 (B7H3), or CD276, was found to be
overexpressed in many cancer cells and have little to no expression on normal cells. It initially was characterized
as a costimulatory molecule promoting the activation of T cells but is now understood to act mainly as a
coinhibitory molecule of the immune system. B7H3’s mechanism of action and receptor remain uncharacterized,
but its preference for malignant cells offers hope for a new therapeutic approach with less toxicity and more
efficiency. Objective: The primary objective of this study was to determine the expression of B7-H3 in primary
TNBC tumors and measure the effect of novel B7-H3 blocking antibody in activation of NK cells against TNBC
cells
Methods: We performed immunohistochemistry to investigate B7-H3 expression in TNBC primary tumors (n=90)
and adjacent normal mammary tissue (n=30). The data was acquired and quantitated using Vectra-Polaris, multispectral imaging system. Natural killer (NK) cells were isolated from buffy coats of healthy donors by Ficoll density
gradient centrifugation. NK cell-mediated apoptosis was measured by IncuCyte live cell imaging system. RFPtagged B7H3+/- TNBC cell lines were co-cultured with primary NK cells at different NK to target cells ratios (2:1,
4:1, 8:1). The cells were simultaneously incubated with annexin V-green and different concentrations of the antiB7H3 mAb or IgG control antibodies for 24 hours in IncuCyte.
Results: Expression of B7H3 was significantly higher in TNBC patients compared to healthy donors (p<0.0001).
Moreover, we found that high B7H3 expression was associated with poor progression free and overall survival
(p<0.01). Co-culture experiments using novel anti-B7H3 mAbs triggered NK cell-mediated apoptosis in a matter of
hours. The annexin V binding to RFP+ TNBC cells was significantly higher in TNBC cells treated with anti-B7H3
blocking antibody compared to TNBC cells treated with NK cells alone, mAb alone, or IgG control with NK cells.
However, no difference in killing was seen in B7H3 negative cells, indicating that treatment with mAbs may inhibit
the immunosuppressive function of B7H3 and activate NK cells against tumor cells.
Conclusion: Our data suggests that B7H3 is overexpressed in TNBC cells and the B7H3 blocking antibody inhibits
its immunomodulatory function and activate NK cells against TNBC cells.
Keywords: B7H3, triple negative breast cancer (TNBC), immunotherapy, natural killer (NK) cell, apoptosis
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Abstract number: 253
Use of CRISPR-Cas9 system to characterize TCF4 and TCF3 mutations in diffuse large B-cell lymphoma
Calla Sullivan; Lymphoma & Myeloma; University of Texas MD Anderson Cancer Center
Zhanyao Tan; Lymphoma & Myeloma; University of Texas MD Anderson Cancer Center
Michael Green; Lymphoma & Myeloma; University of Texas MD Anderson Cancer Center
Background: The most common form of lymphoma, diffuse large B-cell lymphoma (DLBCL), is histologically
characterized by diffuse proliferation of large B-cells. DLBCL is further classified into two subgroups: germinal
center B-cell-like and activated B-cell-like. As part of the humoral immunity component of the adaptive immune
system, each B-cell expresses a unique B-cell receptor (BCR). Due to this diversity of BCRs and gene
expression, the current standard immuno-chemotherapy regimen (R-CHOP: rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone) only cures 60% of DLBCL cases. Gene duplication of oncogenes is a
common mechanism for tumorigenesis, and within ABC-like DLBCL, the most frequent mutation is a DNA copy
number gain of TCF4, an E2 basic helix-loop-helix transcription factor. The TCF4 gene is closely related to TCF3,
which is negatively regulated by ID2 and ID3. ID proteins negatively regulate cellular differentiation and induce
proliferation; the ID2, ID3, and ID4 proteins inhibit the activity of TCF3 and TCF4 by forming heterodimers
incapable of binding DNA. These genes may be potential therapeutic targets for DLBCL tumors resistant to RCHOP.
Methods: To create cell lines with mutations in the genes of interest, homology-directed repair using the Alt-R
CRISPR-Cas9 system and HDR donor oligos was performed. To determine if cells were successfully edited, cells
were collected, lysed, and polymerase chain reactions were performed. Cleavage Under Targets & Release
Using Nuclease (CUT&RUN) was performed to provide high-resolution genome-wide profiles of histone posttranslational modifications and chromatin associated proteins. The KAPA HyperPrep Kit was used to construct
libraries for Illumina sequencing. Drug studies using OTX015 and Venetoclax were done to study the synergistic
effects. Western blot analysis was also performed to determine the presence of TCF3, TCF4, ID3, and ID4 in
several cell lines.
Results: Electroporation allowed for the transfection of cells with an RNP complex of gRNA and Cas9 enzymes
with optimal efficiency. Gel electrophoresis confirmed the presence of DNA before samples were sent for
sequencing and analysis. CUT&RUN procedure resulted in the analysis and sequencing of transcription factors
like TCF3 and TCF4. Drug studies showed that the two drugs have dose-dependent effects and indicated
synergistic effects.
Conclusion: TCF4 is a common copy number gain in DLBCL cancers, and as a result, this gene and the related
TCF3 may be potential therapeutic targets for study. The CRISPR-Cas9 system provides a system to introduce
mutations through homology-directed repair to study the sequence, drug treatments, and expression of these
cancer genes.
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Abstract number: 254
Clinical characteristics may predict lymph node burden in hormone receptor-positive (HR+), human
epidermal growth factor receptor 2-negative (HER2-) breast cancer patients
Elena Wernecke; Breast Surgical Oncology; University of Texas MD Anderson Cancer Center
Puneet Singh MD; Breast Surgical Oncology; University of Texas MD Anderson Cancer Center
Isabelle Bedrosian MD; Breast Surgical Oncology; University of Texas MD Anderson Cancer Center
Constance Albarracin MD, PhD; Pathology; University of Texas MD Anderson Cancer Center
Hui Chen MD, PhD; Pathology; University of Texas MD Anderson Cancer Center
Background: The recently presented RxPONDER trial demonstrated that postmenopausal patients with hormone
receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) and 1-3
positive axillary lymph nodes (LN) who have a low Oncotype DX Recurrence Score (≤ 25) may potentially forgo
chemotherapy. This necessitates a method to accurately assess the extent of axillary LN involvement in these
patients, which is typically determined through complete axillary lymph node dissection (ALND) for patients who
are clinically node-positive and undergoing upfront surgery. However, this may be overtreatment for patients with
limited axillary nodal burden. This study aims to analyze the associations between clinicopathologic factors and
number of suspicious or pathologically positive LNs in patients with clinically axillary node-positive (cN1),
HR+/HER2- BC who underwent upfront ALND.
Methods: Patients with HR+, HER2-, cN1 BC who had undergone ALND were identified (2002-2016). Clinical
characteristics based on imaging and physical examination were compared with pathology. Descriptive statistics
were performed, and variables were assessed for association using Chi-square analysis and Pearson’s
correlation test.
Results: Among 158 patients, the median age was 58 years with a range from 30 to 88 years. Preoperative
ultrasounds (US) identified 1, 2, 3, and >3 suspicious LNs in 61.7%, 18.5%, 18.5%, and 1.3% whereas ALND
identified 1, 2, 3, and >3 positive LNs in 26.6%, 21.5%, 14.6%, and 37.3%. This corresponds to a 96.6% false
negative rate. Further, the median number of suspicious LNs reported in each cohort of ALND-identified
involvement was 1, with no significant correlation between number of suspicious LNs on preoperative US and
total verified positive LNs on ALND. Patients with 1, 2, 3, and >3 suspicious LNs on preoperative US had medians
of 2, 3, 3, and 17.5 positive LNs on ALND, respectively. There was no statistically significant association between
the number of positive LNs on ALND and LN palpability, histology, race, hormone receptor expression, or
histologic grade. Pearson’s correlation test revealed no association between ALND-identified LN burden and
median age, tumor size, or size of index LN found on preoperative US.
Conclusion: Our results demonstrate that preoperative US to determine extent of LN involvement has a high false
negative rate when confirmed by ALND. Furthermore, individual clinicopathologic features cannot be used to
predict the extent of LN involvement in ALND. Multivariate studies are in progress to evaluate whether these
clinicopathologic features can be used in combination to predict the extent of axillary nodal involvement.
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SRMS as a Novel Therapeutic Target in Gastric Cancer Peritoneal Metastases
Jaqueline Quintanilla; The University of Texas Rio Grande Valley
Ailing W Scott; GI Medical Oncology; University of Texas MD Anderson Cancer Center
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Yibo Fan; GI Medical Oncology; University of Texas MD Anderson Cancer Center
Lang Ma; GI Medical Oncology; University of Texas MD Anderson Cancer Center
Jaffer A Ajani; GI Medical Oncology; University of Texas MD Anderson Cancer Center
Shumei Song; GI Medical Oncology; University of Texas MD Anderson Cancer Center
Background: Affecting over 1 million people in the past year, gastric adenocarcinoma (GAC) is the 5th most
common cancer in the population and the 4th most common cause of cancer fatalities. GAC with peritoneal
carcinomatosis (PC) is common affecting ~45% of patients during the course of GAC and leads to poor survival,
but the molecular events leading to PC are not clear. Our recent RNAseq of PC specimen revealed that SRMS
(Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites), a nonreceptor
tyrosine kinase, was amplified in PC samples and highly upregulated in the diffuse type and signet-ring cell (SRC)
subtypes of GAC with especially poor prognosis. Specific function of SRMS in PC is not known.
Methods: The expression of SRMS, other proteins, and genes in the cell lines were assessed using western blot
and real-time polymerase chain reaction (qPCR). Transfection of the AGS cells with the overexpression SRMS
plasmid was achieved using the jetPRIME transfection protocol. GA0518 patient-derived PC cells and AGS GAC
cell lines as well as Flo-1 radiation resistant XTR cells were used to study the functions of SRMS including cell
proliferation, invasion, and tumor sphere forming capacity in vitro.
Results: TCGA data confirmed that SRMS was highly upregulated in GAC tissues compared to normal and
adjacent normal tissues. Based on western blot and qPCR, patient-derived PC cells GA0518 and GA0804 highly
expressed SRMS, while normal gastric GES-1 cells and Kato III GAC cells, had low expression. In addition, when
GA0518 cells were treated with the novel inhibitor HJC0378 (C22H24CIN3O4S), the expression of SRMS,
phosphor-STAT3, phosphor-S6, and other oncoproteins such as TRIM28 and SOX9, were dramatically
suppressed, even greater in comparison to Dasatinib treatment, a known SRMS inhibitor. Most interestingly, we
found that both HJC0378 and Dasatinib significantly suppressed tumor cell growth, invasive capacity, and tumor
sphere formation in vitro especially in radiation resistant Flo-1 XTR cells.
Conclusion: SRMS gene and protein were upregulated in patient-derived PC cells in comparison to normal gastric
cells. The correlation of expression between SRMS and other important markers also suggested the role of
SRMS in important oncogenic signaling. Therefore, SRMS is a promising target in PC from GAC and inhibitor
HJC0378 is a potential inhibitor of SRMS.
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Expanding the Tumor Mutation Burden in Mouse Melanoma Cells
Cesar Augusto Ruiz Elizondo; Melanoma Medical Oncology; University of Texas MD Anderson Cancer Center
Evelyn DeGroot; Medical Melanoma Oncology; University of Texas MD Anderson Cancer Center
Vashisht Gopal Yennu Nanda; Medical Melanoma Oncology; University of Texas MD Anderson Cancer Center
Background: Melanoma is one of three types of skin cancer, predominately caused by exposure to UV radiation.
Previous studies indicate that melanomas have a high tumor mutation burden (TMB), which promotes
immunogenicity and significant anti-tumor immune responses due to translation of these mutations into
neoantigens. A few of these neoantigen-containing tumors are responsive to immunotherapies such as
checkpoint inhibitors. However, many do not respond to such treatments, and it is unclear what differentiates
responding tumors from non-responders. High TMB melanoma cell models that could be studied in
immunocompetent mice would be very beneficial to help understand anti-melanoma immune responses.
Currently there are only two high TMB mouse melanoma cell line models in existence. Therefore, it is critical to
create additional high TMB melanoma cell lines to expand our knowledge in the field.
Methods: We generated a high TMB by irradiating two different mouse melanoma cell lines with a low TMB. One
is a naturally developed B16-F0 and the other, a genetically engineered YUMM 5.2. These cell lines were
exposed to solar-simulating UV-A and UV-B radiation at intensities that generate severe skin burns on the human
skin. Following irradiation, surviving clones were selected and whole exome sequencing was used to determine
their mutation burden. Cell biological studies are being performed to evaluate the phenotypic effects of their
mutation burden, and tumor growth studies in immune competent mice were performed to evaluate immune
effects on these high TMB melanoma cells.
Results: Studies are ongoing to determine cell biological, molecular, and tumor growth characteristics in the high
TMB versus parental cell lines. These results will be presented during the poster presentation.
Conclusion: We expect to see greater immunogenicity, a greater influx of immune cells, and tumor growth
inhibition in the high TMB cells compared to non-irradiated control cells. Our high TMB cell lines will become
important tools for future studies to further clarify the significance of a high TMB in melanoma cells as a predictive
biomarker, and to help understand melanoma responses to immune therapies.
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